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Abstract of Thesis
The ovary is one of the most plastic tissues in the body undergoing constant serial
remodelling throughout its reproductive lifetime, during both folliculogenesis and the
formation and regression of the corpus luteum. The process of follicle growth and
selection is intimately associated with the de novo establishment of vasculature
supporting the developing follicles. Blood vessels are recruited from the ovarian
stroma to form vascular sheaths surrounding each developing follicle supplying
steroid hormone precursors, oxygen and nutrients to the expanding follicle. During
folliculogenesis only the theca of the developing follicle becomes vascularised, the
granulosa cells remaining avascular until ovulation at which point the basement
membrane that has been separating the granulosa and theca breaks down. After
ovulation the granulosa cells become heavily vascularised during the process of
luteinisation and the formation of the corpus luteum. Angiogenesis, the growth of
new blood vessels from the pre-existing vasculature, requires the degradation of the
established vessels followed by endothelial cell proliferation and finally stabilisation
of the new vessels. Recently, techniques to quantify angiogenesis, identify putative
molecular regulators, and inhibit them in vivo have become available. The work in
this thesis applies these advances to the following questions:
1) What is the effect of the inhibition of the gonadotrophins, using a
gonadotrophin releasing hormone (GnRH) antagonist, on follicular angiogenesis?
The hypothesis being tested was that follicular angiogenesis would be dependent on
follicle stimulating hormone (FSH) / luteinising hormone (LH) and be severely
inhibited by GnRH antagonist treatment. In vivo follicular angiogenesis was
assessed by quantitative immunocytochemistry of bromodeoxyuridine and the
endothelial cell marker CD31. The effect of treatment on follicular development and
angiogenesis at the molecular level was assessed by in situ hybridisation of mRNA
for vascular endothelial growth factor (VEGF) and aromatase. The results suggest
that while VEGF expression in the preovulatory follicle is under gonadotrophic
control, it is not dependent on normal gonadotrophin secretion in tertiary follicles,
indicating that there are other paracrine factors regulating VEGF expression in the
XXI
developing ovarian follicle. The second chapter extends the findings by determining
granulosa cell response to FSH stimulation with respect to induction of the VEGF
and aromatase genes.
2) What is the effect of inhibition of vascular endothelial growth factor, using
the antagonist, VEGF trap R1R2, on follicular angiogenesis, follicular development,
ovulation and the establishment of the corpus luteum (CL)? The hypothesis being
tested was that VEGF is essential for increasing permeability and the growth of the
selected follicles. The immunocytochemical techniques used in the first study were
again employed. The effect of treatment on the molecular regulation of angiogenesis
was assessed by in situ hybridisation ofmRNA for VEGF and its two receptors. In
vivo inhibition of VEGF caused dramatic reductions in angiogenesis and in VEGF
receptor expression but did not reliably prevent dominant follicle growth or
ovulation once dominant follicle selection had occurred.
3) Is a novel factor, endocrine gland vascular endothelial growth factor (EG-
VEGF) expressed in our animal model? The hypothesis being tested was that EG-
VEGF is an additional angiogenic factor that is expressed in the marmoset and the
human ovary. This was assessed by in situ hybridisation in various marmoset tissues
as well as in the human corpus luteum. Findings demonstrated that EG-VEGF is
expressed in the granulosa lutein cells in the human corpus luteum while the
marmoset ovary does not appear to express EG-VEGF.
This thesis has improved our understanding of the gonadotrophic control of
follicular angiogenesis and the role VEGF plays in the latter stages of
folliculogenesis.
Chapter 1 Introduction 1
Chapter 1 Introduction
Chapter 1 Introduction 2
1.1 Overview
Angiogenesis is the growth of new blood vessels from the pre-existing vasculature,
and requires the degradation of these vessels, followed by endothelial cell
proliferation and finally stabilisation of these new vessels. Physiological
angiogenesis is rare in the healthy adult apart from in the female reproductive
system, with both the ovaries and uterus undergoing serial angiogenesis. In the
ovary, cyclic angiogenesis occurs during folliculogenesis and the formation of the
corpus luteum. It is the regulation of ovarian follicular angiogenesis that is the
subject of this thesis.
The function of the ovarian follicle is to produce a fertilisable oocyte at
ovulation and to prepare the reproductive tract for pregnancy. Many follicles initiate
development during the female reproductive lifetime; however, through the process
of dominant follicle selection only one (human), or two to three (marmoset monkey)
preovulatory follicle(s) develops per ovarian cycle.
The process of folliculogenesis and dominant follicle selection is intimately
associated with angiogenesis. Blood vessels are recruited from the ovarian stroma to
form vascular sheaths surrounding each developing follicle. The new vasculature
supplies steroid hormone precursors, oxygen and nutrients to the developing follicle.
The extent of follicle vascularisation has also been hypothesised to play an important
role in the process of selection of the dominant follicle. During folliculogenesis,
only the theca of the developing follicle becomes vascularised; the granulosa cells
remain avascular until ovulation, where the basement membrane that has been
separating the granulosa and theca breaks down. After ovulation, the granulosa cells
become heavily vascularised during the process of luteinisation and the formation of
the corpus luteum. Vascular endothelial growth factor (VEGF) is known to be one
of the key regulators of ovarian follicular angiogenesis.
This chapter reviews the current understanding of the factors regulating
ovarian follicle development and the angiogenic process. It focuses on experimental
evidence from studies in women and non-human primates. However, where there is
a lack of available evidence, extrapolation from findings in other species is also used.
First the process of folliculogenesis and ovulation is discussed, followed by the
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control of angiogenesis, including the history, molecular regulation, and therapeutic
relevance of inhibiting angiogenesis. This chapter serves as an introduction to the
following experimental chapters that report studies on the regulation and inhibition
of angiogenesis in the primate ovarian follicle.
1.2 Pituitary-Ovarian axis
Ovarian function is controlled by the brain through the secretion of messages from
the hypothalamus that act on the ovary via the gonadotrophins: follicle stimulating
hormone (FSH); and luteinising hormone (LH). The signal from the hypothalamus
to the pituitary is gonadotrophin releasing hormone (GnRH). GnRH is a decapeptide
secreted in a pulsatile manner by the hypothalamus into the hypophysial portal blood
system that connects the hypothalamus and the pituitary gland. GnRH is perceived
by GnRH receptors at the anterior pituitary, and activation of these receptors
stimulates the production and release of both FSH and LH from the anterior pituitary.
FSH and LH are both heterodimeric polypeptides with a common a-subunit and a
structurally related, but unique, (3-subunit that gives them their biological specificity,
this is reviewed by Clarke (1996).
1.3 Folliculogenesis
The structures we now recognise as ovarian follicles were first noted in 1672 by
Graaf. Whilst examining human ovaries he mistook the developing follicles for what
he thought to be ova (Jocelyn and Setchell 1972).
Folliculogenesis is the growth of ovarian follicles from a primordial or dormant
state to the preovulatory stage of development. For many years it has been thought
that primordial follicle formation only occurred during foetal life, and that all
primordial follicles were formed during the formation of the ovary itself (Pearl and
Schoppe 1921, Baker 1963). However, recent work has challenged this pillar of
female reproductive biology, with new evidence of germline stem cells present in the
adult mouse ovary (Johnson et al. 2004). In the human, there are thought to be
between 266,000 and 472,000 primordial follicles present in each ovary at birth
(Block 1953, Forabosco et al. 1991, Gougeon et al. 1994). However many
primordial follicles there are in the ovary and whether or not they are replenished
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during adult life, only approximately 400 will develop into a preovulatory follicle
and ovulate (Hillier 1994). The rest will be cleared from the ovary by atresia, a topic
discussed later in this chapter.
1.3.1 Follicle recruitment
The signal or cause for a resting primordial follicle to begin to develop is not
completely understood. Current research has uncovered a number of factors
involved in the regulation of the initiation of growth of primordial follicles (initial
recruitment). Basic fibroblast growth factor (bFGF) (Nilsson et al. 2001, Nilsson
and Skinner 2004), leukaemia inhibitory factor (LIF) (Nilsson et al. 2002), kit-ligand
(Motro and Bernstein 1993, Parrott and Skinner 1999, Nilsson and Skinner 2004),
the neurotrophins (Dissen et al. 2001, Paredes et al. 2004), and bone morphogenic
protein-7 (BMP-7) (Lee et al. 2001) have all been implicated in the initiation of
primordial follicle development. It is known that both kit-ligand and bFGF must be
active in order to optimally promote the changes that occur in the oocyte, granulosa
cells and stromal cells when a primordial follicle initiates development in the rat
(Nilsson and Skinner 2004), but the precise mechanism is still unclear.
Strong correlations exist between the number of primordial follicles initiating
development at any one time and the size of the primordial follicle pool at that time:
the more follicles in the resting pool, the more follicles start to develop (Gougeon et
al. 1994). However, as the number of resting primordial follicles decreases through
both ovulation and atresia, the proportion of the remaining follicles which develop
increases (Krarup et al. 1969, Gougeon and Chainy 1987). These observations on
follicular dynamics indicate that there is an inhibitory signal from the developing
follicles that prevents other primordial follicles from initiating development. A
prime candidate for this signalling molecule is now thought to be anti-mullerian
hormone (AMH). AMH is a dimeric glycoprotein related to the transforming growth
factor (3 (TGF|3) family (Cate et al. 1986) and is primarily thought of as being
involved in male sexual differentiation, being essential for the regression of the
Miillerian ducts in the male foetus, the initial step of organogenesis of the male
genital tract (Josso et al. 1977, Josso et al. 1998). However, AMH is also produced
by the granulosa cells of developing follicles in the foetal ovaries from about week
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36 of gestation through to the menopause (Lee et al. 1996, Rajpert-De Meyts et al.
1999) and is implicated in the inhibition of early folliculogenesis through mice
knock-out studies (Ueno et al. 1989, Baarends et al. 1995, Durlinger et al. 2001,
Durlinger et al. 2002a).
A primordial follicle consists of an oocyte arrested in prophase of the first
meiotic division, surrounded by a single layer of flattened epithelial cells (Block
1951, Koering 1969, Dekel and Beers 1978). When primordial follicles leave the
resting pool, the flattened epithelial like granulosa cells become cuboidal and begin
to show signs of proliferation, although the rate of proliferation is slow, with follicles
developing at this level for approximately 65 days in the human (Hirshfield 1985,
Gougeon 1996, Wandji et al. 1996, Wandji et al. 1997). During the early stages of
folliculogenesis, cells close to the developing follicles in the ovarian stroma are
recruited to form the theca surrounding the granulosa cells. A distinct thecal layer is
evident at different stages of folliculogenesis in different species. In rodents, it can
be seen as early as the late primary/early secondary stage of follicle development
(Fortune and Eppig 1979), but cannot be seen in the primate, bovine or ovine follicle
until the mid or late secondary stage of follicular development (Gougeon 1996,
Braw-Tal and Yossefi 1997, Lundy et al. 1999). The mechanism by which the theca
is recruited is poorly understood and requires much further research.
1.3.2 Tertiary follicle development
By the time follicles reach the late secondary stage of development, small fluid filled
pockets between the granulosa cells start to appear. These pockets are caused by the
production of glycosaminoglycans by the granulosa cells under FSH stimulation.
Glycosaminoglycans are a major component of the follicular fluid that fills the antral
cavity (Hillier 1991a) and, as these pockets expand and connect, the continuous
antral cavity is formed. Tertiary, FSH-sensitive, follicles containing an antral cavity
can be observed at all stages of the human ovarian cycle, but it is only the 20 or so
small tertiary follicles present in the late luteal phase of the cycle that will be
selected for further growth and potentially go on to ovulate (Gougeon and Lefevre
1983, McNatty et al. 1983). This is because, during the luteal phase of the ovarian
cycle, the circulating levels of oestradiol, progesterone and inhibin in the blood are
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high and have been shown to inhibit gonadotrophin secretions in the rhesus monkey
(Karsch et al. 1973, Channing et al. 1981, Bassett and Zeleznik 1990). Both
oestradiol and inhibin directly inhibit FSH|3 subunit messenger ribonucleic acid
(mRNA) production (McNeilly et al. 2003), thus the circulating level of FSH is not
sufficient to stimulate selection of a dominant follicle. Flowever, as the corpus
luteum undergoes luteolysis, the circulating levels of oestradiol, progesterone and
inhibin decrease and, in turn, the circulating level of FSH increases so that the
process of dominant follicle selection can begin (Roseff et al. 1989).
The ovarian follicle has two main functions to fulfil: one is to produce a
fertilisable oocyte at ovulation; the other is to prepare the reproductive tract for
pregnancy. Once FSH-dependent folliculogenesis has started, these goals are
achieved by a tightly regulated system controlled by the gonadotrophins. Unlike the
uncertain role of the gonadotrophins in the start of follicular development, they are
essential for the maintenance of follicular endocrine functions in the developing
tertiary follicles. LH stimulation of theca cells leads to the production of
androstenedione (androgen) in the theca cells (Erickson et al. 1985). Stimulation of
FSH receptors on the cell surface of developing granulosa cells leads to the
activation of adenylyl cyclase and cyclic adenosine monophosphate (cAMP)-
dependent protein kinase(s) (Adashi and Resnick 1986). This activation leads in turn
to the activation and expression of a range of genes required for granulosa cell
differentiation including: cytochrome P450 aromatase (P450arom), which is essential
for converting theca produced androgen to oestrogen in the granulosa cells (Falck
1959, Steinkampf et al. 1987, Simpson et al. 1994); cytochrome P450 side chain
cleavage (P450ssc), the cholesterol side chain cleavage enzyme that is essential for
granulosa cell progesterone production (Richards 1994); the LH receptor (Segaloff
and Ascoli 1993); and a range of other genes necessary for ovarian follicle
maturation.
1.3.3 Selection of dominant follicle(s)
By the mid follicular phase of the ovarian cycle, dominant follicle(s) can already be
identified as the largest healthy follicle(s) in the ovaries (Gougeon and Lefevre
1983). As the tertiary follicles continue to grow under the influence of FSH, their
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granulosa cells become steroidogenically active. As discussed above, oestrogen
production has an inhibitory effect on FSH secretion, and it is this negative feedback
via oestrogen that will go on to regulate the acquisition of follicular dominance.
As follicles undergo stimulation by FSH and mature to the preovulatory stage
of development, they become more sensitive to FSH and also begin to express LH
receptors on their granulosa cells (Zeleznik et al. 1974, Segaloff and Ascoli 1993).
These processes serve to protect the selected follicle(s) from the imminent decline in
FSH concentrations that occurs due to the follicular oestrogen production. It is at
this point that the dominant follicle(s) becomes increasingly dependent on LH
relative to FSH (Yong et al. 1992a). As the circulating concentration of FSH
decreases, the FSH-induced expression of the LH receptor on the granulosa cells
provides a protective effect for the dominant follicle(s). The dominant follicle(s)
also starts to produce increasing amounts of androgen and oestrogen in response to
LH stimulation (McNatty et al. 1976), which continues to augment the decrease in
FSH production, and hence the maintenance of follicle dominance. It is probably the
follicle(s) that is most sensitive to FSH during follicle recruitment that will begin to
produce oestradiol before the others, and hence gain dominance (Zeleznik and Kubik
1986). During the preovulatory follicular period in rats, the density of FSH receptors
on the granulosa cells increases to confer dominance to the developing follicle(s) as
the concentration of FSH falls (LaPolt et al. 1992). Less mature follicles have fewer
FSH receptors and may not be as sensitive to FSH stimulation, or express as many
LH receptors, which therefore makes them more susceptible to the decline in FSH
concentrations than are the dominant follicles, and more likely to die.
Of the follicles initially selected to begin preovulatory development, only one
(human), or two to three (marmoset monkey) will eventually go on to secrete enough
oestrogen and become the dominant follicle(s) in that cycle (Goodman et al. 1977,
Zeleznik 1981).
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1.4 Ovulation
Ovulation marks the completion of the follicular phase of the ovarian cycle,
culminating in the rupture of the dominant follicle(s) and the onset of luteinisation.
It is triggered by the LH surge, a large discharge of LH from the anterior pituitary
(Yen eta/. 1975).
1.4.1 The LH surge
Sustained high levels of circulating oestradiol produced by the dominant follicle(s)
trigger the LH surge. How oestrogen exerts this positive feedback mechanism
remains to be fully understood, but it is thought to involve an effect on both the
hypothalamus and pituitary. Oestrogen increases the sensitivity of the gonadotrope
cells in the pituitary to the effects of GnRH, resulting in progressively more and
more LH release throughout the follicular phase, reviewed by Baird (1991). The LH
surge is likely to be due to a pulsatile GnRH release from the hypothalamus acting
on a hypersensitive pituitary, resulting in a large release of LH. Progesterone also
plays an important role in triggering the LH surge. In macaques the LH surge is
caused by an increase in GnRH release that is induced by progesterone (Woller and
Terasawa 1994). In both women (Liu et al. 1987, Ho 2001) and monkeys (Collins
and Hodgen 1986, Wolf et al. 1989), treatment with progesterone antagonists has
been shown to prevent the late follicular LH surge.
The LH surge induces sequential transcription of a number of genes involved
in ovulation (Espey and Richards 2002), which can be broken down into three main
processes: reactivation of oocyte maturation; follicle rupture; and luteinisation of the
granulosa cells (Tsaffiri and Dekel 1994).
1.4.2 Oocyte reactivation
The oocyte does not express LH receptors, so LH responsive cells must therefore
mediate the trigger for reactivation of the oocyte. The oocyte nucleus, otherwise
known as the germinal vesicle, remains arrested in prophase of the first meiotic
division until oocyte maturation commences (Dekel and Beers 1978). It is believed
that intra-oocyte cAMP is critical to the control of meiosis and that it is the oocytes
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intimate contact with the granulosa cell that prevents it from spontaneously maturing
before ovulation. An oocyte will mature spontaneously when removed from its
cumulus granulosa cells (Espey and Lipner 1994). However, this can be prevented
by addition of cAMP to the oocyte as it is thought that the cumulus granulosa cells
supply cAMP to prevent the oocyte from maturing prematurely (Tsafriri and Dekel
1994). Purines present in the follicular fluid are also thought to contribute to the
accumulation of cAMP within the oocyte (Eppig et al. 1985). The LH surge causes
the cytoplasmic oocyte-cumulus granulosa cell connections to break down, thus
lowering oocyte cAMP levels and releasing the oocyte to mature prior to ovulation.
However, the role for a positive stimulus for oocyte maturation has been suggested
from observations that in mouse cumulus-enclosed oocytes meiotic resumption in
vivo (Su et al. 2002), and in vitro (Downs et al. 1988, Su et al. 2002, Su et al. 2003)
under conditions which maintain continued meiotic arrest, can be induced by an
overriding signal originating in the cumulus cells as a direct effect of gonadotrophin
action. However, the chain of events leading to oocyte maturation remains to be
delineated.
1.4.3 Follicle rupture
Approximately 36 hours after the LH surge the follicle wall ruptures, allowing the
oocyte to be extruded from the follicle (Baird and Fraser 1975). Many theories have
been advanced as to the nature of the process of follicle rupture at ovulation, such as
those based on smooth muscle contraction and intrafollicular pressure, reviewed by
Espey and Lipner (1994). However, nowadays ovulation is thought to be similar to
an acute inflammatory response triggered by the LH surge.
Many cell layers that do not express the LH receptor are affected during the
process of follicle rupture. There are therefore many interactions occurring to
prepare the preovulatory follicle for rupture. These interactions are initiated by the
LH surge stimulating steroidogenic cells to induce an inflammatory response (Espey
1980). The inflammatory response leads to the activation of a range of genes
including the expression of cyclooxygenase-2 (COX-2) and epiregulin, both of
which are involved in prostanoid synthesis in the preovulatory follicle (Espey and
Richards 2002). Prostaglandins, including prostaglandin F2a, are produced by the
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granulosa cells in response to the LH surge (Evans et al. 1983). These
prostaglandins are primarily involved in the increase in vascular permeability in the
preovulatory follicle, and help to maintain the positive intrafollicular pressure during
follicular fluid leakage.
The LH surge also stimulates 1 l(3-hydroxysteroid dehydrogenase type 1
(11 (3HSD1) and simultaneously down-regulates 11|3HSD2 expression in the
granulosa cells of preovulatory follicles (Tetsuka et al. 1997, Tetsuka et al. 1999).
Since 1 lpHSDl converts cortisone to Cortisol, whereas 11(3HSD2 inactivates Cortisol
to cortisone (Stewart 1996), the changes induced by LH favour local accumulation of
anti-inflammatory Cortisol at a time when rapid healing of the ruptured surface will
be required to quickly restore normal ovarian function (Hillier and Tetsuka 1998).
This is the mechanism by which the balance between inflammation and wound repair
is maintained at ovulation.
As ovulation approaches, an area of the preovulatory follicle wall becomes
weaker due to proteolytic disintegration and a follicle apex or stigma will form. This
stigma is characterized by a reduction in vascular density and will go on to become
the point of ovulation. A range of specific collagenases mediates these proteolytic
processes. In the mouse model, proteolytic enzymes such as Cathepsin-L and a
disintegrin and metalloproteinase with thrombospondin-like motifs (ADAMTS-1)
are both selectively induced in granulosa cells of preovulatory follicles by the LH
surge (Robker et al. 2000). However, other common proteases such as matrix
metalloproteinase-2 (MMP-2) and MMP-9 are both thought to be redundant during
the process of ovulation, as mice that are null for MMP-9 nevertheless ovulate, and
the LH surge selectively decreases the activation of MMP-2 in follicles (Robker et
al. 2000).
At ovulation, the apex of the follicle ruptures and the cumulus-oocyte complex
flows out of the follicle and onto the ovarian surface, where it will pass into the
oviduct. During this process, the granulosa cells in the preovulatory follicles are also
undergoing luteinisation.
1.4.4 Granulosa cell luteinisation
Luteinisation of the granulosa cells from the preovulatory follicle is vital for the
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formation of the corpus luteum. During luteinisation, there is a dramatic change in
the steroidogenic activity of granulosa cells. During folliculogenesis, the main
steroidogenic process in the granulosa cells is the aromatisation of theca-derived
androgen to oestrogen (Hillier 1991b). In the preovulatory follicle, oestrogen
synthesis declines as a result of the inhibition of thecal cytochrome P450
17ahydroxylase (P450i7a), and the subsequent lack of androgen as a substrate for
aromatisation in the granulosa cells. The LH surge causes an increase in the
expression of P450scc, 3(3 -hydroxysteroid dehydrogenase (3(3-HSD), and
steroidogenic acute regulatory protein (StAR) in the granulosa cells of the
preovulatory follicle. These enzymes are essential for the conversion of cholesterol
to progesterone (Miller 1988, Yong et al. 1992a, Stocco 2001). Thus, as ovulation
approaches, the ovary increasingly produces progesterone while oestrogen
production falls (Hillier 1985). The induction of these enzymes causes follicular
fluid progesterone levels to rise, and it is thought that this preovulatory increase is
essential to follicular rupture. In vitro culture of follicle wall sections in
progesterone has been shown to accelerate the net loss of collagen fibres from the
follicular wall (Tjugum et al. 1984), caused by the up-regulation of plasminogen
activator synthesis that in turn activates collagenases, facilitating follicular wall
breakdown, reviewed by Zeleznik and Hillier (1996). Figure 1.1 illustrates the
different stages of follicular development during the ovarian cycle.






























Figure 1.1 Diagram of the ovary.
The various stages of follicular development, ovulation and luteinisation encountered
throughout the mammalian ovarian cycle are depicted in the diagram. Adapted from
©2001 Benjamin Cummings, an imprint ofAddison Wesley Longman, Inc.
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1.5 Ovarian follicular steroidogenesis
The production of ovarian steroids is critical in regulating ovarian function. The
ovarian steroids play a crucial role in feedback regulation of gonadotrophin secretion
from to pituitary. They also act in both paracrine and autocrine manners in the
ovarian follicle itself (Hillier 2001).
1.5.1 Androgen
Androgens are produced in theca cells through the expression of the P450na enzyme,
whose expression is positively regulated by LH stimulation (Erickson et al. 1985,
Sasano et al. 1989, Smyth et al. 1993). Most, if not all, tertiary follicles contain
thecal cells with LH receptors (Zeleznik et al. 1981), and are therefore capable of
converting acetate and cholesterol to androgen.
During tertiary follicle development, the granulosa cells express androgen
receptors, which allows the theca-produced androgen to stimulate the granulosa cells
in a paracrine fashion (Smyth et al. 1995, Tetsuka et al. 1995, Tetsuka and Hillier
1996). The action of androgen on the granulosa cells is thought to be mediated by
amplifying their responsiveness to FSH stimulation (Hillier 2001). As the
preovulatory follicle matures, the granulosa cells express fewer androgen receptors
(Hillier et al. 1997). This mechanism serves to desensitise the granulosa cells to the
gonadotrophins during the late follicular period, and ensures that luteinisation does
not occur until the high levels of LH achieved during the LH surge is perceived
(Hillier and Tetsuka 1997).
1.5.2 Oestrogen
Granulosa cells are the predominant, if not exclusive, site of oestrogen synthesis in
the ovarian follicle. Immunocytochemical and in situ hybridisation studies have
localised cytochrome P450arom protein (Tamura et al. 1992) and mRNA (Fitzpatrick
and Richards 1991, Whitelaw et al. 1992) to the granulosa cells. Isolated cell
cultures of both granulosa and theca cell have also demonstrated that more than 99%
of a follicle's capacity to aromatise androgens lies in the granulosa cells (Hillier et
al. 1981). However, the granulosa cells are unable to produce oestrogen without
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theca-produced androgen as a substrate because they do not express the P450na
enzyme necessary for androgen production. Conversely, theca cells are not able to
synthesise oestrogen directly as they do not contain the P450arom enzyme. As both
cell types are required for oestrogen production, this has become known as the two-
cell theory of steroidogenesis, illustrated in Figure 1.2 and reviewed by Hillier et al
(1994).
High oestrogen production in a follicle reflects its ability to respond to FSH
stimulation, as FSH regulates expression of the P450arom enzyme that is required to
convert androgen to oestrogen. Oestrogen production is considered the hallmark of
preovulatory follicular development (Hillier 2001). The granulosa cells also express
oestrogen receptors that can mediate autocrine oestrogen action within the granulosa
cell population, again serving to augment the action of FSH on the granulosa cells
(Richards 1994).
1.5.3 Progesterone
As the preovulatory follicle matures, it increasingly produces progesterone.
Progesterone is produced in the granulosa cells under the regulation of P450ssc that
catalyses the rate-limiting conversion of cholesterol to pregnenolone (Richards et al.
1998). Progesterone is not thought to play either an autocrine or a paracrine role in
the developing follicle, as progesterone receptors are not expressed in the developing
follicle until the LH surge (Natraj and Richards 1993, Park-Sarge and Mayo 1994).
However it is essential for the process of ovulation, particularly follicle rupture, as
discussed earlier in this chapter.






Figure 1.2 The two-cell theory of steroidogenesis.
Cholesterol is converted into androgen in theca cells. The androgen is then
transported to the granulosa cells where it is converted into oestrogen. Based on
Armstrong and Dorrington (1977).
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1.6 Follicular paracrine signalling
Folliculogenesis is not solely regulated by the gonadotrophins. Locally produced
factors also act in either an autocrine or paracrine manner to modulate a follicle's
responsiveness to FSH and LH. In the human ovary many locally produced factors
have been shown to modify FSH action in vitro and thus serve to increase a follicle's
sensitivity to the gonadotrophins (Hillier 1991b). The best characterised ovarian
growth factors to date are: insulin-like growth factors I and II (IGF-I and IGF-II)
(Adashi 1998); and members of the transformation growth factor |3 (TGF-|3)
superfamily (Gaddy-Kurten et al. 1995) such as inhibin and activin in the human
(Hillier 1991c). However, there are many other factors thought to be involved
including: TGF-a and TGF-(3 (Magoffin and Erickson 1994); and the angiogenic
factors VEGF and FGF. However this evidence has been collected from a range of
species including human, cynomolgus monkey aswell as bovine, ovine and porcine
tissue (Ravindranath et al. 1992, Laitinen et al. 1997, Reynolds and Redmer 1998)
and cross species inferences must be done with caution.
For example, theca cells from normal human ovaries have been shown to
express receptors for both insulin and the IGFs (Poretsky et al. 1985). Also, both
insulin and IGF-I have been shown to stimulate thecal androgen synthesis in cultured
human theca cells (Bergh et al. 1993, Nahum et al. 1995) and in the rat ovary, FSH
stimulates the production of IGF-I in granulosa cells. However, human granulosa
cells do not produce IGF-I, although they do produce IGF-II, which suggests a
paracrine role for IGF-II produced in the granulosa cells acting on the theca to
stimulate thecal androgen synthesis (Hernandez et al. 1988, Nahum et al. 1995).
Activins and inhibins produced in the granulosa cells also have potent
modulatory effects on thecal androgen production. In the developing human follicle
activin is inhibitory, and inhibin stimulates thecal androgen production (Hsueh et al.
1987, Hillier et al. 1991a, Hillier et al. 1991b). During tertiary follicle development
in the rat, activin predominates over inhibin and promotes FSH stimulated granulosa
cell proliferation and steroidogenic differentiation (Miro and Hillier 1996). As the
dominant follicle matures, both inhibin and the activin-binding follistatin are
produced in relatively larger amounts compared to activin (Nakatani et al. 1991).
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This leads to the stimulatory action of inhibin on the thecal androgen synthesis
increasing as the follicle develops and starts to produce increasing amounts of
oestradiol in the process of follicle selection and dominance.
1.7 Follicular atresia
Follicular atresia is evident at every stage of folliculogenesis, as the majority of
follicles in the ovary will become atretic and never reach ovulation (Gougeon 1986).
In the ovary there are a number of specific regulators affecting apoptosis, reviewed
by Markstrom et al (2002). Once the 'decision' to enter follicular atresia has been
made, the execution of apoptotic cell death requires the coordinated activation of
several cellular sub-programmes (Hengartner 2000). Two main regulatory families
of genes required for apoptosis are the caspases and the Bcl-2 family (Hengartner
2000). Follicular atresia is a stage-dependent process, with different factors effecting
a follicle's decision to die at different stages of follicular development (Markstrom et
al. 2002). The main physiological regulators of ovarian follicle survival are the
gonadotrophins (Markstrom et al. 2002), but there are many other factors regulating
follicular atresia, summarised in Figure 1.3.
1.7.1 Primordial follicle atresia
Follicular apoptosis in primordial follicles is most probably oocyte regulated
(Markstrom et al. 2002). Oocyte apoptosis in rodent speciese has been reviewed by
(Morita and Tilly 1999) and (Reynaud and Driancourt 2000). The importance of kit-
ligand interactions in the survival of primordial follicles in the mouse model has
been highlighted (Driancourt et al. 2000), and growth differentiation factor 9 (GDF-
9) has also been shown to play a major role in primordial follicle survival, as mice
lacking GDF-9 do not develop follicles beyond the primary or early secondary stage
of development (Dong et al. 1996)
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Figure 1.3 Factors regulating stage dependent survival in the ovarian follicle.
Gonadotrophins (Red), locally produced survival factors (Blue) and intracellular
mediators (Green). The data is an amalgamation from studies in a number of
species. Jagged ends indicate studies have not been published regarding earlier or
later stages of folliculogenesis. BFGF: basic fibroblast growth factor; EGF:
epidermal growth factor; GF1: growth hormone; IGF-1: insulin-like growth factor;
IL-1 (3: interleukin 1|3; KGF: keratinocyte growth factor; NO: nitric oxide; P4:
progesterone; PR: progesterone receptor. Adapted from Markstrom et al (2002).
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1.7.2 Preantral follicle atresia
Little is known about follicle survival at this stage of development. FSH stimulation
of cultured rat preantral follicles does not effect rescue from apoptosis, although
follicles are sensitive to FSH at this stage (Dunkel et al. 1994, Rannikki et al. 1995),
and both FSH and LH play important roles in preantral follicle development (McGee
et al. 1997b). From these findings it is suggested that the gonadotrophins do not
only act directly on preantral follicles, but also have effects transduced by follicles at
a later stage of development (Markstrom et al. 2002). Keratinocyte growth factor
(KGF) is produced in the theca cells of preantral follicles and its receptors are found
in granulosa cells. KGF suppresses apoptosis and promotes cellular growth and
differentiation in preantral follicles (McGee et al. 1999). Cyclic guanosine
monophosphate (cGMP) acts as an intracellular mediator for survival of preantral
follicles (Chun et al. 1996, McGee et al. 1997a), and treatment of preantral follicles
with cGMP reduces apoptosis (McGee et al. 1997a). AMH, mentioned earlier as a
suppressor of primordial follicle recruitment, also promotes growth, but not cellular
differentiation of preantral follicles (McGee et al. 2001) and decreases follicle
sensitivity to FSH stimulation (Durlinger et al. 2002b).
1.7.3 Tertiary follicle atresia
Tertiary follicles are dependent upon stimulation by FSH for their survival. A
majority of the developing follicles that reach this stage of development enter atresia
due to lack of FSH support (Hirshfield and Midgley 1978, Hirshfield 1991). In
isolated rat tertiary follicles, FSH is the most crucial follicle survival factor (Chun et
al. 1996), suppressing apoptosis by up to 60%. Locally produced factors such as
IGF-I (Chun et al. 1994, Chun et al. 1996), epidermal growth factor (EGF), and
bFGF (Tilly et al. 1992a, Chun et al. 1996) have all been implicated in their ability
to rescue tertiary follicles from apoptosis to varying extents.
1.7.4 Preovulatory follicle atresia
By the preovulatory stage of follicular development, both FSH and LH play a critical
role in suppressing apoptosis in isolated preovulatory rat follicles (Braw and Tsafriri
1980, Chun et al. 1994). Interestingly, both EGF and bFGF have been shown to be
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equally as effective as the gonadotrophins in suppressing apoptosis in cultured
granulosa cells from preovulatory follicle (Tilly et al. 1992a). IGF-I has been shown
to be a survival factor for cultured preovulatory rat follicles (Chun et al. 1994),
exerting its effect on the granulosa cells through paracrine signalling from the theca
(Tilly et al. 1992b).
1.7.5 Periovulatory follicle atresia
Follicles at this stage of development are dependent upon the LH surge. Inhibition
of the LFI surge at this stage causes such follicles to degenerate (Talbert et al. 1951,
Braw and Tsafriri 1980). After the LH surge, periovulatory follicles are less
susceptible to atresia (Svensson et al. 2000). Expression of the nuclear progesterone
receptor is induced shortly after the LH surge in both rat and human granulosa cells.
Progesterone has been demonstrated to play an important role in the periovulatory
follicle, as mice lacking progesterone receptors are anovulatory (Lydon et al. 1995,
Lydon et al. 1996, Svensson et al. 1999, Makrigiannakis et al. 2000) and treatment
ofwomen with anti-progestins such as RU486 block ovulation (Ledger et al. 1992).
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1.8 Follicular vascularisation
The smallest early growing follicles do not have an independent blood supply and
are essentially devoid of a capillary network. Once a number of granulosa cell layers
have formed and the thecal layer has been established, the follicle will start to recruit
a vascular supply of its own that will continue to develop throughout follicular
growth (Reynolds et al. 1992, Suzuki et al. 1998). The follicular vasculature is
thought to be required for the delivery of steroid hormone precursors, oxygen, and
nutrients to the developing follicle, and it has been hypothesised that adequate
vasculature is a key factor influencing the selection of the dominant follicle that will
continue developing and eventually ovulate (Zeleznik et al. 1981, Augustin 2000).
Follicular angiogenesis is discussed in more detail later in this chapter.
Vascular cells in different organs acquire specialised characteristics that allow
these cells to optimally perform specific functions in each organ (Ruoslahti and
Rajotte 2000). For example, endothelial cells in the brain are tightly linked to each
other, and are surrounded by numerous pericytes that form a barrier to protect the
brain cells from potentially toxic blood-derived molecules. In contrast, vessels in
endocrine glands, i.e. the ovarian follicle, are leaky and their endothelial cells have
fenestrations, allowing hormone trafficking (Carmeliet 2004).
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1.9 Angiogenesis
1.9.1 History of angiogenesis
Blood vessels were recognised thousands of years ago by the Egyptians. Their
physicians recognised that 'there were vessels in him for every part of the body,
which were hollow, having a mouth which opens to absorb medications and
eliminate waste elements' (Carmeliet 2004). More recently, in 1896, J.G. Clark
started to study 'ovarian circulation', he drew detailed illustrations of vasculature
development in ovaries from newborn to post menopausal women (Clark 1900) and
with that began the field of ovarian vascular biology. By the 1930s, vascular biology
had advanced to observing blood vessels at sites of surgical insult. E.R. and E.L.
Clark would insert glass-windowed chambers into the ears of rabbits and make
exceptionally detailed drawings of the branched blood vessel networks they observed
at the wound site (Clark and Clark 1932). Newly formed blood vessel infiltration
was also observed in rabbit tumours using similar techniques (Ide et al. 1939). The
first demonstration that tumours actively attract new blood vessels was carried out in
mouse tumours, when blood vessels were observed migrating toward tumours using
wound chambers adapted from the rabbit for use in the mouse (Algire 1943a, Algire
1943b, Algire et al. 1945).
The process of vascular development takes place by angiogenesis, which is
defined as the growth of new blood vessels by proliferation and migration of pre¬
existing vessels. Angiogenic activity was first described by studies on retinopathic
vessel growth (Michelson 1948). An unknown factor was thought to mediate
abnormal blood vessel growth in the eye. It was not until 20 years later that it was
demonstrated that tumours release diffusible factors that attract new blood vessels to
the tumour site (Ehrmann and Knoth 1968, Greenblatt and Shubi 1968).
In 1971, Judah Folkman and collaborators presented an experimental protocol
to isolate a fraction of ascites fluid that stimulated blood vessel growth (Folkman et
al. 1971). This discovery was pivotal in the field of cancer research. Later that year,
Folkman went on to write the first review of tumour angiogenesis, which literally
defined the birth of this field of scientific research. It was the first suggestion that
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angiogenic inhibitors could be used to treat cancer and other angiogenic dependent
diseases such as diabetic retinopathy (Folkman 1971). Although viewed with some
disbelief and scepticism at the time, Folkman's early work is now viewed as a
seminal step in the field of angiogenesis.
In 1972, the first paper to go beyond circumstantial evidence and show that the
progressive growth of a tumour can indeed be completely dependent on angiogenesis
was published. Experiments using small clusters of tumour cells suspended in
different parts of the eye demonstrated that tumours only grow when they are able to
attract vessels from pre-existing vasculature (Gimbrone et al. 1972).
1.9.2 Physiological angiogenesis
The maxim "blood vessels grow where they are needed" still holds true today, as the
molecular regulation of angiogenesis is increasingly understood (Augustin 2000).
Vasculogenesis and angiogenesis occur primarily during embryonic and foetal
development. The development of a vascular network is essential for organ
development and differentiation during embryogenesis and neonatal growth. In the
healthy adult, angiogenesis is primarily down-regulated as there is very little
physiological growth and tissue remodelling, apart from during wound healing and
during the female reproductive cycle in both the ovaries and uterus.
Angiogenesis is a pivotal event in the endochondral ossification (bone
formation) of the longitudinal bones during vertebrate development (Poole 1991).
The long bones of the limbs are laid down by cartilaginous elements, which then
become ossified. This process requires the precise coupling of cartilage production
and bone formation. Cartilage is usually an avascular tissue, apart from when
capillaries invade the growth plate to convert cartilage into bone. Blood vessels
grow into the hypertrophic cartilage and erode it to produce a scaffold on which
osteoblasts settle to produce woven bone (Alini et al. 1996). Alini et al discovered
that hypertrophic cartilage secretes an angiogenic factor (Alini et al. 1996). Other
angiogenic factors have also been localised to the cartilage growth plate, including
members of the FGF family (Baron et al. 1994), and members of the TGF-|3 family
(Jingushi et al. 1995). VEGF, produced by the hypertrophic chondrocytes in the
cartilage, has also been shown to be required for this process, as inactivation of
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VEGF during this process leads to a complete disruption of the normal vascular
pattern of the growth plate (Gerber et al. 1999b).
VEGF-mediated angiogenesis is also a critical rate limiting step in determining
organ size and function. Inhibition of VEGF in neonatal mice causes abnormal liver
development, severe renal failure and tissue hypoxia (Gerber et al. 1999a). These
effects of VEGF inhibition are only evident during neonatal life, and not in the fully
developed adult. Angiogenesis is a rare event in the healthy adult, apart from
pathological angiogenesis observed during wound healing. However, the female
reproductive system undergoes serial angiogenesis and vessel regression during the
reproductive cycle. In the ovary, angiogenesis occurs during both follicular
development and the establishment of the corpus luteum. This review focuses on
follicular vascularisation.
1.9.3 Follicular angiogenesis
Dormant primordial, small primary and early secondary follicles do not have a
vascular supply of their own and have to rely on vessels in the surrounding stroma
for their supply of nutrients and oxygen. As the recruited follicles develop, they start
to acquire their own vascular network. This network consists of two concentric
vascular sheaths, located in the theca interna and theca externa of the follicle. The
arterioles and venules of the outer vascular network send tiny branches into the theca
interna to form the inner capillary plexus, which consists of a single layer of
endothelial cells. These endothelial cells are immediately outside of the membrana
propria (basement membrane) that separates the granulosa and theca cells. This
vascular network continues to undergo angiogenesis throughout folliculogenesis, but
does not penetrate the granulosa cells of the follicle until after ovulation (Findlay
1986, Reynolds et al. 1992, Gordon et al. 1995, Goede et al. 1998, Suzuki et al.
1998, Augustin 2000). This vasculature is not evenly distributed between the
different classes of ovarian follicle (Hazzard and Stouffer 2000). Colour Doppler
studies have shown that there is a positive correlation between the development of
ovarian follicles and their blood flow (Campbell et al. 1993, Balakier and Stronell
1994). By the time a follicle reaches the preovulatory stage of development it will
have become highly vascularised with blood vessels approximately 2 times larger
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than in other follicles (DiZerega et al. 1980, Zeleznik et al. 1981). It has also been
hypothesised that it is the establishment of an adequate vasculature that is a key
factor influencing the selection of a dominant follicle, which will continue
developing and eventually ovulate (Zeleznik et al. 1981, Augustin 2000).
The principal angiogenic factor with an established role in follicular
angiogenesis is VEGF. VEGF mRNA and protein have been localised (in the ovary)
to the granulosa cells of the developing follicles, and in preovulatory follicles to the
theca (Phillips et al. 1990, Ravindranath et al. 1992, Shweiki et al. 1993). Inhibition
of VEGF in vivo has been shown to severely suppress both thecal vascularisation and
follicle development in the marmoset (Wulff et al. 2001b, Wulff et al. 2002), and to
inhibit the follicular phase of the cycle in macaques (Zimmermann et al. 2001b,
Zimmermann et al. 2002). VEGF is expressed in the granulosa and theca cells of
follicles as they mature, and is concurrent with the acquisition of steroidogenic
activity, suggesting that the expression is hormonally regulated (Shweiki et al. 1993).
It has been demonstrated that VEGF expression in granulosa cells from preovulatory
follicles is up regulated by FSH stimulation in vitro (Christenson and Stouffer 1997,
Hazzard et al. 1999). LH also induces VEGF mRNA expression in both cultured
bovine and primate granulosa cells (Garrido et al. 1993, Hazzard et al. 1999).
Forskolin, a potent activator of adenylate cyclase, also induces VEGF mRNA
expression in cultured bovine granulosa cells (Garrido et al. 1993).
1.9.4 Pathological angiogenesis
As already mentioned, angiogenesis is a relatively rare event in the healthy adult.
However, excessive capillary growth is associated with various pathological
conditions including: tumour growth; psoriasis; retinopathies; and rheumatoid
arthritis (Reynolds et al. 1992, Moretti et al. 1999, Folkman 2001, Kerbel and
Folkman 2002). The female reproductive organs are one of the only sites in the adult
to undergo serial angiogenesis followed by vessel regression and degradation, and it
is therefore not surprising that there are also many pathological conditions associated
with the miss-regulation of angiogenesis in the female reproductive tract. These
include: polycystic ovary syndrome (PCOS); ovarian hyperstimulation syndrome
(OHSS); benign ovarian neoplasms; and menorrhagia (Smith 1998, Geva and Jaffe
Chapter 1 Introduction 26
2000, Livingstone and Fraser 2002).
PCOS affects approximately 5% of women of reproductive age (Franks 1995,
Knochenhauer et al. 1998, Legro and Strauss 2003, Azziz et al. 2004). In women
with PCOS, increased serum concentrations of VEGF are found during in vitro
fertilisation treatment, and Doppler blood flow velocities within the ovarian stromal
vessels are also increased in parallel with the rising levels of VEGF (Agrawal et al.
1998a, Agrawal et al. 1998b). OHSS can be a life-threatening complication of
ovulation induction using gonadotrophins and ovarian steroid hormones. Because
certain steroids are known to stimulate angiogenesis, i.e. stimulation of VEGF
expression (Folkman and Ingber 1987), administration of hCG can lead to excessive
vascular permeability via stimulation of VEGF production in the hCG responsive
granulosa cells (Neulen et al. 1995). These techniques of ovulation induction can
lead to high levels of VEGF expression in follicles that result in vascular leakage.
This leakage can, in turn, lead to extravasation of fluid out of the intravascular space,
accounting for virtually all of the manifestations of OHSS (Golan et al. 1989).
Immunohistochemical studies on ovaries from postmenopausal women have revealed
VEGF staining in epithelial inclusion cysts and in serous cystadenomas. The VEGF
protein has been observed in the epithelial layers of the cysts (Gordon et al. 1996),
suggesting that VEGF in benign serous neoplasms may be responsible for fluid
accumulation. Moreover, if epithelial ovarian cancer originates within epithelial
inclusion cysts (Perez et al. 1991), VEGF within these cysts may represent a means
by which a developing neoplasm is able to induce the formation of an increased
vascular supply (Gordon et al. 1996).
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1.10The angiogenic process
Angiogenesis in vivo is a complex process involving the degradation of the capillary
basement membrane, the migration and proliferation of endothelial cells, and tube
formation. Mature blood vessels comprise lining endothelial cells and one or more
enveloping layers of supporting cells. In arteries and veins, these cells are smooth
muscle cells; in capillaries and venules they are termed pericytes (Rhodin 1968).
Angiogenesis is the remodelling of the existing vasculature through both pruning and
vessel enlargement and can be divided into at least three steps (Folkman and
Klagsbrun 1987).
1)Breakdown of the basement membrane of the existing blood vessel
2)Migration of the endothelial cells toward an angiogenic stimulus
3)Establishment and stabilisation ofblood vessels
Angiogenesis initiates with vasodilatation. Vascular permeability increases in
response to VEGF and is mediated by the formation of fenestrations, vesiculo-
vacuolar organelles and the redistribution of platelet endothelial cell adhesion
molecules (PECAM-1/CD31), and vascular endothelial (VE)-cadherin (Eliceiri et al.
1999). This dilation of the blood vessels may serve to loosen inter-endothelial cell
contacts and render them more responsive to growth factors. As pericytes are
thought to limit the rate of endothelial cell proliferation in both vascular pruning and
remodelling (Orlidge and D'Amore 1987, Benjamin et al. 1998, Sundberg et al.
2001), endothelial cell migration must involve dissociation of the endothelial cells
from their periendothelial cell support. However, pericytes also appear to aid the
earliest stages of capillary sprouting. Pericytes are found lying at and in front of the
advancing tips of endothelial sprouts and, at many sites, pericytes can be observed
bridging the gap between the leading edges of opposing endothelial sprouts, which
are apparently preparing to merge. This suggests that pericytes may serve as guiding
structures aiding the outgrowth of endothelial cells (Nehls et al. 1992).
Extracellular matrix components also play an important role in angiogenesis by
serving as a reservoir of growth factors (Hood and Cheresh 2002, Hynes 2002).
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Proteinases of the plasminogen activator, MMP, chymase and heparinise families aid
angiogenesis by breaking down the extracellular matrix and, in doing so, activate or
liberate many angiogenic growth factors that are sequestered within the extracellular
matrix (Coussens et al. 1999, Carmeliet 2000). This proteolytic degradation of the
extracellular matrix must, however, be tightly controlled, as excessive breakdown
can remove critical support and guidance cues for migrating endothelial cells and can
have a deleterious effect on angiogenesis (Carmeliet 2004). Once the extracellular
matrix has been degraded, endothelial cell proliferation and migration can begin.
Endothelial cells of resting, established, vasculature are generally quiescent.
However, endothelial cell proliferation forms the major component of capillary
growth. Proliferating endothelial cells respond to a mitogenic stimulus by migration,
during which time their morphology is more elongated than usual (Ingber and
Folkman 1989). The majority of proliferation occurs in the endothelial cells behind
the tip of the growing capillary, the tip usually remaining quiescent (Klagsbrun and
D'Amore 1991). VEGF and its receptor VEGF receptor 2 (VEGFR2) are thought to
mediate much of the endothelial cell proliferation and migration during angiogenesis,
as VEGF binding to VEGFR2 results in a chemotactic and pro-survival signal for the
endothelial cells on which it is expressed (Ferrara et al. 2003b).
The generation of new blood vessels is completed by their formation into
capillaries. Endothelial cells stop dividing and form tubes through curvature as they
start to adhere to each other. The recruitment of pericytes— from either pre-existing
microvessels or newly derived pericytes from fibroblasts — to cover the outer walls
of the newly formed vessels and thus to stabilise the new vasculature, is thought to
be controlled by the endothelial cells themselves through secretion of diffusible
factors (Crocker et al. 1970, Hirschi and D'Amore 1996, Goede et al. 1998, Hirschi
et al. 1999, Redmer et al. 2001). Among the diffusible factors secreted by the
endothelial cells are platelet derived growth factor (PDGF) and bFGF, both ofwhich
are thought to act in a paracrine fashion, stimulating mural cell proliferation and
migration towards the new capillaries (Montesano et al. 1986, Westermark et al.
1990). The process of pericyte recruitment is also thought to be relatively rapid, as
pericytes are evident around new blood vessels in the forming corpus luteum (Goede
et al. 1998, Wulff et al. 2001a). Blood flow in these new vessels begins slowly, as
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the new vessels remain highly permeable until a basement membrane surrounding
the endothelial cells is laid down and pericyte recruitment and stabilisation is
complete (Findlay 1986).
1.10.1 Measurement of angiogenesis
There is a long history of measuring tumour vascularity to provide prognostic
information and to study the effect of treatment on a tumour (West et al. 2001).
Intercapillary distances (ICD) have be used as an index of tumour oxygenation and
hence vascularisation, although these have recently been shown to only provide a
weak measure of the hypoxic state of the tissue (West et al. 2001). A more
commonly used histological assessment of tumor angiogenesis is measurement of
microvessel density (MVD) (Vermeulen et al. 1996), where the density of the blood
vessels in areas of neovascularisation is analysed.
Less invasive methods of measuring the extent of vascularisation and blood
flow in an organ are also available. Colour Doppler ultrasonography is a non¬
invasive technique for monitoring vascular function and degree of vascularisation of
an organ. The technique involves scanning the organ of interest with an ultrasound
scanner enabling the calculation of organ volume and rate of blood flow. This
technique has been used to study blood flow in both the preovulatory follicle
(Brannstrom et al. 1998, Acosta et al. 2003) and the corpus luteum (Miyazaki et al.
1998, Acosta et al. 2002). Recent advances in magnetic resonance imaging (MRI)
can now also be applied to the in vivo measurement of blood flow, blood volume,
vessel permeability and extracellular leakage (Padhani and Dzik-Jurasz 2004).
The quantification of vascularisation and angiogenesis in tissue sections using
immunocytochemical markers for the endothelium such, as CD31, has greatly
enhanced the study of angiogenesis. Expression of CD31, a 130-kDa glycoprotein
belonging to the immunoglobulin (Ig) superfamily of cell adhesion molecules
(Newman 1994), is restricted to cells of the vascular system platelets, monocytes,
neutrophils, selected T cells, and endothelial cells (Newman 1997), and is commonly
used as an endothelial specific marker (Ilan et al. 2000). It is the extracellular Ig
domain of CD31 that contains specialised sites that mediate trans-homophilic
interactions between CD31 molecules on adjacent cells (Sun et al. 1996). CD31
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knockout mice have been noted to suffer from prolonged bleeding times after
surgical insult, which is at least in part due to disrupted endothelial-platelet
interactions (Mahooti et al. 2000). In addition to CD31's role in endothelial cell
adhesion, there is growing evidence that CD31 is able to transduce signals that
suppress endothelial cell apoptosis (Noble et al. 1999, Newman and Newman 2003).
Co-localisation of CD31 and a proliferating cell marker, such as BrdU or Ki67, has
also allowed for the quantification of active endothelial cell proliferation in a fixed
tissue (Wulff et al 2001b, Wulff et al. 2002).
There are also several bioassays that have been developed to measure
angiogenesis. The most common ones are endothelial cell migration and
proliferation in vitro (Folkman et al. 1979, Glaser et al. 1980), and capillary growth
in the developing chick chorioallantoic membrane (CAM) or cornea in vivo
(Ausprunk et al. 1974, Gimbrone et al. 1974). The CAM is an extra-embryonic
membrane that serves as a gas exchange surface with its respiratory function
provided by an extensive capillary network (Ausprunk et al. 1974). Because of its
extensive vascularisation the CAM has been used as an in vivo model for the
evaluation of both angiogenic and anti-angiogenic molecules (Ribatti et al. 1996,
Ribatti et al. 2000, Ribatti et al. 2001), Figure 1.4.
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Figure 1.4 Image analysis of CAM vascularisation.
Vascularisation of CAM after incubation with (A) a pro-angiogenic agent, fibroblast
growth factor-2 (FGF-2) and (B) an angiostatic molecule, TNP 470. Numerous
vessels develop radially towards the gelatin sponge (*) soaked with FGF-2 in a
spoked-wheel pattern. Where as very few vessels are recognizable around the
sponge (*) treated with TNP-470. Adapted from (Ribatti et al. 2001)
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1.10.2 Angiogenic promoters
A large number of growth factors have been implicated in the positive regulation of
angiogenesis, aFGF, bFGF, TGF-a, TGF-|3, hepatocyte growth factor (HGF), tumour
necrosis factor-a (TNF-a), interleukin-8 (1L-8) and the angiopoietins (Ang-1 and
Ang-2) have all been shown to be involved (Folkman and Shing 1992, Yancopoulos
et al. 2000). However, of the multitude of growth factors that regulate physiological
and pathological angiogenesis, VEGF is believed to be the most important (Ferrara
2004).
1.10.2.1 VEGF
VEGF is a pro-angiogenic molecule that has been implicated in various steps in the
angiogenic process. It is known also as vascular permeability factor (VPF) on the
basis of its ability to induce vascular leakage (Senger et al. 1983, Dvorak et al.
1995), and has been found to induce fenestrations in endothelial cells of small
venules and capillaries (Roberts and Palade 1995). VEGF is also the only
angiogenic peptide that is mitogenic specifically for vascular endothelial cells.
VEGF was first discovered in 1983 by Senger et al. (Senger et al. 1983) when they
described the partial purification of a protein from the conditioned medium of a
guinea-pig tumor cell line. The protein was able to induce vascular leakage in the
skin and was thus named vascular permeability factor. However, in 1989 a separate
group reported the isolation of a diffusible endothelial-cell specific mitogen from
medium conditioned by bovine pituitary follicular cells, which they named vascular
endothelial growth factor, to reflect the target cell specificity of this molecule
(Ferrara and Henzel 1989). Sequencing of purified VEGF proved that this protein
was distinct from the known endothelial cell mitogens such as aFGF or bFGF
(Ferrara and Henzel 1989) and cloning of VEGF (Leung et al. 1989) and VPF (Keck
et al. 1989) cDNAs demonstrated that VEGF and VPF were in fact the same
molecule. The finding that VEGF is potent, diffusible, and specific for vascular
endothelial cells led to the hypothesis that this molecule might play a role in the
regulation of physiological and pathological growth of blood vessels (Ferrara and
Henzel 1989, Leung et al. 1989).
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VEGF is a member of the heparin-binding growth factor family (Leung et al.
1989). The VEGF family of molecules consists of six growth factors (VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor). VEGF-A
(from here on referred to as VEGF) has six isoforms generated as a result of
alternative splicing of the 8 exons of the VEGF gene: VEGF121, VEGF145, VEGF165,
VEGFi83, VEGFi89 and VEGF206 (Stimpfl et al. 2002). These splice variants are
illustrated in Figure 1.5. The domain encoded by exons 1-5 contains information
required for the recognition of the known VEGF receptors (Keyt et al. 1996), and is
present in all of the VEGF isoforms. The mRNA encoding VEGF165 and VEGF121
are dominant in normal human ovaries (Fujimoto et al. 1998, Otani et al. 1999). In
contrast, VEGF206 is a rare isoform, and has been described only in the human foetal
liver (Ferrara and Davis-Smyth 1997). VEGF-C and VEGF-D are involved in the
regulation of lymphatic angiogenesis (Karkkainen et al. 2002, Stacker et al. 2002).























Figure 1.5 The VEGF isoforms.
Model for alternative splicing of VEGF mRNA generating six VEGF variants.
Exons are represented by rectangles, introns by solid lines. Adapted from (Stimpfl et
al. 2002)
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VEGF mRNA expression and protein secretion is up regulated by a variety of
cytokines and growth factors. IGF-I induces VEGF mRNA and protein production
by both an increase in the transcriptional rate of the VEGF gene, and the stability of
mRNA (Warren et al. 1996). EGF, TGF-a and TGF-p, bFGF, interleukin (IL)-l and
IL-6 all up-regulate VEGF expression (Ferrara and Davis-Smyth 1997). VEGF
mRNA is also highly expressed through induction by hypoxia in vitro and in vivo via
hypoxia-inducing factor (HIF)-l signalling (Shweiki et al. 1992, Popovici et al.
1999), via elevated cyclic adenosine monophosphate (cAMP) concentration,
increased cAMP levels increasing VEGF mRNA expression (Takagi et al. 1996).
Both of the gonadotrophins FSH and LH primarily signal through cAMP post
receptor mechanisms, allowing them to stimulated VEGF expression (Garrido et al.
1993).
All members of the VEGF family bind to cell-surface receptors (VEGFRs) to
initiate a cellular response via activation of an intracellular tyrosine kinase domain.
The biological effects of VEGF are mediated by two main tyrosine kinase receptors,
VEGFR1 (Fit-1) and VEGFR2 (KDR/Flk-1), although other receptors such as
neuropilin-1 and -2 can also bind VEGF. A further tyrosine kinase receptor,
VEGFR3 (flt-4) also exists, but binds VEGF-C and VEGF-D and is more important
in the development of lymphatic vessels (Larrivee and Karsan 2000).
The signalling and biological properties of VEGFR1 and VEGFR2 are
strikingly different. They both have seven immunoglobulin (Ig)-like regions in the
extracellular domain, a single transmembrane region, and a consensus tyrosine
kinase sequence that is interrupted by a kinase-insert domain (Ferrara and Davis-
Smyth 1997). Both VEGFR1 and VEGFR2 bind VEGF with high affinity, although
VEGFR2 has a somewhat lower affinity than VEGFR1 (de Vries et al. 1992). Their
signal transduction properties, however, are very different. In transfected cells
expressing the VEGFR2 receptor, chemotaxis and mitogenic activity have been
found in response to VEGF. In contrast, transfected cells expressing VEGFR1 lack
such responses. VEGFR2 undergoes strong ligand-dependent tyrosine
phosphorylation in intact cells, while phosphorylation of VEGFR1 is weak
(Waltenberger et al. 1994). Therefore, interaction with VEGFR2 is a critical
requirement to induce the full spectrum of VEGF biological responses. Hence,
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VEGFR2 is thought to be the key receptor that triggers angiogenesis and vascular
permeability (Gille et al. 2001), with the role of VEGFR1 being less clear, but
possibly mediating cell migration and vascular permeability (Stacker et al. 1999,
Kanno et al. 2000) and also acting as a decoy receptor when in soluble form,
preventing VEGF binding to VEGFR2 (Park et al. 1994). Park et al were the first to
propose that VEGFR1 may not be the primarily VEGF receptor transmitting the
mitogenic signal, but rather a decoy receptor, able to regulate VEGF activity on the
endothelium in a negative way by sequestering VEGF and rendering it less available
to VEGFR2 (Park et al. 1994).
Much of our understanding of how VEGF and its receptors operate comes from
studies in the mouse. Mice with a homozygous mutation in the VEGFR1 locus die in
utero between days e8.5 and e9.5 (Fong et al. 1995). Further work on VEGFR1
knockout mice revealed a disorganised phenotype in the embryos, due to an increase
in the number of endothelial cell progenitors by altered cell fate determination (Fong
et al. 1999). Work on VEGF mutant mice showed that inactivation of one VEGF
allele is embryonic lethal between days el I and el2 (Carmeliet et al. 1996, Ferrara et
al. 1996). Blood island formation in these VEGF17" embryos was impaired and they
also displayed defects in formation of the nervous system. This VEGF4" phenotype
is due to gene dosage and not maternal imprinting, emphasising the critical need for
the precise regulation of VEGF expression during vasculogenesis and angiogenesis
(Carmeliet et al. 1996).
1.10.2.2 Angiopoietins
The angiopoietins and their receptors constitute another significant signalling system
involved in blood vessel maintenance, growth and stabilisation. The inter¬
relationship between VEGF and the Ang family of angiogenic regulators plays an
important role in angiogenesis. The angiopoietins consist of approximately 500
amino acids, and are ligands for only one of the Tie tyrosine kinase receptors, Tie-2.
Both Tie-1 and Tie-2 are selectively expressed within the vascular endothelium. Tie-
1, however, is an orphan tyrosine kinase receptor (Partanen et al. 1992), which
shares little identity, in it extracellular domains, with Tie-2 and thus does not bind
any of the angiopoietins (Kontos et al. 2002). There are four known angiopoietins,
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Angl-4, all ofwhich bind to Tie-2 (Valenzuela et al. 1999). Northern blot analyses
from adult human tissues has localised expression of the angiopoietins. Ang-1 is
widely expressed, although only in small amounts in the heart and liver. However,
Ang-2 expression is only readily detectable in ovary, placenta and uterus, the three
predominant sites of vascular remodelling in the healthy adult (Maisonpierre et al.
1997).
Ang-1 is known to both promote and inhibit angiogenesis, depending upon the
tissue in which it is expressed. It is primarily involved in the stabilisation of vessel
walls, tightening blood vessels via an effect on PECAM-1/CD31, VE-cadherin and
occludin (Chen et al. 1996, Lawson and Weinstein 2002), and acts as an angiogenic
inhibitor in this sense. However, it stimulates vessel growth in skin, ischaemic
limbs, gastric ulcers and some tumours (Shyu et al. 1998, Suri et al. 1998, Chae et al.
2000, Shim et al. 2002), presumably because of its role as an endothelial cell
survival factor. When acting in conjunction with VEGF, Ang-2 stimulates
angiogenesis by loosening endothelial cell interactions with their pericytic cells, and
aids the degradation of the extracellular matrix by up-regulating proteinase
expression, thus allowing the endothelial cells to migrate. However, without an
angiogenic signal acting on the destabilised endothelial cell, the action of Ang-2
causes vessel regression and endothelial cell death (Maisonpierre et al. 1997).
Hence, the balance between the expression of Ang-1 and Ang-2 competitively
binding Tie-2 needs to be finely tuned during angiogenesis. Mice over-expressing
Ang-2 in their blood vessels have shown that over-expression disrupts blood vessel
formation in the embryo. The embryos have a collapsed endocardium, vascular
abnormalities in and around the heart, and lack a regular dendritic capillary plexus in
the head, reminiscent of embryos lacking Tie-2 or Ang-1. Ang-2 is highly expressed
in the theca of the preovulatory follicle, and during formation of the corpus luteum, a
time at which high levels ofVEGF are also expressed, which promotes angiogenesis.
During luteal regression in both the human (Wulff et al. 2000) and in the macaque
(Hazzard et al. 2000) Ang-2 is again highly expressed where as VEGF is not, leading
to vessel destabilisation and endothelial cell death. In the rat, however, different
mechanisms appear to be involved in luteal vessel destabilisation and degradation as
Ang-2 mRNA is no longer detectable in the regressing CL (Wiegand et al. 2000).
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Figure 1.6 Factors influencing the angiogenic process.
Regulation of vascular morphogenesis, maintenance, and remodelling by the receptor
tyrosine kinases and their ligands. Adapted from Hanahan (1997).
1.10.2.3 Fibroblast growth factors
One of the most potent of the known angiogenic factors is bFGF (Klagsbrun and
D'Amore 1991), which was first purified by heparin-affinity chromatography in 1985
(Esch et al. 1985). FGF in vitro is mitogenic and chemotactic for endothelial cells,
stimulating them to produce collagenases and plasminogen activator proteases
capable of degrading the basement membrane. FGF also induces capillary
endothelial cells to migrate into three-dimensional collagen matrices and to form
capillary like tubes (Klagsbrun and D'Amore 1991). Both aFGF and bFGF are
angiogenic factors in the CAM and cornea assays (Klagsbrun and D'Amore 1991).
However, they are not only endothelial growth factors, but are also mitogenic for
vascular smooth muscle, fibroblasts, and for some epithelial cells. Endothelial cells
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synthesise large amounts of bFGF (Schweigerer et al. 1987), but bFGF is also
synthesised by many other cell types. Neither bFGF nor aFGF contains a consensus
signal peptide in the open reading frame, and are therefore cellular and not secreted
(Abraham et al. 1986, Vlodavsky et al. 1987). Although aFGF and bFGF are both
angiogenic mitogens, it is not clear how they mediate angiogenesis in vivo. Since
they are not secreted proteins, they must be released from cells by alternative
mechanisms, for example by displacement by heparin or cell lysis.
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1.11 Manipulation of angiogenesis
1.11.1 Development of anti-angiogenic agents
The application of angiogenesis inhibitors as anticancer agents is still in its early
stages, but over 25 drugs are currently under development in various stages of trials
(Kerbel and Folkman 2002). These drugs fall into several functional categories,
including inhibitors of: growth factors; endothelial cell signal transduction;
endothelial cell proliferation; matrix metalloproteinases; endothelial cell survival;
and bone marrow precursor cells (Hagedorn and Bikfalvi 2000, Kerbel 2001).
Whereas some agents, such as antibodies to VEGF and VEGFR2, continue to show
promise, a few drugs have proved disappointing. For example, matrix
metalloprotease inhibitors with anti-angiogenic activity have poor efficacy and also
exhibit side effects (Coussens et al. 2002). Naturally occurring inhibitors of
angiogenesis that are encrypted within larger proteins devoid of angiogenic activity
have been identified. Angiostatin, an internal fragment of plasminogen, is a potent
inhibitor of angiogenesis and selectively inhibits endothelial cell proliferation.
Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, specifically inhibits
endothelial proliferation and showed potential to inhibit angiogenesis and tumor
growth (O'Reilly 1997, O'Reilly et al. 1997). Despite generating much publicity at
the time, the potent anti-tumour activity of some of these proteins, such as endostatin
and angiostatin, has proved difficult to reproduce (Marshall 2002). Nevertheless,
there is still intense interest in angiogenesis inhibitors as future clinical tools and
much work is in progress (Kerbel and Folkman 2002, Novak 2002).
Ferrara and colleagues were the first to show that antibodies to VEGF slowed
tumour growth in the mouse model (Kim et al. 1993), and a variety of therapeutic
strategies aimed at blocking VEGF or its receptor signalling system are currently
being developed for the treatment of neoplastic diseases. VEGF/VEGFR blockade
by monoclonal antibodies and inhibition of receptor signalling by tyrosine kinase
inhibitors are to date the most studied approaches. VEGFR1 ribozymes, VEGF toxin
conjugates, and soluble VEGF receptors are also being investigated. Of these,
bevacizumab (rhuMAb VEGF, Avastin™, Genentech Inc, South San Francisco, CA,
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USA), a humanised monoclonal antibody directed at VEGF, is the most advanced in
clinical development, and has shown promising results in clinical trials (Ferrara
2004). In February of this year, the U.S. Food and Drug Administration (FDA)
approved Avastin™ to be used in combination with chemotherapy as a treatment for
patients with first-line or previously untreated metastatic cancer of the colon or
rectum. Although in August, the FDA and Genentech issued an important warning
that there is evidence of an increased risk of serious arterial thromboembolic events,
including cerebrovascular accident, myocardial infarctions, transient ischemic
attacks, and angina related to Avastin™ use.
1.11.2 Vascular targeting
The concept of vascular targeting is related to anti-angiogenesis but involves a
different approach. Rather than inhibiting the formation of new vessels, drugs are
aimed at destroying the existing vasculature, with consequent tumour regression. A
fundamental principle of this approach is that tumour vasculature is different from
that in normal tissues, and much evidence exists to support this (Ruoslahti 2002).
For example, the vasculature is exposed to inflammatory cytokines released by
tumour cells and also hypoxic conditions (Helmlinger et al. 1997). Targeting tumour
vasculature with toxic drugs as an effective anti-tumour strategy was proved when an
anti-major histocompatibility complex class II antibody, coupled to ricin toxin, was
used to destroy tumour vasculature in experimental mice models (Burrows and
Thorpe 1993). They showed that this approach could be used to specifically
eradicate large solid tumours in vivo. The largest stumbling block to further progress
in this field has been the failure to identify candidate targets in human tumour
endothelium. However, two recent advances have led to a resurgence of interest in
vascular targeting: the development of novel, low-molecular-weight drugs that are
selectively toxic to tumour vasculature; and the advances in bioinformatics that have
enabled the analysis and identification of novel targets. For example, the discovery
of three novel tumour endothelial marker (TEM1, 5, 8) genes that display elevated
expression during tumor angiogenesis (Carson-Walter et al. 2001), and magic
roundabout (robo4) (Huminiecki et al. 2002), an endothelial-specific gene in
tumours, are both of considerable interest. Magic roundabout is present on the cell
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surface and is therefore ideal for targeting. Moreover, it appears to be a
developmental gene because it is not expressed in adult tissue and, as such, its
targeting should have no deleterious affects in the adult. Another such gene is
Delta4, which is also endothelial specific, and is only found on tumour endothelium
in the adult (Mailhos et al. 2001). The identification of a tumour-homing peptide
that specifically targets tumour lymphatic vessels (Laakkonen et al. 2002) could also
target therapies to tumour lymphatics. It has been shown recently that active
immunisation against tumour endothelial markers (e.g. the VEGF receptors) (Li et al.
2002b, Niederman et al. 2002) can inhibit tumour growth and metastasis. It has long
been realised that, at the molecular level, angiogenesis is likely to be a complex
process that involves many players. Nevertheless, targeting key molecules, such as
VEGF and its receptor VEGFR2, and the rapid increase in endothelial-specific
markers in tumours that represent targets, confirms that research into angiogenesis
and the tumour vasculature is at an exciting stage (Bikfalvi and Bicknell 2002).
1.12Clinical relevance of follicular angiogenesis research
As discussed above, there is a great deal of research being conducted into the
regulation of tumour angiogenesis and techniques to either inhibit blood vessel
growth or indeed destroy specific vasculature altogether. The lessons learned from
these studies on the regulation of angiogenesis should be applied to the physiological
angiogenesis that occurs in the developing ovarian follicle. It is a tightly regulated
process that, if upset by a disturbance in the balance of angiogenic factors regulating
it, can lead to severe reproductive dysfunction. The parallel systems, such as VEGF
and its receptors, associated with both physiological and pathological angiogenesis
have long been appreciated. However, the endocrine mechanisms regulating
angiogenesis and in the ovarian follicle have received much less attention in the
literature. Understanding the specific mechanisms regulating follicular angiogenesis
may allow formulation of treatments for such reproductive disorders as PCOS and
OHSS.
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1.13Aims of this thesis
At the beginning of this project little was known about the effect of the inhibition of
the gonadotrophins or VEGF on angiogenesis in the primate ovarian follicle. The
angiogenic activity associated with follicular development in the marmoset and
methods for its quantification had already been established in earlier studies (Wulff
et al. 2001b, Wulff et al. 2002). The aims of this thesis were to increase the
understanding of control of primate follicular angiogenesis by comparing the effect
of inhibiting either the gonadotrophins or VEGF directly, and assessing the effect of
these inhibitions on follicular development and vascularisation in a primate model.
To assess the endocrine control of follicular angiogenesis, a GnRH antagonist was
used. This was done to analyse the effect of the inhibition of the gonadotrophins on
follicular angiogenesis. The hypothesis being that follicular angiogenesis would be
dependent upon both FSH and LH, and be severely inhibited by GnRFI antagonist
treatment. To extend this investigation, the availability of primary marmoset
granulosa cell cultures allowed the study of the sensitivity of both angiogenic and
steroidogenic gene expression in response to FSH stimulation in vitro. This was
done to investigate whether a different level of FSH stimulation is required for
activation of genes involved in regulating both follicular angiogenesis and follicular
steroid hormone synthesis. Secondly, the effect of inhibition of angiogenesis directly
was studied by using VEGF trap, a soluble form of the VEGF receptors that is able
to sequester VEGF protein and block its action in vivo. The hypothesis being that
VEGF is essential for increasing permeability and growth of the selected follicles
and that inhibition of VEGF would have serious effects on follicular angiogenesis,
follicular development, ovulation and the establishment of the corpus luteum.
Finally, during this project, the discovery of a novel endocrine gland specific
angiogenic mitogen stimulated the search for this gene in both the marmoset monkey
and the human. The hypothesis being that endocrine gland vascular endothelial
growth factor (EG-VEGF) is an additional angiogenic factor regulating blood vessel
development and maintenance in the primate ovary.
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2.1 Source of reagents
Unless otherwise stated all reagents were supplied by Sigma-Aldrich Company Ltd
(Poole, Dorset, UK).
2.2 Experimental model
The marmoset monkey (Callithrix jacchus) was chosen for this in vivo exploration of
follicular angiogenesis. No one primate model is ideal for investigations pertaining
to the human, but marmosets offer several distinct advantages over other non-primate
models (Fraser and Lunn 1999). Some of the key advantages of the common
marmoset for use in reproductive research are: ease of handling; high fecundity;
absence of post-partum acyclicity related to lactation; and quick sexual maturation
(Torii et al. 1996). Also, the ability to induce luteolysis and synchronise the ovarian
cycle precisely by prostaglandin injection makes the marmoset a very powerful
model in which to study precise stages in the ovarian cycle (Summers et al. 1985,
Duncan et al. 1998, Gilchrist et al. 2001).
2.2.1 Marmoset husbandry
All marmosets were housed in the R. V. Short Building, Bush Estate, Edinburgh.
Staff at the centre were responsible for the care and maintenance of the animals.
Common marmoset monkeys were housed in rooms kept at between 20°C and 25°C,
which were artificially lit between the hours of 07:00 and 19:00. The animals were
housed in cages measuring 1.15m x 1.1m x 0.6m. The cages contained larch
branches and a nest box, and the floor was filled with wood chippings to allow
foraging.
The animals were fed daily with a selection of fruit and SDS Mazuri (E)
primate diet pellets. In addition, they were given high protein porridge with
multivitamin supplements three times per week. Water was continuously available.
Adult females with a body weight of approximately 350g, and who had regular
ovarian cycles, were housed together with a younger sister or prepubertal female,
unless otherwise stated. Blood samples were collected three times per week by
femoral venepuncture without anaesthesia, while the animals were held in a
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restraining device (Hearn et al. 1978). Syringes were sealed and centrifuged for 20
mins at 1000 x g; plasma was then removed and stored at -20°C until required.
2.2.2 The Marmoset ovarian cycle
In marmosets the ovarian cycle starts at approximately 14 to 18 months of age
(McAnulty 1994). The ovarian cycle lasts for approximately 28 days, typically with
two or three ovulations per cycle (Harding et al. 1982, Hearn 1983). The follicular
phase lasts for 8 or 9 days with a luteal phase of 20 days (Harding et al. 1982). In
most cycles, 2 or 3 dominant follicles grow at similar rates with ovulation occurring
at up to 12-hour intervals (Torii et al. 1996).
2.2.3 Synchronisation of follicular development
Induction of luteolysis by administration of PGF2a was used to synchronise follicular
development in the marmoset (Gilchrist et al. 2001). To synchronise the stage of the
ovarian cycle, all control and experimental animals were given 1 pg PGF2a analogue
(cloprostenol, Planate, Coopers Animal Health Ltd., Crewe, UK) intramuscularly
between days 12-16 of the luteal phase of the pre-treatment cycle to induce
luteolysis: this marks day zero of the follicular phase. It has been demonstrated that
after PGF2a induced luteolysis, an average of 10.7 days is required for growth of the
dominant follicle to the preovulatory stage (Summers et al. 1985). PGF2a
administration is also a commonly-used tool in the investigation of marmoset luteal
regression (Summers et al. 1985, Webley et al. 1989, Michael and Webley 1993,
Fraser et al. 1995a, Duncan et al. 1998, Fraser et al. 1999b).
2.2.4 Treatment regimes
Ovaries were collected throughout the follicular phase and into the early luteal phase
of the cycle. The basic principle of the experiments was to prevent follicular
angiogenesis by administering either a GnRH antagonist, Antarelix [N-Ac-D-Nal',D-
pCl-Phe2,D-Pal3,D-(Hci)6,Lys(iPr)8,D-Ala10]GnRH (Europeptides, Argenteuil,
France) (Deghenghi et al. 1993), or the VEGF trap R1R2 (Regeneron
Pharmaceuticals, Tarrytown, NY, USA) (Holash et al. 2002) during either the early-
or the mid-follicular phase of the treatment cycle. An explanation of the nature of
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the VEGF trap can be found in Chapter 5. Details of dose, timing and duration of
treatment can be found in the relevant experimental chapters. Staff at the primate
centre undertook administration of treatments. All experiments were carried out in
accordance with the Animals Scientific Procedures Act 1986, and were approved by
the local ethical review committee.
2.2.5 Classification of follicle stage
Stages of follicular development were classified as follows: primordial (oocyte
surrounded by a single flat layer of follicle epithelial cells); primary (single layer of
cuboidal granulosa cells surrounding an oocyte); early secondary (two to four
granulosa cell layers surrounding an oocyte); late secondary (more than four
granulosa cell layers surrounding an oocyte, no antrum formation); tertiary (follicles
containing an antrum, less than 2000pm in diameter); and dominant (follicles with a
diameter greater than 2000pm). Healthy follicles were classified as having a
normally shaped oocyte and no sign of pycnosis in the granulosa cells. Atretic
follicles were classified as having pycnotic granulosa cells, the first morphological
sign of follicular atresia (Durlinger et al. 2000).
2.2.6 Criteria for follicle analysis
To allow for analysis of follicle populations in the ovaries certain criteria was
established for counting follicles. Every 40th ovarian section was stained with
haematoxilin and eosin (2.6) for analysis. Only follicles with a normal shaped
oocyte surrounded by granulosa cells that were regularly opposed on an intact
basement membrane and did not show any signs of pycnosis were classified as health
and included in analysis. Only follicles with a visible oocyte where included in the
analysis to insure that the same follicle was not included in the analysis twice.
2.2.7 Classification of cycle stage
For a number of cycles before the animals were used, marmoset plasma was
collected three times per week to measure the concentration of plasma progesterone.
Such routine blood sampling has been shown not to disturb ovarian cyclicity or the
hypothalamic-pituitary-adrenal axis (Saltzman et al. 1994, Saltzman et al. 1997a,
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Saltzman et al. 1997b). Plasma was separated and frozen at -20°C. A plasma
progesterone reading of <30nmol/L was taken to indicate the follicular phase; when
the plasma progesterone rose above 30nmol/L and continued to rise, the luteal phase
was deemed to have begun.
2.3 Plasma progesterone plate assay
Ninety-six well plates were coated in DARS coating antibody, Rivanol purified
DARS (Donkey anti-rabbit serum, pH 9.6, SAPU, Scottish Antibody Production
unit, Carluke, Lanarkshire, UK) and left overnight at 4°C. Plates were then washed 5
times with washing solution (302g Tris, 450g NaCl and 25ml Tween 20 up to 2L
with H2O, pH 7.5) diluted 1:25 in water before use. Marmoset plasma samples were
thawed, vortexed and diluted. Plasma (2.5 pi) was added to 97.5pl of assay buffer
(17.85g Na2HPC>4, 7.75g citric acid, lg gelatin, O.lg thiomersalate in 1L deionised
H2O, pH 6). In each assay, a low, medium and high progesterone concentration
quality control (QC) was used. Samples and QCs were prepared in a similar way. A
standard curve was prepared from a serial dilution of progesterone standards diluted
in assay buffer to 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500 and 1000pg/50pl. Fifty
micro litres of each standard plus 2.5pl of charcoal stripped male marmoset plasma
was added to 47.5pl assay buffer. To determine maximum binding (BO), 2.5pl of
charcoal stripped male marmoset plasma was diluted in 97.5pl of buffer. All
samples, standard curve, BO and QC's were prepared in duplicate. Fifty micro litres
of primary antibody, rabbit anti-progesterone (SAPU), diluted 1:50,000 in assay
buffer were added to each well. In addition, to assess non-specific binding, charcoal
stripped male marmoset plasma — which does not contain progesterone — was
diluted in 147.5pl of assay buffer, and primary antibody omitted. Plates were
covered and left overnight at room temperature. After incubation overnight, 50ul per
well of labelled ligand (progesterone-11-glucuronide-biotin complex) diluted
1:20,000 in assay buffer was added with 2mg/ml ANSA (8-anilino-l naphthalene
sulphonic acid). Plates were then covered and left at room temperature for 3 h.
After the incubate was removed, the plates were washed 10 times before lOOpl of
Streptavidin-Horseradish peroxidase diluted 1:2000 with normal phosphate buffer
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(1% casein, pH7.4) was added to each well. After 1 h, the plates were again washed
10 times before 200pl per well of substrate OPD (5mM O-Phenylenediamine/0.03%
H2O2), dissolved in substrate buffer, (10.3g citric acid, 17.79g Na2HP04 dihydrate up
to 1L with deionised H2O, pH 5), was added. After 10-20 mins, the reaction was
stopped by adding 50pl of stopping solution (2N sulphuric acid) to each reaction.
Plates were read at 490nm on a spectrophotometer plate counter (VICTOR 1420
Multilabel Counter, Wallac, Turku, Finland). Inter assay coefficients of variation for
low, medium and high level quality controls were 11.6%, 7.0% and 12.6%
respectively. The detection limit of the assay was 4.6 nmol/L. Our in house assay
lab staff conducted this assay.
2.4 Plasma oestradiol radioimmuno assay
To extract the steroid hormones from the plasma samples and the QCs, plasma
samples and QCs were first thawed and vortexed. Tubes (10mm x 75mm) were set
up with lOpl of sample or QC (high, medium or low) as well as 40pl of distilled
water. Tubes were then vortexed and 2ml of Diethyl Ether was added to each tube.
Tubes were then vortexed for 10 mins on a multitube clamp vortex, after which they
were snap frozen in dry ice and methanol. The unfrozen fraction was then decanted
off and was left to evaporate in a fume hood overnight. After all of the Diethyl Ether
had evaporated, 200pl of 0.1M PGBS (pH 7.4, 11.46g Na2HP04, 2.61g
NaH2P04.2H20, 9.0g NaCl, l.Og Gelatin, O.lg thiomersalate to 1L deionised water)
was added to each tube, tubes were then vortexed and allowed to solvate for 30 mins.
A standard curve was prepared from oestradiol standards diluted in 0.1M PGBS to
0.06, 0.12, 0.24, 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250 and
500pg/100ql. One hundred microlitres of each standard and lOOpl of 0.1M PGBS
was added to fresh tubes. To determine non-specific binding (NSB) 300pl of 0.1M
PGBS was added to fresh tubes. To determine maximum binding (B0), 200pl of
0.1M PGBS was added to fresh tubes. To all tubes, except NSB's, lOOpl of
oestradiol MAIA kit antibody (Adaltis Italia Casalecchio di Reno. Italy), diluted 1:10
from kit stock was added. lOOpl ofMAIA tracer, diluted to 10-12,000cpm, was then
added to all tubes tube and incubated at room temperature for 3-4 h. After
incubation, lOOpl of diluted secondary antibody (1:1 ratio of 1:200 Normal Rabbit
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Serum, SAPU and 1:60 GARG, Valeant Pharmaceuticals International, Costa Mesa,
C.A., U.S.A.) was added to each tube and incubated overnight at 4°C. One millilitre
of 4%PEG/0.2%Triton in 0.9% Saline was then added and all tubes centrifuged at
1600 x g for 30min at 4°C. The supernatant was then poured off and the tubes left to
dry for one hour before being counted on a gamma counter (1261 multigamma,
Wallac). All samples, standards, B0 and QC's were prepared in duplicate. The
detection limit for the assay was 3.7 pmol/1. Inter assay coefficients of variation for
low, medium and high quality controls were 15.5%, 6.5% and 6.4% respectively.
Our in house assay lab staff conducted this assay. There is a caveat associated with
this assay in that the antibody used can cross react with oestrone and thus at low
levels there may be some cross reaction with oestrone which may distort the results
at low levels.
2.5 Collection and processing of tissue
2.5.1 Tissue collection
Animals were sedated with 200|ul ketamine hydrochloride (Park-Davis Veterinary,
Pontypool, UK) intramuscularly, euthanised with a 400pl intravenous injection of
Euthetal (sodium pentobarbitone, Rhone Merieux, Harlow, Essex, UK) and
exsanguinated with a needle and syringe. Ovaries were removed immediately,
weighed, and fixed in 4% NBF for 24 h before paraffin wax embedding.
2.5.2 Tissue fixation and processing.
Tissue fixation was needed to stop autolysis, putrefaction, bacterial attack and other
undesirable cellular changes. It also keeps the tissue in as close a state as possible to
its in vivo form. Ovaries were fixed in 4% neutral buffered formalin (NBF) for 24 h
and then transferred to a 70% alcohol (C2H5OH) solution until processed into
paraffin wax. Processing and paraffin wax embedding was carried out by the Unit
histology laboratory staff. Tissue was dehydrated through a series of graded alcohols
before saturation in paraffin wax. This process was carried out using a 17.5 h
automated cycle on a Leica TP-1050 processor (Leica UK Limited, Milton Keynes,
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UK). The tissue was then embedded onto plastic cassettes for sectioning.
2.5.3 Sectioning of paraffin blocks
All ovaries were serial sectioned at a thickness of 5 pm on to RNase free,
electrostatically charged slides (BDH, Merck Co, Inc, Poole, UK). Slides had to be
RNase free for in situ hybridisation and the electrostatic charging improved the
binding of the tissue to the slides. Sections were cut using a hand-operated
microtome (Leica) with disposable blades. Sections were floated onto diethyl
pyrocarbonate (DEPC) treated water (1ml per litre ultra pure water, autoclaved three
times) at 50°C, then transferred onto slides and dried overnight.
2.5.4 Dewaxing and rehydrating
Sections were dewaxed in two 5 min washes of xylene before being taken through
graded (100%, 90%, 70%) alcohols and finally taken into water.
2.6 Haematoxylin and eosin staining
Haematoxylin and Eosin (H&E) staining is used to visualise the tissue for
morphometric analysis. Haematoxylin is a purple nuclear stain, Eosin is a red
cytoplasmic stain. These stains were prepared by Histology staff. Harris's
haematoxylin is prepared by dissolving 2.5g of haematoxylin (BDH) in absolute
alcohol, which is added to alum previously dissolved in 500ml warm deionised
water. This solution was then boiled and either mercuric oxide (1.25g) or sodium
iodate (0.5g) carefully added. The stain was then rapidly cooled by plunging the
flask into a sink of cold water. Once cold, 20ml of glacial acetic acid was added.
Eosin Y was prepared by making a 1% solution in distilled water and adding 0.5%
volume for volume of acetic acid (Bancroft and Stevens 1996). Once dewaxed,
slides were stained in haematoxylin for 5 mins, washed in water, washed in acid
alcohol for 20 seconds, washed in water, washed in Scott's tap water for 30 seconds,
washed in water, stained in eosin for 20 seconds and finally washed in water.
2.7 Immunocytochemistry
Immunocytochemistry is a method used to localise a specific antigen within a cell or
Chapter 2 Materials and methods 52
on the surface of a cell using an antibody raised to an epitope of the protein of
interest. This is a powerful technique, as it allows an antigen to be localised to a
specific cell type and often a specific cellular location. The immunocytochemical
process involves building up layers of antibodies to increase the available binding
sites for the antibody and detection system applied. Quantification of
immunocytochemical staining is possible and is generally based on parameters such
as: number of positive cells in a population; the area of staining in a given tissue or
structure (in this case the ovarian follicle); or a combination of the two. The advent
of image analysis systems and software has increased the efficiency and accuracy of
quantification of such immuno-staining.
2.7.1 Antigens detected
2.7.1.1 Brdll (proliferating cells)
5-bromo-2-deoxyuridine also known as BrdU is a base analogue of thymidine, one of
the bases of the nucleic acid found in deoxyribonucleic acid (DNA). Since the 1970s
BrdU incorporation has been used as a tool for measuring DNA synthesis in cells and
tissues and is a common chemical used in the detection of proliferating cells
(Dolbeare 1995). BrdU injected into animals one hour prior to euthanasia will
incorporate into the DNA of cells replicating during the interval before euthanasia.
Newly synthesized DNA will (partly) incorporate BrdU instead of thymidine. The
incorporated BrdU can then be visualised by immunocytochemistry. Other
endogenous markers of cellular proliferation are available, such as proliferating cell
nuclear antigen (PCNA) and Ki67, although these are often thought of as 'soft'
markers, as their expression is rarely restricted to a specific cell cycle phase, owing
to time delays in synthesis and degradation (Rew and Wilson 2000).
2.7.1.2 CD31 (endothelial cells)
CD31 is a 130-kDa glycoprotein belonging to the Ig superfamily of cell adhesion
molecules and is commonly used as an endothelial specific marker (Ilan et al. 2000).
CD31 expression begins early in development at the stage of hemangioblast
formation and continues throughout adult life (Newman 1994, Newman 1997,
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Newman 1999). CD31 expression is restricted to cells of the vascular system
platelets, monocytes, neutrophils, selected T cells, and endothelial cells (Newman
1997, Newman 1999). CD31 knockout mice have been noted to suffer from
prolonged bleeding times after surgical insult. Which is at least in part due to
disrupted endothelial-platelet interactions (Mahooti et al. 2000). In addition to the
role of CD31 in endothelial cell adhesion, there is growing evidence that CD31 is
able to transduce signals that suppress endothelial cell apoptosis (Noble et al. 1999,
Newman and Newman 2003).
2.7.1.3 Caspase-3 (apoptotic cells)
Some of the other and more commonly used histological methods for the detection of
apoptosis is the detection of DNA fragments through terminal deoxynucleotidyl
transferase mediated dUTP nick end labelling (TUNEL) or in situ nick translation
(ISNT) techniques (Barrett et al. 2001). Both of these techniques, although useful,
involve issues of specificity and interpretation (Allen et al. 1997). The development
of antibodies specific to more generally distributed apoptotic markers such as the
cleaved form of caspase-3 are more applicable to the detection of apoptosis (Barrett
et al. 2001). The caspase family of proteins are regulators of the apoptotic process,
for review see (Thornberry and Lazebnik 1998). Caspase-3 is one of the
predominant caspases activated in apoptotic cells (Faleiro et al. 1997). A diagram of
caspase-3's position in the apoptotic cascade in ovarian granulosa cells is provided in
Figure 2.1.
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Figure 2.1 Overview of the apoptotic process in follicular granulosa cells.
A range of hormones and locally produced factors regulate the 'decision to die' via
their receptors. Execution of the apoptotic process converges in the mitochondria,
which in turn releases pro-apoptotic molecules that subsequently activate down
stream caspases, such as caspase-3. Down stream of caspase-3, the apoptotic
programme culminates in orchestrated DNA fragmentation. Apoptosis can also be
triggered by DNA damage through radiation and subsequent mitochondrial
activation. The red arrow indicates the position of Caspase-3. Figure adapted from
(Markstrom et al. 2002).
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2.7.2 Antigen retrieval
Fixation and paraffin wax embedding can mask some antigenic epitopes. It was
necessary to expose these antigens using heat treatment (Shi et al. 1991). Slides
were dewaxed, rehydrated, and exposed to 0.01M citrate buffer, pH 6, in a Tefal
Clypso pressure cooker (Tefal, Essex, UK). Two litres of citrate buffer was heated
to boiling point in the pressure cooker. Once boiling, racks containing the dewaxed
and rehydrated slides were placed into the buffer. The lid was sealed and the slides
were heated at high pressure for 7 mins, from the time when full pressure was
reached. After pressure was released, the slides remained in the hot buffer for a
further 20 mins before they were cooled with water and transferred either to 0.05M
Tris buffered saline (TBS (8g NaCl, 0.2g KC1, 10ml 1M Tris-HCL to 1L H20) pH
7.4) for 5 mins or to 3% H2O2 in methanol (CH3OH) for 30 mins depending on
which antigen was being detected.
2.7.3 Blocking non-specific binding
The main cause of non-specific background staining is non-immunological binding
of the specific immune sera by hydrophobic and electrostatic forces to certain sites
within tissue sections (Kraehenbuhl and Jamieson 1974). It is usually the first
immune serum that gives rise to the highest background staining. Blocking the sites
that show a non-specific affinity for the antibodies can reduce this. This is achieved
by incubating the sections in normal whole serum from the species in which the
secondary antibody was raised. For example, when mouse BrdU was localised using
rabbit anti-mouse as a secondary antibody, blocking was performed using normal
rabbit serum. All slides were treated with the relevant blocking serum diluted 1:5 in
TBS with 20% bovine serum albumin (BSA) for 30 mins at room temperature.
Details for each specific antigen are given in Table 2.1.
2.7.4 Immunocytochemical procedure
An automated incubation method, the Sequenza System (Shandon Scientific,
Runcorn, Cheshire, UK), was used for all incubations apart from the peroxidase
block. A Sequenza works by capillary action and reduces the volumes of reagents
required. Each section was retained within its own Sequenza cassette, which
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prevents cross-contamination and antibody-antigen complexes are prevented from
precipitating onto sections, which would give rise to unwanted background staining.
Unbound antibody was washed from each section before the proceeding step in each
protocol. Detection systems vary according to antibody, details are given in Table
2.1. After the appropriate block had been applied and allowed to incubate for 30
mins, sections were given three 5 min washes with TBS. The primary antibody,
diluted in the appropriate blocking serum used for blocking non-specific binding,
was then added to the sections and incubated overnight at 4°C. After overnight
incubation and three 5 min washes with TBS, the secondary antibody, diluted
accordingly in the appropriate blocking serum was added and incubated at room
temperature for 40 mins. Detection systems vary somewhat from this stage of the
protocol and therefore will be dealt with separately.
Primary Species raised Block Secondary Tertiary antibody Detection Counter
Antibody in antibody stain
BrdU Mouse Normal rabbit Rabbit anti Mouse APAAP NBT Yes
monoclonal scrum mouse
CD31 Mouse Normal rabbit Rabbit anti Mouse APAAP NBT No
monoclonal serum mouse
CD31/BrdU Mouse Normal rabbit Rabbit anti Mouse APAAP Fast red Yes
monoclonal serum mouse
Sheep Rabbit anti Mouse APAAP NBT
polyclonal sheep
Caspase-3 Rabbit Normal goat Goat anti Goat anti rabbit peroxidase DAB Yes
polyclonal serum mouse labelled polymer
Table 2.1 Antibodies and reagents used in immunocytochemistry protocols.
Sheep BrdU (Fitzgerald Industries international, Concord, MA, USA), Mouse BrdU
(Boehringer Mannheim, Germany), CD31 (Dako Corp, Carpinteria, CA, USA) and
Cleaved Caspase-3 (Cell Signalling Technology, Beverly, MA, USA).
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2.7.5 Specific immunocytochemistry techniques
2.7.5.1 BrdU and CD31
Slides incubated with non-biotinylated secondary antibodies were subsequently
incubated with a tertiary alkaline phosphatase-anti-alkaline-phosphatase (APAAP)
antibody (Cordell et al. 1984). The secondary antibody was applied in excess so that
one of its two identical binding sites would bind to the primary antibody, the other to
the APAAP complex, illustrated in Figure 2.2. The APAAP was added, again
diluted in the appropriate serum block for 40 mins, before slides were washed in and
then transferred to TBS. The APAAP detection method can be used with a variety of
substrates giving rise to a variety of colours. The two used in this thesis were
nitroblue tetrazolium (NBT), which forms a deep blue/black stain (McGadey 1970),
and fast red used with naphthol AS-MX phosphate sodium, which gives a bright red
stain.
Where NBT was used, slides were transferred to NBT buffer for 10 mins at
room temperature (40ml 0.5M MgCl + 40ml lMTris/lMNaCl + 320ml distilled
water). The area of the slide surrounding the tissue was then dried, and NBT
solution added, 10ml NBT buffer + 45ptl NBT substrate (Boehringer Mannheim) +
35ql Xphosphate (Boehringer Mannheim) +10ql levamisole. Slides were left for
colour to develop over approximately 10 mins.
Where fast red was to be used for detection, slides were removed from TBS
and the area around tissue sections wiped dried. Fast red was added in solution at
lmg/ml in fast red buffer (20mg naphol AS-MX phosphate, 2ml dimethyl formamide
to 98ml 0.1M Tris, pH 8.2) and left for approximately 20-30 mins until a red colour
developed. Reactions were stopped in tap water.
Where appropriate, sections were counterstained in haematoxylin for
approximately 20 seconds before being dehydrated. If stained with NBT, slides were
dehydrated in graded alcohols, cleared in xylene and mounted in pertex (Cell Path,
Hemel Hempstead, UK). If stained with fast red, slides were air dried before being
cleared and mounted.
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Figure 2.2 Illustration of APAAP detection system.
A primary anti-body binds to the specific antigen. The secondary antibody binds to
the primary and also to the APAAP complex. Either NBT or fast red is then used for
detection of stain.
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2.7.5.2 Co-localisation
In order that two antigens could be detected and differentiated on the same slide, two
separate detection systems were used. For the purposes of this thesis, it was required
that BrdU and CD31 were dual-stained. The antibodies to be used were raised in
different species, sheep and mouse respectively. This ensures that no cross reactivity
occurs. The secondary antibody to be used for both antibodies was raised in the
same species, namely rabbit. Thus the blocking serum is the same for both
antibodies, in this case normal rabbit serum. The first primary antibody, CD31
diluted 1:20 in normal rabbit serum, was added and incubated overnight at 4°C. This
was then detected as per the CD31 protocol using the fast red detection as described
above. Sections were then washed and Sequenzas flushed through with TBS before
the sheep BrdU primary antibody was added, diluted to 1:30 in normal rabbit serum
and incubated overnight at 4°C. After three 5 min washes with TBS, a rabbit anti-
mouse secondary antibody was added and incubated for 40 mins, followed by mouse
APAAP for 40 mins. Slides were then transferred to NBT buffer for 10 mins before
staining with NBT. Reactions were stopped in tap water, slides were then
counterstained with haematoxylin before being air dried, cleared in xylene, and
mounted using pertex.
2.7.5.3 Caspase-3
For the purposes of this thesis, a polyclonal antibody to cleaved (activated) caspase-3
(Cell Signalling Technology) was used as a marker of cellular apoptosis. Instead of
NBT or fast red used for other immunocytochemical visualisation, a peroxidase
labelled polymer was used with 3,3' diaminobenzadine tetrahydrochloride (DAB) as
a detection chromagen. DAB yields a crisp, insoluble, dark brown reaction product
(Graham and Karnovsky 1966), a diagram illustrating this technique is provided in
Figure 2.3. Some endogenous peroxidases in the animal tissue can react with the
DAB, and cause a blurring of the resulting stain. Treatment with saturating amounts
of hydrogen peroxide results in the irreversible inactivation of these endogenous
peroxidases. Therefore, immediately after the pressure cooking step of the protocol,
slides were incubated in absolute methanol containing 3% hydrogen peroxide for 30
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mins, without being transferred to TBS first (Streefkerk 1972). After methanol
incubation, slides were transferred to TBS, sections were then washed three times for
5 mins with TBS then incubated for 30 mins at room temperature with a goat anti-
rabbit secondary antibody conjugated to an EnVision peroxidase labelled polymer
complex. Slides were washed and transferred to TBS before the tissue sections were
dried around and DAB substrate added. Staining was produced after approximately
1 min. Reactions were stopped in tap water and sections were counterstained in
haematoxylin for approximately 20 seconds before being dehydrated through graded
alcohols, cleared and mounted using pertex.
2.7.6 Negative controls
For immunocytochemical detection using a specific antibody for the first time on a
specific tissue, negative control experiments were carried out to assess the potential
of false positive results. The primary antibody was replaced with IgG from the same
species the primary was raised in and at the same concentration. No sign of false
negative results were observed for any of the antibodies used.
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Figure 2.3 Illustration of EnVision DAB immunocytochemical detection.
The primary antibody binds to its specific antigen. The secondary antibody that
binds to the primary is conjugated to a peroxidase labelled polymer. A coloured
substrates chromagen (DAB) is then used for visualisation of detection.
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2.8 Quantification of immunocytochemistry
BrdU and CD31 immunostaining were quantified using Image Pro Plus 3.0 software
(Media Cybernectics, Silver Spring, Maryland, USA). Image were captured at x200
magnification and converted to grey scale. The area (CD31) or number of dark
objects (BrdU) was measured per area of interest, theca and granulosa. In all cases,
the threshold for recognition of a "dark" object was set so that the captured image
mirrored the live image as closely as possible. Dual-stained follicles were analysed
manually at x400 magnification using a tally counter. These analysis techniques are
commonly used to quantify immunocytochemistry (Wulff et al. 2001b, Wulff et al.
2001c, Rowe et al. 2002, Wulff et al. 2002). The pairs of ovaries removed from
each animal was treated as n=l for analysis. Not all immunohistochemical stains
were quantified: caspase-3 was performed purely for the purpose of confirming
follicle characterisation and health.
2.8.1 Bromodeoxyuridine
Sections were analysed under x200 magnification. The image analysis package was
set up to analyse the number of BrdU positive cells and the total number of cells in
the outlined cellular compartment of interest, theca and granulosa. The proliferation
index is expressed as the percentage of cells proliferating from the total number of
cells in that compartment. Calculated for the granulosa and thecal compartments
separately, the proliferation index is expressed as a mean value for each follicular
stage per animal assessed.
2.8.2 CD31
The endothelial cell area was measured at x200 magnification. Capturing and
thresholding a grey scale image into a binary image measured CD-31 positive cells.
The whole area of the thecal compartment and the CD31 positive area were
measured, and the CD31 positive area was calculated per unit area of the thecal
compartment. It is expressed as a mean value for each follicular stage per animal
assessed.
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2.8.3 BrdU/CD31 co-localisation
The number of dual-stained cells (both BrdU and CD31 positive cells) and the total
number of proliferating cells (BrdU positive cells) were counted in the thecal
compartment. The proportion of dual-stained cells of proliferating endothelial cells
(dual-stained cells) is expressed as a percentage of the total number of proliferating
cells. The mean value was calculated for the number of follicles assessed within
each follicular class and per animal. Non-endothelial cell proliferation was
calculated by multiplying the total thecal proliferation index (BrdU index) by the
percentage of proliferation that was not endothelial (not dual stained, BrdU positive
cells on a dual stained slide), per follicle class per animal.
2.8.4 Caspase-3
Although not quantified, caspase-3 staining was used to assess that morphological
characterisation of follicular attresia, for example pyknotic granulosa cells, was
correct. Figure 2.4.
Figure 2.4 Caspase-3 staining of atretic follicles
Two atretic dominant follicles from a GnRH antagonist days 5-10 treated animal
stained for cleaved caspase-3. The staining is isolated to the degenerating pyknotic
granulosa cells, g = granulosa, t = theca.
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2.9 Construction of riboprobes for in situ hybridisation
In situ hybridisation was used for the detection of specific mRNAs in tissue sections
by hybridisation to complementary radio labelled riboprobes, and subsequent
detection using photographic emulsion. This is again a very powerful technique
allowing the localisation and quantification of specific mRNAs to tissues and cells of
interest.
2.9.1 Design of riboprobes
Riboprobes were designed and constructed for human endocrine gland vascular
endothelial growth factor (EG-VEGF) and marmoset aromatase mRNAs, the
accession numbers for the sequences are: NM 032414 and AY034779 respectively.
Specific primers were designed for each gene sequence using primer 3 software,
available at: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Details of
the primers are provided in Table 2.2.







Table 2.2 Details of primers used to generate riboprobes.
The corresponding sets of primers were used to generate complimentary DNA
(cDNA) fragments corresponding to nucleotides 10-533 (523 base pairs (bp)) of the
human sequence for EG-VEGF and nucleotides 188-609 (421 bp) of the marmoset
aromatase sequence.
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2.9.2 Reverse transcription of RNA
Total RNA extracted from the human corpus luteum was used to construct the EG-
VEGF probe. Total RNA extracted from marmoset ovaries was used to construct the
aromatase probe. RNA was reverse transcribed using Oligo DT priming from a
taqman reverse transcription (RT) kit (Roche Applied Bioscience, Lewes, Sussex,
UK). The following RT protocol was used was used:
Nuclease free H2O 96pl
RNA (2pg/pl) lOjul
xlORT Buffer 20pl
dNTPs (lOmM, 2.5mM of each) 20pl
Rnase inhibitor (20U/pl) 10pl
01igo(dT)s (50pM) lOpl
Reverse transcriptase (50U/pl) lOpl
MgCl2 (25mM) 24pl
Final Volume 200pl
Reaction mix was split in to 20pl reactions to allow efficient heating to occur. The




2.9.3 PCR of specific cDNA insert
Using the single stranded DNA synthesised in the RT reaction, specific cDNA
fragments were generated by Polymerase Chain Reaction (PCR) using the primers
designed to generate each probe (Table 2.2). Firstly a PCR was carried out to
determine the optimal temperature for primer annealing. PCR reagents were from
Abgene, Epson, Surrey, UK. A standard PCR mix used was:
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Nuclease free H2O 47.2pl
1Ox Thermostart buffer 8pi
dNTP mix (5mM mixture, 5mM each of A, C, G and T) 8pi
Forward and reverse primers (5pM) 8pl




The Thermostart enzyme requires a heat activation step at the beginning of the PCR.
A standard thermostart PCR protocol used was:
95°C lOmin Enzyme activation
95°C 30secs Denature
Gradient 51.2°C-63.9°C 30secs Primer annealing
72°C 90secs Extension
72°C lOmin Final extension
The optimal temperature for both primer pairs was determined by eye as the intensity
of the PCR product when run out on a 1% agarose gel (0.5g agarose dissolved in
50ml TBE buffer: 1M Tris, 1M boric acid and 0.02M EDTA in distilled water, 2pl
ethidium bromide, then set in a gel tray and wells made with a comb). The gel was
run at 120V for 30 mins and the PCR products visualised and photographed under
ultra violet (UV) light. Once the optimal annealing temperatures had been
determined, 80pl PCRs were performed at the optimum temperature to obtain large
quantities of the specific cDNAs required for purification and ligation into vectors.
2.9.4 PCR product purification
The PCR products were then purified using a Boehringer High Pure PCR Product
purification kit (Boehringer Mannheim) as per the manufacturer's instructions.
Simply, the PCR product is bound to the purification column while the PCR primers
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and other contaminants are washed through with a series of washing buffers. The
purified product is then eluted off the column using nuclease free water.
Concentrations of PCR products were measured on a GeneQuant Pro
spectrophotometer (Amersham Pharmacia Biotech, Cambridge Science Park,
Cambridge, UK). The products were run on a 1% agarose gel as before, to verify the
correct products had been purified, as the length of the expected PCR product
sequences was known (Table 2.3). The purified product was also sequenced for
extra confirmation.
Probe Vector Host Bacterium Length of cDNA
insert (bp)
































Table 2.3 Riboprobe plasmids, orientations and cDNA insert lengths.
Epicurian Coli XL1 - blue (Stratagene, La Jolla, CA, US)
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2.9.5 Ligation of purified PCR products
The purified PCR products were ligated into vectors using a TA bidirectional cloning
system. The pGEM-T Easy vector system (Promega Corporation, Madison, WI,
USA) was used as per the manufactures instruction, with in insert to vector ratio of




Figure 2.5 Circle map of the pGEM-T Easy vector.
Restriction enzyme cleavage sites are present on either side of the insertion site in the
vector that interrupts the lacZ gene. The numbers corresponding to the restriction
sites are measured from the T7 transcription initiation site. Adapted from pGEM-T
and pGEM-T Easy Vector Systems Technical manual No. 042 (Promega Corp).
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2.9.6 Transformation of plasmid constructs
Once the ligation reactions were complete the vector-insert constructs (plasmids)
were transformed into JM109 competent cells (Promega Corp.) as per the
manufactures instructions. LB Broth agar plates containing ampicillin at lOOpg/ml
(Gibco BRL, Life Technologies Ltd., Paisley, UK) were poured and once set, each
plate had lOOpl of lOOmM isopropyl-|3-D-thiogalactopyranoside (IPTG) (Promega)
and 20pl of 50mg/ml X-Gal (Promega) spread over their surface and allowed to
absorb for 30 mins at 37°C. A blue/white selection screen was set up on these plates
to select colonies that contained the plasmid constructs. As the plasmids containing
the insert will have their LacZ gene broken (Figure 2.5) they will appear white
because they are unable to metabolise the X-Gal on the plates. Clonal expansion of
single white colonies was used to ensure that only single colonies were selected with
the insert in only one orientation. After clonal expansion, selected cells were grown
up overnight in 10ml LB Broth (Anachem, Luton Beds, UK) containing ampicillin at
lOOpg/ml (Gibco) on a shaking platform at 37°C. A control tube containing broth
and ampicillin was also prepared. After overnight growth, plasmids were purified
from their host cells as detailed below, if the control solution remained clear, i.e. if
no contamination was present in the LB Broth. Glycerol stocks of the cells
containing the plasmid constructs were also taken at this stage, 700pl of cells in LB
and 300pl of 50% glycerol was vortexed and stored at -20°C for future use.
2.9.7 Purification of plasmids
Plasmids were purified from their host bacterium using a QIAprep Spin miniprep kit
(QIAGEN Ltd, Crawley, West Sussex, UK) as per the manufacturers instructions.
DNA concentration was determined using the GeneQuant Pro spectrophotometer
(Amersham). Purified plasmids were then sequenced (See 2.13) and the results
aligned to the genes they had been constructed to verify specificity.
2.9.8 Validation of probes
To validate that the constructed probes only detected the mRNA they were designed
to hybridise to, Northern analysis was conducted. An agarose gel containing 2.0g
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agarose dissolved in 20ml xlO MOPS (41.86g of 3[n-morpholino]propane sulphonic
acid, 6.805g of sodium acetate and 3.722g of EDTA to 1 litre of deionised water), 34
ml formaldehyde and 146 ml of deionised water was prepared. Ten micrograms of
each RNA sample (marmoset testicular and ovarian RNA, human luteal and
placental RNA) was loaded into the gel along with 2pl of a 0.2-10 Kb RNA ladder.
Samples were run out on the gel at 80V for 3 h and then photographed and the
position of both the 18S and 28S RNA measured. The separated RNA was then
transferred to a nylon membrane (Amersham) by capillary action in 20x salt sodium
chloride (SSC) [20xSSC: 175.3g NaCl, 88.2g Citric acid (Tri Sodium salt) to 1L
H20, pH 7.0] overnight and baked for 2 h at 80°C the following day to permanently
bond the RNA to the membrane. The dry blot could then be stored in a plastic bag at
4°C for future use.
Blots were prepared for hybridisation by placing them in hybridisation tubes,
adding 16ml of Ultrahyb (Ambion) and incubating at 42°C for 1 h whilst rotating.
The Probes were labelled by adding 25ng of purified probe plasmid in 45pi ofwater
and 5pi of [a-32P] dCTP (Amersham) to Rediprime II DNA Labelling System tubes
(Amersham) and incubated as per the manufacturers instructions. The probes were
then fractionated to 400pl volumes using NICK sephadex G-50 DNA grade
purification columns (Amersham), with 4pl of each fraction being collected and
counted in 3.5ml of scintillant on a (3 counter (Microbeta Trilux 1450, Wallac) to
check the probe had labelled properly. The second and third fractions (the fractions
containing labelled probe) were then heated at 99°C for 5 mins and then quenched in
ice to linearise the probes. Probes were then added to the hybridisation tubes
containing the blots and Ultrahyb and incubated overnight at 42°C whilst rotating.
The following day two 5 min 2xSSC/0.1%SDS, followed by two 15 min
0.1xSSC/0.1%SDS stringency washes, were used to remove un-hybridised probe
from the blots. All washes were carried out 42°C. Blots were then removed from the
hybridisation tubes, wrapped in Saran film and analysed on an autoradiograph
(instant imager, Canberra Packard, Pangbourne, Berkshire, UK) and exposed to
photographic film.
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2.10/n situ hybridisation technique
2.10.1 Preparation of plasmids
Riboprobes were generated from plasmids containing the specific cDNA insert of
interest and RNA polymerase initiation sites. Probes for VEGF, VEGFR1 and
VEGFR2 were gifts from Dr Stephen Charnock-Jones (Department of Obstetrics and
Gynaecology, University of Cambridge) and were received pre-inserted into their
host plasmid. The vector, host bacterium, cDNA insert length and orientation in the
vector for each probe are detailed in Table 2.3. The complete nucleotide sequence
and probe binding region are given in Appendix A.
Plasmids were grown overnight on a shaking platform at 37°C by taking 10pl
of glycerol stock and inoculating 10ml LB Broth (Anachem) containing lOOqg/ml
ampicillin (Gibco), a control tube containing broth and ampicillin was again prepared
to check the LB Broth was not contaminated. After overnight growth, plasmids were
purified from their host cells as detailed in 2.9.7.
2.10.2 PCR of plasmid
In order to amplify the sequence of interest within the plasmid, specific forward and
reverse PCR primers were designed to the RNA polymerase initiation sites contained




PCRs were performed using the standard reaction mix and protocol as detailed in
2.9.3. The only differences in standard PCR protocol between probes were the
annealing temperatures, which were: 52°C (VEGF, VEGFR1, VEGFR2); and 59°C
(EG-VEGF and aromatase). PCR products were then purified using a Boehringer
High Pure PCR Product purification kit (Boehringer Mannheim) as detailed in 2.9.4.
The concentration ofDNA was measured on the GeneQuant Pro spectrophotometer
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(Amersham) and the products run on a 1% agarose gel as before, to verify that the
correct product had been amplified.
2.10.3 Synthesis of riboprobes (cold labelling)
Riboprobes were synthesised from the purified the PCR products. First it was
necessary to check that the PCR product could be transcribed into sense and
antisense RNA probes by cold labelling. Sense and antisense riboprobes were
synthesised from the purified PCR products using T7, T3 or SP6 RNA polymerases.
A MAXIscript in vitro transcription kit (Ambion Inc., Austin, Texas, USA) was used
for riboprobe synthesis. The following protocol was used:
This mixture was incubated at 37°C for 1 h. After 1 h, 1U DNase
(deoxyribonuclease) was added and the reaction was incubated for a further 15 mins
at 37°C. The product was run on a 1% agarose gel to check that transcription had
been successful.
Nuclease free H2O
300ng DNA in H20
10 x transcription buffer
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2.10.4 Synthesis of riboprobes (hot labelling)
This is essentially the same as the cold labelling detailed above with the addition of
radiolabeled UTP. The following protocol was used.
IS
A 1:100 dilution of unlabelled UPT is included in the reaction mix because S
labelled UTP (NEN life science products, Boston, MA, USA) is a large molecule and
if every UTP in the probe were to be radio labelled stereo inhibition may occur. By
adding a low concentration of unlabelled UTP, stereo inhibition is prevented as not
all UTP will be radiolabeled 35S UTP.
Reaction mixtures were incubated at 37°C for 45 mins and then for a further 45
mins after the addition of another 10U enzyme. Finally, 1U ofDNase was added and
incubated for 15 mins at 37°C. After riboprobe synthesis, the percentage of
incorporated S UTP was measured by counting the total radioactivity (counts per
min, cpm) of lpl of the final reaction mixture; then spinning the remaining solution
through a ChromaSpin column (Clonetech Laboratories Inc., Palo Alto, CA, USA),
as per manufacturer's instructions, to retain any free radioactivity before counting
lpl of the eluate. The incorporated count was expressed as a percentage of total
counts per min (cpm).
Nuclease free H2O
300ng DNA in H20
RNA polymerase
10 x transcription buffer
rCTP, rGTP ,rATP (lOmM)
rUTP (0.1mM)











1 |ol of each
2.10.5 In situ hybridisation procedure
In situ hybridisation experiments were conducted for VEGF, VEGFR1, VEGFR2,
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aromatase and EG-VEGF. For each tissue of interest two serial sections were used,
one was treated with the sense probe and the other with the antisense probe. It was
essential that solutions and all equipment used for the experiment were ribonuclease
(RNase) free. To ensure this was the case, sterile plastics were utilised and
glassware and metal racks were baked at 180°C. All solutions used on the first day
of the in situ hybridisation were made up with DEPC treated water. After
hybridisation, subsequent solutions were made up in ultra pure water. Additionally,
chemicals were only retained for in situ use if they had been used exclusively with
sterile equipment and gloves. Fresh xylene and alcohols were prepared before each
experiment. Tissue sections were dewaxed, rehydrated, incubated in 0.2N HCL (to
denature proteins) for 20 mins, followed by two 5 min DEPC water washes.
Proteolytic digestion of tissues was performed using 5pg/ml proteinase K in 1M Tris,
0.5M EDTA, for 30 mins at 37°C. Next, the proteinase K digestion was inhibited by
transferring the slides to a 0.2% glycine solution at 4°C for 10 mins. Slides were
then transferred to 0.1M triethanolamine buffer (TEA, pH 8 with 5M NaOH) for 5
mins before incubation in TEA buffer/0.25% acetic anhydride for 10 mins. Slides
were then washed in 4x SSC for 5 mins.
Tissue sections were dried around, laid in sterile humid boxes and incubated
for 2 h at 55°C. Each tissue section was covered by lOOpl of prehybridisation buffer
containing: 50% deionised formamide, 4x SSC, lxDenhardts, 125pg/ml salmon
testes DNA, 125pg/ml yeast transfer ribonucleic acid (tRNA), and lOmM
dithiothreitol (DTT). Prehybridisation buffer was drained off and replaced with 50ql
per slide of hybridisation buffer (containing the same as the prehybridisation buffer
plus 10% dextran sulphate, to increase the rate of reassociation of nucleic acids, and
approximately 0.5 xlO6 cpm of probe per 50pl (VEGF, aromatase) and 1 xlO6 cpm
per 50pl for all other probes. Before the addition of hybridisation buffer to the
slides, the probe (in buffer) was denatured immediately before use by heating to
95°C for 10 mins. Sections were coverslipped (Gel Bond) and incubated overnight
at 55 °C in a humid box.
The following day, RNase free conditions were no longer necessary. After
removal of coverslips and a subsequent 10 min wash in fresh 4xSSC, slides
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underwent RNase-A treatment (20pg/ml RNase-A in 1M Tris, 0.5M EDTA, 0.5M
NaCl buffer, pH 8) at 37°C for 30 mins. This was followed by a wash in RNase
buffer containing no RNase-A for 30 mins. Slides were then subjected to repeated
30 min, stringency washes to remove unhybridised probe (2xSSC, 1 x SSC at 65°C
and 0.1 x SSC).
Finally, slides were dehydrated in 50% (v/v) ethanol/0.3M ammonium acetate,
85% ethanol/0.3M ammonium acetate and 94% ethanol/0.3M ammonium acetate for
2 mins each, before being allowed to air dry for 3-4 h. Slides were dipped in G5
emulsion (Illford, H + A West, Edinburgh, UK), diluted 1:1 in distilled water, and
heated at 45°C in a dark room until liquefied.
Slides were then dried overnight in a lightproof humid box at 4°C, before
desiccant was added and the emulsion exposed at 4°C for a varying number of
weeks, depending on probe. VEGF in situs were exposed for 4 weeks , VEGFR1
and VEGFR2 for 9 weeks and EG-VEGF and aromatase 3 weeks. Exposure times
were determined by including trial slides in each in situ hybridisation experiment for
each probe and tissue type developed at intervals until such time as optimum
hybridisation had occurred. All experimental slides within one run were developed
at the same time. Slides were developed in filtered Kodak D19 developer
(Edinburgh Cameras, Edinburgh, UK) for 4 mins at 14°C, rinsed in distilled water,
then fixed in Kodak GBS Fixer diluted 1:5 in distilled water, for 10 mins at room
temperature. Slides were again rinsed in distilled water, counterstained with
haematoxylin for 20 seconds, dehydrated in graded alcohols, cleared in xylene and
mounted in pertex.
2.10.6 Negative controls
In all in situ hybridisation experiments negative control were included. These
negative controls were the sense transcription of the specific probe used, as opposed
to the antisense that binds to the mRNA to give specific binding. All sense slides
were devoid of specific hybridisation and only displayed background levels of
hybridisation.
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2.10.7 Quantification of in situ hybridisation
Slides were analysed qualitatively under light field and quantitatively under dark
field illumination. Specific hybridisation to follicular compartments of interest was
quantified by grain density measurements. Grain density was either determined at
x400 magnification using image analysis software and is given as number of grains
per pm , or scoring by eye.
Scoring by eye was carried out by Paul Taylor and Hamish Fraser with the
following classification: - (0) No detectable specific signal above background levels;
+ (1) low grain density clearly above background levels; ++ (2) moderate grain
density; +++ (3) high grain density. Scoring of tissues was blind and random by
each observer.
2.11 Statistical analysis of data
Data was first tested for normality using a Shapiro-Wilk test. Where more than two
variables were being compared analysis of variance (ANOVA) with a least
significant difference (LSD) post-hoc test was used if the data was parametric. Non-
parametric data was tested using a Kruskal-Wallis test with Dunn's post-hoc test.
Where two variables were being compared a two-tailed unpaired t-test was used for
normally distributed data. A Mann-Whittney test was used for data that was not
normally distributed. The level of significance for all tests was P<0.05. Tests were
performed using SPSS 11 for Macintosh OSX (SPSS, Inc, Chicago, IL, USA) or
Prisms 2.0 for Macintosh OS 9 (GraphPad Softwaer, Inc. San Diego, CA, USA).
2.12Digital photomicroscopy
Tissue sections were photographed using a digital camera, Kodak DCS420 (Eastman
Kodak, Rochester, NY, USA) mounted on an Olympus Provis microscope (Olympus
Optical, London, UK). Figures were compiled using Adobe Photoshop 7.0 for
Macintosh OSX (Adobe Systems Inc., Mountain View, CA, USA).
2.13DNA sequencing
All DNA sequencing was carried out by the either the Medical Research Council
Human Reproductive Sciences Unit genomics and proteomics service or the Medical
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Research Council Human Genetics Unit sequencing service.
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Chapter 3 Effect of GnRH Antagonist Treatment on
Follicular Development and Angiogenesis
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3.1 Introduction
The ovary is one of few organs in the body to undergo serial angiogenesis which is
intimately involved in ovarian follicle development (Fraser and Wulff 2001, Wulff et
al. 2001b, Zimmermann et al. 2001b, Wulff et al. 2002, Zimmermann et al. 2003).
Angiogenesis in the ovarian follicle is restricted to the thecal compartment, the
resulting capillaries forming a vascular sheath around the growing follicle that
continues to develop during folliculogenesis (Wulff et al. 2001b). The degree of
vascularisation achieved has been hypothesised to be involved in the establishment
of follicle dominance (Zeleznik et al. 1981), facilitating the delivery of
gonadotrophins, steroid precursors, oxygen and nutrients from the blood stream, but
whether an abundant vasculature is a cause or consequence of follicle dominance
remains to be determined.
The principal angiogenic factor with an established role in follicular
angiogenesis is VEGF. VEGF mRNA and protein have been localised in the ovary
to the granulosa cells of the developing follicles and the theca of preovulatory
follicles (Phillips et al. 1990, Ravindranath et al. 1992, Shweiki et al. 1993).
Inhibition of VEGF in vivo in the marmoset monkey has been shown to severely
suppress both thecal vascularisation and follicle development (Wulff et al. 2001b,
Wulff et al. 2002) and to inhibit the follicular phase of the cycle in macaques
(Zimmermann et al. 2001b, Zimmermann et al. 2002). As VEGF is expressed in the
granulosa and thecal cells of follicles as they mature it is concurrent with the
acquisition of steroidogenic activity, suggesting that the expression is hormonally
regulated (Shweiki et al. 1993). It has also been demonstrated that VEGF expression
in granulosa cells from preovulatory follicles is up regulated by FSH stimulation in
vitro (Christenson and Stouffer 1997, Hazzard et al. 1999).
In this study, the role of the gonadotrophins was assessed by administration of
a GnRH antagonist in vivo during follicular development in the marmoset, a species
in which the development of the follicular vasculature has been described in detail
(Wulff et al. 2001b, Wulff et al. 2002). Since it is established that GnRH antagonist
treatment suppresses follicular development by inhibiting both FSH and LH
secretion from the pituitary (Fluker et al. 1991, Hall et al. 1991, Fraser et al. 1999a),
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the aim of this study was to test the hypothesis that this suppression resulted in a
reduced production of follicular VEGF mRNA with resultant inhibition of
angiogenesis. The effects of the antagonist on follicular angiogenesis were examined
using BrdU immunocytochemistry as a proliferation marker, CD31 as an endothelial
specific cell marker and dual staining to distinguish proliferating endothelial cells.
Effects of treatment on expression of VEGF and aromatase mRNA was determined
by in situ hybridisation.
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3.2 Specific methods
Tissue collection, immunocytochemistry and in situ hybridisation in this chapter
were conducted as described in Chapter 2.
3.2.1 GnRH antagonist treatment
We employed the GnRH antagonist, Antarelix, a gift from Dr R. Deghenghi
(Europeptides, Argenteuil, France) (Deghenghi et al. 1993), dissolved in water to
concentration of 10 mg/ml. To provide a slow-release depot, Antarelix was
administered at a dose of 12mg/kg, injected subcutaneously on follicular day 0 (n=4),
treatment schedule 1 or follicular day 5 (n=6), treatment schedule 2 (Figure 3.1).
Timing of ovarian cyclicity was synchronised by PG injection and ovaries from the
treated animals were collected 10 days after PG administration, corresponding to the
peri-ovulatory period in control animals. Control marmosets were studied on day 0
(n=3), day 5 (n=4) and day 10 (n=6) relative to PG administration. After PG
administration, blood samples continued to be collected from the animals 3 times a
week to monitor progesterone levels. All animals were injected i.v. with 20 mg
BrdU (Roche) in saline 1 h before being sedated.
To confirm the potency of the GnRH antagonist treatment, 3 marmosets with
regular ovarian cycles were given a single 12mg/kg dose of Antarelix and allowed to
recover normal cycles as determined by measuring plasma progesterone in blood
samples collected 3 times per week. Ovulation was suppressed in all three animals
and a progesterone rise was not observed until between 80-110 days post treatment.
The results from one treated animal are shown in Figure 3.2.
3.2.2 In situ hybridisation quantification
In situ slides were analysed blind by two investigators, separately. A scoring system
of 0 = no hybridisation above background, + = detectable but low grain density
clearly above background levels, ++ = moderate grain density, +++ = high grain
density was employed to denote the level of hybridisation observed in each follicle
and the results compared for agreement.
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Figure 3.1 GnRH antagonist treatment schedule.
Two treatment regimes were employed in this study. Regime 1 consisted of a single
GnRH antagonist injection on the day of PG injection. Regime 2 consisted of a
single GnRH antagonist injection 5 days after PG injection. Ovaries from treated
animals were collected on follicular day 10. The two grey boxes denote the two
treatment regimes. Note the sharp decline in progesterone associated with induction
of luteolysis, the ovulatory progesterone rise and the follicular phase increase in
oestradiol that would be observed in control animals.
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Days relative to GnRH antagonist treatment
Figure 3.2 Circulating progesterone after GnRH antagonist treatment.
Circulating progesterone after a single injection of GnRH antagonist (12mg/kg). A
sharp decline in progesterone is observed and an ovulatory rise in progesterone is not
observed until 110 days post treatment in this case.
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3.3 Results
3.3.1 Hormonal changes
All marmosets responded to PG injection with a rapid fall in plasma progesterone
concentration that remained at follicular phase levels for the duration of the study.
Treatment also suppressed serum oestradiol-17(3 levels, consistent with inhibition of
gonadotrophin release, significant reductions being observed between late follicular
controls (1096+332pmol/L) and both treatment groups days 0-10 (72+10pmol/L,
















LF Control GnRH antag 0-10 GnRH antag 5-10
Figure 3.3 Terminal plasma oestradiol concentrations.
Significant reductions in terminal plasma oestradiol were observed after both GnRH
antagonist treatments (days 0-10, 72+10pmol/L, p=0.022 and days 5-10,
127±41pmol/L, p=0.027) compared to late follicular controls (1096±332pmol/L).
Values are means ± sem. Superscripts a and b denotes statistical significance.
Statistics used: one way ANOVA with an LSD post hoc test.
Chapter 3 GnRH antagonist 85
3.3.2 Ovarian Morphology
Both of the GnRH antagonist treatment schedules significantly reduced paired ovary
weight, days 0-10 (102.5±20.9mg, p=0.026), days 5-10 (109.2±8.0mg, p=0.029)
compared to pre-ovulatory weight of late follicular control ovaries (165.0±22.2mg),
Figure 3.4.
In cross-section through a typical control ovary at day 12-16 of the luteal
phase, the time of PG injection, Figure 3.5A, the corpus luteum was the dominant
tissue in the organ, accompanied by numerous small and medium sized tertiary
follicles. The late luteal control tissue was collected specifically for these
experiments by monitoring progesterone and collecting the ovaries at the time
prostaglandin would be injected in both follicular phase control and treated animals.
By day 5 after PG injection, the mid-follicular phase, Figure 3.5B, the corpus luteum
had regressed as a result of PG treatment, and many healthy and atretic tertiary
follicles dominated the ovary. In the day 10 control ovaries, the periovulatory
period, Figure 3.5C, the predominant feature was either the presence of 1 to 3
healthy dominant follicles together with a combination of atretic and small antral
follicles (n=3 marmosets) or collapsed follicles indicating that ovulation had just
occurred in the remaining 3 animals, Figure 3.5D. After GnRH antagonist treatment
between days 0-10 of the follicular phase, there was no evidence of dominant follicle
development or freshly ovulated follicles although tertiary follicles were present,
Figure 3.5E. In contrast, after GnRH antagonist treatment between days 5-10 of the
follicular phase, there were follicles of preovulatory size present in the ovaries, but
these follicles were atretic and cyst like in appearance, Figure 3.5F. Details of
specific animals are provided in Appendix D.
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Figure 3.4 Paired ovarian weight.
Both days 0-10 (102.5±20.9mg, p=0.026) and days 5-10 (109.2±8.0mg, p=0.029)
GnRH antagonist regimes significantly reduced the mean paired ovary weight
compared to preovulatory late follicular controls (165.0±22.2mg). Values are means
± sem. Superscripts a and b denote statistical significance. Statistics used: one way
ANOVA with an LSD post hoc test.
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Figure 3.5 Haematoxylin and eosin stained ovary sections.
Sections of control day 0 early follicular phase (A), day 5 mid follicular phase with
tertiary follicles (B), day 10 late follicular phase with healthy dominant follicles
containing intact granulosa cells (inset) (C) or early luteal phase (D), GnRH
antagonist treatment days 0-10 (E) and GnRH antagonist treatment days 5-10
showing atretic granulosa cells (inset) (F). Note the lack of healthy dominant
follicles in both of the treated groups.
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3.3.3 Effect on tertiary follicle development
Frequency measurements of follicle populations are shown in Figure 3.6. Healthy
follicles with diameters >2000pm present in late follicular controls (Figure 3.6A)
were absent in both treatment groups (Figure 3.6B & 3.6C). The mean diameter of
the remaining tertiary follicles in late follicular control ovaries was 684.6+9.Opm.
After GnRH antagonist the mean follicle diameter increased to 768.2+27.2pm and
733.2+29.lpm for treatment between days 0-10 and days 5-10 respectively.
Comparison of the mean diameter (Figure 3.7) confirmed a significant increase
(p=0.048) in mean tertiary follicle diameter after GnRH antagonist treatment
between days 0-10 compared with late follicular controls. The number of atretic
tertiary follicles (Figure 3.8) was significantly decreased in both the treatment
groups, days 0-10 (5.7+1.6, p=0.007) and days 5-10 (7.4+1.6, p=0.044) compared to
late follicular controls (12.4+1.5). Atretic dominant follicles were unique to the day
5-10 GnRH antagonist treatment group, pictured in Figure 3.5F.
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Figure 3.6 Tertiary follicle frequency.
Histograms showing distribution of tertiary follicle size in late follicular control
animals (A), day 0-10 GnRH antagonist treated animals (B) and day 5-10 GnRH
treated animals (C). The effect of both the treatments was to positively skew the
frequency of antral follicles present in the ovaries compared to controls.
Measurements are in microns.
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Figure 3.7 Mean tertiary follicle diameter.
After both GnRH antagonist treatment for 0-10 days (768.2+27.2pm) and 5-10 days
(733.2+29. lpm) the mean tertiary follicle diameter increased compared to late
follicular controls (684.6+9.0pm). A significant increase was observed between late
follicular controls and GnRH antagonist treatment between days 0-10 (p=0.048).
Values are means ± sem. Superscripts a and b denote statistical significance.
Statistics used: one way ANOVA with an LSD post hoc test.
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Figure 3.8 Atretic tertiary follicles per ovary.
Analysis showed a significant decrease in the number of atretic follicles between
controls (12.4+1.5) and either treatment group, day 0-10 (5.7+1.2, p=0.007) and day
5-10 (7.4+1.6, p=0.044). Values are means ± sem. Superscripts a and b denote
statistical significance. Statistics used: one way ANOVA with an LSD post hoc test.
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3.3.4 Effect on cellular proliferation
A typical tertiary follicle from a late follicular control ovary is shown in Figure
3.9A. The total numbers of proliferating cells were counted as a percentage of the
total number of cells present in the follicle compartment in question. Analysis of
granulosa cell proliferation in different classes of follicles from late follicular control
ovaries revealed a statistically significant increase in proliferation between early
secondary (6.3%+0.9) and late secondary follicles (12.4%+1.6, p=0.004) and a
significant decrease in proliferation between late secondary (12.4%+1.6) and
dominant follicles (5.8%±0.6, p=0.008) (Figure 3.10A). Similarly, significant
increases in the rate of theca cell proliferation were observed between early
secondary (0.7%+0.3) and late secondary follicles (8.0%+0.8, p=0.001), and late
secondary (8.0%+0.8) and tertiary follicles (12.5%±1.8, p=0.041). A significant
decrease in the rate of proliferation was observed between tertiary (12.5%+1.8) and
dominant follicles (4.1%+0.2, p=0.002) (Figure 3.1 IB).
Comparison of typical tertiary follicles from a late follicular control (Figure
3.9A), a GnRH antagonist treated ovary from day 0-10 (Figure 3.9B) and a GnRH
antagonist treated ovary from day 5-10 (Figure 3.9C) showed a decrease in both
granulosa and thecal proliferation after both treatment schedules. Quantitative
analyses confirmed significantly decreased cell proliferation in the granulosa, day 0-
10 (4.6%±1.5, p=0.013) and day 5-10 (6.5%±0.4, p=0.009)(Figure 3.10B) and theca
day 0-10 (5.55%±2.0, p=0.034) day 5-10 (7.1%±1.3, p=0.029)(Figure 3.11B) of
tertiary follicles after treatment compared to late follicular controls (granulosa
9.0%+0.6, theca 12.5%+1.8). In the dominant follicles, a significant reduction in
cellular proliferation in both the granulosa (5.8%+0.6 to 1.4%+0.7, p=0.044)(Figure
3.10B) and theca (4.1%+0.2 to l.l%+0.5, p=0.01)(Figure 3.11B) compartments was
also seen after GnRH antagonist treatment between days 5-10 of the follicular phase
compared to late follicular controls.
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Figure 3.9 BrdU immunocytochemistry in tertiary follicles.
Tertiary follicles of (A) late follicular control, (B) day 0-10 GnRH antagonist treated
and (C) day 5-10 GnRH antagonist treated ovaries are shown. Note the decrease in
both granulosa and theca proliferation after both treatment schedules. Proliferation
cells have a black nuclear stain. g=granulosa, t=theca.
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Figure 3.10 Granulosa cell proliferation index.
Analysis of granulosa cell proliferation (A) in different classes of follicles from late
follicular control ovaries. Quantitative analysis confirmed a significant increase in
proliferation between early secondary (6.3%+0.9) and late secondary follicles
(12.4%+1.6, p=0.004) and a significant decrease in proliferation between late
secondary (12.4%+1.6) and dominant follicles (5.8%+0.6 p=0.008). (B) A
significant decreased in granulosa cell proliferation in tertiary (day 0-10, 4.6%±1.5,
p=0.013 and day 5-10, 6.5%+0.4, p=0.009) and dominant follicles (day 5-10
1,4%±0.7, p=0.044) was also confirmed compared to late follicular controls (tertiary
9.0%+0.6 and dominant 5.8%+0.6). Values are means ± sem. Superscripts a, b, y
and z denote statistical significance. Statistics used: one way ANOVA with LSD
post hoc tests.
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Figure 3.11 Thecal proliferation index.
Analysis of theca cell proliferation in (A) different classes of follicles from late
follicular control ovaries. Quantitative analysis confirmed significant increases in
proliferation between early secondary (0.7%+0.3) and late secondary follicles
(8.0%±0.8, p=0.001), late secondary (8.0%+0.8) and tertiary follicles (12.5%+1.8,
p=0.041) and a significant decrease in proliferation between tertiary (12.5%+1.8) and
dominant follicles (4.1%+0.2, p=0.002). (B) Significant decreases in theca cell
proliferation in tertiary (day 0-10, 7.1%+1.3, p=0.034 and day 5-10, 5.5%±2.0,
p=0.029) and dominant follicles (day 5-10, l.l%+0.5, p=0.01) compared to late
follicular controls was also confirmed (tertiary=12.5%+1.8, dominant=4.1%+0.2).
Values are means ± sem. Superscripts a, b, c, y and z denote statistical significance.
Statistics used: one way ANOVA with LSD post hoc tests.
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3.3.5 Endothelial cell proliferation
An index of the number of proliferating cells in the thecal compartment that were
endothelial cells by co-localisation of CD31 and BrdU was used to determine the
extent to which the treatment had impaired endothelial cell division and hence
ongoing angiogenesis. In late follicular control ovaries (Figure 3.12A), dual-
labelled cells were readily apparent. Quantitative analysis of follicles from late
follicular control ovaries showed no rise in endothelial cell proliferation between late
secondary and tertiary stages of follicle development (Figure 3.13A). A significant
increase in the proportion of proliferating cells that were endothelial was observed
between tertiary (16.8%+3.1) and dominant follicles (51.0%+1.8, p<0.001) (Figure
3.13A). In late secondary follicles from ovaries from GnRH antagonist treatment
between days 0-10 (Figure 3.12B) dual labelled cells were reduced significantly
(7.2%+1.5, p=0.014) compared to late follicular controls (19.7%+2.6) (Figure
3.13B). In tertiary follicles from ovaries from GnRH antagonist treatment between
days 0-10 dual labelled cells were reduced significantly (16.8%+3.1 to 7.2%+2.0,
p=0.043)(Figure 3.13B). After treatment between days 5-10 (Figure 3.13C) there
was no reduction in dual labelled cells in tertiary follicles. Endothelial cell
proliferation was also significantly reduced between dominant but atretic follicles
from the day 5-10 GnRH antagonist treatment group (20.7%+9.90) and dominant
follicles from late follicular controls (51.0%+1.8, p=0.036) (Figure 3.13B).
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Figure 3.12 BrdU and CD31 dual staining immunocytochemistry in tertiary
follicles.
Tertiary follicles of (A) late follicular control, (B) day 0-10 GnRH antagonist treated
and (C) day 5-10 GnRH antagonist treated ovary are shown. Note the decrease in the
number of co-localised BrdU and CD31 cells. Proliferating cells have a black
nuclear stain, endothelial cells have a red stain, co-localised cells have both.
g=granulosa, t=theca.
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Figure 3.13 Proliferating endothelial cell index.
Analysis of thecal dual staining in (A) different classes of follicles from late
follicular control ovaries. Quantitative analysis confirmed a significant increase in
dual staining cells proliferation between tertiary (16.8%+3.1) and dominant follicles
(51.0%+1.8, p<0.001). (B) Significant decreases in dual cell proliferation in late
secondary (day 0-10, 7.2%+1.5 compared to 19.7%+2.6, p=0.014), tertiary (day 0-
10, 7.2%+2.0 compared to 16.8%±3.1, p=0.043) and dominant follicles (day 5-10,
20.7%+9.9 compared to 51.0%+1.8, p=0.036) compared to late follicular controls
was also confirmed. Values are means ± sem. Superscripts a, b, y and z denote
statistical significance. Statistics used: one way ANOVA with LSD post hoc tests.
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3.3.6 Non-endothelial cell proliferation
Analysis of non-endothelial, presumably predominantly thecal, cell proliferation in
the theca showed a significant increase between late secondary (6.5%+0.7) and
tertiary follicles (10.7%+1.5, p=0.041)(Figure 3.14A), a significant decrease was
observed between tertiary (10.7%±1.5) and dominant follicles (1.9%+0.2,
p=0.001)(Figure 3.14A).
After GnRH antagonist treatment the amount of non-endothelial cell
proliferation in the theca was also examined. GnRH antagonist treatment between
days 0-10 resulted in a significant (5.0%+1.8) reduction in the number of non-
endothelial cells proliferating in tertiary follicles compared to late follicular controls
(10.7%+1.5, p=0.029) (Figure 3.14B). GnRH antagonist treatment from days 5-10
resulted in a non-significant (6.1%+1.3) reduction in non-endothelial cell
proliferation in tertiary follicles compared to late follicular controls (10.7%±1.5,
p=0.051) and a significant reduction in non-endothelial cell proliferation in dominant
but atretic follicles (0.8%+0.3) compared with late follicular controls (1.9%+0.2,
p=0.018) (Figure 3.14B).
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Figure 3.14 Non endothelial cell proliferation.
Analysis of non-endothelial cell proliferation in the theca showed (A) a significant
increase between late secondary (6.5%+0.7) and tertiary follicles (10.7%±1.5,
p=0.041) and a significant decrease between tertiary (10.7%±1.5) and dominant
follicles (1.9%+0.2, p=0.001). (B) GnRH antagonist treatment between days 0-10
resulted in a significant (5.0%±1.8 compared to 10.7%+1.5, p=0.029) reduction in
non-endothelial cell proliferation in tertiary follicles and a significant (0.8%+0.3
compared to 1.9%+0.2, days 5-10 p=0.018) reduction in non-endothelial cell
proliferation in dominant but atretic follicles compared with late follicular controls.
Values are means ± sem. Superscripts a, b, c, y and z denote statistical significance.
Statistics used: one way ANOVA with LSD post hoc tests.
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3.3.7 Effect on vasculature
Localisation of blood vessels using an endothelial cell marker in tertiary follicles is
shown in Figure 3.15. Large vessels were located in the outer theca while smaller
vessels were observed within the vicinity of the lamina basalis. Extensive
vascularisation was observed in both controls (Figure 3.15A) and after GnRH
antagonist treatment between days 0-10 (Figure 3.15B) and days 5-10 (Figure
3.15C) of the follicular phase. Quantitative analysis of staining of follicles from late
follicular control ovaries showed a significant increase in the extent of
vascularisation between tertiary (5.8%±0.3) and dominant follicles (12.3%+0.8,
p<0.001) (Figure 3.16A). Analysis indicated that there was no difference in the
extent of thecal vascularisation between the groups treated and control groups
(Figure 3.16B).
However, as follicles develop the theca becomes thicker. Significant increases
in thecal diameter were observed between late secondary (24.9+2.0/<m) and tertiary
(57.3±2.7/<m, p<0.001) and between tertiary (57.3+2.7//m) and dominant follicles
(74.9+4.1/mi, p=0.002) from late follicular control ovaries, Figure 3.17A. A
thinning of the theca was observed between follicles from late follicular controls and
both treatment groups, with a significant decrease in the mean thecal thickness
between dominant follicles from GnRH antagonist treatment between days 5-10
(52.21+4.5/*m) of the follicular phase and dominant follicles from late follicular
controls (74.9+4.1/im, p=0.006) (Figure 3.17B). To adjust for the effect of the
thinner theca, a conversion factor was used to quantify an absolute value of CD31
positive staining in each class of follicle, based on a technique applied by Wulff et al
(Wulff et al. 2001a). The conversion factors were calculated as a ratio of mean
thecal thickness against the late follicular control mean for each class of follicle,
giving the late follicular control conversion a value of one. After adjustment, no
increase in thecal vascularisation was observed between late secondary and tertiary
follicles from late follicular control ovaries. Although a significant increase in thecal
vascularisation was observed between tertiary (5.8%+0.3) and dominant follicles
from late follicular control ovaries (12.3%+0.9, p<0.001)(Figure 3.18A). Also, after
GnRH antagonist treatment a significant reduction in thecal vascularisation was
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demonstrated between tertiary follicles from late follicular controls (5.8%±0.3) and
day 0-10 GnRH antagonist treatment (4.0%+0.6, p=0.04) (Figure 3.18B). A
significant reduction was also observed between dominant follicles after day 5-10
GnRH antagonist treatment (8.1%+0.4) and late follicular controls (12.3%±0.9,
p=0.014) after adjustment for thecal thickness (Figure 3.18B).
Chapter 3 GnRH antagonist 103
Figure 3.15 CD31 immunocytochemistry in tertiary follicles.
Tertiary follicles of (A) late follicular control, (B) day 0-10 GnRH antagonist treated
and (C) day 5-10 GnRH antagonist treated ovary are shown. Note the uniform
positioning of the blood vessels in ovaries from both treated and control animals.
g=granulosa, t=theca
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Figure 3.16 Quantification of thecal CD31 staining.
Quantitative analysis of the CD31 staining in the theca showed (A) a significant
increase in the extent of follicular vascularisation between tertiary (5.8%+0.3) and
dominant follicles in late follicular control ovaries (12.3%+0.8, p<0.001). (B) No
difference in the extent of vascularisation after either treatment. Values are means ±
sem. Superscripts a, b and y denote statistical significance. Statistics used: one way
ANOVA with an LSD post hoc test.
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Figure 3.17 Quantification of thecal thickness.
(A) Significant increases in thecal diameter were observed between late secondary
(24.9+2.0pm) and tertiary (57.3+2.7pm, p<0.001) and between tertiary
(57.3+2.7pm) and dominant follicles from late follicular control ovaries
(74.9+4. lpm, p=0.002). (B) A significant decrease in the mean thecal thickness
between dominant follicles from GnRH antagonist treatment between days 5-10 of
the follicular phase (52.2+4.5pm) and dominant follicles from late follicular controls
(74.9+4.lpm, p=0.006) was also observed. Values are means ± sem. Superscripts a,
b, c, y and z denote statistical significance. Statistics used: one way ANOVA with
LSD post hoc tests.
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Figure 3.18 Relative vascularisation of theca
After adjustment a significant increase in thecal vascularisation was observed (A)
between tertiary (5.8%+0.3) and dominant follicles (12.3%+0.9, p<0.001) from late
follicular control ovaries. (B) After GnRH antagonist treatment a significant
reduction in thecal vascularisation was demonstrated between tertiary follicles from
late follicular controls and day 0-10 GnRH antagonist treatment (4.0%±0.6 compared
to 5.8%±0.3 p=0.04) and between dominant follicles after day 5-10 GnRH antagonist
treatment and late follicular controls (8.1%+0.4 compared to 12.3%+0.9, p=0.014).
Values are means ± sem. Superscripts a, b, y and z denote statistical significance.
Statistics used: one way ANOVA with LSD post hoc tests.
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3.3.8 Localisation of VEGF mRNA
In situ hybridisation revealed VEGF mRNA in both control and treated groups was
absent in primordial, primary and early secondary follicles. VEGF mRNA was
expressed in the granulosa of late secondary and tertiary follicles from late follicular
controls (Figure 3.19A&B), after GnRH antagonist treatment between days 0-10
(Figure 3.19E&F), days 5-10 (Figure 3.19G&H)(Figure 3.21B) and in mid
follicular controls (Figure 3.19I&J). VEGF mRNA was also expressed in the theca
of atretic follicles in the late follicular controls (Figure 3.19C&D), with a significant
increase in the level of expression between tertiary (1.3+0.2) and atretic follicles
(2.4+0.2, p=0.019) from late follicular control ovaries (Figure 3.19A-D)(Figure
3.22A). However, thecal expression was absent in the theca of atretic follicles from
both the days 0-10 and days 5-10 GnRH antagonist treatment groups (0.2+0.15,
p=0.024 and 0.4+0.1, p=0.004 respectively)(Figure 3.22B), and the mid follicular
controls (Figure 3.19E-J).
In the dominant follicles of late follicular controls, VEGF mRNA continued to
be expressed in the granulosa cells (Figure 3.20A&B). However, in follicles that
appeared to be closer to the time of ovulation, VEGF mRNA expression in the
granulosa cells was reduced and an intense punctate expression pattern in cells in the
thecal layer on the border of the granulosa cells was observed (2.4+0.3), being
significantly increased compared to tertiary follicles (1.3+0.2, p=0.024) (Figure
3.20C&D, 3.22A). This punctate pattern was also observed in postovulatory
follicles (Figure 3.20E&F) at the edge of the newly forming corpus luteum. In
contrast, VEGF mRNA expression was absent from both granulosa and theca in all
the dominant follicles from the day 5-10 GnRH antagonist treatment group (Figure
3.20G&H). Quantitative analysis confirmed these observations (1.7+0.3 compared
to 0.25+0.25, p=0.016 and 2.4+0.3 compared to 0.4+0.2, p<0.001 respectively)
(Figure 3.2IB, 3.22B).










Figure 3.19 Dark and light field photomicrographs showing in situ hybridisation
for VEGF mRNA.
(A&B) VEGF mRNA localised in the granulosa of late follicular phase tertiary
follicles. The same expression pattern was found in both treatment groups days 0-10
(E&F), days 5-10 (G&H) and in mid follicular controls (I&J). VEGF mRNA was
also expressed in the theca of atretic follicles in the late follicular controls (C&D) but
was absent in atretic follicles in both treatment groups and the mid follicular controls
(E&J). Note frequent occurrence of high expression in cumulus cells surrounding
the oocyte. g=granulosa, t=theca, o=oocyte.
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Figure 3.20 Dark and light field photomicrographs showing in situ hybridisation
for VEGF mRNA.
(A&B) VEGF mRNA localised in the dominant follicles of late follicular controls
VEGF mRNA is expressed in the granulosa cells. (C&D) Before ovulation, VEGF
mRNA expression in the granulosa cells is reduced while a punctate expression
pattern in the theca cells on the border of the granulosa cells is observed. (E&F)
This punctate pattern is also observed in postovulatory follicles at the edge of the
newly forming CL. (G&H) This expression is absent in the dominant follicles from
the 5-10 day GnRH antagonist treatment group while expression is maintained in the
granulosa of tertiary follicles. g=granulosa, t=theca, a=antrum















Figure 3.21 Quantification of VEGF mRNA expression in granulosa cells.
Quantitative analysis of VEGF mRNA expression in granulosa cells from: (A)
Different follicle classes from late follicular control ovaries showed no significant
difference in VEGF mRNA expression; (B) GnRH antagonist treatment for days 5-
10 significantly reduced VEGF mRNA expression in the granulosa cells of dominant
but atretic follicles (0.25+0.25) compared to late follicular controls (1.7+0.3,
p=0.016). Values are means ± sem. Superscripts a, b, y and z denote statistical
significance. Statistics used: two tailed unpaired t-test in panel A and one way
ANOVA with LSD post hoc tests in panel B.
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Figure 3.22 Quantification of VEGF mRNA expression in the theca.
Quantitative analysis of VEGF mRNA expression in the theca showed: (A) a
significant increase between tertiary (1.3+0.2) and dominant follicles (2.4+0.3,
p=0.024) and between tertiary (1.3+0.2) and atretic follicles (2.4+0.2 p=0.019) in late
follicular control ovaries; (B) After GnRH antagonist treatment for days 0-10 a
significant reduction in VEGF expression was seen in atretic follicle (0.2+0.15
compared to 2.4+0.2, p=0.024) and after treatment for days 5-10 significant
reduction in both dominant and atretic follicles (0.4+0.2 compared to 2.4+0.3,
p<0.001 and 0.4+0.1 compared to 2.4+0.2, p=0.004 respectively). Values are means
± sem. Superscripts a, b, y and z denote statistical significance. Statistics used: one
way ANOVA with LSD post hoc tests.
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3.3.9 Aromatase mRNA
Aromatase mRNA expression was measured to establish the level of differentiation
of the granulosa cells. In control preovulatory follicles, aromatase mRNA was
expressed in the mural granulosa cells closest to the membrana propria (Figure
3.23A&B), along with some expression in old luteal tissue and newly forming extra-
luteal tissue. After both the GnRH antagonist treatment regimes there was an
absence of aromatase mRNA expression (day 5-10 shown Figure 3.23C&D). Some
expression in old luteal tissue was maintained. Quantitative analysis confirmed this





Figure 3.23 Photomicrograph of in situ hybridisation for aromatase mRNA.
(A&B) Aromatase in situ in a preovulatory follicle and Day 5-10 GnRH antagonist
treated (C&D). Note the absence of aromatase mRNA expression in the treated
ovary. g=granulosa, t=theca.
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Figure 3.24 Quantification of aromatase mRNA expression.
Quantification of aromatase mRNA expression showed a significant reduction in
expression in dominant follicle after GnRH antagonist treatment for days 5-10
compared to late follicular controls (p=0.016). Values are means ± sem.
Superscripts a and b denote statistical significance. Statistics used: Rank Sum of
independent samples (Mann-Whitney test).
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3.4 Discussion
3.4.1 Key results
-The development of dominant follicles was completely inhibited by the 0-10 day
GnRH antagonist treatment.
-Dominant follicles did develop after 5-10 day GnRH antagonist treatment, although
these follicles were abnormal and cystic in appearance.
-Follicular angiogenesis was moderately inhibited by GnRH antagonist treatment.
-In preovulatory follicles VEGF mRNA expression was absent from granulosa cells
but activated in an intense punctate pattern in the theca.
-VEGF mRNA expression in tertiary follicles in ovaries from GnRH antagonist
treated animals was similar to that seen in controls.
-VEGF mRNA was highly expressed in the theca of atretic follicles from late
follicular ovaries, this expression is absent after GnRH antagonist treatment.
3.4.2 Background
GnRH antagonists are widely used in the clinic during ovarian hyperstimulation
programmes to block endogenous gonadotrophin secretion and the pre-ovulatory LH
surge while exogenous gonadotrophins are being administered (Evans et al. 2002,
Huirne et al. 2004). Many studies have examined the effects of GnRH antagonist
treatment on pituitary-ovarian function throughout the follicular phase in non-human
primates and in women and have demonstrated a suppression in LH and FSH
secretion associated with a fall in serum oestradiol production (Ditkoff et al. 1991,
Fluker et al. 1991, Hall et al. 1991, Karnitis et al. 1994, Nelson et al. 1995, Fraser et
al. 1999a). However, the effect upon vascularisation of the follicles during GnRH
antagonist treatment has not been determined. Previous studies have shown that
GnRH antagonist treatment ofmarmosets during the early luteal phase had a marked
inhibitory effect upon the intense angiogenesis normally observed in the corpus
luteum at this time (Dickson and Fraser 2000) and that this was associated with luteal
cellular degeneration (Dickson and Fraser 2000) and a marked reduction in
expression of VEGF as demonstrated by in situ hybridisation (H.M. Fraser,
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unpublished observations).
Angiogenesis is intimately involved in ovarian follicle development (Fraser
and Wulff 2001, Zimmermann et al. 2001b, Zimmermann et al. 2003) and is
necessary for normal follicular growth (Wulff et al. 2001b, Wulff et al. 2002). The
expression pattern of VEGF mRNA in the ovarian follicle suggests it is regulated by
gonadotrophic stimulation (Ravindranath et al. 1992, Shweiki et al. 1993). Hence
the effect of GnRH antagonist treatment on follicular development and
vascularisation in the marmoset ovary might be expected to result in a suppression of
VEGF expression, inhibition of angiogenesis and follicular development.
3.4.3 Analysis
The most expected findings were observed in the day 0-10 GnRH antagonist treated
animals in which development of large dominant follicles was completely inhibited
and oestradiol secretion was markedly suppressed. In the remaining healthy tertiary
follicles, granulosa and theca cell proliferation was reduced. Angiogenesis was also
lower in these follicles and this resulted in a reduction in endothelial cell area after
the reduction in thecal thickness was taken into account. However, these effects
were much less than after inhibition of VEGF by a specific antagonist (Wulff et al.
2002) and Chapter 5. Surprisingly, VEGF mRNA expression was similar to controls
in these tertiary follicles. Similarly, in the day 5-10 treated group, VEGF mRNA
continued to be highly expressed in the granulosa cells of tertiary follicles. This
suggests that at this stage of development, follicular VEGF expression is not tightly
controlled by the gonadotrophins.
3.4.3.1 Gonadotrophin inhibition
It is reasonable to suggest that follicular development and angiogenesis may be
maintained by residual gonadotrophin secretion. Unfortunately LH and FSH could
not be measured in the present study because these assays are problematic in the
marmoset and there are restrictions in the volume of plasma that can be collected.
However, a degree of residual gonadotrophin secretion would be expected to persist
after GnRH antagonist treatment with FSH being less suppressed than LH. Evidence
from a series of clinical studies using GnRH antagonists in humans would suggest
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the concentration of FSH to be suppressed by approximately 33%, with LH
concentrations suppressed by approximately 70%, although the concentrations of
antagonist used in these studies was in some cases over one hundred times less than
those used in this study (Ditkoff et al. 1991, Fluker et al. 1991, Hall et al. 1991,
Nelson et al. 1995, Oberye et al. 1999). While this suppression is sufficient to
reduce the ability of mature follicles to produce oestradiol, low levels of LH and
FSH remaining may be sufficient to maintain the activity of tertiary follicles. In
addition, the possibility of stimulation of VEGF expression by hypoxia, as seen in
solid tumours (Shweiki et al. 1992) and the endometrium (Sharkey et al. 2000),
occurring in granulosa cells in tertiary follicles deprived of gonadotrophic support
requires to be investigated. However, this phenomenon does not appear to occur in
follicular granulosa cells from pre-ovulatory follicles (Martinez-Chequer et al.
2003). Paracrine mechanisms could also be acting in these tertiary follicles that may
still function during the withdrawal of the gonadotrophins to help maintain VEGF
mRNA expression. Recent evidence also suggests that locally produced factors and
cytokines such as insulin-like growth factors -1 and -2 play a role in regulating
ovarian VEGF mRNA expression in pre-ovulatory follicles (Martinez-Chequer et al.
2003). Such mechanisms may also explain the continued VEGF mRNA expression
in tertiary follicles in the current study. The fact that there was a decrease in
endothelial cell proliferation in these follicles after 10 days GnRH antagonist
treatment does suggest that a deleterious effect on the VEGF pathway was occurring,
perhaps at the level of translation ofVEGF mRNA into biologically active protein or
by disruption of the process of transfer of the VEGF protein from the granulosa cells
to the thecal layer.
One further point that should be considered is that there is evidence that GnRH
can act directly on the ovary though specific, high-affinity receptors in a number of
species, including the rat (Knecht et al. 1981), pig (Maruo et al. 1985) and rabbit
(Koos and LeMaire 1985). Some of the effects of GnRH antagonist treatment may
therefore be mediated by the direct inhibition of GnRH and not via the
gonadotrophins. Studies in the marmoset do suggest that GnRH can directly affect
ovarian function although not through the high affinity receptors found in other
species (Wickings et al. 1990, Fraser et al. 1996).
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3.4.3.2 Follicle dynamics
Although pre-ovulatory follicles developed during treatment with GnRH antagonist
between days 5-10, these follicles were abnormal and cystic in appearance. This
indicates a stage of development after which normal levels of gonadotrophic support
for follicle expansion is not required, presumably because the dominant follicles
have already been selected by the mid follicular phase, as suggested by Gilchrist et al
(2001). Angiogenesis was decreased in these cyst-like follicles and VEGF mRNA
was absent from both the theca and the granulosa cell layers. The observation that
follicles grew to pre-ovulatory size but undergo atresia and fail to produce oestradiol
indicates a differential level of gonadotrophic stimulation required for proliferation
(growth) and cellular differentiation (steroid synthesis) in the dominant follicle. In
addition, the marked reduction in aromatase mRNA expression in these dominant but
atretic follicles gives further support to the hypothesis that a differential level of
gonadotrophic support is required for dominant follicle expansion and
differentiation. GnRH antagonist treatment in cynomolgus monkeys has shown that
FSH alone is cable of stimulating follicle expansion as determined by ultrasound
monitoring, whilst not stimulating oestradiol production due to lack of LH stimulated
androgen production (Karnitis et al. 1994) although the health of these large follicles
was not assessed.
It might have been expected that the rate of follicular atresia would have
increased after GnRH antagonist treatment. However, there was a reduction in the
number of atretic follicles and an increase in the mean tertiary follicle diameter after
both GnRH antagonist treatment schedules. This may be explained by the fact that
tertiary follicles not having sufficient FSH stimulation to continue developing appear
to be held in an arrested state of development and fail to be cleared from the ovary
by apoptosis (Tsafriri and Braw 1984) as they would be in a normal follicular phase
ovary approaching ovulation. Also, the reduction in thecal thickness observed in the
dominant follicle from the day 5-10 treatment group is probably due to a deficiency
in gonadotrophic support for both the theca directly and the granulosa cells
stimulating thecal development in a paracrine manor.
Chapter 3 GnRH antagonist 119
3.4.3.3 VEGF mRNA expression
In follicles close to the point of ovulation in control ovaries, a shift in the VEGF
mRNA expression pattern was observed, disappearing from the granulosa cells but
switching on in an intense punctate pattern in the theca in cells close to the blood
vessels. In healthy pre-ovulatory follicles the reduction in VEGF mRNA expression
is consistent with the finding that VEGF production is switched off in the granulosa
cells of gilts after treatment with human chorionic gonadotrophin (hCG) (Barboni et
al. 2000). The punctate VEGF mRNA expression observed in the thecal
compartment of dominant follicles on follicular day 10 in the marmoset appears to be
similar to that first noted in the rhesus monkey ovary (Ravindranath et al. 1992). It
has also been suggested from observations in the sheep ovary that pericytes in the
thecal layer play a key role in the transition from preovulatory follicle to the new
corpus luteum (Redmer et al. 2001). The VEGF mRNA positive cells observed in
the marmoset theca are possibly vascular pericytes. However, these conclusions do
not appear to concur with other studies on expression of VEGF mRNA and protein in
the rhesus monkey (Christenson and Stouffer 1997, Hazzard et al. 1999), where
cultures of aspirated granulosa cells exposed to regimes of FSH and LH in vivo
showed that VEGF expression is stimulated by the gonadotrophins.
The absence of VEGF mRNA expression in the theca of atretic dominant
follicles from the day 5-10 GnRH antagonist treatment group indicates that the
expression of VEGF in the thecal cells directly prior to ovulation is dependent upon
the LH surge and not hypoxia as suggested by Neeman et al (1997). The LH surge is
absent in both GnRH antagonist treated groups, while the morphologically intact
theca of these follicles would still be responsive to LH. The absence in VEGF
mRNA expression in the dominant atretic follicles from the day 5-10 GnRH
antagonist treated group also suggests that normal physiological levels of VEGF are
not required for dominant follicle expansion between the mid to late follicular
period, even though VEGF is thought to play a role as a permeability factor in
follicle development (Koos 1995), allowing the movement of fluid into the follicle to
expand the antral cavity. Surprisingly, VEGF mRNA expression was also detected
in the theca of atretic tertiary follicles in the late follicular control animals. This
expression was again absent in GnRH antagonist treated animals and was not present
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in atretic follicles from mid-follicular phase ovaries. This suggests that the LH surge
triggers the strong expression of VEGF mRNA in the theca of atretic follicles at the
time of ovulation, which may play a role in the establishment of extra luteal tissue
from the atretic tertiary follicles present at ovulation, a common feature in the
marmoset (McAnulty 1994).
3.4.4 Conclusion
In conclusion, the use of a potent GnRH antagonist to block gonadotrophin release
did not result in complete inhibition of follicular angiogenesis as had been predicted
from the results of their use during the luteal phase of the cycle. This raises the
possibility of other factors and paracrine mechanisms regulating VEGF and
angiogenesis in the primate ovarian follicle. Also, the dynamic expression pattern of
VEGF mRNA evident as the dominant follicles develop towards ovulation poses
interesting question as to VEGF's regulation during the periovulatory period.
3.4.5 The next step
To further investigate and extend the findings of this chapter, the next chapter
assesses the level of FSH stimulation required to stimulate follicular angiogenesis
and follicular steroid hormone synthesis as evidence from this chapter suggests that
angiogenic activity should be stimulated at a lower threshold of FSH stimulation than
steroid hormone production. This evidence being that whilst angiogenesis was
moderately inhibited by GnRH antagonist treatment ovarian hormone production
was severely suppressed. Use of primary granulosa cell cultures and measurement of
angiogenic (VEGF) and steroidogenic (aromatase) gene induction under graded FSH
stimulation will be used to test this hypothesis.
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Chapter 4 The Effect of FSH Stimulation on VEGF
and Aromatase Gene Expression in vitro
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4.1 Introduction
Data presented in Chapter 3 suggested that there could be a differential level of FSH
stimulation required for follicular angiogenesis (VEGF expression) and granulosa
cell differentiation (aromatase expression), with follicles becoming vascularised but
not undergoing differentiation or producing steroid hormones. This chapter aims to
further investigate the level of FSH stimulation required for VEGF and aromatase
gene expression in granulosa cells from the marmoset ovarian follicle. The
hypothesis being that VEGF production will be stimulated at a lower concentration
of FSH than aromatase, i.e. angiogenesis is stimulated in follicles before steroid
production is.
In order to investigate this issue, it is necessary to appreciate the mechanisms
that regulate FSH stimulated gene expression in the granulosa cells. FSH signals
through the FSH receptor, a single 75kDa polypeptide with a 348 residue
extracellular domain containing three N-linked glycosylation sites, which is identical
in its structural design to the LH receptor (Sprengel et al. 1990). Furthermore, both
receptors display 50% sequence similarity in their large extracellular domains and
80% identity across the seven transmembrane segments (Sprengel et al. 1990). The
first direct evidence that granulosa cells express the FSH receptor was obtained by
autoradiographic localisation of 125I-labelled FSH binding to immature rat ovarian
sections (Zeleznik et al. 1974). The post-receptor signalling systems that relay FSH
stimulation to the granulosa cell nucleus rests mainly on adenylyl cyclase, cAMP
production, and activation of protein kinase A (PKA) (Richards 1994). At the early
stages of follicular growth FSH supports mitotic cell division in the granulosa cells
(Hirshfield 1986), whereas during the final stages of preovulatory development, FSH
induces the expression of specific genes, leading to major changes in granulosa cell
differentiation (Richards 1980). Despite the presence of similar numbers of FSH
receptors per cell, granulosa cells of small antral follicles produce less cAMP in
response to FSH than do granulosa cells of preovulatory follicles (Richards 1980).
This highlights the possibility of different transducers to which the FSH receptor can
couple or that the activity of the adenylyl cyclase enzyme is modified in some way
between different classes of follicle.
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In order to better understand the level of FSH stimulation required for follicular
angiogenesis versus differentiation, primary granulosa cell cultures were employed.
VEGF mRNA was used as a marker of angiogenesis, VEGF being expressed in the
granulosa cell in vivo, signalling to the endothelial cells in the theca to promote
angiogenesis. Aromatase mRNA was used as a marker of granulosa cell
differentiation and maturation. The granulosa cells sensitivity to FSH stimulation
with respect to the expression of these two genes was measured after the cells were
cultured in the presence of increasing concentrations of FSH in vitro.
4.2 Specific methods
4.2.1 Source of marmoset tissue
Subordinate adult female marmosets, in which follicular development and ovulation
are known to be suppressed (Abbott et al. 1981) were euthanised as detailed in
Chapter 2. The ovaries were immediately removed and transferred to serum free
medium 199 (Gibco-Europe, Glasgow, UK) containing Earle's salts, 25mM HEPES,
2.68mM L-glutamine, penicillin (50 IU/ml), streptomycin (50pg/ml) and 0.1% BSA
and transported back to the laboratory on ice.
4.2.2 Collection and separation of marmoset granulosa cells
Antral follicles, >500pm, were dissected from the ovaries under a stereomicroscope
using watchmaker's forceps. Granulosa cells were harvested into fresh culture
medium by puncturing individual follicles with a 12-gauge needle. Examples of
dissected follicles both before and after granulosa cell removal are shown in Figure
4.1. Follicles that displayed gross signs of atresia (either degenerate or absent
oocyte) or fragmentation of the granulosa cells were not studied and discarded. The
granulosa cells were then pooled, centrifuged for 5 mins at 300g and re-suspended in
fresh medium. At this point, cellular viability was assessed by trypan blue exclusion
using a haemocytometer.




Figure 4.1 H&E of isolated follicles before and after granulosa cell removal.
(A) Example of a tertiary follicle isolated from a subordinate marmoset ovary before
removal of the granulosa cells. (B) Example of a follicle once it had been punctured
and had the granulosa cells removed.
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4.2.3 Cell culture
Twentyfour wells plates (Nunc plastic dishes, Gibco) were precoated with aseptic
donor calf serum (Gibco) overnight at 37°C then washed twice with Dulecco's
phosphate buffered saline (DPBS, Gibco) before use. FSH was added to the plates at
double the required concentration in 250pl of culture medium. Each well was then
inoculated with a further 250pl of culture medium containing 70,000 viable
granulosa cells, halving the concentration of FSH to the final required concentration
in the wells. The dishes were then incubated at 37°C in 5% CO2 in air for 48 h, in a
humidified incubator. Each treatment was performed in quadruplicate. Recombinant
FSH (Puregon, Organon, Cambridge, UK) at concentrations of 0, 0.1, 1 and 10
mlU/ml were used to stimulate the cells.
To quantify the amount of aromatase enzyme activity elicited by FSH
stimulation, a separate cell culture was set up during the above experiments. These
experiments were carried out as above, but using only 25,000 cells per well. After
45 h incubation the cell monolayers were rinsed twice with 1ml pre-warmed (37°C)
DPBS containing 0.1% BSA to remove all traces of residual steroid. Five hundred
micro litres of fresh pre-warmed culture medium containing (lpM) testosterone (3
wells) or control medium (1 well) was then added to each dish. The added
testosterone acts as an exogenous androgen substrate that the aromatase enzyme
converts to oestradiol. After a 3h incubation at 37°C the culture medium from each
well was collected and stored at -20°C until assayed for oestradiol. Aromatase
activity was expressed as the level of oestradiol produced during a 3 h incubation in
the presence of testosterone, corrected for the level accumulated in the absence of
testosterone.
4.2.4 Total RNA extraction from cells
Total RNA was extracted from cultured cells after 48 h incubation using a Qiagen
RNA extraction kit as per the manufacturers instructions (Qiagen, Crawley, West
Sussex, UK). After removal and storage of culture medium from wells, the cells
were washed in 37°C DPBS to remove any dead, non-adherent cells, (live cells
remained adherent to the well surface). The remaining cells were then trypsinised at
37°C for lOmins and pipetted repeatedly to dislodge them from the base of the wells.
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Cells from all four replicate wells were pooled into a microfuge tube and centrifuged
for 5 mins at 300g. The resulting cell pellet was then washed in PBS. After re-
sedimenting, PBS was removed and 350pl of RLT extraction buffer (containing
guanidine thiocyanate) added. The cells were then passed through a 12-gauge needle
10 times to aid lysis. Threehundred and fifty microlitres of 70% ethanol was then
added and the mix loaded on a Qiagen RNA silica gel column. Washes and elution
of RNA was then performed as per the manufacturer instructions, and stored at
-70°C until required. One micro litre of the harvested RNA was taken for analysis of
quality and concentration using an Agilent 2100 Bioanalyzer (Agilent Technologies
Ltd, South Queensferry, UK) in conjunction with RNA nano chips (Agilent)
4.2.5 Reverse transcription
In order that expression of specific genes of interest can be assessed by quantitative
real time PCR, cDNA was produced from the extracted RNA. Reverse transcription
(RT) was conducted using a Taqman reverse transcription kit (Applied Biosystems,
Cheshire, UK), according to manufacturers instructions. A mixture of buffer,
dNTPs, random hexamers, RT enzyme, MgCk, RNase free water and RNA (200ng
per 20pl reaction mixture) was incubated at room temperature for 10 min before
heating to 42°C for 1 h followed by a 10 min incubation at 95°C. For every sample
an RT-negative was included. This contained all reagents apart from reverse
transcriptase.
4.2.6 Quantitative real time PCR
The LightCycler (Roche, East Sussex, UK) was used to amplify the cDNA in a
cyclic process ofDNA denaturation, specific primer annealing and primer extension
to exponentially increase the primer specified cDNA fragment.
Quantification of real time PCR using this method is based on calculations of
amount of PCR produced per cycle, taking into account both the specific gene of
interest (VEGF or aromatase) and a control (house keeping) gene (|3 actin in this
case).
The fluorescent dye SYBR Green I, used in these reactions, binds to the minor
groove of the DNA double helix. The unbound dye exhibits very little fluorescence,
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however, fluorescence is greatly enhanced upon DNA-binding. As the PCR reaction
continues, the amount of double stranded DNA the SYBR Green can bind to
increases, therefore fluorescence emitted by the SYBR Green also increases. The
LightCycler's optics are set to detect the wavelengths of excitation and emission by
SYBR Green. A measurement of fluorescence is taken after each individual cycle,
therefore the total amount of PCR product in the reaction is measured per cycle.
This principle is outlined in Figure 4.2.
The fluorescence of each individual reaction is measured at a specific
temperature after each cycle. This is to make sure that no non-specific double
stranded DNA is detected, which would disturb the results. The measuring
temperature for all of these reactions was 82°C. Figure 4.3 illustrates the melt peaks
for both the VEGF and (3 actin PCR products, both just above 82°C. The melt peaks
are the points at which the PCR products dissociate and are no longer detectable.
This analysis was also used to determine if more than one PCR product was being
produced due to genomic contamination, as different PCR products have different
melt peaks. Genomic contamination would produce larger PCR products, as all
primers were designed over intron-exon boundaries, with different melt points and
thus different melt peaks.
Relative quantification of the specific PCR products is achieved by
normalisation to known concentrations of serial diluted standards. For these
experiments serially diluted whole ovarian marmoset cDNA was used, and was
reversed transcribed in the same reverse transcription experiment as the experimental
samples to eliminate any variation in RT efficiency. A standard curve was then
generated from the concentration of the standards. The standard curve for each run
was constructed using second derivative maximum software incorporated into the
FightCycler programme. An example of a standard curve is shown in Figure 4.4.
The concentration of the PCR products can then be calculated using the standard
curves from both the gene of interest and the control gene. All samples were run in
duplicate.
4.2.7 Statistical analysis
Data was first tested for normality using a Shapiro-Wilk test. Where more than two
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variables were being compared analysis of variance (ANOVA) with a least
significant difference (LSD) post-hoc test was used if the data was parametric. Non-
parametric data was tested using a Kruskal-Wallis test with Dunn's post-hoc test.
Figure 4.2 The principal behind SYBR Green DNA detection.
(A) At the beginning of amplification, the reaction mixture contains the denatured
DNA, the primers, and the dye. The unbound dye molecules weakly fluoresce. (B)
After annealing of the primers, a few dye molecules can bind to the double strand.
DNA binding results in a dramatic increase in the amount of fluorescence from the
SYBR Green. (C) During elongation, more and more SYBR Green binds to the
newly synthesized DNA. If the reaction is monitored continuously, an increase in
fluorescence is viewed in real-time. Figure adapted from pictures at
http://www.roche-applied-science.com/lightcycler-online/.
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Figure 4.3 Melt peak analysis
Each coloured line on the chart identifies one PCR reaction tube. Two melt peaks
are evident in the analysis, one for VEGF and the other for (3 actin, both of which lie
just above 82°C, the optimised measuring temperature for these LightCycler
reactions.
Log Concentration
Figure 4.4 Standard curve
This standard curve was constructed using the second derivative maximum software
to apply a line of best fit through the points generated by the standards in the
reaction.
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4.2.8 Probe design and optimisation
For quantification purposes on the LightCycler, the PCR primers designed for use
must give a short product, no bigger than ~200bp. Figure 4.5 shows the three PCR
products generated from the three sets of primer pairs designed for use in these
experiments. Primers should also be designed so that they span an intron of the gene
of interest. This is to insure that genomic DNA contamination in a sample can be
detected due to the fact that it would produce a larger PCR product because of the
inclusion of the intron in the PCR product and therefore show up as a different
product during melt point analysis. Complementary DNA sequences for target genes
were acquired from GenBank and primers designed using Primer 3 software;
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Details of the primers
and their positions in the genes of interest and the housekeeping gene are given in
Appendix B. All PCR conditions were optimised on the LightCycler, details of the
reaction conditions are given below:
VEGF Aromatase
LightCycler SYBR Green (enzyme)
Nuclease free H2O
MgCl2




















The housekeeping gene ((3 actin) operated optimally in both reaction conditions.
Chapter 4 Cell culture
1000 bp—*■
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100 bp—-
VEGF Aromatase 0 actin
Figure 4.5 PCR products generated using LightCycler primers
The three PCR products are all of between 155 and 202 bp in length. Note the single
bands in all three lanes indicating the generation of a single PCR product, i.e. no
genomic contamination.
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4.2.9 Steroid hormone assay on culture medium
4.2.9.1 Progesterone
Ninety-six well plates were coated in DARS coating antibody and left overnight at
room temperature. Plates were then washed 5 times with washing solution (302g
Tris, 450g NaCl and 25ml Tween 20, to 2L pure H2O pH 7.5), diluted 1:25 in pure
water before use. Culture medium samples were then diluted 1:50 in assay buffer
(17.85g Na2HPC>4, 7.75g citric acid, lg gelatin, O.lg thiomersalate in 1L pure H2O,
pH 6) and 50pl of diluted medium was then added to the plates. In each assay, a
low, medium and high progesterone concentration QC was used. A standard curve
was prepared from a progesterone standard serially diluted in assay buffer to 3.9, 7.8,
15.6, 31.2, 62.5, 125, 250, 500 and 1000pg/50ql. Fifty micro litres of each standard
in assay buffer was added to the plate. To determine maximum binding (B0), lOOpl
of assay buffer was added separately. To determine none-specific binding 150pl of
assay buffer was added separately. All samples, standard curve, B0, NSB and QC's
were prepared in duplicate. Fifty micro litres of primary antibody, rabbit anti-
progesterone (SAPU), diluted 1:50000 in assay buffer were added to each well
(except NSBs). Plates were covered and left overnight at room temperature. After
incubation overnight, 50ptl per well of labelled ligand (progesterone-11-glucuronide-
biotin complex) diluted 1:7000 in assay buffer was added with 2mg/ml ANSA.
Plates were then covered and left at room temperature for 3 h. After the incubate
was removed, the plates were washed 5 times before 100ql of Streptavidin-
Horseradish peroxidase diluted 1:2000 with normal phosphate buffer (1% casein,
pH7.4) was added to each well. After 1 h, the plates were again washed 5 times
before 200pl per well of substrate OPD (5mM O-Phenylenediamine/0.03% H2O2),
dissolved in substrate buffer,(10.3g citric acid, 17.79g Na2HP04 dihydrate up to 1L
with deionised H2O, pH 5), was added. After 10-20 mins, the reaction was stopped
by adding 50ql of stopping solution (2N sulphuric acid) to each reaction. Plates
were read at 490nm on a spectrophotometer plate counter. Inter assay coefficients of
variation for low-, medium- and high-level quality controls were 20.5%, 15.6% and
19.8% respectively.
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4.2.9.2 Oestradioi
The method for the oestradioi assay was similar to that of the progesterone assay,
however the specifics of the assay were: Coating antibody DAGS (Donkey anti-goat
serum) not DARS; primary antibody is Sheep anti-oestradiol, diluted 1:750,000 in
assay buffer; assay buffer is 11.46g Na2HP04, 2.61g Na2HP04.2H20, 9.0g NaCl, lg
gelatin, O.lg Thiomersalate in 1L deionised H2O, pH 7.4; oestradiol-biotin complex
is used instead of progesterone complex and it is added along with the primary
antibody at the end of day two and not at the start of day three; the standard curve
was prepared from an oestradioi standard serially diluted in assay buffer to 0.06,
0.12, 0.24, 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250 and 500pg/100pl; no
medium-level QC used; and the culture medium was added undiluted. Inter assay
coefficients of variation for low- and high-level quality controls were 13.3% and
16.9% respectively.
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4.3 Results
4.3.1 mRNA
The level of VEGF mRNA increased with increasing levels of FSH stimulation.
There was a significant increase in the expression of VEGF mRNA with 1 mlU/ml
FSF1 (0.27+0.04) compared to no stimulation controls (0.09+0.04, p=0.016) (Figure
4.6). Aromatase mRNA showed similar trends in expression although there were no
statistically significant results (Figure 4.7). It is interesting to note that after 10
mlU/ml FSH stimulation there appears to be a trend for the level of mRNA
expression of both genes to decrease.
4.3.2 Progesterone assay
Measurement of the amount of progesterone present in the culture medium after the
48 h FSH treatments displayed an increase in the level of progesterone produced as
the level of FSH stimulation increased. Statistically significant increases were
observed after 1 (145.5+56.4nmol, p=0.049) and 10 (220.5+106.4nmol, p=0.014)
FSH mlU/ml stimulation compared to controls (24.0+5.7nmol) (Figure 4.8).
4.3.3 Oestradiol assay
Measurement of the amount of oestradiol produced over a 3 h period, after the
granulosa cells had been cultured for 45 h under increasing concentrations of FSH
stimulation. FSH stimulation elicited dose dependent increases in the amount of
oestradiol produced by the granulosa cells. Stimulation with 1 (167.5+63.4pmol,
p=0.016) and 10 (655.2+81.8pmol, p<0.001) mlU FSH caused statistically
significant increases in the amount of oestradiol produced compared to controls
(13.2+3.1pmol) (Figure 4.9).
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Figure 4.6 VEGF mRNA.
VEGF mRNA expression in granulosa cells stimulated for 48 h by graded
concentrations of FSH. A statistically significant increase was observed after 1
mlU/ml (0.27+0.4) FSH stimulation compared to controls (0.09±0.04, p=0.016).
Superscripts a and b denote statistical significance. Statistics used: Kruskal-Wallis
test with Dunn's post hoc test.















Figure 4.7 Aromatase mRNA.
Aromatase mRNA expression in granulosa cells stimulated for 48 h by graded
concentrations of FSH. Superscript a denotes statistical significance. Statistics used:
Kruskal-Wallis test with Dunn's post hoc test.
Chapter 4 Cell culture
Figure 4.8 Progesterone concentration in culture medium.
Progesterone accumulation in culture medium from 48 h FSH culture experiments.
Progesterone concentration showed a dose dependent increase in response to FSH
stimulation. Statistically significant increases were observed after both 1
(145.5+56.4nmol, p=0.049) and 10 (220.5±106.4nmol, p=0.014) FSH mlU/ml
compared to control (24.0+5.7nmol). Superscripts a and b denote statistical
significance. Statistics used: one way ANOVA with an LSD post hoc test.






















Figure 4.9 Granulosa cell oestradiol production.
The amount of oestradiol produced by the granulosa cells over a 3 h period after 45 h
of culture. Oestradiol production elicited a dose dependent response following FSH
stimulation. Statistically significant increases were observed after both 1
(167.5+63.4pmol, p=0.016) and 10 (655.2+81.8pmol, p<0.001) mlU/ml FSH
stimulation compared to controls (13.2+3.1pmol). Superscripts a, b and c denote
statistical significance. Statistics used: one way ANOVA with LSD post hoc tests.
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4.4 Discussion
4.4.1 Key results
-Both VEGF and aromatase mRNA was increased by FSH stimulation, however little
can be drawn from these results because of the lack of sensitivity of the techniques
used.
4.4.2 Background
Data presented in Chapter 3 suggested that there could be a differential level of FSH
stimulation required for follicular angiogenesis (VEGF expression) and granulosa
cell differentiation (aromatase expression), with follicles becoming vascularised but
producing low levels of oestradiol. Therefore, lower levels of FSH stimulation may
be required for follicular angiogenesis than are necessary for follicular oestradiol
production. To this end, experiments in this chapter were designed to further
investigate the level of FSH stimulation required for follicular angiogenesis and
follicular oestradiol production. Granulosa cells isolated from subordinate female
marmoset ovaries were cultured in graded concentrations of FSH and the activation
of the VEGF and aromatase genes measured.
4.4.3 Analysis
Although the mRNA results presented in this chapter may suggest that there is a
differential level of FSH stimulation required for the expression of VEGF mRNA
than there is for aromatase mRNA in cultured granulosa cells, much further work is
required to confirm this hypothesis. Stimulation with 1 mlU/ml of FSH caused a
significant increase in VEGF mRNA compared to no FSH stimulation controls,
whereas there was no significant rise in aromatase mRNA expression over the same
range of stimulation. Although there were very similar trends in stimulation between
the two genes, the aromatase results were not statistically significant. Also, there
was a significant increase in the level of aromatase enzyme activity after 1 mlU/ml
FSH stimulation compared to controls. The measurement of the amount of
oestradiol produced by the cells shows that the cells were stimulated sufficiently to
elicit aromatase enzyme activity and therefore activation of the gene. Further
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quantification of the amount of VEGF protein secreted by the cells in culture would
allow for quantification of the actual amounts of functional gene translation elicited
by FSH stimulation and not only the mRNA expression.
4.4.3.1 Granulosa cell sensitivity to FSH
The mechanism by which granulosa cell sensitivity to FSH stimulation is regulated is
as yet unclear. One possible of explanation is to look at what is known about the
promoter regions of the genes. The granulosa cells response to FSH stimulation may
involve changes in expression or activation of either cis- or trans-acting factors that
regulate the expression of specific genes. Analysis of the VEGF gene promoter
region reveals a single major transcription start that lies near a cluster of potential
Spl factor-binding sites along with several potential binding sites for the cis acting
transcription factors AP-1 (a transcription factor formed from a heterodimer of the
products of the proto-oncogenes fos and jun, also known as c-jun) and AP-2
(activating enhancer binding protein 2a), thought to be involved in cAMP regulated
gene expression (Tischer et al. 1991). VEGF expression has been shown to be
regulated by elevated cyclic cAMP concentration, as cAMP levels increase, VEGF
mRNA expression also increases (Takagi et al. 1996). Forskolin (a naturally
occurring diterpene that directly activates adenylyl cyclase) can mimic the effects of
FSH stimulation on granulosa cells and studies using bovine granulosa cells
stimulated with forskolin have shown that activation of adenylyl cyclase can regulate
VEGF gene expression in a time-dependent fashion (Garrido et al. 1993). The
aromatase promoter contains a cis-acting DNA element known to respond to
cAMP/A-kinase. This cAMP response element (CRE) is found in the promoter
regions ofmany genes induced by cAMP (Kurten and Richards 1989, Habener 1990,
Fitzpatrick and Richards 1993, Fitzpatrick and Richards 1994). Functional studies of
the aromatase gene promoter have identified two regions involved in regulating
cAMP inducibility in granulosa cells (Fitzpatrick and Richards 1993, Fitzpatrick and
Richards 1994).
With respect to this it is of interest to discuss previous work regarding the
different effect of FSH and LH on cultured granulosa cells. FSH and LH are both
presumed to act predominantly, if not exclusively, via cAMP mediated post-receptor
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signalling (Yong et al. 1992a, Richards 1994). FSH positively regulates granulosa
cell growth and at the same time initiates steroid synthesis, whereas LH has a
negative effect on cell growth but causes maximal steroid production (Yong et al.
1992b). This is thought to be possible because LH stimulates greater levels of
endogenous cAMP than FSH in cultured human granulosa cells (Yong et al. 1992a).
It is therefore possible that the level of receptor activation may mediate the
differential gene expression. There is evidence that individual cAMP responsive
genes show varying sensitivity to cAMP (Karin 1989). These responses could be
mediated through the multiple isoforms of A-kinase within the ovary (Richards
1994), one of which (RII|3) has been shown to be hormonally regulated during
folliculogenesis (Kurten et al. 1992). Also, inhibitors of A-kinase subunit activity,
known as protein kinase inhibitors (PKI) may play a role in this regulation. PKIs
have been shown to be regulated by FSH in the testis (Tash et al. 1981) and PKIa
has been shown to be expressed in the ovary (Van Patten et al. 1992).
4.4.3.2 Intra-follicular regulators of FSH sensitivity
In vivo, there are also many other factors that may mediate FSH induced gene
expression in the granulosa cells. It is known that intra-follicular androgens and
oestrogens can act to enhance the responsiveness of the granulosa cells to FSH
(Richards 1980, Hsueh et al. 1984, Richards et al. 1987) and androgens have been
shown to augment oestradiol production in cultured granulosa cells (Harlow et al.
1986). This begs the question as to a potential role for the steroid hormones in
modulating VEGF gene expression in vivo? In addition to the gonadotrophins and
the steroids influencing granulosa cell gene expression, granulosa cell development
is also modulated by oocyte factors capable of stimulating granulosa cell
proliferation but suppressing their differentiation. The nature of these oocyte factors
is unclear (Vitt et al. 2000), but factors like GDF-9 have been shown to regulate the
proliferation and differentiation of rat granulosa cells in vitro (Vitt et al. 2000).
GDF-9 has been shown to stimulate granulosa cell proliferation in both tertiary and
dominant follicles but also suppress FSH-induced differentiation of the same cells
(Vitt et al. 2000). The inhibitory effects of GDF-9 on FSH-induced granulosa cell
differentiation is also accompanied by decreases in the FSH-induced cAMP
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production, the major route through which FSH signals. Thus, other factors, such as
oocyte-derived factors, the granulosa cells would be exposed to in vivo, should not
be overlooked when examining the regulation of granulosa cell gene expression.
There is also a possibility that VEGF gene expression in granulosa cells is up
regulated by hypoxia as is it in other cell and tissue types (Shweiki et al. 1992,
Sharkey et al. 2000). However, the mechanism(s) responsible for hypoxic induction
of VEGF has not been clearly delineated and it appears that the same hypoxic
response seen in both tumour biology and in the uterus do not appear to operate in
differentiated granulosa cells from preovulatory follicles (Martinez-Chequer et al.
2003). Thus, it remains unclear whether regulators of VEGF production in these
other cell types and tissues, such as hypoxia (Shweiki et al. 1992, Sharkey et al.
2000) local cytokines and growth factors (Robinson and Stringer 2001) influence the
expression of VEGF in the developing ovarian follicle. Notably IGF-I, which plays
a key local role in ovarian biology (Poretsky et al. 1999), induces VEGF mRNA and
protein production by both an increase in the transcriptional rate of the VEGF gene,
and the stability of mRNA (Warren et al. 1996). IGF-I has also been shown to
influence VEGF production in granulosa cells isolated from preovulatory follicles
(Martinez-Chequer et al. 2003) and other tissues such as the retina (Bermont et al.
2001, Hellstrom et al. 2001). To further characterise the regulation of gene
expression by FSH stimulation, promoter-enhancer regions of genes of interest will
be required. Looking at which FSH responsive genes are modulated by cAMP
versus cAMP-independent pathways would also be very interesting.
4.4.3.3 Further experiments
In addition to the granulosa cell cultures conducted in this chapter it would also have
been interesting to harvest and culture the theca cells collected during these
experiments. Stimulation of the theca cells with either graded concentrations of
VEGF or possibly the medium the granulosa cells were cultured in would allow for
the analysis of thecal cell response to the indirect FSH stimulation they would be
subjected to in vivo. Although VEGF receptors are not localised to the theca cells by
in situ hybridisation there is the possibility that unknown mechanisms may transduce
VEGF signalling to the theca directly, as evidenced by the large reduction in theca
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cells proliferation when blocking VEGF action (Wulff et al. 2002). Although the
theca cell response would have to be separated from the endothelial cell response as
there would undoubtedly be endothelial cells associated with the theca in follicles at
this stage of development. Stimulation of the theca cells with the medium the
granulosa cells were cultured in would also be very interesting, although FSH would
probably still be present in the medium that could possible mediate an effect on its
own biasing the results. Human umbilical vein endothelial cell response to the
culture medium would also be interesting to measure extent of angiogenesis elicited
by the culture medium from the graded FSH stimulate culture medium, functioning
as a bio assay.
4.4.3.4 Limitations of study
The mRNA results may be in agreement with the hypothesis that the induction of
VEGF gene expression is more sensitive to FSH stimulation than the aromatase
gene. However, the differences between the aromatase mRNA and the aromatase
activity results suggest that there are caveats associated with the results. Steroid
hormone assays being generally more robust than mRNA data, the discrepancy in
results probably resides in the mRNA data. The stability of the mRNAs of the
respective genes may influence the data, one mRNA species may be more stable than
the other, thus skewing the results. The inclusion of a time-course experiment to
determine the point at which maximal mRNA production was elicited in the cells
would also identify if there was indeed a period before 48h at which mRNA levels
reached their maximal expression and if they had declined by 48h. Forty eight hours
was chosen for these experiments based on previous work in primary cell cultures of
both marmoset (Harlow et al. 1986, Harlow et al. 1988) and rat (Harlow et al. 2002)
granulosa cells. Furthermore, the technique used to measure the abundance of the
two genes may not be sensitive enough to quantify changes over the scale that the
genes were expressed at in these experiments.
The amount of progesterone produced by the cells in these experiments was
measured to assess if the cells were healthy and that the doses of FSH they were
exposed to were physiologically relevant. The progesterone results indicate that the
range of FSH concentrations used was within physiological parameters, as a dose
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dependent response to FSH stimulation would be expected. However, when
comparing the oestradiol and the progesterone results it must be remembered that
there was no progesterone precursor (low density lipoprotein) added to the culture
medium as there was for oestradiol (testosterone) and this may bias the results in
favour of oestradiol production.
4.4.4 Conclusion
In conclusion it would appear that there are very complex mechanisms regulating
FSH induced gene expression in the developing granulosa cells that require a great
deal more investigation in order that the exact mechanisms by which angiogenesis is
regulated in the developing ovarian follicle are delineated. This preliminary
experiment suggests that VEGF may be more sensitive to FSH stimulation than
aromatase.
4.4.5 The next step
This chapter has looked at the level of FSH stimulation required induce both
angiogenesis and steroid hormone production in the ovarian follicle. The next
chapter moves away from the regulation of the VEGF gene and hence angiogenesis
by the gonadotrophins to the direct inhibition of VEGF, using specific antagonist
designed to block VEGF action in vivo. The next chapter has been designed to
assess the effects of inhibition of angiogenesis through the direct blocking of VEGF
action on follicle selection, development, ovulation and establishment of the CL.
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Chapter 5 Effect of VEGF Trap R1R2 Treatment on
Follicular Angiogenesis and Development
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5.1 Introduction
As discussed in Chapter 1, the ovary is one of few organs in the body to undergo
serial angiogenesis, which is intimately involved in ovarian follicle development
(Fraser and Wulff 2001, Wulff et al. 2001b, Zimmermann et al. 2001b, Wulff et al.
2002, Zimmermann et al. 2003). The principal angiogenic factor with an established
role in follicular angiogenesis is VEGF (Wulff et al. 2001b, Wulff et al. 2002).
VEGF mRNA and protein have been localised in the ovary to the granulosa cells of
the developing follicles and the theca of preovulatory follicles in a number of species
(Phillips et al. 1990, Ravindranath et al. 1992, Shweiki et al. 1993), including the
marmoset as shown in Chapter 3 (Taylor et al. 2004).
It is well established that angiogenesis plays a key role in normal luteal
function, with inhibition of VEGF severely disrupting luteal angiogenesis and the
maintenance of the established corpus luteum (Ferrara et al. 1998, Fraser et al. 2000,
Dickson et al. 2001, Wulff et al. 2001c). Previous studies have also established the
importance of angiogenesis in follicular development (Wulff et al. 2001b, Wulff et
al. 2002). Inhibition of VEGF in vivo in the marmoset monkey has been shown to
severely suppress both thecal vascularisation and follicular development (Wulff et al.
2001b, Wulff et al. 2002) and to inhibit the follicular phase of the cycle in both
macaques (Zimmermann et al. 2001b) and mice (Zimmermann et al. 2003). This
study aims to extend previous experiments using the VEGF trap and assess the
effects of inhibition of VEGF action, and hence angiogenesis, on follicular
development from both the time of follicle selection and dominant follicle
maturation. The hypothesis being tested was that inhibition ofVEGF would result in
inhibition of dominant follicle maturation and ovulation and that VEGF is essential
for increasing permeability and the growth of the selected follicles. The VEGF trap
has been designed to inhibit VEGF by preventing it from binding to its receptors. It
has been previously used to inhibit follicular development in the marmoset (Wulff et
al. 2002) and has also been used to inhibit the ovarian cycle in macaques (Fraser et
al. 2005b).
The effects of VEGF trap treatment on follicular angiogenesis were examined
using BrdU immunocytochemistry as a proliferation marker, CD31 as an endothelial
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specific cell marker and dual staining to distinguish proliferating endothelial cells.
Effects of treatment on expression ofVEGF and its receptors mRNA was determined
by in situ hybridisation.
5.2 Specific methods
Tissue collection, immunocytochemistry and in situ hybridisation in this chapter
were conducted as described in Chapter 2.
5.2.1 The VEGF trap R1R2
The VEGF trap R1R2 used in this study is a recombinant chimeric protein
comprising the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2
expressed in sequence with the Fc portion of human IgG. The incorporation of the
Fc domain results in homodimerisation of the recombinant protein, creating a high
affinity VEGF trap (Holash et al. 2002, Wulff et al. 2002). The VEGF trap was
expressed in Chinese hamster ovary cells and was purified by protein-A affinity
chromatography followed by size-exclusion chromatography. The VEGF trap binds
all isoforms of both VEGF-A, VEGF-B and placental growth factor (P1GF) (S. J.
Wiegand, personal communication). The specificity of VEGF binding to the VEGF
trap was determined by Biacore (Uppsala, Sweden) (Wulff et al. 2002). The VEGF
trap was a gift from Dr Stanley. J. Wiegand (Regeneron Pharmaceuticals). A
schematic of the VEGF trap is provided in Figure 5.1.
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Figure 5.1 Structure of VEGF receptors and the VEGF trap.
(A) VEGFR1 and (B) VEGFR2 both contain seven extracellular domains (Ferrara
and Davis-Smyth 1997), which differ between the two receptors. Four of these
extracellular domains make up the VEGF binding portion of VEGF trap (C). Figure
adapted from Wulff et al (2002).
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5.2.2 Animals and treatment
Both animals receiving the VEGF trap and control animals were given lpg of
prostaglandin F2a analogue intramuscularly on days 12-15 of the 21 day luteal phase
of the pre-treatment cycle to induce luteolysis marking follicular day 0. Using this
technique to induce luteolysis creates a 10-day follicular phase with control animals
ovulating on follicular day 10. Early follicular (n=3), midfollicular (n=4) and late
follicular controls (n=7) were used for these experiments. Three treatment regimes
where used for these experiments. Each regime consisted of one 25mg/kg dose of
the VEGF trap administered subcutaneously at the start of each treatment regime.
Treatment regime 1 was for 10 days starting from follicular day 0 (n=3). Treatment
regime 2 was for 5 days from follicular day 5 (n=5). Treatment regime 3 was for 10
days starting from follicular day 5 (n=7). The treatment regimes are illustrated in
Figure 5.2. At the end of each treatment schedule ovaries were collected and fixed
as detailed in Chapter 2.
The dose of 25mg/kg was chosen as previous studies by Wulff et al (2002) had
used 25mg/kg every other day throughout the follicular phase to severely suppress
angiogenesis. Further to this, recent work by Fraser et al (2005b) using the VEGF
trap in the Macaque has shown that ovarian function is suppressed for more than 40
days with a single 12.5mg/kg dose and a dose of 0.25mg/kg in the mid follicular
phase of the cycle, one hundredth that used in this study, suppresses a rise in
progesterone for approximately 20 days. Thus, the 25mg/kg does used in this study
was designed to severely and permanently suppress angiogenesis and ovarian
function throughout the short study period, a maximum of 10 days.
5.2.3 In situ hybridisation
In situ hybridisation for VEGF, VEGFR1, VEGFR2 and aromatase was conducted
using the probes and protocols detailed in Chapter 2. In situ hybridisation
experiments were quantified using image analysis software at x400 magnification.
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Figure 5.2 Treatment schedules for VEGF trap experiments.
Prostaglandin (PG) was administered in the late luteal phase of the pre-treatment
cycle to induce luteolysis, marking follicular day 0. Treatment regime 1 was for 10
days starting from follicular day 0. Treatment regime 2 was for 5 days from
follicular day 5. Treatment regime 3 was for 10 days starting from follicular day 5.
Treatment regimes are denoted as grey bars in the figure. Note the sharp decline in
progesterone associated with induction of luteolysis, the ovulatory progesterone rise
and the follicular phase increase in oestradiol that would be observed in control
animals.
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5.3 Results
5.3.1 Hormonal changes
All marmosets responded to PG with a rapid fall in plasma progesterone
concentration due to the induction of luteolysis. Terminal plasma progesterone
concentrations for regimes 1 and 2 are shown in Figure 5.3A. Significant inhibition
of plasma progesterone is observed after both days 0-10 (20.8+2.3nmol, p=0.024)
and 5-10 (21.9±1.4nmol, p=0.042) VEGF trap treatment compared to late follicular
controls (38.4+6.2nmol). Treatment with VEGF trap for days (5-15 21.2+3.lnmol,
p=0.002) caused a significant reduction in plasma progesterone levels compared to
early luteal control animals (136+20.5nmol), Figure 5.3B.
Terminal plasma oestradiol concentrations were also significantly suppressed
by both VEGF trap treatment regimens. Days 0-10 (252+21.3, p=0.010) and days 5-
10 (614+300.0, p=0.024) compared to late follicular controls (1871.3+392.4), Figure
5.4.
5.3.2 Effect of treatment on ovary weight
Treatment with VEGF trap for follicular days 0-10 significantly reduced paired
ovary weight (84.3+2.7mg) compared to late follicular controls (165.0+22.2mg,
p=0.032). A non-significant reduction was observed after treatment with the trap for
5-10 days (124.8+18.8mg), Figure 5.5A. Treatment with the VEGF trap for days 5-
15 (91.9+10.4mg) caused a significant reduction in paired ovary weight compared to
early luteal controls (225.3+25.9mg, p=0.001), Figure 5.5B.
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Figure 5.3 Terminal plasma progesterone.
Terminal plasma progesterone levels from (A) late follicular control (38.4+6.2nmol)
and VEGF trap days 0-10 (20.8±2.3nmol, p=0.024) and days 5-10 (21.9±1.4nmol,
p=0.042) treated animals and (B) Early luteal control (136.0+20.5nmol) and VEGF
trap day 5-15 (21.2+3.1nmol) treated animals that had ovulated (p=0.002). Values
are means + sem. Superscripts a, b, y and z denote statistical significance. Statistics
used: ANOVA with an LSD post hoc test in panel A and two-tailed unpaired t test in
panel B. Statistics used: one way ANOVA with an LSD post hoc test in panel A and
a two-tailed unpaired t test in panel B.

















Figure 5.4 Terminal plasma oestradiol.
Terminal plasma oestradiol levels from late follicular control and VEGF trap days 0-
10 and days 5-10 treated animals. Significant reduction were seen after both VEGF
trap treatments days 0-10 (252.3+21.3pmol/L, p=0.010) and days 5-10
(614.0_+300.0pmol/L, p=0.024) compared to late follicular control values
(1871,3±392.4pmol/L). Statistics used: ANOVA with an LSD post hoc test.
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Figure 5.5 Paired ovary weights.
(A) Mean paired ovary weight of late follicular control ovaries and ovaries from
animals treated with VEGF trap for either follicular days 0-10 or 5-10. A significant
reduction in weight was observed after treatment for days 0-10 (84.3+2.7mg,
p=0.032) compared to late follicular controls (165.0+22.2mg). (B) Mean paired
ovary weight of early luteal control and days 5-15 VEGF trap treated animals. A
significant reduction was observed after days 5-15 VEGF trap treatment
(91.9+10.4mg, p=0.001) compared to luteal controls (225.3+25.9mg). Superscripts
a, b, y and z denote statistical significance. Statistics used: one way ANOVA with an
LSD post hoc test in panel A and a two-tailed unpaired t test in panel B.
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5.3.3 Ovarian morphology
Late follicular control ovaries contained either preovulatory follicles (Figure 5.6A)
or recently ovulated follicles (Figure 5.6B). Luteal day 5 control ovaries contained
new luteal tissue forming from ovulated follicles (Figure 5.6C). After VEGF trap
treatment between days 0-10 of the follicular phase, there was no evidence of
dominant follicle development or freshly ovulated follicles although healthy tertiary
follicles were present in all ovaries (Figure 5.6D). In contrast, after VEGF trap
treatment between days 5-10 of the follicular phase, ovaries displayed a
heterogeneous response to treatment ranging from healthy preovulatory follicles
(Figure 5.6E) to fresh points of ovulation (Figure 5.6F). The mean diameter of the
dominant follicles present in the days 5-10 VEGF trap treated ovaries was
significantly reduced (2367.80pm, n=4) compared to dominant follicles (3232.90pm,
n=4) present in the late follicular control ovaries (p=0.017), Figure 5.7. VEGF trap
treatment for days 5-15 also resulted in heterogeneous morphology with varying
degrees of luteinisation and ovulation occurring. A new "micro CL" (Figure 5.6G)
and a healthy non-ovulated dominant follicle (Figure 5.6H) from the days 5-15 trap
treatment groups are shown. See Appendix D for descriptions of the gross
morphology of the ovaries.





Figure 5.6 Ovarian morphology.
Haematoxylin and eosin stained sections of control late follicular phase (A&B), early
luteal control (C), VEGF trap days 0-10 (D), days 5-10 (E&F) and days 5-15 (G&H)
treated ovaries. Note the reduction in size of the ovaries after all of the treatment
regimes. Pre Ov = Preovulatory follicle, Ov = Ovulated follicle, New CL = New
corpus luteum, Micro CL = small, avascular formed after ovulation in VEGF trap
treated animals, Dom = dominant but unovulated follicle found in VEGF trap treated
animals.
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Figure 5.7 Dominant follicle diameter
The mean diameter of the dominant follicles present in late follicular control and
days 5-10 VEGF trap treated ovaries. The mean dominant follicle diameter
(3232.90+226.4pm n=4) was significantly reduced after trap treatment
(2367.80+135.3pm n=4, p=0.017). Eight follicles from 4 animals were assessed
from both control and treated ovaries. Values shown are means + sem. Superscripts
a and b denote statistical significance. Statistics used: two-tailed unpaired t test.
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5.3.4 Effect of VEGF trap treatment on cellular proliferation
Tertiary and dominant follicles from ovaries from late follicular control and VEGF
trap treated animals are shown in (Figure 5.8, 5.9) respectively. The total number of
proliferating (BrdU positive) cells was counted as a percentage of the total number of
cells present in the follicle compartment in question, granulosa or theca. In late
follicular control ovaries a significant increase in granulosa cell proliferation is
observed in the transition between early secondary (6.6%±1.5) to late secondary
stages of follicle development (16.8%+1.8, p=0.007). Between late secondary and
tertiary follicles the rate of proliferation remained relatively constant. The rate of
granulosa cell proliferation in dominant follicles (7.8%+2.2) decreased significantly
from tertiary proliferation (17.7%+2.4, p=0.029), (Figure 5.10A). VEGF trap
treatment for 0-10 and 5-10 days did not significantly reduce granulosa cell
proliferation in both early secondary or late secondary follicles. Tertiary follicles,
shown in (Figure 5.8), displayed significant reductions in granulosa cell proliferation
after VEGF trap treatment for both 0-10 (2.1%+0.2) and 5-10 (4.3%+0.4) days
compared to tertiary follicles from late follicular controls (17.7%+2.4, p<0.001 and
p=0.001 respectively), (Figure 5.10B). Sections of the follicle wall of dominant
follicles from late follicular control and VEGF trap 5-10 day treated ovaries is shown
in (Figure 5.9). VEGF trap treatment between days 5-10 resulted in no significant
reduction in granulosa cell proliferation in dominant follicles. In late follicular
control ovaries, theca cell proliferation showed a significant increase in the rate of
proliferation from early secondary (0.7%+0.3) to late secondary stages of follicle
development (8.1%+0.7, pO.001). A further increase was observed between late
secondary (8.1%+0.7) and tertiary follicles (12.5%+1.8, p=0.044) and a decrease in
the rate of theca cell proliferation was observed between tertiary (12.5%+1.8) to
dominant follicles (5.0%+1.0, p=0.002), (Figure 5.11A). Both VEGF trap treatment
for 0-10 and 5-10 days had marked inhibitory effects on the rate of thecal
proliferation in all follicles from the late secondary stage of development onwards.
Late secondary follicles showed significant reductions in cellular proliferation after
VEGF trap treatment between days 0-10 (8.1%+0.7 to 1.9%+0.2, p=0.001) and 5-10
(8.1%+0.7 to 2.1%+0.8, pO.001). Tertiary follicles showed the same pattern of
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suppression after 0-10 (12.5%+1.8 to 0.1%+0.02, p<0.001) and 5-10 days
(12.5%+1.8 to 0.5%+0.3, pO.OOl). This pattern continued in the dominant
preovulatory follicles (5.0%+1.0) seen in the late follicular control ovaries and the
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Figure 5.8 The effect of VEGF trap on cellular proliferation in tertiary follicles.
BrdU stained tertiary follicles from (A) late follicular control ovaries, (B) 0-10 day
VEGF trap treated ovaries and (C) 5-10 day treated ovaries. Note the reduction in
granulosa cell proliferation and the severe reduction of proliferation in the thecal
layer in both treatment groups. Also note the only remaining proliferating granulosa
cells are located close to the oocyte.
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Figure 5.9 The effect of VEGF trap treatment on cellular proliferation in
dominant follicles.
BrdU stained dominant follicles from (A) late follicular control ovaries and (B) 5-10
day VEGF trap treated ovaries. Note the reduction in granulosa cell proliferation and
the absence of proliferation in the thecal layer in treated ovaries. Red arrows
highlight proliferating thecal cells.
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Figure 5.10 Quantitative analysis of granulosa cell proliferation.
(A) Analysis of granulosa cell proliferation from developing follicles from late
follicular control ovaries. A significant increase between early secondary
(6.6+1.5%) and late secondary follicles (16.8+1.8%, p=0.007) and a significant
decrease between tertiary (17.7+2.4%) and dominant follicles (7.8+2.2%, p=0.029)
was observed. (B) VEGF trap treatment for both 0-10 and 5-10 days significantly
reduced granulosa cells proliferation in tertiary follicles (2.1+0.2%, p<0.001 and
4.3+0.4%, p=0.001 respectively when compared to the control value of 17.7±2.4%).
Values shown are means + sem. Superscripts a, b, y and z denote statistical
significance. Statistics used: one way ANOVA with LSD post hoc tests.
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Figure 5.11 Quantitative analysis of theca cell proliferation.
(A) Analysis of theca cell proliferation from developing follicles from late follicular
control ovaries. Significant increases between early secondary (0.7+0.3%) and late
secondary (8.1+0.7%, p<0.001), late secondary (8.1+0.7%) and tertiary (12.5+1.8%,
p=0.044) and a significant decrease between tertiary (12.5+1.8%) and dominant
follicles (5.0+1.0%, p=0.002) were observed. (B) VEGF trap treatment severely
inhibited cellular proliferation in the theca. Significant decreases after both
treatment for both days 0-10 and 5-10 in late secondary (1.9+0.2%, p=0.001 and
2.1+0.8%, p<0.001 respectively), tertiary (0.1+0.02%, p<0.001 and 0.5+0.3%,
p<0.001 respectively) and dominant follicles from days 5-10 trap treatment
(0.2+0.1% p=0.002) compared to late follicular controls. Values are mean + sem.
Superscripts a, b, c, y and z denote statistical significance. Statistics used: one way
ANOVA with LSD post hoc tests.
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5.3.5 Endothelial cell proliferation
The effect of VEGF trap treatment on endothelial cell proliferation was assessed by
quantification of co-localisation of BrdU and CD31 in the theca of developing
follicles. Tertiary follicles from late follicular control ovaries and both days 0-10
and 5-10 VEGF trap treatment groups are shown in (Figure 5.12), dominant follicles
from late follicular controls and days 5-10 VEGF trap are shown in (Figure 5.13).
Quantitative analysis of follicles from late follicular control ovaries showed no rise
in the proportion of endothelial cell proliferation between late secondary and tertiary
stages of follicle development, (Figure 5.14A). A significant increase in the
proportion of proliferating cells that were endothelial was observed between tertiary
(18.7%+2.3) and dominant follicles (56.0%±5.9, p<0.001), (Figure 5.14A). Both
the 0-10 day and the 5-10 day VEGF trap treatment regimes almost completely
ablated endothelial cell proliferation in all classes of follicle. Quantitative analysis
revealed significant reductions in endothelial cell proliferation in late secondary
follicles from both treatment groups (0.8%±0.8, p<0.001 and 0.0%+0.0, p<0.001
respectively compared to controls 19.8%+2.6). This trend continued in the tertiary
follicles (0.0%+0.0, p<0.00l and 0.8%+0.5, p<0.001 respectively compared to late
follicular controls 18.7%+2.3) and the dominant follicles from the days 5-10 VEGF
trap treatment group (0.0%±0.0, p<0.001 compared to late follicular controls
56.0%±5.9), (Figure 5.14B).
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Figure 5.12 The effect of VEGF trap treatment on endothelial cell proliferation
in tertiary follicles.
Dual (BrdU/CD31) stained tertiary follicles from (A) late follicular control ovaries,
(B) VEGF trap treatment for days 0-10 and (C) 5-10 of the follicular phase ovaries.
Note the reduction in co-localisation of BrdU (black nuclear) and CD31 (red
endothelial) in the theca ofboth treatment groups.
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Figure 5.13 The effect of VEGF trap treatment on endothelial cell proliferation
in dominant follicles.
Dual (BrdU/CD31) stained dominant follicles from (A) late follicular control ovaries
and (B) days 5-10 trap treated ovaries. Note the reduction in co-localisation of BrdU
(black nuclear) and CD31 (red endothelial) in the theca of follicles from treated
ovaries. Red arrows indicate dual stained cells.
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Figure 5.14 Quantitative analysis of endothelial cell proliferation.
(A) Analysis of endothelial cell proliferation in the theca of developing follicles from
late follicular control ovaries. Significant increase between tertiary (18.7+2.3%) and
dominant follicles (56.0+5.9%, p<0.001). (B) VEGF trap treatment for both days 0-
10 and 5-10 severely inhibited endothelial cell proliferation in late secondary
(0.8+0.8%, p<0.001 and 0.0+0.0%, p<0.001 respectively), tertiary (0.0+0.0%,
p<0.001 & 0.8+0.5%, p<0.001 respectively) and dominant follicles (0.0+0.0%
p<0.001) in trap treated days 5-10 ovaries. Values are means + sem. Superscripts a,
b, y and z denote statistical significance. Statistics used: one way ANOVA with
LSD post hoc tests.
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5.3.6 Endothelial cell area
Typical tertiary and dominant follicles from ovaries from late follicular control and
VEGF trap treated animals are shown in (Figure 5.15, 5.16) respectively. The effect
of VEGF trap treatment on vascular abundance in the theca layer was determined by
measurement of endothelial cell area in the theca. Quantitative analysis of CD31
staining / endothelial cell area in follicles from late follicular control ovaries showed
a progressive significant increase between late secondary (3.8%+0.4) and tertiary
follicles (6.1%+0.2, p=0.002) and between tertiary (6.1%+0.2) and dominant
follicles (12.9%+0.7, p<0.001), (Figure 5.17A). Treatment with VEGF trap between
days 0-10 and 5-10 of the follicular phase significantly reduced the CD31 positive
area in the theca of late secondary follicles (1.9%+0.3, p=0.014 and 2.2%+0.2,
p=0.014 respectively) and tertiary follicles (2.0%+0.3, p<0.001 and 4.0%+0.4,
p=0.001 respectively). Typical examples of tertiary follicles from late follicular
control, and both VEGF trap treatment for days 0-10 and 5-10 are shown in (Figure
5.15). Follicles at the tertiary stage of development in late follicular control ovaries
had a vascular networking that reached the membrana propria that separates the
granulosa cells from the theca cells (Figure 5.15A). Both VEGF trap treatment for
days 0-10 and 5-10 prevented this development, (Figure 5.15B&C). Sections of
dominant follicle walls from late follicular control and days 5-10 VEGF trap treated
ovaries are shown in (Figure 5.16). A fully developed follicular vascular was
evident in dominant follicles from both late follicular controls and days 5-10 VEGF
trap treated ovaries. Quantitative analysis of endothelial cell area in dominant
follicles showed no reduction after VEGF trap treatment for follicular days 5-10,
(Figure 5.17B).
Chapter 5 VEGF trap 168
/ ' 1 I
.-'/c
' ■' t ft?/ <' v \
7'/ t»
A
f- * v. * *-k '■< *> > y
V ' v « .v s k
t -
;•: • 5i >•<
I *"
L
'•o r~ -C <3
*"., r 4 '■. Cit
€/ v
• .r 'v' q^ o ■ '■ V
0 It *U ■ J t
^ tf , * :\ <
• '!/>: ;C''/'^V• TS T\' . Kv J
•- "<ti ' . v C\ •
SjJ, • ' |(> *.
^ Xj r*t^. * ft *





£ '' » -W f 1
✓ , 1 .^v.
J *tj£. / '.
■■",• 'v.»• •'"'.<*•"■£ v
. .■ -' 7 *
t N
g
100pm:\;;. / - ' '
• j $f - *•'''
.. • i.V.r • - -"\
Figure 5.15 Effect ofVEGF trap on endothelial cell area in tertiary follicles.
CD31 stained tertiary follicles from (A) late follicular control ovaries, (B) days 0-10
VEGF trap treated ovaries and (C) days 5-10 VEGF trap treated ovaries. Note the
absence of vascular growth in the vicinity of the membrana propria separating the
granulosa and theca cells after both treatments. g=granulosa, t=theca.
Chapter 5 VEGF trap 169
Figure 5.16 Effect of VEGF trap on endothelial cell area in dominant follicles.
CD31 stained dominant follicles from (A) late follicular control ovaries and (B) days
5-10 VEGF trap treated ovaries. Note the uniform pattern of endothelial cells
throughout the theca of both control and treated follicles. g=granulosa, t=theca.
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Figure 5.17 Quantitative analysis of endothelial cell area.
(A) Analysis of endothelial cell area in the theca of developing follicles from late
follicular control ovaries. Significant increases in endothelial cell area were
observed between late secondary (3.8+0.4%) and tertiary (6.1+0.2%, p=0.002) and
tertiary (6.1+0.2%) and dominant follicles (12.9+0.7%, p<0.001). (B) VEGF trap
treatment for both days 0-10 and 5-10 reduced endothelial cells area in late
secondary (1.9+0.3%, p=0.014 and 2.2+0.2%, p=0.014 respectively) and tertiary
follicles (2.0+0.3%, p<0.001 and 4.0+0.4%, p=0.001 respectively). Values are mean
+ sem. Superscripts a, b, c, x, y and z denote statistical significance. Statistics used:
one way ANOVA and LSD post hoc tests.
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Quantification of thecal thickness in follicles from late follicular control
ovaries revealed significant increases in thecal thickness as the follicles developed
from late secondary (27.0+2.3pm) to tertiary (57.0+3.5pm, p<0.001) and from
tertiary (57.0+3.5pm) to dominant (74.9+4. lpm, p=0.009), (Figure 5.18A). VEGF
trap treatment between days 0-10 (17.7+0.6pm, p=0.015) or days 5-10 (18.6+0.9pm,
significantly reduced thecal thickness in late secondary and tertiary (29.6+3.lpm,
<0.001 and 32.8+2.0pm, p<0.001 respectively) and dominant follicles (44.7+5.8pm,
p=0.003) compared to late follicular controls, (Figure 5.18B). Taking the diameter
of the theca into account allows the quantification of the total 'amount' of
vasculature associated with the follicles. After thecal diameter is taken into account
analysis again showed significant increases in thecal vascularisation as follicles
developed: Late secondary (3.8%+0.4) to tertiary (6.1%+0.2, p=0.002); tertiary
(6.1%+0.2) to dominant follicles (12.9+0.7, p<0.001), (Figure 5.19A). This analysis
revealed that there was a significant reduction in the amount of blood vessels in
every class of follicle after both of the VEGF trap treatment regimes: VEGF trap
treatment significantly reduced the thecal vascularisation in late secondary
(1.3%+0.2, p=0.001 and 1.5%+0.1, p=0.001 respectively), tertiary (1.1%+0.1,
p<0.001 and 2.3%+0.2, p<0.001) and dominant follicles (6.2%+0.4, p=0.001),
(Figure 5.19B).
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Figure 5.18 Analysis of thecal diameter.
(A) Analysis of theca diameter of follicles from late follicular control ovaries.
Significant increases in thecal diameter were observed between late secondary
(27.0+2.3 pm) and tertiary follicles (57.0+3.5jam, p<0.001) and between tertiary
(57.0+3.5 pm) and dominant follicles (74.9+4.lpm, p=0.009). (B) VEGF trap
treatment for both days 0-10 and 5-10 reduced thecal diameter in late secondary
(17.7_+0.6pm, p=0.015 and 18.6+0.9pm, p=0.012 respectively), tertiary
(27.029.6+3.lpm, p<0.001 and 32.8+2.0pm p<0.001 respectively) and dominant
follicles in the days 5-10 trap treated group (44.7+5.8pm p=0.003). Values are
means + sem. Superscripts a, b, y and z denote statistical significance. Statistics
used: one way ANOVA with LSD post hoe tests.
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Figure 5.19 Analysis of total thecal vasculature.
Accounting for thecal diameter, the total thecal vasculature of (A) follicles from late
follicular control ovaries showed significant increases between late secondary
(3.8+0.4%) and tertiary (6.1+0.2%, p=0.002) and tertiary (6.1+0.2%) and dominant
follicles (12.9+0.7%, p<0.001). (B) VEGF trap treatment for both days 0-10 and 5-
10 reduced the total vasculature in late secondary (1.3+0.2%, p=0.001 and 1.5+0.1%,
p=0.001 respectively), tertiary (1.1+0.1%, p<0.001 and 2.3+0.2%, p<0.001
respectively) and dominant follicles present in the days 5-10 trap treatment group
(6.2+0.4% p=0.001). Values are means + sem. Superscripts a, b, c, y and z denote
statistical significance. Statistics used: one way ANOVA and LSD post hoc tests.
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5.3.7 VEGF mRNA expression
VEGF mRNA expression was localised to the granulosa and theca cells in
developing follicles from late follicular control ovaries (Figure 5.20A&B,
5.21A&B). Quantitative analysis of the level of VEGF mRNA expression in
granulosa cells of follicles from late follicular control ovaries showed a significant
increase in expression between late secondary (0.011+0.0005) and tertiary follicles
(0.024+0.0016, p<0.001), (Figure 5.22A). Examples of late follicular and days 0-10
and 5-10 VEGF trap treated tertiary follicles showing VEGF mRNA expression are
shown in (Figure 5.20). Similarly, sections of dominant follicles from late follicular
controls and VEGF trap treated days 5-10 ovaries are shown (Figure 5.21). A
significant decrease in VEGF mRNA expression in the granulosa cells was observed
between tertiary (0.024+0.0016) and dominant follicles (0.015+0.0021, p= 0.010),
(Figure 5.22A). Both VEGF trap treatment for days 0-10 and 5-10 caused non¬
significant increases in the level of VEGF mRNA expressed in the granulosa cells of
each class of follicle after either treatment, (Figure 5.22B).
VEGF mRNA expression in the theca of follicles from late follicular control
ovaries showed a significant increase in VEGF gene expression between tertiary
(0.009+0.002) and atretic follicles (0.024+0.004, p=0.033). There was also a non¬
significant increase in VEGF expression between tertiary and dominant follicles,
(Figure 5.23A). Neither the 0-10 or the 5-10 days VEGF trap treatment regimes
caused significant increases in VEGF mRNA expression in the theca, (Figure
5.23B).
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Figure 5.20 In situ hybridisation of VEGF mRNA in tertiary follicles.
VEGF mRNA expression in tertiary follicles from (A&B) late follicular control,
(C&D) days 0-10 VEGF trap treated and (E&F) days 5-10 VEGF trap treated
ovaries. g=granulosa, t=theca, o=oocyte.


















Figure 5.21 In situ hybridisation of VEGF mRNA in dominant follicles.
VEGF mRNA expression in dominant follicles from (A&B) late follicular control
and (C&D) day 5-10 VEGF trap treated ovaries. Red arrows indicate punctate
VEGF mRNA observed bordering the granulosa and theca cells in preovulatory
follicles in dominant follicles from both follicular control and VEGF trap 5-10 days
treatment groups. g=granulosa, t=theca.
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Figure 5.22 Quantitative analysis of granulosa cell VEGF mRNA expression.
(A) VEGF mRNA expression in follicles from late follicular control ovaries. A
significant increase between late secondary (0.011+0.0005) and tertiary follicles
(0.024+0.0016, p<0.001) and a significant decrease between tertiary (0.024+0.0016)
and dominant follicles (0.015+0.0021, p=0.010) was observed. (B) VEGF trap
treatment for both 0-10 and 5-10 did not cause any significant differences in VEGF
mRNA expression in the granulosa. Values are means + sem. Superscript a, b and z
denote statistical significance. Statistics used: one way ANOVA with LSD post hoc
tests.









































■ VEGF trap 0-10
■ VEGF trap 5-10
Figure 5.23 Quantitative analysis of thecal VEGF mRNA expression.
(A) VEGF mRNA expression in follicles from late follicular control ovaries. A
significant increase between tertiary (0.009+0.002) and atretic (0.024+0.004,
p=0.033) follicle VEGF mRNA expression was observed. (B) VEGF trap treatment
for both days 0-10 or 5-10 did not cause any significant changes in expression.
Values are means + sem. Superscripts a, b and z denote statistical significance.
Statistics used: one way ANOVA with LSD post hoc tests.
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5.3.8 VEGFR1 mRNA expression
VEGFRl mRNA was localised to the endothelial cells in the theca of both
developing and atretic follicles. VEGFRl mRNA expression in tertiary follicles
from late follicular control ovaries and both VEGF trap treatment for days 0-10 and
5-10 are shown in (Figure 5.24). Similarly VEGF mRNA expression in dominant
follicles from late follicular and days 5-10 treated ovaries is shown in (Figure 5.25).
VEGFRl mRNA expression in the theca of follicles from late follicular control
ovaries showed no significant variation apart from a significant decrease between
tertiary (0.010+0.002) and atretic follicles (0.004+0.001, p=0.028), (Figure 5.26A).
VEGF trap treatment for both days 0-10 or days 5-10 of the follicular phase
significantly reduced VEGFRl mRNA expression in all follicular classes: Late
secondary (0.002_+0.0006, p=0.018 and 0.001+0.0003, p=0.006); tertiary
(0.0014+0.0002, p<0.001 and 0.0018±0.0003, p<0.001); dominant (0.002+0.000,
p<0.001); and atretic (0.0016+0.0001, p=0.009 and 0.0019+0.0003, p=0.012),
(Figure 5.26B).
5.3.9 VEGFR2 mRNA expression
VEGFR2 mRNA expression was localised to the endothelial cells in the theca of
both developing and atretic follicles. VEGFR2 mRNA expression in tertiary follicles
from both late follicular control and VEGF trap treated ovaries is shown in (Figure
5.27). Similarly VEGFR2 mRNA expression in dominant follicles from late
follicular control and 5-10 day VEGF trap treated ovaries is shown in (Figure 5.28).
Quantitative analysis of VEGF mRNA expression in follicles from late follicular
control ovaries showed no significant variation across follicle class in late follicular
control ovaries, (Figure 5.29A). VEGF trap treatment between days 0-10 and days
5-10 of the follicular phase significantly reduced VEGF mRNA expression in all
classes of follicle observed: late secondary (0.0026±0.0007, p=0.001 and
0.0026.+0.0003, p=0.001 respectively); tertiary (0.003+0.001, p=0.001 and
0.002+0.0002, p<0.001 respectively); dominant (0.0016+0.0003, p=0.005); and
atretic (0.0019+0.0003, p=0.002 and 0.0024+0.0008, p=0.003 respectively), (Figure
5.29B).
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Figure 5.24 In situ hybridisation ofVEGFR1 mRNA in tertiary follicles.
VEGFR1 mRNA expression in tertiary follicles from (A&B) late follicular control,
(C&D) 0-10 day VEGF trap treated and (E&F) VEGF trap 5-10 day treated ovaries.
Note the absence of VEGFR1 mRNA expression after both treatment regimes. Red
arrow highlight expression.
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Figure 5.25 In situ hybridisation of VEGFR1 mRNA in dominant follicles.
VEGFR1 mRNA expression in dominant follicles from (A&B) late follicular control
and (C&D) 5-10 day VEGF trap treated ovaries. Note absence of VEGFR1 mRNA
expression after treatment. Red arrows highlight expression.
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Figure 5.26 Quantitative analysis of thecal VEGFR1 mRNA expression.
(A) VEGFR1 mRNA expression in follicles from late follicular control ovaries. A
significant decrease in expression was observed between tertiary (0.01+0.002) and
atretic follicles (0.004+0.001, p=0.028). (B) VEGF trap treatment for both 0-10 and
5-10 days caused significant reductions in expression in late secondary
(0.002_+0.0006, p=0.018 and 0.001+0.0003, p=0.006 respectively), tertiary
(0.004J-0.0002, p<0.001 and 0.0018+0.0003, p<0.001 respectively), atretic
(0.01+0.002 p=0.009 & p=0.012 respectively) and dominant follicle present in the
days 5-10 treatment group (0.002+0.0001 p<0.001) compared to late follicular
controls (0.005±0.0013, 0.010±0.0022, 0.008±0.0020 and 0.004+0.0009
respectively). Values are means + sem. Superscripts a, b, y and z denote statistical
significance. Statistics used: one way ANOVA with LSD post hoc tests.
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Figure 5.27 In situ hybridisation of VEGFR2 mRNA in tertiary follicles.
VEGFR2 mRNA expression in tertiary follicles from (A&B) late follicular control,
(C&D) 0-10 day VEGF trap treated and (E&F) VEGF trap 5-10 day treated ovaries.
Note the absence of expression after trap treatment. Red arrows highlight
expression.





Figure 5.28 In situ hybridisation ofVEGFR2 mRNA in dominant follicles.
VEGFR2 mRNA expression in dominant follicles from (A&B) late follicular control
and (C&D) 5-10 day VEGF trap treated ovaries. Note the lack of expression after
VEGF trap treatment. Red arrows highlight expression.
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Figure 5.29 Quantitative analysis of thecal VEGFR2 mRNA expression.
(A) VEGFR2 mRNA expression in follicles from late follicular control ovaries. No
significant variation was observed between different classes of follicle. (B) VEGF
trap treatment for between days 0-10 and 5-10 days both significantly reduced
expression in late secondary (0.0026+0.0007, p=0.001 and 0.0026+0.0003, p=0.001
respectively), tertiary (0.003+0.001, p=0.001 and 0.002+0.0002, p<0.001
respectively), atretic (0.0019+0.0003, p=0.002 and 0.0024+0.0008, p=0.003
respectively) and dominant follicles (0.0016+0.0003, p=0.005) present in the days 5-
10 trap treatment group compared to late follicular controls (0.008+0.0017,
0.011+0.0021, 0.010+0.0019 and 0.007+0.0017 respectively). Values are means +
sem. Superscripts a, b, y and z denote statistical significance. Statistics used: one
way ANOVA with LSD post hoc tests.
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5.3.10 Characteristics of the 'micro CL'
The follicles that did ovulate in the VEGF trap days 5-15 VEGF treated group
formed small 'micro CL' after ovulation, these CLs where much smaller than those
found in early luteal control ovaries. Haematoxylin and eosin stained sections of
early luteal control and 'micro CL' are shown in Figures 5.30A&B respectively.
Although not quantified the rate of cellular proliferation in the 'micro CLs' also
appeared to be drastically reduced compared to early luteal controls (Figures 5.30C
control, 5.30D micro CL). The extent of vascularisation achieved in these micro CL
also appeared to be severely reduced compared to early luteal controls (Figures
5.30E control, 5.30F micro CL). The rate of angiogenesis in the micro CL also
appeared to be severely inhibited compared to early luteal controls (Figures 5.30G
control, 5.30H micro CL).
Also, however not quantified, the expression of both VEGF and aromatase
mRNA appeared to remain at levels similar to those found in early luteal controls.
The punctate VEGF mRNA observed in the large steroid producing cells in the early
luteal control tissue (Figure 5.31A&B) was also evident in the luteal cells in the
micro CLs (Figure 5.31E&F). Similarly expression of aromatase mRNA observed
in early luteal controls (Figure 5.31C&D) was also expressed in the micro CLs
(Figure 5.31G&H).
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Figure 5.30 Characteristics of CL from early luteal control and VEGF trap
treated micro CL ovaries.
Haematoxylin and eosin stained CL from early luteal control (A) and day 5-15
VEGF trap treated ovaries (B). BrdU stained CL from early luteal control (C) and
day 5-15 VEGF trap treated ovaries (D). CD31 stained CL from early luteal control
(E) and day 5-15 VEGF trap treated ovaries (F). Dual stained (black nuclear stain
proliferating cells and red stained vasculature, co-localised staining indicates
proliferating endothelial cells) CL from early luteal control (G) and day 5-15 VEGF
trap treated ovaries (H).
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Figure 5.31 In situ hybridisation of VEGF and aromatase mRNA.
VEGF mRNA expression in early luteal control CL (A&B). Aromatase mRNA
expression in early luteal control (C&D). VEGF mRNA expression in micro CL
formed in day 5-15 VEGF trap treated animals (E&F). Aromatase mRNA
expression in micro CL formed in day 5-15 VEGF trap treated animals (G&H).
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5.4 Discussion
5.4.1 Key results
-A single injection of VEGF trap on follicular day 0 achieved the same results as
those previously observed by Wulff et al (2002), when using multiple injections
throughout the follicular phase.
-Ovulation was not definitively inhibited when the trap was administered in the mid
follicular phase of the cycle.
-If ovulation did occur, a functional CL was not established.
-Both angiogenesis and thecal proliferation severely inhibited by VEGF trap
treatment.
-In all follicles assessed, the volume of endothelial cells associated with each class of
follicle was reduced after VEGF trap treatment.
-VEGF mRNA expression was maintained whilst VEGFR1 and VEGFR2 ligand
dependant expression was inhibited.
5.4.2 Background
It is established that thecal development precedes follicular angiogenesis, with
marmoset follicles developing a vascular supply during the late secondary stage of
development, after the theca has begun to form (Wulff et al. 2001b). Angiogenesis
and VEGF have been shown to be intimately involved in ovarian follicle
development (Fraser and Wulff 2001, Zimmermann et al. 2001b, Zimmermann et al.
2003) and are necessary for normal follicular growth (Wulff et al. 2001b, Wulff et
al. 2002). VEGF is also know as a potent vascular permeability factor on the basis
of its ability to induce vascular leakage (Senger et al. 1983, Dvorak et al. 1995), and
is thought to play a role as a permeability factor in the final stages of follicle
development (Koos 1995) allowing the movement of fluid into the follicle and has
been shown to be the mediator of hCG induced vascular permeability associated with
OHSS (Gomez et al. 2002). Hence, the effect of VEGF trap treatment on follicular
development and expansion in the marmoset ovary would be expected to result in
suppression of dominant follicle expansion and ovulation.
Previous studies have examined the effects of inhibition of VEGF during
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folliculogenesis and ovulation using either the VEGF trap (Wulff et al. 2002), earlier
prototypes of the trap (Wulff et al. 2001b, Hazzard et al. 2002) and antibodies
against VEGF (Zimmermann et al. 2001b) or VEGFR2 (Zimmermann et al. 2002,
Zimmermann et al. 2003). Through the inhibition of VEGF, these studies
established the requirement for VEGF during follicle vascularisation, antrum
formation and ovulation. The requirement for angiogenesis and VEGF during
formation and maintenance of a functional corpus luteum has also already been
demonstrated (Ferrara et al. 1998, Fraser et al. 2000, Dickson et al. 2001, Wulff et
al. 2001c). The most recently published work using the VEGF trap in the marmoset
monkey involved a series of VEGF trap (25 mg/kg) injections, one injection every
other day, throughout the follicular phase to prevent follicular vascularisation,
antrum development and ovulation (Wulff et al. 2002).
5.4.3 Analysis
The use of a single injection of VEGF trap on follicular day 0 achieved the same
results as those previously observed by Wulff et al (2002), when using multiple
injections. Also, in this current study the dissection of the follicular phase and
assessment of the requirement for VEGF during both dominant follicle selection and
the expansion of the dominant follicles through to ovulation has extended those
previous findings. The results in this study reveal that inhibition of VEGF and thus
both angiogenesis and vascular permeability have dramatic effects on both dominant
follicle maturation and ovulation.
5.4.3.1 Cellular proliferation
The effects of VEGF trap treatment on thecal and endothelial cell proliferation were
as expected from experience in previous studies, where thecal angiogenesis and
thecal steroid producing cell proliferation in all stages of follicle development
assessed, were almost completely suppressed (Wulff et al. 2002). The effect on both
endothelial and theca proliferation was thought to be due to the effect of the lack of
paracrine VEGF signalling from the granulosa cells acting on the endothelium in the
theca. VEGF inhibition has an obvious role in reducing the rate of endothelial cell
proliferation, however VEGF trap treatment also having a major effect on the rate of
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theca cell proliferation may also possibly be a consequence of a reduction in the level
of perceived LH stimulation due to reduced vessel permeability. The observed
reduction in the rate of granulosa cell proliferation is thought to be a secondary effect
of the reduction in thecal proliferation and vessel permeability as insufficient FSH
stimulation would slow granulosa proliferation, although it is also possible that
VEGF plays an autocrine role in promoting granulosa cell proliferation as it has
recently been shown to protect granulosa cells from atresia (Greenaway et al. 2004).
Although, in situ hybridisation results in this chapter do not localise VEGFR1 or
VEGFR2 mRNA to the granulosa cells of any class of follicle. It is also very
interesting to examine the localisation of the few proliferating granulosa cells after
VEGF trap treatment, they were all located close to the oocyte. This observation is
almost certainly due to oocyte secreted factors stimulating granulosa cell
proliferation locally, candidate molecules for this role are GDF-9 and BMP-15,
although interspecies variation of the effects elicited by these molecules has recently
been reported (McNatty et al 2005).
5.4.3.2 Vascularisation
In all follicles assessed, the volume of endothelial cells associated with each class of
follicle was reduced after VEGF trap treatment. Again, this was as predicted from
previous work using the VEGF trap (Wulff et al. 2002). However, the dominant
follicles that developed in the VEGF trap days 5-10 and 5-15 treatment groups had a
well developed vascular network penetrating into the theca up to basement
membrane separating the theca from the granulosa cells. This is as far as the
vascular network would be expected to penetrate until the basement membrane
breaks down during ovulation. It is therefore proposed that even though the
angiogenesis usually associated with dominant follicle maturation was severely
inhibited, the dominant follicles already selected by follicular day 5 had a sufficient
vascular supply to continue developing up to and past the point of ovulation.
Although the necessity for angiogenesis again became apparent after ovulation as
follicles that had ovulated did not form functional CLs with, although not quantified
in this chapter, a severely reduced vascular supply. Thus, the crux of whether these
dominant follicles have the potential to ovulated or not is dependent upon the state of
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the follicle vasculature at the start ofVEGF treatment.
5.4.3.3 mRNA
It was predicted that the inhibition of VEGF using the VEGF trap would result in the
increased expression of VEGF mRNA, however no significant increase in VEGF
mRNA expression was observed in these studies. Increases in VEGF mRNA
expression have been reported after VEGF trap treatment, although these increases
were not quantified in those previous studies (Wulff et al. 2002). The decrease in
mRNA expression for the VEGF receptors due to lack of the positive feed back
mechanisms that stimulate VEGFR1 and VEGFR2 by VEGF was also as previously
reported (Barleon et al. 1997, Shen et al. 1998, Sato et al. 2000, Wulff et al. 2002).
5.4.3.4 Steroid hormone production
The VEGF traps effects on progesterone secretion observed after each of the VEGF
treatments were as predicted. Only small differences would be expected between the
late follicular controls and treatment with the VEGF trap for both days 0-10 or 5-10,
as follicular phase (low) progesterone levels would be expected in control animals as
well as those treated with the VEGF trap. The suppression of progesterone secretion
in the animals that ovulated from the VEGF trap days 5-15 treatment group were also
as would be expected as luteal angiogenesis and therefore establishment of a
functional corpus luteum was suppressed by VEGF trap treatment, this also concurs
with findings administering the VEGF trap in the macaque (Fraser et al. 2005b). The
suppression of oestradiol production after VEGF trap treatment for both days 0-10
and 5-10 is concurrent with the inhibition of follicular development, particularly in
the days 0-10 group. In the 5-10 day VEGF trap treatment group oestradiol was
suppressed but residual production remained. This moderate production from the
selected follicles again highlights the persistence of the selected follicles to continue
their development, all be it at a reduced level.
5.4.3.5 Morphology
The morphological appearance and the major structures in the ovaries after VEGF
trap treatment are of great interest. The results from the days 0-10 VEGF trap
treatment group were as would have been predicted, with a complete absence of
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either dominant follicle development or newly ovulated follicles due to the inhibition
of angiogenesis in developing follicles that is essential for follicle selection (Wulff et
al. 2002). VEGF trap treatment for days 0-10 also caused significant reductions in
paired ovary weights, presumably through the inhibition of follicle development and
suppression of vessel permeability. VEGF trap treatment for days 5-10 resulted in
ovaries displaying a range of phenotypes similar to those observed in late follicular
control ovaries. Preovulatory and recently ovulated follicles could be observed in
the ovaries, although the size of the preovulatory follicles was reduced compared to
those in late follicular control ovaries. Other phenotypes included follicles in which
the granulosa cells appeared to be luteinising but have not ruptured, although this can
also be observed during ovulation in late follicular control ovaries.
The 5-15 days VEGF trap treatment resulted in a range of outcomes different
from those seen in early luteal control ovaries. These ranged from the presence of
healthy follicles of large preovulatory size to the presence of new 'micro CL' in the
ovary. The most likely explanation for this heterogeneity in results is the level in
gonadotrophin the developing follicles were exposed during treatment. As already
discussed, these follicles have an established vascular supply, however vessel
permeability must also be considered.
5.4.3.6 Vessel permeability
Vascular cells in different organs acquire specialized characteristics that allow them
to perform organ specific functions (Ruoslahti and Rajotte 2000). For example,
endothelial cells in the brain are tightly linked to each other and are surrounded by
numerous pericytes that form a barrier to protect the brain cells from potentially
toxic blood-derived molecules. In contrast, vessels in endocrine glands, i.e. the
ovarian follicle, are 'leaky' and their endothelial cells have fenestrations, which
allows hormone trafficking to occur (Carmeliet 2004). VEGF is also known as VPF
on basis of its ability to induce vascular leakage (Senger et al. 1983, Dvorak et al.
1995) has been found to induce these fenestrations in endothelial cells of small
venules and capillaries (Roberts and Palade 1995). Specific inhibition of VEGFR2 is
known to inhibit vascular permeability (Gomez et al. 2002). Therefore, inhibition of
VEGF using the VEGF trap causes the endothelial cells in the developing follicles
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and the 'micro CL' to behave more like the vasculature observed in the brain and
hence minimizes that amount of hormone trafficking, thus inhibiting proper
endocrine function. This restriction on vascular permeability has to be considered
when assessing the results from the ovaries in both the VEGF trap days 5-10 and 5-
15 treatment groups.
5.4.3.7 Removal of negative feedback...
Unfortunately the levels of both LH and FSH could not be measured in this study
because these assays are problematic in the marmoset and there are restrictions in the
volume of plasma that can be collected. However, extrapolation from other studies
using the VEGF trap in the macaque may be able to explain these observation. With
angiogenesis inhibited and vascular permeability reduced, the amount of
gonadotrophin perceivable by the developing dominant follicles in the day 5-10 and
5-15 treatment groups would be severely reduced. However, after VEGF trap
treatment during the follicular phase in the macaque, both FSH and LH become
extremely elevated. FSH levels rise to well above those seen at any stage of the
normal cycle and LH rises to levels equivalent to those observed during the LH surge
(Fraser et al. 2005b). The gonadotrophins remain at these elevated levels until the
circulating levels of the VEGF trap have subsided to very low levels compared to
doses given in this study. Similar results have also been demonstrated in the
macaque using anti-VEGFR2 antibody during the early follicular period
(Zimmermann et al. 2001b). This hypergonadotrophism is thought to arise in
response to the removal of negative feed back from the developing follicles as it is
associated with sharp decreases in both oestradiol (Fraser et al. 2005b) and inhibin B
(H.M. Fraser, unpublished results). This is concurrent with the significant inhibition
of oestradiol observed in the chapter.
It is interesting to note that the punctate VEGF mRNA expression observed in
Chapter 3, hypothesised to be stimulated by the LH surge, was also evident in the
dominant follicles present in the VEGF trap days 5-10 treatment group suggesting
that high levels of LH were being perceived in the theca of these follicles. It is also
interesting to comment upon the morphology of the luteal cells present in follicles
with varying degrees of luteinisation and in the micro CLs. The luteal cells appeared
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healthy with few morphological changes and little sign of atresia. This is in contrast
with observations on the characteristic effect of withdrawal of LH during the early
luteal phase where cellular degradation is prevalent (Dickson and Fraser 2000),
suggesting that significant levels of LH were being perceived by the cells in this
study. This also concurs with the observations from ovaries in the VEGF trap treated
days 5-15 group that ovulated that appear to have steroidogenically active luteal cells
expressing both aromatase and VEGF mRNA in the 'micro CL' formed after
ovulation. The steroidogenic luteal cells would be either starved of steroid hormone
precursors or unable to secrete the hormones that they produce due to both the lack
of vasculature and the reduced permeability of the available blood vessels. The
failure of ovulated follicles to form functioning CLs has been shown to be primarily
due to the lack of vascularisation of the luteal tissue (Wulff et al. 2001c). However
the remaining hormone producing cells that would be trying to drive the
establishment of the CL via VEGF production are still expressing both VEGF and
aromatase mRNA and show little sign of luteolytic change as would be expected
after removal of LH stimulation (Fraser et al. 1999b, Dickson and Fraser 2000).
The results from the VEGF trap days 5-15 treatment group are similar to those
of Zimmermann (Zimmermann et al. 2001a), when administering an anti-VEGFR2
antibody immediately prior to induction of ovulation in the mouse. Blocking
VEGFR2 function results in a reduced number of corpora lutea present in the ovaries
and a major reduction in vasculature in the corpora lutea that were present. They
also found that treatment had reduced secretion of progesterone, but not by the level
to which they had expected (Zimmermann et al. 2001a). Again this is similar to the
results reported in this chapter where there is both morphological and in situ
hybridisation evidence that luteinisation had occurred. Similar results have also been
demonstrated in the rat (S. J. Wiegand, personal communication). Combining the
changes in vascular permeability and the vastly elevated level of gonadotrophins
observed in other species, it is clear that the VEGF trap treatment drastically alters
the ovarian environment the developing follicles were exposed to.
5.4.4 Conclusion
In conclusion, this study has demonstrated that inhibition of VEGF and hence
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angiogenesis is able to prevent dominant follicle selection and ovulation when
administered during follicle selection. Administration after dominant follicle
selection has taken place, although having drastic effect on angiogenesis, vessel
permeability and follicle expansion, does not inhibit ovulation to the extent of which
may have been predicted from previous studies. VEGF trap treatment drastically
alters the ovarian environment and follicle development. This study also confirms
that VEGF mediate angiogenesis is essential for establishment of the corpus luteum.
5.4.5 The next step
VEGF, as studied in this chapter, is known as one of the most pivotal mediators of
the angiogenic process. However, it is not the only angiogenic mitogen thought to be
functioning in the ovary. In 2001 a novel endothelial cell mitogen, endocrine gland
vascular endothelial growth factor (EG-VEGF), was described (Li et al 2001,
LeCouter et al. 2001). Unrelated to the VEGF family, or any of the other known
families of endothelial cell mitogens (LeCouter and Ferrara 2003), EG-VEGF posed
a very exciting prospect as it appeared that a pro-angiogenic, specific to the
endocrine glands had been discovered. The next chapter looks at the expression of
this new angiogenic factor in both the human and the marmoset.
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Chapter 6 EG-VEGF mRNA Expression in the
Marmoset and the Human
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6.1 Introduction
EG-VEGF is a novel endothelial cell mitogen discovered in 2001 (Li et al 2001,
LeCouter et al. 2001) unrelated to the VEGF family, or any of the other known
families of endothelial cell mitogens (LeCouter and Ferrara 2003). In the human
ovary EG-VEGF is thought to play a role in both early folliculogenesis and corpus
luteum development (Ferrara et al. 2003a) and has also been implicated as having a
potential function in PCOS (Ferrara et al. 2003a). EG-VEGF has recently also been
implicated in testicular development and function (Samson et al. 2004) and the
expression pattern of EG-VEGF in the endometrium is consistent with its regulation
by the steroid hormones (Battersby et al. 2004). Given the tissue specific expression
of EG-VEGF to the endocrine glands, it is potentially as a very exciting new target
for tissue specific modulation and inhibition of angiogenesis in the reproductive
organs. The aim of this study was to investigate whether EG-VEGF is expressed in
the marmoset and if so, which cell types is its expression localised to. This was
assessed by in situ hybridisation in various marmoset tissues.
6.1.1 Discovery of EG-VEGF
EG-VEGF or Prokineticin-1 (PK-1), as it was originally termed, was first identified
in human gastrointestinal smooth muscle in 2001 (Li et al. 2001). It was discovered
as one of a pair of human homologues to either the mamba intestinal toxin (PK-1)
(Schweitz et al. 1999) or the yellow bellied toad secreted protein Bv8 (PK-2)
(Joubert and Strydom 1980). Later that year, in a separate study, EG-VEGF was
identified from a library of purified human secreted proteins for its ability to induce
proliferation in primary bovine adrenal-cortex-derived capillary endothelial (ACE)
cells and termed endocrine-gland-derived vascular endothelial growth factor
(LeCouter et al. 2001). EG-VEGF promotes proliferation, survival and chemotaxis
ofACE cells but does not stimulate the same reactions in other endothelial cell types
such as human umbilical vein endothelial cells (LeCouter et al. 2001).
6.1.2 Expression of EG-VEGF
Northern blot analysis of RNAs from a range of human tissues has revealed EG-
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VEGF expression in ovary, testis, adrenal gland, placenta (LeCouter et al. 2001) and
stomach (Li et al. 2001). EG-VEGF mRNA has been localised to the human CL,
were its expression is not detectable until the early- to mid-stage of luteal
development, persisting at least throughout the mid-luteal phase, a point at which
VEGF mRNA expression is much reduced (Ferrara et al. 2003a), presumably giving
EG-VEGF an alternate role to VEGF in the corpus luteum. Ferrara and colleagues
also localised EG-VEGF mRNA to the granulosa cells of small follicles that are
initiating folliculogenesis and also in the stroma and theca of PCOS ovaries (Ferrara
et al. 2003a) giving EG-VEGF a complimentary pattern of expression to that of
VEGF (Ferrara et al. 2003a). EG-VEGF has also been identified in the macaque
corpus luteum (R. L. Stouffer, personal communication). Also, more recently, EG-
VEGF has been implicated in playing a role in both early testis development and
adult testis function in the human (Samson et al. 2004).
6.1.3 Structure of EG-VEGF
EG-VEGF does not belong to the VEGF family, or any of the other known families
of endothelial cell mitogens (LeCouter and Ferrara 2003). It is a member of a
structurally related class of peptides including the digestive enzyme colipase; the
Xenopus head organiser gene, dickkopf (Glinka et al. 1998); mamba intestinal toxin
1 (MIT1) (Schweitz et al. 1999) also known as venom protein A (VPRA) (Joubert
and Strydom 1980), a non-toxic protein purified from the venom of the black mamba
snake; and the secreted yellow bellied toad protein Bv8 (Joubert and Strydom 1980).
Both VPRA (Schweitz et al. 1999) and Bv8 (Mollay et al. 1999) have been shown to
induce gastrointestinal motility. The common structural motif between these
proteins is 10 cysteine residues that form five disulfide bridges within a conserved
span (Aravind and Koonin 1998). G proteins are thought to be involved in EG-
VEGF signalling (Li et al. 2001) and EG-VEGF has been identified as the ligand for
two, until recently, orphan G protein-coupled receptors (GPCRs) of the neuropeptide
Y receptor class (Lin et al. 2002, Masuda et al. 2002).
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6.2 Materials and Methods
6.2.1 Human luteal tissue
Laboratory stocks of human luteal tissue collected by the Obstetrics and
Gynaecology department in the New Royal Infirmary of Edinburgh were used in this
study. Briefly, corpora lutea were enucleated from healthy woman aged 32-45 with
regular menstrual cycles, who were undergoing hysterectomy and who had not
received hormonal treatment during the previous three months. Informed consent
was obtained from all patients before tissue collection. Once collected, portions of
the corpus luteum where fixed in NBF for 24 hours as described for marmoset tissue
in Chapter 2. Five-micron sections were then taken from the tissue blocks as and
when required.
6.2.2 Marmoset tissue
Laboratory stocks of marmoset organs obtained from control animals were used for
this study. Ovaries at different stages of the cycle where used along with uterine
tissue and portions of small intestine.
6.2.3 In situ hybridisation
In situ hybridisation was performed as described in Chapter 2. EG-VEGF slides
were left exposed for 3 weeks.
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6.3 Results
In situ hybridisation revealed EG-VEGF mRNA expression in the granulosa lutein
cells of the mid stage corpus luteum. No hybridisation was evident in any of the
marmoset tissues (Figure 6.1).
Figure 6.1 EG-VEGF mRNA expression.
All figures shown are corresponding dark and light field images. EG-VEGF mRNA
expression in: The mid-stage human corpus luteum (A&B); the mid-stage marmoset
corpus luteum (C&D); the marmoset ovarian follicle (E&F); the marmoset placenta
(G&H); and the marmoset small intestine (I&J). The only detectable expression was
observed in the human CL. g=granulosa, t=theca.
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6.4 Discussion
6.4.1 Key results
-EG-VEGF mRNA is expressed in the granulosa lutein cells of the human corpus
luteum.
-No EG-VEGF mRNA was detected in any of the marmoset tissue analysed.
6.4.2 Background
EG-VEGF was first discovered in 2001 (Li et al. 2001, LeCouter et al. 2001) and to
this day posses intriguing questions regarding organ specific regulation of
angiogenesis and offers a very exciting opportunity to modulate and inhibit
angiogenesis in reproductive tissues specifically, which will lead to a better
understanding of, or even treatments for, angiogenic related reproductive disorders.
6.4.3 Analysis
This chapter identifies that EG-VEGF mRNA is expressed in the granulosa lutein
cells of the human corpus luteum and not the thecal lutein cells as suggested by other
studies (Ferrara et al. 2003a). Also, no expression of EG-VEGF was observed in any
marmoset tissue, suggesting that the marmoset does not make use of the EG-VEGF
system for endocrine gland angiogenesis.
In the human, the expression pattern of EG-VEGF suggests that it is regulated
by specific factors in the endocrine glands. To this end, consensus-binding sites for
the NR5A1 orphan nuclear receptor are present within the human EG-VEGF
promoter (LeCouter et al. 2003). NR5A1 is considered to be a key regulator of
endocrine development and function (Parker et al. 2002) and the NR5A1 protein is
strongly expressed in both theca and granulosa cells of antral follicles (Takayama et
al. 1995). Recent data from the human endometrium suggests that EG-VEGF
expression may be regulated by progesterone as its expression is elevated during the
secretory phase of the cycle (Battersby et al. 2004). This may occur by a direct
effect of progesterone on EG-VEGF gene transcription, as analysis of the promoter
region of the human EG-VEGF gene also identifies two putative progesterone-
receptor binding sites (Battersby et al. 2004).
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To address the question of why no EG-VEGF mRNA was detected in any of
the marmoset tissue, it is interesting to look at what is known about cross species
expression of EG-VEGF. For example there is a strong possibility that the lack of
EG-VEGF expression in the marmoset results from changes in the gene promoter
sequence. Examples of divergent regulation of the EG-VEGF gene is found between
different species. For example EG-VEGF has also been identified in the mouse. The
mouse EG-VEGF gene encodes a peptide 88% identical and 93% homologous to the
human protein (LeCouter et al. 2003). Mouse EG-VEGF also maps to a region of
chromosome 3 that is syntenic with human chromosome 1 p 13.1, the locus for human
EG-VEGF (LeCouter et al. 2003). However, the expression pattern of mouse EG-
VEGF mRNA is very different from that of human. The predominant sites ofmouse
EG-VEGF mRNA expression are hepatocytes in the foetal liver and the epithelial
tubule cells in the adult kidney (LeCouter et al. 2003). The NR5A1 nuclear receptor
present within the human EG-VEGF promoter is absent in the mouse promoter
(LeCouter et al. 2003), giving EG-VEGF a very different role between these species.
Therefore, although the EG-VEGF gene may be well conserved between humans and
mice, and show the same pattern of expression in old world primates (humans and
macaques), the marmoset being a new world primate may have evolved either
mutations in the EG-VEGF gene or different mechanisms of regulation of the EG-
VEGF gene, leading to lack of expression in reproductive tissue. To assess this
hypothesis, the sequence of the marmoset EG-VEGF gene would need to be
analysed, looking for either mutations in the promoter sequence arresting its
transcription or other regulatory elements in the promoter giving it a different pattern
of expression from other primates.
The findings in this chapter that contradict Ferrara and colleagues previous
work on localisation of EG-VEGF in the human CL (Ferrara et al. 2003a) are likely
to be due to the misidentification of the cell type the mRNA was observed in. This
chapter clearly identifies the granulosa lutein cells as the cells expressing EG-VEGF
mRNA. Further work by H. M. Fraser and colleagues has conclusively demonstrated
EG-VEGF mRNA expression in granulosa lutein cells by immunocytochemistry of
3|3-HSD, a granulosa lutein cell specific enzyme and 17a hydroxylase, to localise
theca derived lutein cells (Fraser et al. 2005a). They have also demonstrated that
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EG-VEGF expression increases as the CL matures (Fraser et al. 2005a). EG-VEGF
has also been found to be expressed in immortalized human granulosa lutein cells
(Kisliouk et al. 2003). It is interesting to note that once the marmoset CL has formed
there is no distinguishable differences between the granulosa and the theca lutein
cells, this difference in cell lineage is obvious in both the human and the macaque
CL. This difference in CL structure may have implications in the differential
expression in EG-VEGF mRNA between human and marmoset observed in this
chapter.
Another possibility that should not be overlooked is that the marmoset EG-
VEGF mRNA sequence may have diverged so far from human sequence, against
which the probe was designed, that the probe was unable to hybridise to marmoset
EG-VEGF mRNA. However, considering the conservation between the human and
the mouse sequence, this is unlikely. Further work on the sequencing of the
marmoset EG-VEGF gene will help to reveal both its function and pattern of
expression in the marmoset.
6.4.4 Conclusion
In conclusion, the localisation of EG-VEGF to the granulosa lutein cells of the
human CL provides support for the role of EG-VEGF in the corpus luteum with
respect to the regulation of luteal angiogenesis. The lack of EG-VEGF expression in
the marmoset tissues requires further investigation, but indicates variation between
species that raises the question of how important EG-VEGF is when compared to
other ubiquitously expressed angiogenic factors such as VEGF in the regulation of
luteal angiogenesis and vessel stabilisation.
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7.1 Introduction
This thesis has presented the results of a series of investigations into the control of
ovarian follicular angiogenesis in the primate and its in vivo manipulation in the
marmoset monkey. The results from each experimental chapter have been discussed
in the relevant chapters. This section therefore provides an opportunity to summarise
the main findings of the thesis, discuss the relevant merits of the model used for
inhibition of follicular angiogenesis, clinical implications of the thesis findings in
both reproductive medicine and other angiogenesis related disorders and to suggest
areas for further study.
7.2 The findings of this thesis
Angiogenesis has long been hypothesised to play an essential role in follicular
development and the establishment of follicle dominance (Zeleznik et al. 1981).
Subsequently, it has been demonstrated by direct in vivo manipulation that VEGF is
one of the principal angiogenic factors involved in follicular angiogenesis (Wulff et
al. 2001b, Zimmermann et al. 2001b, Wulff et al. 2002, Zimmermann et al. 2002).
VEGF mRNA and protein have been localised in the ovary to the granulosa cells of
the developing follicles, concurrent with the acquisition of steroidogenic activity, and
the theca of preovulatory follicles (Phillips et al. 1990, Ravindranath et al. 1992,
Shweiki et al. 1993, Taylor et al. 2004). It has also been demonstrated that VEGF
expression in granulosa cells of preovulatory follicles is up regulated by FSFI
stimulation in vitro (Christenson and Stouffer 1997, Hazzard et al. 1999). This
evidence suggested that the expression is hormonally regulated. Therefore, the
rationale behind the first hypothesis was to use the marmoset monkey, a species in
which the development of the follicular vasculature has been described in great detail
(Wulff et al. 2001b, Wulff et al. 2002), as a model for in vivo inhibition of the
gonadotrophins during the follicular phase. It was postulated that their suppression
would inhibit follicular angiogenesis, as had been demonstrated for the CL using a
similar approach in the luteal phase in the marmoset (Dickson and Fraser 2000). The
finding that blocking gonadotrophin release did not result in complete inhibition of
follicular angiogenesis as had been predicted raises the possibility that there are other
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factors and paracrine mechanisms regulating VEGF and angiogenesis in the primate
ovarian follicle. For example the oocyte-granulosa interactions that coordinate
follicle development (Eppig 2001, Eppig et al. 2002) could play an important role in
VEGF regulation in the granulosa cells. It follows that the reason GnRH antagonist
treatment is more effective in suppressing early luteal angiogenesis (Dickson and
Fraser 2000) is likely to be because the corpus luteum is heavily dependent upon LH
(Fraser et al. 1986). This dependence would include the local compensatory
mechanisms that are relatively gonadotrophin independent in the developing follicle
with the coordinate stimulation of both the gonadotrophins and the oocyte both
playing their part.
The in vivo inhibition of VEGF has been shown to severely suppress thecal
vascularisation, follicle development and inhibit the ovarian cycle (Wulff et al.
2001b, Zimmermann et al. 2001b, Wulff et al. 2002, Zimmermann et al. 2002). The
second hypothesis to be tested in this thesis was based on these previous studies and
was that VEGF is essential for the increasing permeability and the growth of the
follicles selected for dominance by the mid-follicular point in the cycle. In vivo
inhibition of VEGF caused dramatic reductions in angiogenesis and in VEGF
receptor expression but did not reliably prevent dominant follicle growth or
ovulation once dominant follicle selection had occurred. As mentioned in the
previous paragraph the role of the oocyte was again highlighted in this study where
granulosa proliferation was marginally maintained, presumably by stimulation from
oocyte secreted factors. Comparing these results to the direct inhibition of
angiogenesis throughout the follicular phase with the VEGF trap (Wulff et al 2002)
has demonstrated that is the developing follicle grows it becomes less dependant
upon angiogenesis. Also, comparing these results to the direct inhibition ofVEGF in
the CL (Ferrara et al. 1998, Fraser et al. 2000, Wulff et al. 2001c) indicates that
luteal function is more dependant upon VEGF than the developing dominant follicle.
At this point it is of interest to compare the results of inhibiting the
gonadotrophins with a GnRH antagonist and the effects of the specific targeting of
VEGF using the VEGF trap, on follicular angiogenesis and development. A much
higher degree of inhibition of follicular angiogenesis was observed when directly
inhibiting VEGF rather than inhibiting the gonadotrophins (Figure 7.1). In the case
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of the GnRH antagonist treatment, angiogenesis continued in the follicles, although
at a reduced level, as the VEGF system was not severely inhibited by the treatment.
The GnRH antagonist inhibition of gonadotrophin secretion may have had little
effect on the ability of hypoxia and local paracrine mechanisms to mediate or
modulate VEGF synthesis and action in the ovarian follicle. These compensatory
mechanisms may have been responsible for continued angiogenesis. In contrast, the
VEGF trap had a much more dramatic effect in follicular angiogenesis and it is
suggested that no matter what compensatory mechanisms came into operation to
restore VEGF action, the VEGF trap negated them.
The effect of both GnRH antagonist or VEGF trap treatment from the early
follicular period was as had been predicted, with both treatments inhibiting the
selection and development of a dominant follicle. When the GnRH antagonist or
VEGF trap were given from the mid-follicular phase the selected dominant follicles
were severely effected in terms of their 'health', some becoming anovulatory and
displaying signs of atresia, however neither treatment managed to consistently inhibit
expansion of the selected follicles to a preovulatory size. This suggests that neither
the gonadotrophic support nor the normal physiological vessel permeability and
angiogenesis associated with the development of the dominant follicle play major
roles in its mechanical expansion. There is evidence that reductions in the frequency
of the GnRH pulse has severe inhibitory effects on the quality of follicle
development in the rhesus monkey (Pohl et al 1983), although these studies
determine follicle development and quality in terms of the gonadotrophins and
circulating progesterone and oestradiol concentrations, and do not look directly at the
mechanical expansion of the follicle, where as evidence from this thesis suggests that
there is a dissociation between mechanical expansion and follicular steroid
production as a follicle matures.
Finally, the identification of the novel angiogenic molecule EG-VEGF in the
granulosa lutein cells of the human CL is a very exciting and intriguing result, which
has fuelled further research into its regulation and pattern of expression throughout
the luteal phase.
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Figure 7.1 Comparison of the inhibition of follicular endothelial proliferation.
The effect of the administration of either a GnRH antagonist or the VEGF trap on
follicular endothelial cell proliferation. Note the difference in suppression between
the GnRH antagonist (14.1+2.6) and the VEGF trap (0.3+0.2) compared to controls
(25.0+4.3). Sources are Chapter 3 and Chapter 5. Values are the combined means of
late secondary, tertiary and dominant follicles + sem.
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7.3 The marmoset model
7.3.1 Use in biomedical research
The common marmoset is used extensively in biomedical research and has typically
been used in reproductive biology, neuroscience, infectious disease and behavioural
research (Mansfield 2003). During the last 40 years there has been a steady increase
in the number of research publications using marmosets, with over 40 times more
being published in the 1990s than in the 1960s (Abbott et al. 2003) and, in Europe,
the marmoset has become the most commonly used primate in research laboratories
(Scott 1994).
Marmosets and humans diverged from a common anthropoid ancestor about
35-40 million years ago (Goodman 1999) and marmosets are considered as an
"anchor" species within their genus in terms of molecular phylogeny (Abbott et al.
2003). Because of this, they are one of six non-human primates proposed for
complete genome mapping (Eichler and DeJong 2002). The Affymetrix GeneChip
has recently been validated for use in the marmoset, being used to investigate gene
expression in brain tissue (Marvanova et al. 2003). Also, their small size
(approximately 350g) compared to the macaque (12-15 kg) makes them ideal for use
when only small amounts of highly valuable recombinant or synthetically produced
antagonist are available for in vivo studies.
As far as female reproductive biology is concerned, the marmoset has an
ovarian cycle of approximately 28 days with ovulation occurring on day 10 when
synchronised using PG injection (Gilchrist et al. 2001) and shows similar
gonadotrophin and steroid hormone profiles to the human throughout the cycle
(Harlow et al. 1984). Their use in reproductive biology has facilitated the
development of human embryonic stem cell biology (Thomson et al. 1996, Thomson
et al. 1998) and they are an oft used model in the study of both luteal angiogenesis
(Dickson et al. 2001, Fraser and Lunn 2001, Wulff et al. 2001a, Wulff et al. 2001c,
Rowe et al. 2002) and luteal regression (Fraser et al. 1995a, Fraser et al. 1995b,
Duncan et al. 1998, Fraser et al. 1999b).
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7.3.2 The marmoset as a model for follicular angiogenesis
The marmoset is a commonly used primate for the study of female reproductive
medicine (Fraser and Lunn 1999, Mansfield 2003). The availability of healthy,
cyclic marmosets, through our in-house breeding programme permitted their use in
these terminal studies, where it is necessary to collect tissue for cellular and
molecular analysis.
The studies in this thesis utilised the marmoset monkey as an experimental
model in which to investigate factors regulating ovarian follicular angiogenesis, a
species in which the development of the follicular vasculature has been described in
great detail (Wulff et al. 2001b, Wulff et al. 2002). Using prostaglandin injection,
the ability to synchronise the timing of the ovarian cycle in such a precise fashion
makes the marmoset an extremely useful and practical model with which to study
primate reproductive biology. Previous work in our laboratory has used the
marmoset model to great effect, dissecting the necessity for both the gonadotrophins
and VEGF during precise time points in the luteal phase of the cycle (Fraser et al.
2000, Dickson et al. 2001). The studies in this thesis applied those timing techniques
to study the effects of treatment at specific points in the follicular phase of the cycle.
7.3.3 Limitations of the model
The marmoset model does have its limitations when extrapolating data to the human.
The marmoset is not a mono-ovulatory species, it does not menstruate as humans do,
and there is debate over the existence of an age related decline in the rate of
ovulation (Tardif and Jaquish 1997, Gilchrist et al. 2001). The reproductive cycles
of old world primates are more similar to the human, but the invasiveness of the
techniques used in these studies dictated that higher primates were not used. Also, as
Chapter 6 of this thesis highlights, the recent identification of a novel angiogenic
molecule that the marmoset does not appear to express draws scrutiny as to the
relationship between the molecular mechanisms functioning during ovarian
angiogenesis between the marmoset and the human.
It would also be valuable to be able to evaluate the changes in both
gonadotrophin and steroid hormone concentrations after treatment. However the
marmoset is not a good model in which to measure the gonadotrophins, because
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suitable assays are not yet available. An FSH assay is available but has only been
reported to measure urinary FSH successfully (Gilchrist et al. 2001). The marmosets
in these studies could not be housed in urinary collection cages, as ethical approval
was not obtained. It may have been possible to harvest unrine from the bladder of
the animals after they had been euthanised, however this was not done and the
bladder was disposed of after other organs had been removed. An LH assay based
upon an antibody to bovine LH, as described by Saltzman et al (1998), has been
tested in our laboratory, but it was found to lack the sensitivity to monitor changes in
the cycle successfully. This may possibly be due to the recent finding that
marmosets have a missing exon in the LH receptor gene (Zhang et al. 1997) and the
hypothesised redundancy of LH in the marmoset, with the absence of LH expression,
the role of LH being replaced by chorionic gonadotrophin produced by gonadotropes
in the pituitary (Gromoll et al. 2003, Muller et al. 2003, Muller et al. 2004). A new
oestradiol assay has been used in this thesis, but is still temperamental and remains
problematic. In addition, because of the small volume of blood taken from the
marmoset at each sampling interval, assay ofmultiple hormones is restricted.
7.4 Clinical implications of the thesis findings
The vascularisation of the developing ovarian follicles is a tightly regulated process.
A disturbance in the balance of angiogenic factors regulating it may play a role in
severe reproductive dysfunction, specifically, PCOS and OHSS. PCOS is probably
the most common but least understood reproductive endocrine disorder, affecting
approximately 5% ofwomen in the developed world (Franks 1995, Knochenhauer et
al. 1998, Legro and Strauss 2003, Azziz et al. 2004) and there is growing evidence
that suggests familial inheritance of this disorder (Franks et al. 1997, Legro et al.
1998), although there are inherit problems associated with establishment of the
maternal phenotype (Legro and Strauss 2003). PCOS is generally characterised by
hyperandrogenism and ovulatory dysfunction (Zawadzki and Dunaif 1992). The
ovarian dysfunction is manifest by chronic anovulation, hypervascularisation of the
theca and increases in stromal blood flow (Zawadzki and Dunaif 1992, Ehrmann et
al. 1995, Franks 1995, Pan et al. 2002). An increase in VEGF is associated with the
hyperthecotic ovarian stroma of these patients (Kamat et al. 1995) and it has been
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suggested that VEGF may play an important role in this pathogenesis.
OHSS is a severe and potentially life-threatening complication that can arise
through treatment with gonadotrophins given during in vitro fertilisation (IVF)
procedures (Pellicer et al. 1999). It is associated with enlargement of the ovaries,
ascites, an increase in vascular permeability and is associated with increased
expression in VEGF via hCG stimulation (Wang et al. 2002). An increased
concentration of VEGF in the follicular fluid is also associated with the condition
(Pellicer et al. 1999, Albert et al. 2002) and although having many years of clinical
experience there are no precise methods or protocols to completely prevent severe
OHSS (Orvieto 2005), apart from withholding the ovulation inducing hCG trigger
and hence aborting the procedure, costing not only valuable clinical time and money
but also causing devastating disappointment for couples struggling to conceive.
Since both PCOS and OHSS are associated with increases in both angiogenesis and
vascular permeability, both studies on the mechanisms regulating ovarian follicular
angiogenesis and its inhibition may allow formulation of treatments for these major
cause of infertility, and the complications that can be associated with IVF treatment.
Until this study, the endocrine mechanisms regulating angiogenesis in the ovarian
follicle had received little attention in the literature. This study has made inroads
into unravelling the complicated process of ovarian angiogenesis.
Also, the discovery that EG-VEGF is expressed in the granulosa lutein cells of
the human corpus luteum (Chapter 6) and the endometrium (Battersby et al. 2004)
provides another putative target for manipulation of luteal function and perhaps
inhibition of blastocyst implantation as an emergency contraceptive, as the ability to
specifically modulate and inhibit angiogenesis in the endocrine glands potentially
offers a much more selective treatment for angiogenic disorders than inhibiting
angiogenesis per se, with more generally targeted antagonists.
7.5 Relevance to other systems
Forming new blood vessels is a complex and delicate process. If insufficient
vasculature forms, tissue can become ischaemic and die. If over-vascularisation
occurs, both tumours and chronic inflammatory disorders can become aggravated
(Carmeliet 2004). Novel insights into the regulation of angiogenesis are therefore
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relevant for the future treatment of many angiogenic disorders, the most prevalent
being: cancer; abnormal uterine bleeding; arthritis; psoriasis; and retinopathies
(Folkman 2001, Kerbel and Folkman 2002, Carmeliet 2004). But, even a high fat
diet has been shown to lead to the activation of angiogenic gene expression in
adipose tissue (Li et al. 2002a) and studies using the angiogenic inhibitor TNP-470
have shown that inhibition of angiogenesis can be used to control the deposit of
adipose tissue (Rupnick et al. 2002).
Conversely there are also a number of disorders associated with under-
vascularisation of tissues. Studies in women have shown that elevated levels of
VEGFR1 are associated with the incidence of preeclampsia (Levine et al. 2004) and
the progressive loss of the microvasculature underlies many age related diseases
(Carmeliet 2004). Age-related bone loss is associated with a decrease in the
osteoblastic secretion of VEGF (Martinez et al. 2002), angiogenesis is positively
correlated with the survival rate in stroke patients (Krupinski et al. 1994,
Manoonkitiwongsa et al. 2001) and insufficient VEGF levels cause can cause motor
neurone degradation (Oosthuyse et al. 2001). Therefore, with an increasing
understanding of the mechanisms that regulate angiogenesis can come treatments for
a large number of angiogenic-related disorders.
There are a large number of anti-angiogenic molecules currently undergoing
various stages of clinical trials. Of these, Avastin™ (bevacizumab), a humanised
monoclonal antibody directed at VEGF, is the most advanced, and has showed
promising results in clinical trials (Ferrara 2004). In February 2004, the FDA
approved Avastin™ to be used in combination with chemotherapy as a treatment for
patients with first-line or previously untreated metastatic cancer of the colon or
rectum. Flowever, six months later, the FDA and the manufactures of Avastin™
issued an important warning that there is evidence of an increased risk of serious
arterial thromboembolic events related to Avastin™ use. All of these anti-
angiogenic agents can generally be divided into two distinct classes, direct inhibitors
and indirect inhibitors. The direct inhibitors prevent endothelial cells from
proliferating, migrating or avoiding apoptosis in response to a spectrum of pro-
angiogenic proteins, including VEGF. Indirect inhibitors prevent the expression or
block the activity of proteins that activate angiogenesis or block the expression of
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their receptors on endothelial cells (Kerbel and Folkman 2002). A summary of some
of these molecules is given in Table 7.1.
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Action Drug Target
Direct Arresten Believed to bind integrin-o^Pi to inhibit endothelial-cell
proliferation, migration, tube formation and
neovascularisation
Direct AvastiniM Recombinant humanised monoclonal antibody against
VEGF
Direct Canstatin Believed to bind integrin-avp3 to inhibit endothelial-cell
proliferation, migration and tube formation 1
Direct NM-3 An isocoumarin small-molecule inhibitor of VEGF. Is
shown to selectively inhibit endothelial-cell proliferation,
sprouting and tube formation in vitro
Direct 2-methoxyoestradiol Inhibits microtubule function in proliferating endothelial
cells, resulting in endothelial-cell apoptosis
Direct VEGF Trap R1R2 Chimeric protein of VEGFR1 and VEGFR1, inhibits
endothelial cell proliferation and migration
Direct Vitaxin A humanised monoclonal antibody against integrin av|33 |
Action Drug Production of Proteins effected
Indirect Herceptin Inhibits VEGF, angiopoietin-1, TGF-fl, PAI1; up
regulates thrombospondin-1
Indirect IFN-a Inhibits expression of bFGF by cancer cells
Indirect PTK787; ZD6474; 166,168
SU6668; SU11248
Inhibits VEGF receptor expression on endothelium
Indirect PTK787; SU11248 Inhibits PDGF receptor expression
Table 7.1 Novel anti-angiogenic agents
Novel angiogenesis inhibitors in various stages of development. Table adapted from
Kerbel and Folkman (2002).
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7.6 Suggestions for further study
It is established that during the process of ovulation, blood vessel permeability in the
ovulating follicle increases (Cavender and Murdoch 1988, Koos 1995). These
changes in vascular permeability are likely to be very important in the function of the
ovarian follicle and the treatment of ovarian reproductive disorders. There are few
studies to date that assess the molecular regulation of vascular permeability in the
primate. The results reported in this thesis, specifically Chapter 5, demonstrate that
inhibition of VEGF in the marmoset does not reliably inhibit follicle expansion and
subsequent ovulation. Further experiments should be conducted to assess follicular
blood vessel permeability in ovaries from control and both GnRH antagonist and
VEGF trap treated animals. This is possible through either the use of Doppler flow
studies or the injection of dyes prior to euthanasia, to allow for the
immunocytochemical analysis of vessel permeability.
The establishment of a model in which to study both PCOS and OHSS would
also be invaluable to the progression of the development of treatment for both the
disorders. Exposure to androgen excess during early gestation has been shown to
cause LH hypersecretion (Dumesic et al. 1997), impaired insulin secretion (Eisner et
al. 2000), hyperandrogenism, anovulation (Eisner et al. 2002) and increased
adiposity (Eisner et al. 2003) in adult female rhesus monkeys. All of these
consequences of foetal androgenisation bare a striking resemblance to manifestations
of PCOS (Ehrmann et al. 1995, Franks 1995, Dunaif 1997). Establishment of a
model in which terminal studies could be conducted, i.e. the marmoset, could lead to
advances in the treatment of PCOS. The marmosets short time to sexual maturation
and ovarian cyclicity would expedite the establishment of a primate model of PCOS
in which terminal studies could be conducted on the effects of inhibition of
angiogenic factors.
In 2001, just before work on this thesis commenced, a novel endocrine gland
specific vascular endothelial growth factor was described. Chapter 6 describes the
localisation of EG-VEGF to the granulosa lutein cells in the human corpus luteum,
but fails to identify EG-VEGF in any of the marmoset tissues examined. To progress
the identification of EG-VEGF in the marmoset, analysis of the promoter region of
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the gene should be conducted. The human and mouse promoters have both been
sequenced and have been found to be relatively divergent from one another
(LeCouter et al. 2003). Promoter analysis of the marmoset sequence may shed
further light on EG-VEGF expression in the marmoset model.
7.7 Summary
Overall, this thesis has demonstrated that the developing ovarian follicle, though
susceptible to insult by either depravation of gonadotrophic support or the inhibition
of angiogenesis, is a much more robust structure than the corpus luteum after
dominant follicle selection has occurred. Suppressing gonadotrophic support,
angiogenesis and vessel permeability has a much less of an effect on follicle
development than had been hypothesised from previous studies. The dissociation of
the mechanical functioning of the ovary, i.e. follicle expansion and ovulation and the
steroid hormone profile throughout the follicular phase of the cycle observed in this
thesis, specifically chapters 3 and 5, raises the possibility of alternative interpretation
of results previously published in the literature that directly infer suppression of
follicle expansion and ovulation on purely hormonal evidence, highlighting the
importance of extrapolating data to far.
Also, the localisation of the novel angiogenic molecule EG-VEGF to human
granulosa lutein cells has contradicted findings from other research groups and has
helped initiate the elucidation of the function of EG-VEGF in the human CL.
In a broader context, this thesis forms part of the ongoing research into
reproductive angiogenesis by Prof Hamish Fraser's team. There is still plenty of
exciting work to be done to develop a full understanding of the regulation of blood
vessel development and regretion in the female reproductive system and how this




Abbott DH, Barnett DK, Colman RJ, Yamamoto ME, Schultz-Darken NJ
(2003) Aspects of common marmoset basic biology and life history important
for biomedical research. Comp Med 53(4):339-50
Abbott DH, McNeilly AS, Lunn SF, Hulme MJ, Burden FJ (1981) Inhibition of
ovarian function in subordinate female marmoset monkeys (Callithrix jacchus
jacchus). J Reprod Fertil 63(2):335-45
Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA,
Gospodarowicz D, Fiddes JC (1986) Nucleotide sequence of a bovine clone
encoding the angiogenic protein, basic fibroblast growth factor. Science
233(4763):545-8
Acosta TJ, Hayashi KG, Ohtani M, Miyamoto A (2003) Local changes in blood
flow within the preovulatory follicle wall and early corpus luteum in cows.
Reproduction 125(5):759-67
Acosta TJ, Yoshizawa N, Ohtani M, Miyamoto A (2002) Local changes in blood
flow within the early and midcycle corpus luteum after prostaglandin F(2
alpha) injection in the cow. Biol Reprod 66(3):651-8
Adashi EY (1998) The IGF family and folliculogenesis. J Reprod Immunol 39(1-
2): 13-9
Adashi EY, Resnick CE (1986) 3',5'-cyclic adenosine monophosphate as an
intracellular second messenger of luteinizing hormone: application of the
forskolin criteria. J Cell Biochem 31(3):217-28
Agrawal R, Conway G, Sladkevicius P, Tan SL, Engmann L, Payne N, Bekir J,
Campbell S, Jacobs H (1998a) Serum vascular endothelial growth factor
and Doppler blood flow velocities in in vitro fertilization: relevance to
ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril
70(4):651-8
Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan
SL, Campbell S, Jacobs HS (1998b) Serum vascular endothelial growth
factor concentrations and ovarian stromal blood flow are increased in women
with polycystic ovaries. Hum Reprod 13(3):651 -5
Albert C, Garrido N, Mercader A, Rao CV, Remohi J, Simon C, Pellicer A
(2002) The role of endothelial cells in the pathogenesis of ovarian
hyperstimulation syndrome. Mol Hum Reprod 8(5):409-18
Algire GH (1943a) An adaptation of the transparent-chamber technique to the
mouse. J. Natl. Cancer Inst. 4:1-11
Algire GH (1943b) Microscopic studies of the early growth of a transplantable
melanoma of the mouse, using the transparent-chamber technique. J. Natl. Cancer
References 221
Inst. 4:13-20
Algire GH, Chalkley HW, Legallais FY, Park HD (1945) Vascular reactions of
normal and malignant tumors in vivo. I. Vascular reactions ofmice to
wounds and to normal and neoplastic transplants. J. Natl. Cancer Inst. 6:73-
85
Alini M, Marriott A, Chen T, Abe S, Poole AR (1996) A novel angiogenic
molecule produced at the time of chondrocyte hypertrophy during
endochondral bone formation. Dev Biol 176(1): 124-32
Allen RT, Hunter WJ, 3rd, Agrawal DK (1997) Morphological and biochemical
characterization and analysis of apoptosis. J Pharmacol Toxicol Methods
37(4):215-28
Aravind L, Koonin EV (1998) A colipase fold in the carboxy-terminal domain of
the Wnt antagonists—the Dickkopfs. Curr Biol 8(14):R477-8
Armstrong DT, Dorrington JH (1977) Estrogen biosynthesis in the ovaries and
testes. Adv Sex Horm Res 3:217-58
Augustin HG (2000) Vascular morphogenesis in the ovary. Baillieres Best Pract Res
Clin Obstet Gynaecol 14(6):867-82
Ausprunk DH, Knighton DR, Folkman J (1974) Differentiation of vascular
endothelium in the chick chorioallantois: a structural and autoradiographic
study. Dev Biol 38(2):237-48
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The
prevalence and features of the polycystic ovary syndrome in an unselected
population. J Clin Endocrinol Metab 89(6):2745-9
Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC,
Themmen AP, Grootegoed JA (1995) Anti-mullerian hormone and anti-
mullerian hormone type II receptor messenger ribonucleic acid expression in
rat ovaries during postnatal development, the estrous cycle, and
gonadotropin-induced follicle growth. Endocrinology 136(11):4951-62
Baird DT (1991) The Ovarian Cycle, in Ovarian Endocrinology,{Hillier SG ed), pp
1-14. Blackwell Scientific, Oxford
Baird DT, Fraser IS (1975) Concentration of oestrone and oestradiol in follicular
fluid and ovarian venous blood ofwomen. Clin Endocrinol (Oxf) 4(3):259-66
Baker TG (1963) A Quantitative and Cytological Study of Germ Cells in Human
Ovaries. Proc R Soc Lond B Biol Sci 158:417-33
Balakier H, Stronell RD (1994) Color Doppler assessment of folliculogenesis in in
References 222
vitro fertilization patients. Fertil Steril 62(6): 1211-6
Bancroft JD, Stevens A (1996) Theory andpractice ofhistological techniques.
Churchill Livingston, Edinburgh
Barboni B, Turriani M, Galeati G, Spinaci M, Bacci ML, Forni M, Mattioli M
(2000) Vascular endothelial growth factor production in growing pig antral
follicles. Biol Reprod 63(3):858-64
Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marme D
(1997) Vascular endothelial growth factor up-regulates its receptor fms-like
tyrosine kinase 1 (FLT-1) and a soluble variant ofFLT-1 in human vascular
endothelial cells. Cancer Res 57(23):5421-5
Baron J, Klein KO, Yanovski JA, Novosad JA, Bacher JD, Bolander ME,
Cutler GB, Jr. (1994) Induction of growth plate cartilage ossification by
basic fibroblast growth factor. Endocrinology 135(6):2790-3
Barrett KL, Willingham JM, Garvin AJ, Willingham MC (2001) Advances in
cytochemical methods for detection of apoptosis. J Flistochem Cytochem
49(7):821-32
Bassett SG, Zeleznik AJ (1990) Acute suppression of FSH secretion by oestradiol
in the ovariectomized rhesus monkey. J Reprod Fertil 88(2):441-6
Battersby S, Critchley HO, Morgan K, Millar RP, Jabbour HN (2004)
Expression and regulation of the prokineticins (endocrine gland-derived
vascular endothelial growth factor and Bv8) and their receptors in the human
endometrium across the menstrual cycle. J Clin Endocrinol Metab
89(5):2463-9
Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel
remodelling is defined by pericyte coverage of the preformed endothelial
network and is regulated by PDGF-B and VEGF. Development 125(9): 1591-
8
Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T (1993) Regulation of
androgen production in cultured human thecal cells by insulin-like growth
factor I and insulin. Fertil Steril 59(2):323-31
Bermont L, Lamielle F, Lorchel F, Fauconnet S, Esumi H, Weisz A, Adessi GL
(2001) Insulin up-regulates vascular endothelial growth factor and stabilizes
its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab
86(l):363-8
Bikfalvi A, Bicknell R (2002) Recent advances in angiogenesis, anti-angiogenesis
and vascular targeting. Trends Pharmacol Sci 23(12):576-82
References 223
Block E (1951) Quantitative morphological investigations of the follicular system in
women; variations in the different phases of the sexual cycle. Acta
Endocrinol (Copenh) 8(l):33-54
Block E (1953) A quantitative morphological investigation of the follicular system
in newborn female infants. Acta Anat (Basel) 17(3):201-6
Brannstrom M, Zackrisson U, Hagstrom HG, Josefsson B, Hellberg P,
Granberg S, Collins WP, Bourne T (1998) Preovulatory changes of blood
flow in different regions of the human follicle. Fertil Steril 69(3):435-42
Braw RH, Tsafriri A (1980) Follicles explanted from pentobarbitone-treated rats
provide a model for atresia. J Reprod Fertil 59(2):259-65
Braw-Tal R, Yossefi S (1997) Studies in vivo and in vitro on the initiation of follicle
growth in the bovine ovary. J Reprod Fertil 109(1): 165-71
Burrows FJ, Thorpe PE (1993) Eradication of large solid tumors in mice with an
immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A
90(19):8996-9000
Campbell S, Bourne TH, Waterstone J, Reynolds KM, Crayford TJ, Jurkovic
D, Okokon EV, Collins WP (1993) Transvaginal color blood flow imaging
of the periovulatory follicle. Fertil Steril 60(3):433-8
Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med
6(4):389-95
Carmeliet P (2004) Manipulating angiogenesis in medicine. J Intern Med
255(5):538-61
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M,
Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling
J, Moons L, Collen D, Risau W, Nagy A (1996) Abnormal blood vessel
development and lethality in embryos lacking a single VEGF allele. Nature
380(6573):435-9
Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix
B (2001) Cell surface tumor endothelial markers are conserved in mice and
humans. Cancer Res 61(18):6649-55
Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa
EG, Frey AZ, Gash DJ, Chow EP, Fisher RA, Bertonis JM, Torres G,
Wallner BP, Ramachandran KL, Ragin RC, Manganaro TF,
MacLaughlin DT, Donahoe PK (1986) Isolation of the bovine and human
genes for Mullerian inhibiting substance and expression of the human gene in
animal cells. Cell 45(5):685-98
References 224
Cavender JL, Murdoch WJ (1988) Morphological studies of the microcirculatory
system of periovulatory ovine follicles. Biol Reprod 39(4):989-97
Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh GY
(2000) Coadministration of angiopoietin-1 and vascular endothelial growth
factor enhances collateral vascularization. Arterioscler Thromb Vase Biol
20(12):2573-8
Channing CP, Anderson LD, Hoover DJ, Gagliano P, Hodgen G (1981)
Inhibitory effects of porcine follicular fluid on monkey serum FSH levels and
follicular maturation. Biol Reprod 25(4):885-903
Chen JN, Haffter P, Odenthal J, Vogelsang E, Brand M, van Eeden FJ,
Furutani-Seiki M, Granato M, Hammerschmidt M, Heisenberg CP,
Jiang YJ, Kane DA, Kelsh RN, Mullins MC, Nusslein-Volhard C (1996)
Mutations affecting the cardiovascular system and other internal organs in
zebrafish. Development 123:293-302
Christenson LK, Stouffer RL (1997) Follicle-stimulating hormone and luteinizing
hormone/chorionic gonadotropin stimulation of vascular endothelial growth
factor production by macaque granulosa cells from pre- and periovulatory
follicles. J Clin Endocrinol Metab 82(7):2135-42
Chun SY, Billig H, Tilly JL, Furuta I, Tsafriri A, Hsueh AJ (1994) Gonadotropin
suppression of apoptosis in cultured preovulatory follicles: mediatory role of
endogenous insulin-like growth factor I. Endocrinology 135(5): 1845-53
Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ (1996)
Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating
hormone as a major survival factor. Endocrinology 137(4): 1447-56
Clark ER, Clark EL (1932) Observations on living preformed blood vessels as seen
in a transparent chamber inserted into the rabbit ear. Am. J. Anat 49:441-7
Clark JG (1900) The origin, development and degradation of the blood vessels of
the human ovary. John Hopkins Hospital Report 9:594-676
Clarke IJ (1996) The Hypothalamo-Pituitary Axis, in Scientific Essentials of
Repproductive Medicine,(Hilier SG, Kitchener HC, Neilson JP eds), pp 120-
132. W B Saunders Company Ltd, London
Collins RL, Hodgen GD (1986) Blockade of the spontaneous midcycle
gonadotropin surge in monkeys by RU 486: a progesterone antagonist or
agonist? J Clin Endocrinol Metab 63(6): 1270-6
Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S,
Pulford KA, Stein H, Mason DY (1984) Immunoenzymatic labeling of
monoclonal antibodies using immune complexes of alkaline phosphatase and
References 225
monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem
Cytochem 32(2):219-29
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase
inhibitors and cancer: trials and tribulations. Science 295(5564):2387-92
Coussens LM, RaymondWW, Bergers G, Laig-Webster M, Behrendtsen O,
Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-
regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev
13(11): 1382-97
Crocker DJ, Murad TM, Geer JC (1970) Role of the pericyte in wound healing.
An ultrastructural study. Exp Mol Pathol 13(1):51-65
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The
fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science 255(5047):989-91
Deghenghi R, Boutignon F, Wuthrich P, Lenaerts V (1993) Antarelix (EP 24332)
a novel water soluble LHRH antagonist. Biomed Pharmacother 47(2-3): 107-
10
Dekel N, Beers WH (1978) Rat oocyte maturation in vitro: relief of cyclic AMP
inhibition by gonadotropins. Proc Natl Acad Sci USA 75(9):4369-73
Dickson SE, Bicknell R, Fraser HM (2001) Mid-luteal angiogenesis and function
in the primate is dependent on vascular endothelial growth factor. J
Endocrinol 168(3):409-16
Dickson SE, Fraser HM (2000) Inhibition of early luteal angiogenesis by
gonadotropin-releasing hormone antagonist treatment in the primate. J Clin
Endocrinol Metab 85(6):2339-44
Dissen GA, Romero C, Hirshfield AN, Ojeda SR (2001) Nerve growth factor is
required for early follicular development in the mammalian ovary.
Endocrinology 142(5):2078-86
Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Paul WL, Rivier J, Yen SS,
Lobo RA (1991) The gonadotropin-releasing hormone antagonist (Nal-Glu)
acutely blocks the luteinizing hormone surge but allows for resumption of
folliculogenesis in normal women. Am J Obstet Gynecol 165(6 Pt 1): 1811-7
DiZerega GS, Richardson CL, Davies TF, Hodgen GD, Catt KJ (1980)
Fluorescence localization of luteinizing hormone/human chorionic
gonadotropin uptake in the primate ovary: characterizatin of the preovulatory
ovary. Fertil Steril 34(4):379-85
Dolbeare F (1995) Bromodeoxyuridine: a diagnostic tool in biology and medicine,
References 226
Part I: Historical perspectives, histochemical methods and cell kinetics.
Histochem J 27(5):339-69
Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM (1996)
Growth differentiation factor-9 is required during early ovarian
folliculogenesis. Nature 383(6600):531-5
Downs SM, Daniel SA, Eppig JJ (1988) Induction of maturation in cumulus cell-
enclosed mouse oocytes by follicle-stimulating hormone and epidermal
growth factor: evidence for a positive stimulus of somatic cell origin. J Exp
Zool 245(l):86-96
Driancourt MA, Reynaud K, Cortvrindt R, Smitz J (2000) Roles of KIT and KIT
LIGAND in ovarian function. Rev Reprod 5(3): 143-52
Dumesic DA, Abbott DH, Eisner JR, Goy RW (1997) Prenatal exposure of female
rhesus monkeys to testosterone propionate increases serum luteinizing
hormone levels in adulthood. Fertil Steril 67(1): 155-63
Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism
and implications for pathogenesis. Endocr Rev 18(6):774-800
Duncan WC, Illingworth PJ, Young FM, Fraser HM (1998) Induced luteolysis in
the primate: rapid loss of luteinizing hormone receptors. Hum Reprod
13(9):2532-40
Dunkel L, Tilly JL, Shikone T, Nishimori K, Hsueh AJ (1994) Follicle-
stimulating hormone receptor expression in the rat ovary: increases during
prepubertal development and regulation by the opposing actions of
transforming growth factors beta and alpha. Biol Reprod 50(4):940-8
Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal
MW, Uilenbroek JT, Grootegoed JA, Themmen AP (2002a) Anti-
Mullerian hormone inhibits initiation ofprimordial follicle growth in the
mouse ovary. Endocrinology 143(3): 1076-84
Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, MatzukMM,
Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP
(2001) Anti-Mullerian hormone attenuates the effects of FSH on follicle
development in the mouse ovary. Endocrinology 142(11):4891-9
Durlinger AL, Kramer P, Karels B, Grootegoed JA, Uilenbroek JT, Themmen
AP (2000) Apoptotic and proliferative changes during induced atresia of pre¬
ovulatory follicles in the rat. Hum Reprod 15(12):2504-11
Durlinger AL, Visser JA, Themmen AP (2002b) Regulation of ovarian function:
the role of anti-Mullerian hormone. Reproduction 124(5):601-9
References 227
Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability
factor/vascular endothelial growth factor, microvascular hyperpermeability,
and angiogenesis. Am J Pathol 146(5): 1029-39
Ehrmann DA, Barnes RB, Rosenfield RL (1995) Polycystic ovary syndrome as a
form of functional ovarian hyperandrogenism due to dysregulation of
androgen secretion. Endocr Rev 16(3):322-53
Ehrmann RL, Knoth M (1968) Choriocarcinoma. Transfilter stimulation of
vasoproliferation in the hamster cheek pouch. Studied by light and electron
microscopy. J. Natl. Cancer Inst. 41(6):1329-1341
Eichler EE, DeJong PJ (2002) Biomedical applications and studies ofmolecular
evolution: a proposal for a primate genomic library resource. Genome Res
12(5):673-8
Eisner JR, Barnett MA, Dumesic DA, Abbott DH (2002) Ovarian
hyperandrogenism in adult female rhesus monkeys exposed to prenatal
androgen excess. Fertil Steril 77(1): 167-72
Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH (2000) Timing of prenatal
androgen excess determines differential impairment in insulin secretion and
action in adult female rhesus monkeys. J Clin Endocrinol Metab 85(3): 1206-
10
Eisner JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH (2003) Increased
adiposity in female rhesus monkeys exposed to androgen excess during early
gestation. Obes Res 11(2):279-86
Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA (1999)
Selective requirement for Src kinases during VEGF-induced angiogenesis
and vascular permeability. Mol Cell 4(6):915-24
Eppig JJ (2001) Oocyte control of ovarian follicular development and function in
mammals. Reproduction 122(6):829-38
Eppig JJ, Ward-Bailey PF, Coleman DL (1985) Hypoxanthine and adenosine in
murine ovarian follicular fluid: concentrations and activity in maintaining
oocyte meiotic arrest. Biol Reprod 33(5): 1041-9
Eppig JJ, Wigglesworth K, Pendola FL (2002) The mammalian oocyte
orchestrates the rate of ovarian follicular development. Proc Natl Acad Sci U
S A 99(5):2890-4
Erickson GF, Magoffin DA, Dyer CA, Hofeditz C (1985) The ovarian androgen
producing cells: a review of structure/function relationships. Endocr Rev
6(3):371 -99
References 228
Esch F, Baird A, Ling N, Ueno N, Hill F, Denoroy L, Klepper R, Gospodarowicz
D, Bohlen P, Guillemin R (1985) Primary structure of bovine pituitary basic
fibroblast growth factor (FGF) and comparison with the amino-terminal
sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A 82(19):6507-
11
Espey LL (1980) Ovulation as an inflammatory reaction—a hypothesis. Biol Reprod
22(1):73-106
Espey LL, Lipner H (1994) Ovulation, in The Physiology ofReproduction,{Knobil
E, Neill JD eds), Second Edition ed., pp 725-780. Raven Press, Ltd, New
York
Espey LL, Richards JS (2002) Temporal and spatial patterns of ovarian gene
transcription following an ovulatory dose of gonadotropin in the rat. Biol
Reprod 67(6): 1662-70
Evans G, Dobias M, King GJ, Armstrong DT (1983) Production of prostaglandins
by porcine preovulatory follicular tissues and their roles in intrafollicular
function. Biol Reprod 28(2):322-8
Evans MJ, Kitson NE, Alexander SL, Irvine CH, Turner JE, Perkins NR,
Livesey JH (2002) Effectiveness of an antagonist to gonadotrophin releasing
hormone on the FSH and LH response to GnRH in perifused equine pituitary
cells, and in seasonally acyclic mares. Anim Reprod Sci 73(l-2):37-51
Falck B (1959) Site of production of oestrogen in rat ovary as studied in micro-
transplants. Acta Physiol Scand 47(Suppl 163): 1-101
Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y (1997) Multiple species of
CPP32 and Mch2 are the major active caspases present in apoptotic cells.
Embo J 16(9):2271-81
Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer
therapy. Oncologist 9 Suppl 1:2-10
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-
Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic
lethality induced by targeted inactivation of the VEGF gene. Nature
380(6573):439-42
Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm
V, Hillan KJ, Schwall RH (1998) Vascular endothelial growth factor is
essential for corpus luteum angiogenesis. Nat Med 4(3):336-40
Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth
factor. Endocr Rev 18(l):4-25
References 229
Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A,
Giordano T, Peale F (2003a) Differential expression of the angiogenic
factor genes vascular endothelial growth factor (VEGF) and endocrine gland-
derived VEGF in normal and polycystic human ovaries. Am J Pathol
162(6):1881-93
Ferrara N, Gerber HP, LeCouter J (2003b) The biology ofVEGF and its
receptors. Nat Med 9(6):669-76
Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular endothelial cells. Biochem
Biophys Res Commun 161(2):851-8
Findlay JK (1986) Angiogenesis in reproductive tissues. J Endocrinol 111(3):357-
66
Fitzpatrick SL, Richards JS (1991) Regulation of cytochrome P450 aromatase
messenger ribonucleic acid and activity by steroids and gonadotropins in rat
granulosa cells. Endocrinology 129(3): 1452-62
Fitzpatrick SL, Richards JS (1993) cis-acting elements of the rat aromatase
promoter required for cyclic adenosine 3',5'-monophosphate induction in
ovarian granulosa cells and constitutive expression in R2C Leydig cells. Mol
Endocrinol 7(3):341 -54
Fitzpatrick SL, Richards JS (1994) Identification of a cyclic adenosine 3',5'-
monophosphate-response element in the rat aromatase promoter that is
required for transcriptional activation in rat granulosa cells and R2C leydig
cells. Mol Endocrinol 8(10): 1309-19
Fluker MR, Marshall LA, Monroe SE, Jaffe RB (1991) Variable ovarian response
to gonadotropin-releasing hormone antagonist-induced gonadotropin
deprivation during different phases of the menstrual cycle. J Clin Endocrinol
Metab 72(4):912-9
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.
285(21):1182-1186
Folkman J (2001) Angiogenesis-dependent diseases. Semin Oncol 28(6):536-42
Folkman J, Haudenschild CC, Zetter BR (1979) Long-term culture of capillary
endothelial cells. Proc Natl Acad Sci U S A 76(10):5217-21
Folkman J, Ingber DE (1987) Angiostatic steroids. Method of discovery and
mechanism of action. Ann Surg 206(3):374-83
Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235(4787):442-7
References 230
Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor
responsible for angiogenesis. J. Exp. Med. 133(2):275-288
Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267(16): 10931-4
Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1
receptor tyrosine kinase in regulating the assembly of vascular endothelium.
Nature 376(6535):66-70
Fong GH, Zhang L, Bryce DM, Peng J (1999) Increased hemangioblast
commitment, not vascular disorganization, is the primary defect in flt-1
knock-out mice. Development 126(13):3015-25
Forabosco A, Sforza C, De Pol A, Vizzotto L, Marzona L, Ferrario VF (1991)
Morphometric study of the human neonatal ovary. Anat Rec 231(2):201-8
Fortune JE, Eppig JJ (1979) Effects of gonadotropins on steroid secretion by
infantile and juvenile mouse ovaries in vitro. Endocrinology 105(3):760-8
Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333(13):853-61
Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R,
McCarthy M (1997) The genetic basis of polycystic ovary syndrome. Hum
Reprod 12(12):2641-8
Fraser HM, Abbott M, Laird NC, McNeilly AS, Nestor JJ, Jr., Vickery BH
(1986) Effects of an LH-releasing hormone antagonist on the secretion of LH,
FSH, prolactin and ovarian steroids at different stages of the luteal phase in
the stumptailed macaque (Macaca arctoides). J Endocrinol 111 (1 ):83-90
Fraser HM, Bell J, Wilson H, Taylor PD, Morgan K, Anderson RA, Duncan
WC (2005a) Localisation and quantification of cyclic changes in the
expression of endocrine gland vascularendothelial growth factor in the human
corpus luteum. J Clin Endocrinol Metab 90(l):427-434
Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, Bicknell R
(2000) Suppression of luteal angiogenesis in the primate after neutralization
of vascular endothelial growth factor. Endocrinology 141(3):995-1000
Fraser HM, Groome NP, McNeilly AS (1999a) Follicle-stimulating hormone-
inhibin B interactions during the follicular phase of the primate menstrual
cycle revealed by gonadotropin-releasing hormone antagonist and
antiestrogen treatment. J Clin Endocrinol Metab 84(4): 1365-9
Fraser HM, Lunn SF (2001) Regulation and manipulation of angiogenesis in the
primate corpus luteum. Reproduction 121(3):355-62
Fraser HM, Lunn SF, Cowen GM, Illingworth PJ (1995a) Induced luteal
References 231
regression in the primate: evidence for apoptosis and changes in c-myc
protein. J Endocrinol 147(1): 131-V
Fraser HM, Lunn SF, Harrison DJ, Kerr JB (1999b) Luteal regression in the
primate: different forms of cell death during naturaland gonadotropin-
releasing hormone antagonist or prostaglandin analogue-induced luteolysis.
Biol Reprod 61(6): 1468-79
Fraser HM, Lunn SF, Whitelaw PF, Hillier SG (1995b) Induced luteal regression:
differential effects on follicular and luteal inhibin/activin subunit mRNAs in
the marmoset monkey. J Endocrinol 144(2):201-8
Fraser HM, Lunn SH (1999) Nonhuman primates and female reproductive
medicine, in Reproduction in Nonhuman /Vhwates,(Weinbauer GF, Korte R
eds), pp 27-59. Waxmann,
Fraser HM, Sellar RE, Illingworth PJ, Eidne KA (1996) GnRH receptor mRNA
expression by in-situ hybridization in the primate pituitary and ovary. Mol
Hum Reprod 2(2): 117-21
Fraser HM, Wilson H, Rudge JS, Wiegand SJ (2005b) Single injections of
vascular endothelial growth factor trap block ovulation in the macaque and
produce prolonged, dose-related suppression of ovarian function. J Clin
Endocrinol Metab 90(2): 1114-22
Fraser HM, Wulff C (2001) Angiogenesis in the primate ovary. Reprod Fertil Dev
13(7-8):557-66
Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T (1998) Biologic
implications of the expression of vascular endothelial growth factor subtypes
in ovarian carcinoma. Cancer 83(12):2528-33
Gaddy-Kurten D, Tsuchida K, Vale W (1995) Activins and the receptor serine
kinase superfamily. Recent Prog Horm Res 50:109-29
Garrido C, Saule S, Gospodarowicz D (1993) Transcriptional regulation of
vascular endothelial growth factor gene expression in ovarian bovine
granulosa cells. Growth Factors 8(2): 109-17
Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L,Wright
BD, Radtke F, Aguet M, Ferrara N (1999a) VEGF is required for growth
and survival in neonatal mice. Development 126(6): 1149-59
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999b) VEGF
couples hypertrophic cartilage remodeling, ossification and angiogenesis
during endochondral bone formation. Nat Med 5(6):623-8
Geva E, Jaffe RB (2000) Role of vascular endothelial growth factor in ovarian
References 232
physiology and pathology. Fertil Steril 74(3):429-38
Gilchrist RB, WicherekM, Heistermann M, Nayudu PL, Hodges JK (2001)
Changes in follicle-stimulating hormone and follicle populations during the
ovarian cycle of the common marmoset. Biol Reprod 64(1): 127-35
Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N,
Ferrara N (2001) Analysis of biological effects and signaling properties of
Fit-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel
receptor-specific vascular endothelial growth factor mutants. J Biol Chem
276(5):3222-30
Gimbrone MA, Jr., Cotran RS, Leapman SB, Folkman J (1974) Tumor growth
and neovascularization: an experimental model using the rabbit cornea. J Natl
Cancer Inst 52(2):413-27
Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J (1972) Tumor
dormancy in vivo by prevention of neovascularization. J. Exp. Med.
136(2):261-276
Glaser BM, D'Amore PA, Seppa H, Seppa S, Schiffmann E (1980) Adult tissues
contain chemoattractants for vascular endothelial cells. Nature
288(5790):483-4
Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C (1998)
Dickkopf-1 is a member of a new family of secreted proteins and functions in
head induction. Nature 391(6665):357-62
Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG (1998) Analysis of
blood vessel maturation processes during cyclic ovarian angiogenesis. Lab
Invest 78(11): 13 85-94
Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E (1989) Ovarian
hyperstimulation syndrome: an update review. Obstet Gynecol Surv
44(6):430-40
Gomez R, Simon C, Remohi J, Pellicer A (2002) Vascular endothelial growth
factor receptor-2 activation induces vascular permeability in hyperstimulated
rats, and this effect is prevented by receptor blockade. Endocrinology
143(11):4339-48
Goodman AL, Nixon WE, Johnson DK, Hodgen GD (1977) Regulation of
folliculogenesis in the cycling rhesus monkey: selection of the dominant
follicle. Endocrinology 100(1): 155-61
Goodman M (1999) The genomic record ofHumankind's evolutionary roots. Am J
Hum Genet 64(1):31-9
References 233
Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB (1996) Vascular endothelial
growth factor localization in human ovary and fallopian tubes: possible role
in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab
81(l):353-9
Gordon JD, Shifren JL, Foulk RA, Taylor RN, Jaffe RB (1995) Angiogenesis in
the human female reproductive tract. Obstet Gynecol Surv 50(9):688-97
Gougeon A (1986) Dynamics of follicular growth in the human: a model from
preliminary results. Hum Reprod 1 (2):81-7
Gougeon A (1996) Regulation of ovarian follicular development in primates: facts
and hypotheses. Endocr Rev 17(2): 121-55
Gougeon A, Chainy GB (1987) Morphometric studies of small follicles in ovaries
ofwomen at different ages. J Reprod Fertil 81(2):433-42
Gougeon A, Ecochard R, Thalabard JC (1994) Age-related changes of the
population of human ovarian follicles: increase in the disappearance rate of
non-growing and early-growing follicles in aging women. Biol Reprod
50(3):653-63
Gougeon A, Lefevre B (1983) Evolution of the diameters of the largest healthy and
atretic follicles during the human menstrual cycle. J Reprod Fertil 69(2):497-
502
Graham RC, Jr., Karnovsky MJ (1966) The early stages of absorption of injected
horseradish peroxidase in the proximal tubules ofmouse kidney:
ultrastructural cytochemistry by a new technique. J Histochem Cytochem
14(4):291-302
Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J, Petrik J
(2004) Vascular endothelial growth factor and its receptor, Flk-l/KDR, are
cytoprotective in the extravascular compartment of the ovarian follicle.
Endocrinology 145(6):2896-905
Greenblatt M, Shubi P (1968) Tumor angiogenesis: transfdter diffusion studies in
the hamster by the transparent chamber technique. J. Natl. Cancer Inst.
41(1):111 -124
Gromoll J, Wistuba J, Terwort N, Godmann M, Muller T, Simoni M (2003) A
new subclass of the luteinizing hormone/chorionic gonadotropin receptor
lacking exon 10 messenger RNA in the New World monkey (Platyrrhini)
lineage. Biol Reprod 69(l):75-80
Habener JF (1990) Cyclic AMP response element binding proteins: a cornucopia of
transcription factors. Mol Endocrinol 4(8): 1087-94
References 234
Hagedorn M, Bikfalvi A (2000) Target molecules for anti-angiogenic therapy: from
basic research to clinical trials. Crit Rev Oncol Hematol 34(2):89-l 10
Hall JE, Bhatta N, Adams JM, Rivier JE, Vale WW, CrowleyWF, Jr. (1991)
Variable tolerance of the developing follicle and corpus luteum to
gonadotropin-releasing hormone antagonist-induced gonadotropin
withdrawal in the human. J Clin Endocrinol Metab 72(5):993-1000
Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science
277(5322):48-50
Harding RD, Hulme MJ, Lunn SF, Henderson C, Aitken RJ (1982) Plasma
progesterone levels throughout the ovarian cycle of the common marmoset
(Callithrix jacchus). J Med Primatol 1 l(l):43-51
Harlow CR, Davidson L, Burns KH, Yan C, Matzuk MM, Hillier SG (2002)
FSH and TGF-beta superfamily members regulate granulosa cell connective
tissue growth factor gene expression in vitro and in vivo. Endocrinology
143(9):3316-25
Harlow CR, Hearn JP, Hodges JK (1984) Ovulation in the marmoset monkey:
endocrinology, prediction and detection. J Endocrinol 103(1): 17-24
Harlow CR, Hillier SG, Hodges JK (1986) Androgen modulation of follicle-
stimulating hormone-induced granulosa cell steroidogenesis in the primate
ovary. Endocrinology 119(3): 1403-5
Harlow CR, Shaw HJ, Hillier SG, Hodges JK (1988) Factors influencing follicle-
stimulating hormone-responsive steroidogenesis in marmoset granulosa cells:
effects of androgens and the stage of follicular maturity. Endocrinology
122(6):2780-7
Hazzard TM, Christenson LK, Stouffer RL (2000) Changes in expression of
vascular endothelial growth factor and angiopoietin-1 and -2 in the macaque
corpus luteum during the menstrual cycle. Mol Hum Reprod 6(11):993-8
Hazzard TM, Molskness TA, Chaffin CL, Stouffer RL (1999) Vascular
endothelial growth factor (VEGF) and angiopoietin regulation by
gonadotrophin and steroids in macaque granulosa cells during the peri-
ovulatory interval. Mol Hum Reprod 5(12): 1115-21
Hazzard TM, Stouffer RL (2000) Angiogenesis in ovarian follicular and luteal
development. Baillieres Best Pract Res Clin Obstet Gynaecol 14(6):883-900
Hazzard TM, Xu F, Stouffer RL (2002) Injection of soluble vascular endothelial
growth factor receptor 1 into the preovulatory follicle disrupts ovulation and
subsequent luteal function in rhesus monkeys. Biol Reprod 67(4): 1305-12
References 235
Hearn JP (1983) The common marmoset, in Reproduction in New World
Primates,{Hearn JP ed), pp 181-216. MTP Press, Lancaster
Hearn JP, Abbott DH, Chambers PC, Hodges JK, Lunn SF (1978) Use of the
common marmoset, Callithrix jacchus, in reproductive research. Primates
Med 10:40-9
Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-
Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR,
Smith LE (2001) Low IGF-I suppresses VEGF-survival signaling in retinal
endothelial cells: direct correlation with clinical retinopathy of prematurity.
Proc Natl Acad Sci U S A 98(10):5804-8
Helmlinger G, Yuan F, Deliian M, Jain RK (1997) Interstitial pH and p02
gradients in solid tumors in vivo: high-resolution measurements reveal a lack
of correlation. Nat Med 3(2): 177-82
Hengartner MO (2000) The biochemistry of apoptosis. Nature 407(6805):770-6
Hernandez ER, Resnick CE, Svoboda ME, Van Wyk JJ, Payne DW, Adashi EY
(1988) Somatomedin-C/insulin-like growth factor I as an enhancer of
androgen biosynthesis by cultured rat ovarian cells. Endocrinology
122(4): 1603-12
Hillier SG (1985) Sex steroid metabolism and follicular development in the ovary.
Oxf Rev Reprod Biol 7:168-222
Hillier SG (1991a) Cellular basis of follicular endocrine function, in Ovarian
Edocrinology, (Hilier SG ed), pp 25-72. Blackwell Scientific Publications,
Oxford
Hillier SG (1991b) Paracrine control of follicular estrogen synthesis. Semin Reprod
Endocrinol 9:332-340
Hillier SG (1991c) Regulatory functions for inhibin and activin in human ovaries. J
Endocrinol 131(2): 171-5
Hillier SG (1994) Hormonal Control of Folliculogenesis and luteinization, in
Molecular Biology of the Female Reproductive System,(Findlay JK ed), pp 1-
37. Academic Press, London
Hillier SG (2001) Gonadotropic control of ovarian follicular growth and
development. Mol Cell Endocrinol 179( 1 -2):39-46
Hillier SG, Reichert LE, Jr., Van Hall EV (1981) Control of preovulatory
follicular estrogen biosynthesis in the human ovary. J Clin Endocrinol Metab
52(5):847-56
References 236
Hillier SG, Tetsuka M (1997) Role of androgens in follicle maturation and atresia.
Baillieres Clin Obstet Gynaecol 11(2):249-60
Hillier SG, Tetsuka M (1998) An anti-inflammatory role for glucocorticoids in the
ovaries? J Reprod Immunol 39(l-2):21-7
Hillier SG, Tetsuka M, Fraser HM (1997) Location and developmental regulation
of androgen receptor in primate ovary. Hum Reprod 12(1): 107-11
Hillier SG, Whitelaw PF, Smyth CD (1994) Follicular oestrogen synthesis: the
'two-cell, two-gonadotrophin' model revisited. Mol Cell Endocrinol 100(1-
2):51-4
Hillier SG, Yong EL, Illingworth PJ, Baird DT, Schwall RH, Mason AJ (1991a)
Effect of recombinant activin on androgen synthesis in cultured human thecal
cells. J Clin Endocrinol Metab 72(6): 1206-11
Hillier SG, Yong EL, Illingworth PJ, Baird DT, Schwall RH, Mason AJ (1991b)
Effect of recombinant inhibin on androgen synthesis in cultured human thecal
cells. Mol Cell Endocrinol 75(2):Rl-6
Hirschi KK, D'Amore PA (1996) Pericytes in the microvasculature. Cardiovasc Res
32(4):687-98
Hirschi KK, Rohovsky SA, Beck LH, Smith SR, D'Amore PA (1999) Endothelial
cells modulate the proliferation of mural cell precursors via platelet-derived
growth factor-BB and heterotypic cell contact. Circ Res 84(3):298-305
Hirshfield AN (1985) Comparison of granulosa cell proliferation in small follicles
of hypophysectomized, prepubertal, and mature rats. Biol Reprod 32(4):979-
87
Hirshfield AN (1986) Patterns of [3H] thymidine incorporation differ in immature
rats and mature, cycling rats. Biol Reprod 34(l):229-35
Hirshfield AN (1991) Development of follicles in the mammalian ovary. Int Rev
Cytol 124:43-101
Hirshfield AN, Midgley AR, Jr. (1978) Morphometric analysis of follicular
development in the rat. Biol Reprod 19(3):597-605
Ho PC (2001) Mifepristone: a potential postcoital contraceptive. Expert Opin
Pharmacother 2(9): 1383-8
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P,
Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey
K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002)
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad
References 237
SciUS A99(17): 11393-8
Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat
Rev Cancer 2(2):91-100
Hsueh AJ, Adashi EY, Jones PB, Welsh TH, Jr. (1984) Hormonal regulation of
the differentiation of cultured ovarian granulosa cells. Endocr Rev 5(1):76-
127
Hsueh AJ, Dahl KD, Vaughan J, Tucker E, Rivier J, Bardin CW, Vale W (1987)
Heterodimers and homodimers of inhibin subunits have different paracrine
action in the modulation of luteinizing hormone-stimulated androgen
biosynthesis. Proc Natl Acad Sci U S A 84(14):5082-6
Huirne JA, Lambalk CB, van Loenen AC, Schats R, Hompes PG, Fauser BC,
Macklon NS (2004) Contemporary pharmacological manipulation in assisted
reproduction. Drugs 64(3):297-322
Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R (2002) Magic
roundabout is a new member of the roundabout receptor family that is
endothelial specific and expressed at sites of active angiogenesis. Genomics
79(4):547-52
Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med
8(9):918-21
Ide AG, Baker NH, Warren SL (1939) Vascularization of the Brown Pearce rabbit
epithelioma transplant as seen in the transarent ear chamber. Am. J.
Roentgenol 42:891-9
Ilan N, Cheung L, Pinter E, Madri JA (2000) Platelet-endothelial cell adhesion
molecule-1 (CD31), a scaffolding molecule for selected catenin family
members whose binding is mediated by different tyrosine and
serine/threonine phosphorylation. J Biol Chem 275(28):21435-43
Ingber DE, Folkman J (1989) How does extracellular matrix control capillary
morphogenesis? Cell 58(5):803-5
Jingushi S, Scully SP, Joyce ME, Sugioka Y, Bolander ME (1995) Transforming
growth factor-beta 1 and fibroblast growth factors in rat growth plate. J
Orthop Res 13(5):761 -8
Jocelyn HD, Setchell BP (1972) Regnier de Graaf on the human reproductive
organs. An annotated translation of Tractatus de Virorum Organis
Generationi Inservientibus (1668) and De Mulierub Organis Generationi
Inservientibus Tractatus Novus (1962). J Reprod Fertil Suppl 17:1-222
Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL (2004) Germline stem cells
References 238
and follicular renewal in the postnatal mammalian ovary. Nature
428(6979): 145-50
Josso N, Picard JY, Tran D (1977) The anti-Mullerian hormone. Birth Defects Orig
Artie Ser 13(2):59-84
Josso N, Racine C, di Clemente N, Rey R, Xavier F (1998) The role of anti-
Mullerian hormone in gonadal development. Mol Cell Endocrinol 145(1-
2):3-7
Joubert FJ, Strydom DJ (1980) Snake venom. The amino acid sequence of protein
A from Dendroaspis polylepis polylepis (black mamba) venom. Hoppe
Seylers Z Physiol Chem 361(12): 1787-94
Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF (1995) Expression
of vascular permeability factor/vascular endothelial growth factor by human
granulosa and theca lutein cells. Role in corpus luteum development. Am J
Pathol 146(1): 157-65
Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M,
Sato Y (2000) Roles of two VEGF receptors, Fit-1 and KDR, in the signal
transduction ofVEGF effects in human vascular endothelial cells. Oncogene
19(17):2138-46
Karin M (1989) Complexities of gene regulation by cAMP. Trends Genet 5(3):65-7
Karkkainen MJ, Makinen T, Alitalo K (2002) Lymphatic endothelium: a new
frontier ofmetastasis research. Nat Cell Biol 4(l):E2-5
Karnitis VJ, Townson DH, Friedman CI, Danforth DR (1994) Recombinant
human follicle-stimulating hormone stimulates multiple follicular growth, but
minimal estrogen production in gonadotropin-releasing hormone antagonist-
treated monkeys: examining the role of luteinizing hormone in follicular
development and steroidogenesis. J Clin Endocrinol Metab 79(l):91-7
Karsch FJ, Weick RF, Hotchkiss J, Dierschke DJ, Knobil E (1973) An analysis
of the negative feedback control of gonadotropin secretion utilizing chronic
implantation of ovarian steroids in ovariectomized rhesus monkeys.
Endocrinology 93(2):478-86
Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989)
Vascular permeability factor, an endothelial cell mitogen related to PDGF.
Science 246(4935): 1309-12
Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev
Cancer 2(10):727-39
Kerbel RS (2001) Clinical trials of antiangiogenic drugs: opportunities, problems,
References 239
and assessment of initial results. J Clin Oncol 19(18 Suppl):45S-51S
Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N
(1996) Identification of vascular endothelial growth factor determinants for
binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF
variants by site-directed mutagenesis. J Biol Chem 271(10):5638-46
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993)
Inhibition of vascular endothelial growth factor-induced angiogenesis
suppresses tumour growth in vivo. Nature 362(6423):841-4
Kisliouk T, Levy N, Hurwitz A, Meidan R (2003) Presence and regulation of
endocrine gland vascular endothelial growth factor/prokineticin-1 and its
receptors in ovarian cells. J Clin Endocrinol Metab 88(8):3700-7
Klagsbrun M, D'Amore PA (1991) Regulators of angiogenesis. Annu Rev Physiol
53:217-39
Knecht M, Katz MS, Catt KJ (1981) Gonadotropin-releasing hormone inhibits
cyclic nucleotide accumulation in cultured rat granulosa cells. J Biol Chem
256(l):34-6
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R
(1998) Prevalence of the polycystic ovary syndrome in unselected black and
white women of the southeastern United States: a prospective study. J Clin
Endocrinol Metab 83(9):3078-82
Koering MJ (1969) Cyclic changes in ovarian morphology during the menstrual
cycle in Macaca mulatta. Am J Anat 126(1):73-101
Kontos CD, Cha EH, York JD, Peters KG (2002) The endothelial receptor
tyrosine kinase Tiel activates phosphatidylinositol 3-kinase and Akt to
inhibit apoptosis. Mol Cell Biol 22(6): 1704-13
Koos RD (1995) Increased expression of vascular endothelial growth/permeability
factor in the rat ovary following an ovulatory gonadotropin stimulus:
potential roles in follicle rupture. Biol Reprod 52(6): 1426-35
Koos RD, LeMaire WJ (1985) The effects of a gonadotropin-releasing hormone
agonist on ovulation and steroidogenesis during perfusion of rabbit and rat
ovaries in vitro. Endocrinology 116(2):628-32
Kraehenbuhl JP, Jamieson JD (1974) Localization of intracellular antigens by
immunoelectron microscopy. Int Rev Exp Pathol 13(0): 1-53
Krarup T, Pedersen T, Faber M (1969) Regulation of oocyte growth in the mouse
ovary. Nature 224(215): 187-8
References 240
Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM (1994) Role of
angiogenesis in patients with cerebral ischemic stroke. Stroke 25(9): 1794-8
Kurten RC, Levy LO, Shey J, Durica JM, Richards JS (1992) Identification and
characterization of the GC-rich and cyclic adenosine 3',5'-monophosphate
(cAMP)-inducible promoter of the type II beta cAMP-dependent protein
kinase regulatory subunit gene. Mol Endocrinol 6(4):536-50
Kurten RC, Richards JS (1989) An adenosine 3'5'-monophosphate-responsive
deoxyribonucleic acid element confers forskolin sensitivity on gene
expression by primary rat granulosa cells. Endocrinology 125(3): 1345-57
Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E (2002) A tumor-homing
peptide with a targeting specificity related to lymphatic vessels. Nat Med
8(7):751-5
Laitinen M, Ristimaki A, Honkasalo M, Narko K, Paavonen K, Ritvos O (1997)
Differential hormonal regulation of vascular endothelial growth factors
VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured
human granulosa-luteal cells. Endocrinology 138(11):4748-56
LaPolt PS, Tilly JL, Aihara T, Nishimori K, Hsueh AJ (1992) Gonadotropin-
induced up- and down-regulation of ovarian follicle-stimulating hormone
(FSH) receptor gene expression in immature rats: effects of pregnant mare's
serum gonadotropin, human chorionic gonadotropin, and recombinant FSH.
Endocrinology 130(3): 1289-95
Larrivee B, Karsan A (2000) Signaling pathways induced by vascular endothelial
growth factor (review). Int J Mol Med 5(5):447-56
Lawson ND, Weinstein BM (2002) Arteries and veins: making a difference with
zebrafish. Nat Rev Genet 3(9):674-82
LeCouter J, Ferrara N (2003) EG-VEGF and Bv8. a novel family of tissue-
selective mediators of angiogenesis, endothelial phenotype, and function.
Trends Cardiovasc Med 13(7):276-82
LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G,
Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ,
Ferrara N (2001) Identification of an angiogenic mitogen selective for
endocrine gland endothelium. Nature 412(6850):877-84
LeCouter J, Lin R, Frantz G, Zhang Z, Hillan K, Ferrara N (2003) Mouse
endocrine gland-derived vascular endothelial growth factor: a distinct
expression pattern from its human ortholog suggests different roles as a
regulator of organ-specific angiogenesis. Endocrinology 144(6):2606-16
Ledger WL, Sweeting VM, Hillier H, Baird DT (1992) Inhibition of ovulation by
References 241
low-dose mifepristone (RU 486). Hum Reprod 7(7):945-50
Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa
Y, Noto RA, Schoenfeld D, MacLaughlin DT (1996) Mullerian inhibiting
substance in humans: normal levels from infancy to adulthood. J Clin
Endocrinol Metab 81(2):571-6
Lee WS, Otsuka F, Moore RK, Shimasaki S (2001) Effect of bone morphogenetic
protein-7 on folliculogenesis and ovulation in the rat. Biol Reprod 65(4):994-
9
Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF, 3rd, Dunaif A (1998)
Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm
Res 53:217-56
Legro RS, Strauss JFI (2003) Polycystic ovarian syndrome, in Reproductive
Medicine. Molecular, Cellular and Genetic Fundamentals,'(Fauser BC ed),
pp 601-614. The Parthenon Publishing Group, London
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular
endothelial growth factor is a secreted angiogenic mitogen. Science
246(4935): 1306-9
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman
EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP,
Karumanchi SA (2004) Circulating angiogenic factors and the risk of
preeclampsia. N Engl J Med 350(7):672-83
Li J, Yu X, Pan W, Unger RH (2002a) Gene expression profde of rat adipose tissue
at the onset of high-fat-diet obesity. Am J Physiol Endocrinol Metab
282(6):E 1334-41
Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY (2001) Identification of two
prokineticin cDNAs: recombinant proteins potently contract gastrointestinal
smooth muscle. Mol Pharmacol 59(4):692-8
Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT,
Bohlen P, Hicklin DJ (2002b) Active immunization against the vascular
endothelial growth factor receptor flkl inhibits tumor angiogenesis and
metastasis. J Exp Med 195(12): 1575-84
Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H, Zhou QY (2002)
Identification and molecular characterization of two closely related G
protein-coupled receptors activated by prokineticins/endocrine gland vascular
endothelial growth factor. J Biol Chem 277(22): 19276-80
Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS (1987) Disruption of
follicular maturation and delay of ovulation after administration of the
References 242
antiprogesterone RU486. J Clin Endocrinol Metab 65(6): 1135-40
Livingstone M, Fraser IS (2002) Mechanisms of abnormal uterine bleeding. Hum
Reprod Update 8(l):60-7
Lundy T, Smith P, O'Connell A, Hudson NL, McNatty KP (1999) Populations of
granulosa cells in small follicles of the sheep ovary. J Reprod Fertil
115(2) :251-62
Lydon JP, DeMayo FJ, Conneely OM, O'Malley BW (1996) Reproductive
phenotpes of the progesterone receptor null mutant mouse. J Steroid Biochem
Mol Biol 56(1-6 Spec No):67-77
Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Jr.,
Shyamala G, Conneely OM, O'Malley BW (1995) Mice lacking
progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes
Dev 9(18):2266-78
Magoffin DA, Erickson GF (1994) Control systems of theca-interstitial cells, in
Molecular Biology of the Female Reproductive System,{Findlay JK ed), pp
39-66. Academic Press, London
Mahooti S, Graesser D, Patil S, Newman P, Duncan G, Mak T, Madri JA (2000)
PECAM-1 (CD31) expression modulates bleeding time in vivo. Am J Pathol
157(l):75-81
Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D (2001)
Delta4, an endothelial specific notch ligand expressed at sites of
physiological and tumor angiogenesis. Differentiation 69(2-3): 135-44
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski
C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis
S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist
for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55-60
Makrigiannakis A, Coukos G, Christofidou-Solomidou M, Montas S, Coutifaris
C (2000) Progesterone is an autocrine/paracrine regulator of human
granulosa cell survival in vitro. Ann N Y Acad Sci 900:16-25
Manoonkitiwongsa PS, Jackson-Friedman C, McMillan PJ, Schultz RL, Lyden
PD (2001) Angiogenesis after stroke is correlated with increased numbers of
macrophages: the clean-up hypothesis. J Cereb Blood Flow Metab
21(10):1223-31
Mansfield K (2003) Marmoset models commonly used in biomedical research.
Comp Med 53(4):383-92
Markstrom E, Svensson E, Shao R, Svanberg B, Billig H (2002) Survival factors
References 243
regulating ovarian apoptosis — dependence on follicle differentiation.
Reproduction 123(l):23-30
Marshall E (2002) Cancer therapy. Setbacks for endostatin. Science
295(5563):2198-9
Martinez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martinez ME (2002)
Age-related changes in parathyroid hormone-related protein and vascular
endothelial growth factor in human osteoblastic cells. Osteoporos Int
13(11):874-81
Martinez-Chequer JC, Stouffer RL, Hazzard TM, Patton PE, Molskness TA
(2003) Insulin-Like Growth Factors-1 and -2, but not Hypoxia, Synergize
with Gonadotropin Hormone to Promote Vascular Endothelial Growth
Factor-A Secretion by Monkey Granulosa Cells from Preovulatory Follicles.
Biol Reprod 68(4): 1112-8
Maruo T, Otani T, Mochizuki M (1985) Antigonadotropic actions ofGnRH
agonist on ovarian cells in vivo and in vitro. J Steroid Biochem 23(5B):765-
70
Marvanova M, Menager J, Bezard E, Bontrop RE, Pradier L, Wong G (2003)
Microarray analysis of nonhuman primates: validation of experimental
models in neurological disorders. Faseb J 17(8):929-31
Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi Y, Suenaga M, Abe M,
Fukusumi S, Watanabe T, Shintani Y, Yamada T, Hinuma S, Inatomi N,
Ohtaki T, Onda H, Fujino M (2002) Isolation and identification ofEG-
VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled
receptors. Biochem Biophys Res Commun 293(1 ):396-402
McAnulty PA (1994) Marmoset Care and Reproduction, in The Marmoset - Role in
Pharmaceutical Development,{Fowler JS ed), pp 7-12. Pharmaco LSR,
Ipswich
McGadey J (1970) A tetrazolium method for non-specific alkaline phosphatase.
Histochemie 23(2): 180-4
McGee E, Spears N, Minami S, Hsu SY, Chun SY, Billig H, Hsueh AJ (1997a)
Preantral ovarian follicles in serum-free culture: suppression of apoptosis
after activation of the cyclic guanosine 3',5'-monophosphate pathway and
stimulation of growth and differentiation by follicle-stimulating hormone.
Endocrinology 138(6):2417-24
McGee EA, Chun SY, Lai S, He Y, Hsueh AJ (1999) Keratinocyte growth factor
promotes the survival, growth, and differentiation of preantral ovarian
follicles. Fertil Steril 71(4):732-8
References 244
McGee EA, Perlas E, LaPolt PS, Tsafriri A, Hsueh AJ (1997b) Follicle-
stimulating hormone enhances the development of preantral follicles in
juvenile rats. Biol Reprod 57(5):990-8
McGee EA, Smith R, Spears N, Nachtigal MW, Ingraham H, Hsueh AJ (2001)
Mullerian inhibitory substance induces growth of rat preantral ovarian
follicles. Biol Reprod 64(l):293-8
McNatty KP, Baird DT, Bolton A, Chambers P, Corker CS, McLean H (1976)
Concentration of oestrogens and androgens in human ovarian venous plasma
and follicular fluid throughout the menstrual cycle. J Endocrinol 71(l):77-85
McNatty KP, Hillier SG, van den Boogaard AM, Trimbos-Kemper TC,
Reichert LE, Jr., van Hall EV (1983) Follicular development during the
luteal phase of the human menstrual cycle. J Clin Endocrinol Metab
56(5): 1022-31
McNatty KP, Juengel JL, Reader KL, Lun S, Myllymaa S, Lawrence SB,
Western A, Meerasahib MF, Mottershead DG, Groome NP, Ritvos O,
Laitinen MP (2005) Bone morphogenetic protein 15 and growth
differentiation factor 9 co-operate to regulate granulosa cell function.
Reproduction 129(4):473-80
McNeilly AS, Crawford JL, Taragnat C, Nicol L, McNeilly JR (2003) The
differential secretion of FSH and LH: regulation through genes, feedback and
packaging. Reprod Suppl 61:463-76
Michael AE, Webley GE (1993) Roles of cyclic AMP and inositol phosphates in the
luteolytic action of cloprostenol, a prostaglandin F2 alpha analogue, in
marmoset monkeys (Callithrix jacchus). J Reprod Fertil 97(2):425-31
Michelson IC (1948) The mode of development of the vascular system of the retina
with some observations on its significance for certain retinal disorders. Trans.
Ophthalmol. Soc. UK 68:137-180
Miller WL (1988) Molecular biology of steroid hormone synthesis. Endocr Rev
9(3):295-318
Miro F, Hillier SG (1996) Modulation of granulosa cell deoxyribonucleic acid
synthesis and differentiation by activin. Endocrinology 137(2):464-8
Miyazaki T, Tanaka M, Miyakoshi K, Minegishi K, Kasai K, Yoshimura Y
(1998) Power and colour Doppler ultrasonography for the evaluation of the
vasculature of the human corpus luteum. Hum Reprod 13(10):2836-41
Mollay C, Wechselberger C, Mignogna G, Negri L, Melchiorri P, Barra D, Kreil
G (1999) Bv8, a small protein from frog skin and its homologue from snake
venom induce hyperalgesia in rats. Eur J Pharmacol 374(2): 189-96
References 245
Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L (1986) Basic fibroblast
growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A
83(19):7297-301
Moretti S, Spallanzani A, Pinzi C (1999) Skin angiogenesis: biologic bases for
pathological processes. Clin Dermatol 17(6):629-31
Morita Y, Tilly JL (1999) Oocyte apoptosis: like sand through an hourglass. Dev
Biol 213(1):1-17
Motro B, Bernstein A (1993) Dynamic changes in ovarian c-kit and Steel
expression during the estrous reproductive cycle. Dev Dyn 197(l):69-79
Muller T, Gromoll J, Simoni M (2003) Absence of exon 10 of the human
luteinizing hormone (LH) receptor impairs LH, but not human chorionic
gonadotropin action. J Clin Endocrinol Metab 88(5):2242-9
Muller T, Simoni M, Pekel E, Luetjens CM, Chandolia R, Amato F, Norman
RJ, Gromoll J (2004) Chorionic gonadotrophin beta subunit mRNA but not
luteinising hormone beta subunit mRNA is expressed in the pituitary of the
common marmoset (Callithrix jacchus). J Mol Endocrinol 32(1): 115-28
Nahum R, Thong KJ, Hillier SG (1995) Metabolic regulation of androgen
production by human thecal cells in vitro. Hum Reprod 10(1):75-81
Nakatani A, Shimasaki S, Depaolo LV, Erickson GF, Ling N (1991) Cyclic
changes in follistatin messenger ribonucleic acid and its protein in the rat
ovary during the estrous cycle. Endocrinology 129(2):603-11
Natraj U, Richards JS (1993) Hormonal regulation, localization, and functional
activity of the progesterone receptor in granulosa cells of rat preovulatory
follicles. Endocrinology 133(2):761-9
Neeman M, Abramovitch R, Schiffenbauer YS, Tempel C (1997) Regulation of
angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Int
J Exp Pathol 78(2):57-70
Nehls V, Denzer K, Drenckhahn D (1992) Pericyte involvement in capillary
sprouting during angiogenesis in situ. Cell Tissue Res 270(3):469-74
Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE (1995) Suppression of follicular
phase pituitary-gonadal function by a potent new gonadotropin-releasing
hormone antagonist with reduced histamine-releasing properties (ganirelix).
Fertil Steril 63(5):963-9
Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D,
Breckwoldt M (1995) Human chorionic gonadotropin-dependent expression
References 246
of vascular endothelial growth factor/vascular permeability factor in human
granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin
Endocrinol Metab 80(6): 1967-71
Newman PJ (1994) The role of PECAM-1 in vascular cell biology. Ann N Y Acad
Sci 714:165-74
Newman PJ (1997) The biology ofPECAM-1. J Clin Invest 100(11 Suppl):S25-9
Newman PJ (1999) Switched at birth: a new family for PECAM-1. J Clin Invest
103(l):5-9
Newman PJ, Newman DK (2003) Signal transduction pathways mediated by
PECAM-1: new roles for an old molecule in platelet and vascular cell
biology. Arterioscler Thromb Vase Biol 23(6):953-64
Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM,
Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes
engineered to target vascular endothelial growth factor receptors. Proc Natl
Acad Sci U S A 99(10):7009-14
Nilsson E, Parrott JA, Skinner MK (2001) Basic fibroblast growth factor induces
primordial follicle development and initiates folliculogenesis. Mol Cell
Endocrinol 175(1-2): 123-30
Nilsson EE, Kezele P, Skinner MK (2002) Leukemia inhibitory factor (LIF)
promotes the primordial to primary follicle transition in rat ovaries. Mol Cell
Endocrinol 188(1 -2):65-73
Nilsson EE, Skinner MK (2004) Kit ligand and basic fibroblast growth factor
interactions in the induction of ovarian primordial to primary follicle
transition. Mol Cell Endocrinol 214( 1-2): 19-25
Noble KE, Wickremasinghe RG, DeCornet C, Panayiotidis P, Yong KL (1999)
Monocytes stimulate expression of the Bcl-2 family member, Al, in
endothelial cells and confer protection against apoptosis. J Immunol
162(3): 1376-83
Novak K (2002) Angiogenesis inhibitors revised and revived at AACR. American
Association for Cancer Research. Nat Med 8(5):427
O'Reilly MS (1997) Angiostatin: an endogenous inhibitor of angiogenesis and of
tumor growth. Exs 79:273-94
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E,
Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous
inhibitor of angiogenesis and tumor growth. Cell 88(2):277-85
References 247
Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ (1999) Pharmacokinetic
and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part
II. Dose-proportionality and gonadotropin suppression after multiple doses of
ganirelix in healthy female volunteers. Fertil Steril 72(6): 1006-12
Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van
Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin
M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van
Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx
F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W,
Herbert JM, Collen D, Carmeliet P (2001) Deletion of the hypoxia-
response element in the vascular endothelial growth factor promoter causes
motor neuron degeneration. Nat Genet 28(2): 131-8
Orlidge A, D'Amore PA (1987) Inhibition of capillary endothelial cell growth by
pericytes and smooth muscle cells. J Cell Biol 105(3): 1455-62
Orvieto R (2005) Can we eliminate severe ovarian hyperstimulation syndrome?
Hum Reprod 20(2):320-2
Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, Otani T,
Nakano R (1999) The vascular endothelial growth factor/fms-like tyrosine
kinase system in human ovary during the menstrual cycle and early
pregnancy. J Clin Endocrinol Metab 84(10):3845-51
Padhani AR, Dzik-Jurasz A (2004) Perfusion MR imaging of extracranial tumor
angiogenesis. Top Magn Reson Imaging 15(l):41-57
Pan HA, Cheng YC, Li CH, Wu MH, Chang FM (2002) Ovarian stroma flow
intensity decreases by age: a three-dimensional power doppler
ultrasonographic study. Ultrasound Med Biol 28(4):425-30
Paredes A, Romero C, Dissen GA, DeChiara TM, Reichardt L, Cornea A,
Ojeda SR, Xu B (2004) TrkB receptors are required for follicular growth and
oocyte survival in the mammalian ovary. Dev Biol 267(2):430-49
Park JE, Chen HH, Winer J, Houck KA, Ferrara N (1994) Placenta growth
factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro
and in vivo, and high affinity binding to Flt-1 but not to Flk-l/KDR. J Biol
Chem 269(41):25646-54
Park-Sarge OK, Mayo KE (1994) Regulation of the progesterone receptor gene by
gonadotropins and cyclic adenosine 3',5'-monophosphate in rat granulosa
cells. Endocrinology 134(2):709-18
Parker KL, Rice DA, Lala DS, Ikeda Y, Luo X, Wong M, Bakke M, Zhao L,
Frigeri C, Hanley NA, Stailings N, Schimmer BP (2002) Steroidogenic
factor 1: an essential mediator of endocrine development. Recent Prog Horm
References 248
Res 57:19-36
Parrott JA, Skinner MK (1999) Kit-ligand/stem cell factor induces primordial
follicle development and initiates folliculogenesis. Endocrinology
140(9):4262-71
Partanen J, Armstrong E, Makela TP, Korhonen J, Sandberg M, Renkonen R,
Knuutila S, Huebner K, Alitalo K (1992) A novel endothelial cell surface
receptor tyrosine kinase with extracellular epidermal growth factor homology
domains. Mol Cell Biol 12(4): 1698-707
Pearl R, Schoppe WF (1921) Studies on the physiology of reproduction in the
domestic fowl. J. Exp. Zool. 34:101-118
Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C (1999)
The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies
investigating the role of interleukin-lbeta, interleukin-6, and vascular
endothelial growth factor. Fertil Steril 71(3):482-9
Perez RP, Godwin AK, Hamilton TC, Ozols RF (1991) Ovarian cancer biology.
Semin Oncol 18(3): 186-204
Phillips HS, Hains J, Leung DW, Ferrara N (1990) Vascular endothelial growth
factor is expressed in rat corpus luteum. Endocrinology 127(2):965-7
Pohl CR, Richardson DW, Hutchison JS, Germak JA, Knobil E (1983)
Hypophysiotropic signal frequency and the functioning of the pituitary-
ovarian system in the rhesus monkey. Endocrinology 112(6):2076-80
Poole AR (1991) Cartilage: Molecular Aspects. CRC Press, Boca Raton
Popovici RM, Irwin JC, Giaccia AJ, Giudice LC (1999) Hypoxia and cAMP
stimulate vascular endothelial growth factor (VEGF) in human endometrial
stromal cells: potential relevance to menstruation and endometrial
regeneration. J Clin Endocrinol Metab 84(6):2245-8
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC (1999) The insulin-related
ovarian regulatory system in health and disease. Endocr Rev 20(4):535-82
Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS (1985) Distribution and
characterization of insulin and insulin-like growth factor I receptors in normal
human ovary. J Clin Endocrinol Metab 61(4):728-34
Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek
NE (1999) Expression of anti-Mullerian hormone during normal and
pathological gonadal development: association with differentiation of Sertoli
and granulosa cells. J Clin Endocrinol Metab 84(10):3836-44
References 249
Rannikki AS, Zhang FP, Huhtaniemi IT (1995) Ontogeny of follicle-stimulating
hormone receptor gene expression in the rat testis and ovary. Mol Cell
Endocrinol 107(2): 199-208
Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N, Zeleznik AJ (1992)
Vascular endothelial growth factor messenger ribonucleic acid expression in
the primate ovary. Endocrinology 13 l(l):254-60
Redmer DA, Doraiswamy V, Bortnem BJ, Fisher K, Jablonka-ShariffA,
Grazul-Bilska AT, Reynolds LP (2001) Evidence for a role of capillary
pericytes in vascular growth of the developing ovine corpus luteum. Biol
Reprod 65(3):879-89
Rew DA, Wilson GD (2000) Cell production rates in human tissues and tumours and
their significance. Part 1: an introduction to the techniques ofmeasurement
and their limitations. Eur J Surg Oncol 26(3):227-38
Reynaud K, Driancourt MA (2000) Oocyte attrition. Mol Cell Endocrinol 163(1-
2): 101-8
Reynolds LP, Killilea SD, Redmer DA (1992) Angiogenesis in the female
reproductive system. Faseb J 6(3):886-92
Reynolds LP, Redmer DA (1998) Expression of the angiogenic factors, basic
fibroblast growth factor and vascular endothelial growth factor, in the ovary.
J Anim Sci 76(6): 1671-81
Rhodin JA (1968) Ultrastructure of mammalian venous capillaries, venules, and
small collecting veins. J Ultrastruct Res 25(5):452-500
Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, Djonov V (2001)
Chorioallantoic membrane capillary bed: a useful target for studying
angiogenesis and anti-angiogenesis in vivo. Anat Rec 264(4):317-24
Ribatti D, Vacca A, Roncali L, Dammacco F (1996) The chick embryo
chorioallantoic membrane as a model for in vivo research on angiogenesis.
Int J Dev Biol 40(6): 1189-97
Ribatti D, Vacca A, Roncali L, Dammacco F (2000) The chick embryo
chorioallantoic membrane as a model for in vivo research on anti-
angiogenesis. Curr Pharm Biotechnol 1 (1 ):73-82
Richards JS (1980) Maturation of ovarian follicles: actions and interactions of
pituitary and ovarian hormones on follicular cell differentiation. Physiol Rev
60(1):51-89
Richards JS (1994) Hormonal control of gene expression in the ovary. Endocr Rev
15(6):725-51
References 250
Richards JS, Jahnsen T, Hedin L, Lifka J, Ratoosh S, Durica JM, Goldring NB
(1987) Ovarian follicular development: from physiology to molecular
biology. Recent Prog Horm Res 43:231-76
Richards JS, Russell DL, Robker RL, Dajee M, Alliston TN (1998) Molecular
mechanisms of ovulation and luteinization. Mol Cell Endocrinol 145(l-2):47-
54
Roberts WG, Palade GE (1995) Increased microvascular permeability and
endothelial fenestration induced by vascular endothelial growth factor. J Cell
Sci 108 ( Pt 6):2369-79
Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth
factor (VEGF) and their receptors. J Cell Sci 114(Pt 5):853-65
Robker RL, Russell DL, Yoshioka S, Sharma SC, Lydon JP, O'Malley BW,
Espey LL, Richards JS (2000) Ovulation: a multi-gene, multi-step process.
Steroids 65(10-11):559-70
Roseff SJ, Bangah ML, Kettel LM, Vale W, Rivier J, Burger HG, Yen SS (1989)
Dynamic changes in circulating inhibin levels during the luteal-follicular
transition of the human menstrual cycle. J Clin Endocrinol Metab
69(5): 1033-9
Rowe AJ, Morris KD, Bicknell R, Fraser HM (2002) Angiogenesis in the corpus
luteum of early pregnancy in the marmoset and the effects of vascular
endothelial growth factor immunoneutralization on establishment of
pregnancy. Biol Reprod 67(4): 1180-8
Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2(2):83-
90
Ruoslahti E, Rajotte D (2000) An address system in the vasculature of normal
tissues and tumors. Annu Rev Immunol 18:813-27
Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R,
Folkman MJ (2002) Adipose tissue mass can be regulated through the
vasculature. Proc Natl Acad Sci U S A 99(16): 10730-5
Saltzman W, Schultz-Darken NJ, Scheffler G, Wegner FH, Abbott DH (1994)
Social and reproductive influences on plasma Cortisol in female marmoset
monkeys. Physiol Behav 56(4):801-10
Saltzman W, Schultz-Darken NJ, Severin JM, Abbott DH (1997a) Escape from
social suppression of sexual behavior and of ovulation in female common
marmosets. Ann N Y Acad Sci 807:567-70
References 251
Saltzman W, Schultz-Darken NJ, Wegner FH,Wittwer DJ, Abbott DH (1998)
Suppression ofCortisol levels in subordinate female marmosets: reproductive
and social contributions. Horm Behav 33(l):58-74
Saltzman W, Severin JM, Schultz-Darken NJ, Abbott DH (1997b) Behavioral
and social correlates of escape from suppression of ovulation in female
common marmosets housed with the natal family. Am J Primatol 41(1): 1-21
Samson M, Peale FV, Jr., Frantz G, Rioux-Leclercq N, Rajpert-De Meyts E,
Ferrara N (2004) Human endocrine gland-derived vascular endothelial
growth factor: expression early in development and in leydig cell tumors
suggests roles in normal and pathological testis angiogenesis. J Clin
Endocrinol Metab 89(8):4078-88
Sasano H, Okamoto M, Mason JI, Simpson ER, Mendelson CR, Sasano N,
Silverberg SG (1989) Immunolocalization of aromatase, 17 alpha-
hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary.
J Reprod Fertil 85(1): 163-9
Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M (2000) Properties
of two VEGF receptors, Fit-1 and KDR, in signal transduction. Ann N Y
Acad Sci 902:201-5; discussion 205-7
Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC,
Gospodarowicz D (1987) Capillary endothelial cells express basic fibroblast
growth factor, a mitogen that promotes their own growth. Nature
325(6101):257-9
Schweitz H, Pacaud P, Diochot S, Moinier D, Lazdunski M (1999) MIT(l), a
black mamba toxin with a new and highly potent activity on intestinal
contraction. FEBS Lett 461(3): 183-8
Scott L (1994) Marmosets as Models for Man, in The Marmoset - Role in
Pharmaceutical Development,(Fowler JS ed), pp 1-5. Pharmaco LSR,
Ipswich
Segaloff DL, Ascoli M (1993) The lutropin/choriogonadotropin receptor ... 4 years
later. Endocr Rev 14(3):324-47
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983)
Tumor cells secrete a vascular permeability factor that promotes
accumulation of ascites fluid. Science 219(4587):983-5
Sharkey AM, Day K, McPherson A, Malik S, Licence D, Smith SK, Charnock-
Jones DS (2000) Vascular endothelial growth factor expression in human
endometrium is regulated by hypoxia. J Clin Endocrinol Metab 85(l):402-9
Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF (1998)
References 252
Homologous up-regulation of KDR/Flk-1 receptor expression by vascular
endothelial growth factor in vitro. J Biol Chem 273(45):29979-85
Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-
embedded tissues: an enhancement method for immunohistochemical
staining based on microwave oven heating of tissue sections. J Histochem
Cytochem 39(6):741-8
Shim WS, Teh M, Bapna A, Kim I, Koh GY, Mack PO, Ge R (2002)
Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of
human cervical cancer in mice. Exp Cell Res 279(2):299-309
Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E (1993) Patterns of
expression of vascular endothelial growth factor (VEGF) and VEGF
receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin
Invest 91(5):2235-43
Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature
359(6398):843-5
Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM (1998) Direct
intramuscular injection of plasmid DNA encoding angiopoietin-1 but not
angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb.
Circulation 98( 19):2081-7
Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM,
Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD,
Mendelson CR, Bulun SE (1994) Aromatase cytochrome P450, the enzyme
responsible for estrogen biosynthesis. Endocr Rev 15(3):342-55
Smith SK (1998) Angiogenesis, vascular endothelial growth factor and the
endometrium. Hum Reprod Update 4(5):509-19
Smyth CD, Miro F, Howies CM, Hillier SG (1995) Effect of luteinizing hormone
on follicle stimulating hormone-activated paracrine signalling in rat ovary.
Hum Reprod 10(l):33-9
Smyth CD, Miro F, Whitelaw PF, Howies CM, Hillier SG (1993) Ovarian
thecal/interstitial androgen synthesis is enhanced by a follicle-stimulating
hormone-stimulated paracrine mechanism. Endocrinology 133(4): 1532-8
Sprengel R, Braun T, Nikolics K, SegaloffDL, Seeburg PH (1990) The testicular
receptor for follicle stimulating hormone: structure and functional expression
of cloned cDNA. Mol Endocrinol 4(4):525-30
Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K (2002)
Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2(8):573-83
References 253
Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG,
Wilks AF (1999) A mutant form of vascular endothelial growth factor
(VEGF) that lacks VEGF receptor-2 activation retains the ability to induce
vascular permeability. J Biol Chem 274(49):34884-92
SteinkampfMP, Mendelson CR, Simpson ER (1987) Regulation by follicle-
stimulating hormone of the synthesis of aromatase cytochrome P-450 in
human granulosa cells. Mol Endocrinol 1(7):465-71
Stewart PM (1996) 11 beta-Hydroxysteroid dehydrogenase: implications for clinical
medicine. Clin Endocrinol (Oxf) 44(5):493-9
Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S,
Zeillinger R (2002) Vascular endothelial growth factor splice variants and
their prognostic value in breast and ovarian cancer. Clin Cancer Res
8(7):2253-9
Stocco DM (2001) StAR protein and the regulation of steroid hormone biosynthesis.
Annu Rev Physiol 63:193-213
Streefkerk JG (1972) Inhibition of erythrocyte pseudoperoxidase activity by
treatment with hydrogen peroxide following methanol. J Histochem
Cytochem 20(10):829-31
Su YQ, Denegre JM, Wigglesworth K, Pendola FL, O'Brien MJ, Eppig JJ
(2003) Oocyte-dependent activation ofmitogen-activated protein kinase
(ERK1/2) in cumulus cells is required for the maturation of the mouse
oocyte-cumulus cell complex. Dev Biol 263(l):126-38
Su YQ, Wigglesworth K, Pendola FL, O'Brien MJ, Eppig JJ (2002) Mitogen-
activated protein kinase activity in cumulus cells is essential for
gonadotropin-induced oocyte meiotic resumption and cumulus expansion in
the mouse. Endocrinology 143(6):2221-32
Summers PM, Wennink CJ, Hodges JK (1985) Cloprostenol-induced luteolysis in
the marmoset monkey (Callithrix jacchus). J Reprod Fertil 73(1): 133-8
Sun QH, DeLisser HM, Zukowski MM, Paddock C, Albelda SM, Newman PJ
(1996) Individually distinct Ig homology domains in PECAM-1 regulate
homophilic binding and modulate receptor affinity. J Biol Chem
271(19):11090-8
Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, Manseau EJ,
Dvorak AM, Dvorak HF (2001) Glomeruloid microvascular proliferation
follows adenoviral vascular permeability factor/vascular endothelial growth
factor-164 gene delivery. Am J Pathol 158(3): 1145-60
References 254
Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato
TN, Yancopoulos GD (1998) Increased vascularization in mice
overexpressing angiopoietin-1. Science 282(5388):468-71
Suzuki T, Sasano H, Takaya R, Fukaya T, Yajima A, Nagura H (1998) Cyclic
changes of vasculature and vascular phenotypes in normal human ovaries.
Hum Reprod 13(4):953-9
Svensson EC, Markstrom E, Andersson M, Billig H (2000) Progesterone receptor-
mediated inhibition of apoptosis in granulosa cells isolated from rats treated
with human chorionic gonadotropin. Biol Reprod 63(5): 1457-64
Svensson PA, Johnson MS, Ling C, Carlsson LM, Billig H, Carlsson B (1999)
Scavenger receptor class B type I in the rat ovary: possible role in high
density lipoprotein cholesterol uptake and in the recognition of apoptotic
granulosa cells. Endocrinology 140(6):2494-500
Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP (1996) Adenosine
mediates hypoxic induction of vascular endothelial growth factor in retinal
pericytes and endothelial cells. Invest Ophthalmol Vis Sci 37(11 ):2165-76
Takayama K, Sasano H, Fukaya T, Morohashi K, Suzuki T, Tamura M, Costa
MJ, Yajima A (1995) Immunohistochemical localization ofAd4-binding
protein with correlation to steroidogenic enzyme expression in cycling human
ovaries and sex cord stromal tumors. J Clin Endocrinol Metab 80(9):2815-21
Talbert GB, Meyer RK, Me SW (1951) Effect of hypophysectomy at the beginning
of proestrus on maturing follicles in the ovary of rat. Endocrinology
49(6):687-94
Tamura T, Kitawaki J, Yamamoto T, Osawa Y, Kominami S, Takemori S,
Okada H (1992) Immunohistochemical localization of 17 alpha-
hydroxylase/C 17-20 lyase and aromatase cytochrome P-450 in the human
ovary during the menstrual cycle. J Endocrinol 135(3):589-95
Tardif SD, Jaquish CE (1997) Number of ovulations in the marmoset monkey
(Callithrix iacchus): relation to body weight, age and repeatability. Am J
Primatol 42(4):323-9
Tash JS, Welsh MJ, Means AR (1981) Regulation of protein kinase inhibitor by
follicle-stimulating hormone in Sertoli cells in vitro. Endocrinology
108(2):427-34
Taylor PD, Hillier SG, Fraser HM (2004) Effects ofGnRH antagonist treatment on
follicular development and angiogenesis in the primate ovary. J Endocrinol
183(1): 1-17
Tetsuka M, Hillier SG (1996) Androgen receptor gene expression in rat granulosa
References 255
cells: the role of follicle-stimulating hormone and steroid hormones.
Endocrinology 137(10):4392-7
Tetsuka M, Milne M, Simpson GE, Hillier SG (1999) Expression of 1 lbeta-
hydroxysteroid dehydrogenase, glucocorticoid receptor, and
mineralocorticoid receptor genes in rat ovary. Biol Reprod 60(2):330-5
Tetsuka M, Thomas FJ, Thomas MJ, Anderson RA, Mason JI, Hillier SG
(1997) Differential expression ofmessenger ribonucleic acids encoding
1 lbeta-hydroxysteroid dehydrogenase types 1 and 2 in human granulosa
cells. J Clin Endocrinol Metab 82(6):2006-9
Tetsuka M, Whitelaw PF, Bremner WJ, Millar MR, Smyth CD, Hillier SG
(1995) Developmental regulation of androgen receptor in rat ovary. J
Endocrinol 145(3):535-43
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ,
Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from
human blastocysts. Science 282(5391): 1145-7
Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Hearn JP (1996)
Pluripotent cell lines derived from common marmoset (Callithrix jacchus)
blastocysts. Biol Reprod 55(2):254-9
Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science
281(5381): 1312-6
Tilly JL, Billig H, Kowalski KI, Hsueh AJ (1992a) Epidermal growth factor and
basic fibroblast growth factor suppress the spontaneous onset of apoptosis in
cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-
dependent mechanism. Mol Endocrinol 6(11): 1942-50
Tilly JL, LaPolt PS, Hsueh AJ (1992b) Hormonal regulation of follicle-stimulating
hormone receptor messenger ribonucleic acid levels in cultured rat granulosa
cells. Endocrinology 130(3): 1296-302
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC,
Abraham JA (1991) The human gene for vascular endothelial growth factor.
Multiple protein forms are encoded through alternative exon splicing. J Biol
Chem 266(18): 11947-54
Tjugum J, Dennefors B, Norstrom A (1984) Influence of progesterone,
androstenedione and oestradiol-17 beta on the incorporation of [3H]proline in
the human follicular wall. Acta Endocrinol (Copenh) 105(4):552-7
Torii R, Abbott DH, Nigi H (1996) Morphological changes of the ovary and
hormonal changes through the ovarian cycle of the common marmoset
(iCallithrix jacchus). Primates 37(l):49-56
References 256
Tsafriri A, Braw RH (1984) Experimental approaches to atresia in mammals. Oxf
Rev Reprod Biol 6:226-65
Tsafriri A, Dekel N (1994) Molecular mechanisms in ovulation, in Molecular
Biology of the Female Reproductive System,(Findlay JK ed), pp 207-258.
Academic Press, London
Ueno S, Kuroda T, Maclaughlin DT, Ragin RC, Manganaro TF, Donahoe PK
(1989) Mullerian inhibiting substance in the adult rat ovary during various
stages of the estrous cycle. Endocrinology 125(2): 1060-6
Valenzuela DM, Griffiths JA, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain
J, Copeland NG, Gilbert DJ, Jenkins NA, Huang T, Papadopoulos N,
Maisonpierre PC, Davis S, Yancopoulos GD (1999) Angiopoietins 3 and 4:
diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A
96(5): 1904-9
Van Patten SM, Howard P, Walsh DA, Maurer RA (1992) The alpha- and beta-
isoforms of the inhibitor protein of the 3',5'-cyclic adenosine monophosphate-
dependent protein kinase: characteristics and tissue- and developmental-
specific expression. Mol Endocrinol 6(12):2114-22
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella
F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of
angiogenesis in solid human tumours: an international consensus on the
methodology and criteria of evaluation. Eur J Cancer 32A(14):2474-84
Vitt UA, Hayashi M, Klein C, Hsueh AJ (2000) Growth differentiation factor-9
stimulates proliferation but suppresses the follicle-stimulating hormone-
induced differentiation of cultured granulosa cells from small antral and
preovulatory rat follicles. Biol Reprod 62(2):370-7
Vlodavsky I, Fridman R, Sullivan R, Sasse J, Klagsbrun M (1987) Aortic
endothelial cells synthesize basic fibroblast growth factor which remains cell
associated and platelet-derived growth factor-like protein which is secreted. J
Cell Physiol 131(3):402-8
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994)
Different signal transduction properties ofKDR and Fltl, two receptors for
vascular endothelial growth factor. J Biol Chem 269(43):26988-95
Wandji SA, Srsen V, Nathanielsz PW, Eppig JJ, Fortune JE (1997) Initiation of
growth of baboon primordial follicles in vitro. Hum Reprod 12(9): 1993-2001
Wandji SA, Srsen V, Voss AK, Eppig JJ, Fortune JE (1996) Initiation in vitro of
growth of bovine primordial follicles. Biol Reprod 55(5):942-8
References 257
Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK
(2002) Human chorionic gonadotropin-induced ovarian hyperstimulation
syndrome is associated with up-regulation of vascular endothelial growth
factor. J Clin Endocrinol Metab 87(7):3300-8
Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB (1996) Induction of
vascular endothelial growth factor by insulin-like growth factor 1 in
colorectal carcinoma. J Biol Chem 271(46):29483-8
Webley GE, Richardson MC, Summers PM, Given A, Hearn JP (1989)
Changing responsiveness of luteal cells of the marmoset monkey (Callithrix
jacchus) to luteotrophic and luteolytic agents during normal and conception
cycles. J Reprod Fertil 87(1):301-10
West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M (2001) Tumor
vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res
61(7):2907-10
Westermark B, Siegbahn A, Heldin CH, Claesson-Welsh L (1990) B-type
receptor for platelet-derived growth factor mediates a chemotactic response
by means of ligand-induced activation of the receptor protein-tyrosine kinase.
Proc Natl Acad Sci U S A 87(1): 128-32
Whitelaw PF, Smyth CD, Howies CM, Hillier SG (1992) Cell-specific expression
of aromatase and LH receptor mRNAs in rat ovary. J Mol Endocrinol
9(3):309-12
Wickings EJ, Eidne KA, Dixson AF, Hillier SG (1990) Gonadotropin-releasing
hormone analogs inhibit primate granulosa cell steroidogenesis via a
mechanism distinct from that in the rat. Biol Reprod 43(2):305-l 1
Wiegand SJ, Boland P, Yancopoulos GD (2000) Cooperative roles for the
angiopoietins and vascular endothelial growth factor in ovarian angiogenesis,
in Ovulation: Evolving Scientific and Clinical Concepts.,{Adashi EY ed), pp
175-186. Springer-Verlag, New York
Wolf JP, Hsiu JG, Anderson TL, Ulmann A, Baulieu EE, Hodgen GD (1989)
Noncompetitive antiestrogenic effect ofRU 486 in blocking the estrogen-
stimulated luteinizing hormone surge and the proliferative action of estradiol
on endometrium in castrate monkeys. Fertil Steril 52(6): 1055-60
Woller MJ, Terasawa E (1994) Changes in pulsatile release of neuropeptide-Y and
luteinizing hormone (LH)-releasing hormone during the progesterone-
induced LH surge in rhesus monkeys. Endocrinology 135(4): 1679-86
Wulff C, Dickson SE, Duncan WC, Fraser HM (2001a) Angiogenesis in the
human corpus luteum: simulated early pregnancy by HCG treatment is
associated with both angiogenesis and vessel stabilization. Hum Reprod
References 258
16(12):2515-24
Wulff C, Wiegand SJ, Saunders PT, Scobie GA, Fraser HM (2001b)
Angiogenesis during follicular development in the primate and its inhibition
by treatment with truncated Flt-1-Fc (vascular endothelial growth factor
Trap(A40)). Endocrinology 142(7):3244-54
Wulff C, Wilson H, Largue P, Duncan WC, Armstrong DG, Fraser HM (2000)
Angiogenesis in the human corpus luteum: localization and changes in
angiopoietins, tie-2, and vascular endothelial growth factor messenger
ribonucleic acid. J Clin Endocrinol Metab 85(11):4302-9
Wulff C, Wilson H, Rudge JS, Wiegand SJ, Lunn SF, Fraser HM (2001c) Luteal
angiogenesis: prevention and intervention by treatment with vascular
endothelial growth factor trap(A40). J Clin Endocrinol Metab 86(7):3377-86
Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM (2002) Prevention of
thecal angiogenesis, antral follicular growth, and ovulation in the primate by
treatment with vascular endothelial growth factor Trap R1R2. Endocrinology
143(7):2797-807
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000)
Vascular-specific growth factors and blood vessel formation. Nature
407(6801):242-8
Yen SS, Lasley BL, Wang CF, Leblanc H, Siler TM (1975) The operating
characteristics of the hypothalamic-pituitary system during the menstrual
cycle and observations of biological action of somatostatin. Recent Prog
Horm Res 31:321-63
Yong EL, Baird DT, Hillier SG (1992a) Mediation of gonadotrophin-stimulated
growth and differentiation of human granulosa cells by adenosine-3',5'-
monophosphate: one molecule, two messages. Clin Endocrinol (Oxf)
37(1):51-8
Yong EL, Baird DT, Yates R, Reichert LE, Jr., Hillier SG (1992b) Hormonal
regulation of the growth and steroidogenic function of human granulosa cells.
J Clin Endocrinol Metab 74(4):842-9
Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome,
in Polycystic ovary syndrome,(DunaifA, Haseltine F, Merriam GR eds), pp
377-384. Blackwell Scientific Publication, Boston
Zeleznik AJ (1981) Premature elevation of systemic estradiol reduces serum levels
of follicle-stimulating hormone and lengthens the follicular phase of the
menstrual cycle in rhesus monkeys. Endocrinology 109(2):352-5
Zeleznik AJ, Hillier SG (1996) The Ovary: Endocrine Function, in Scientific
References 259
Essentials ofReproductive Medicine,(Hillier SG, Kitchener HC, Neilson JP
eds), pp 133-145. W.B. Saunders Company Ltd, London
Zeleznik AJ, Kubik CJ (1986) Ovarian responses in macaques to pulsatile infusion
of follicle-stimulating hormone (FSH) and luteinizing hormone: increased
sensitivity of the maturing follicle to FSH. Endocrinology 119(5):2025-32
Zeleznik AJ, Midgley AR, Jr., Reichert LE, Jr. (1974) Granulosa cell maturation
in the rat: increased binding of human chorionic gonadotropin following
treatment with follicle-stimulating hormone in vivo. Endocrinology
95(3):818-25
Zeleznik AJ, Schuler HM, Reichert LE, Jr. (1981) Gonadotropin-binding sites in
the rhesus monkey ovary: role of the vasculature in the selective distribution
of human chorionic gonadotropin to the preovulatory follicle. Endocrinology
109(2):356-62
Zhang FP, Rannikko AS, Manna PR, Fraser HM, Huhtaniemi IT (1997)
Cloning and functional expression of the luteinizing hormone receptor
complementary deoxyribonucleic acid from the marmoset monkey testis:
absence of sequences encoding exon 10 in other species. Endocrinology
138(6):2481-90
Zimmermann RC, Hartman T, Bohlen P, Sauer MV, Kitajewski J (2001a)
Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits
angiogenesis in corpora lutea. Microvasc Res 62(1): 15-25
Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV,
Kitajewski J (2003) Vascular endothelial growth factor receptor 2-mediated
angiogenesis is essential for gonadotropin-dependent follicle development. J
Clin Invest 112(5):659-69
Zimmermann RC, Xiao E, Bohlen P, Ferin M (2002) Administration of
antivascular endothelial growth factor receptor 2 antibody in the early
follicular phase delays follicular selection and development in the rhesus
monkey. Endocrinology 143(7):2496-502
Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J, Ferin
M (2001b) Short-term administration of antivascular endothelial growth
factor antibody in the late follicular phase delays follicular development in




Appendix A: Sequences for in situ hybridisation riboprobes
Nucleotide sequence of the gene is in black. The region of the mRNA that the
riboprobe recognises is in red.
VEGF
1 tcgcggaggc ttggggcagc cgggtagctc ggaggtcgtg gcgctggggg ctagcaccag
61 cgctctgtcg ggaggcgcag cggttaggtg gaccggtcag cggactcacc ggccagggcg
121 ctcggtgctg gaatttgata ttcattgatc cgggttttat ccctcttctt ttttcttaaa
181 catttttttt taaaactgta ttgtttctcg ttttaattta tttttgcttg ccattcccca
241 cttgaatcgg gccgacggct tggggagatt gctctacttc cccaaatcac tgtggatttt
301 ggaaaccagc agaaagagga aagaggtagc aagagctcca gagagaagtc gaggaagaga
361 gagacggggt cagagagagc gcgcgggcgt gcgagcagcg aaagcgacag gggcaaagtg
421 agtgacctgc ttttgggggt gaccgccgga gcgcggcgtg agccctcccc cttgggatcc
481 cgcagctgac cagtcgcgct gacggacaga cagacagaca ccgcccccag ccccagctac
541 cacctcctcc ccggccggcg gcggacagtg gacgcggcgg cgagccgcgg gcaggggccg
601 gagcccgcgc ccggaggcgg ggtggagggg gtcggggctc gcggcgtcgc actgaaactt
661 ttcgtccaac ttctgggctg ttctcgcttc ggaggagccg tggtccgcgc gggggaagcc
721 gagccgagcg gagccgcgag aagtgctagc tcgggccggg aggagccgca gccggaggag
781 ggggaggagg aagaagagaa ggaagaggag agggggccgc agtggcgact cggcgctcgg
841 aagccgggct catggacggg tgaggcggcg gtgtgcgcag acagtgctcc agccgcgcgc
901 gctccccagg ccctggcccg ggcctcgggc cggggaggaa gagtagctcg ccgaggcgcc
961 gaggagagcg ggccgcccca cagcccgagc cggagaggga gcgcgagccg cgccggcccc
1021 ggtcgggcct ccgaaaccat gaactttctg ctgtcttggg tgcattggag ccttgccttg
1081 ctgctctacc tccaccatgc caagtggtcc caggctgcac ccatggcaga aggaggaggg
1141 cagaatcatc acgaagtggt gaagttcatg gatgtctatc agogcagcta ctgccatcca
1201 atcgagaccc tggtggacat cttccaggag taccctgatg agatcgagta catcttcaag
1261 ccatcctgtg tgcccctgat gcgatgcggg ggctgctgca atgacgaggg cctggagtgt
1321 gtgcccactg aggagtccaa catcaccatg cagattatgc ggatcaaacc tcaccaaggc
1381 cagcacatag gagagatgag cttcctacag cacaacaaat gtgaatgcag accaaagaaa
1441 gatagagcaa gacaagaaaa atgtgacaag ccgaggcggt gagccgggca ggaggaagga
1501 gcctccctca gggtttcggg aaccagatct ctcaccagga aagactgata cagaacgatc
1561 gatacagaaa ccacgctgcc gccaccacac catcaccatc gacagaacag tccttaatcc
1621 agaaacctga aatgaaggaa gaggagactc tgcgcagagc actttgggtc cggagggcga
1681 gactccggcg gaagcattcc cgggcgggtg acccagcacg gtccctcttg gaattggatt
1741 cgccatttta tttttcttgc tgctaaatca ccgagcccgg aagattagag agttttattt
1801 ctgggattcc tgtagacaca cccacccaca tacatacatt tatatatata tatattatat
1861 atatataaat taa
VEGFR1
1 gcggacactc ctctcggctc ctccccggca gcggcggcgg ctcggagcgg gctccggggc
61 tcgggtgcag cggccagcgg gcctggcggc gaggattacc cggggaagtg gttgtctcct
121 ggctggagcc gcgagacggg cgctcagggc gcggggccgg cggcggcgaa cgagaggacg
181 gactctggcg gccgggtcgt tggccggggg agcgcgggca ccgggcgagc aggccgcgtc
241 gcgctcacca tggtcagcta ctgggacacc ggggtcctgc tgtgcgcgct gctcagctgt
301 ctgcttctca caggatctag ttcaggttca aaattaaaag atcctgaact gagtttaaaa
361 ggcacccagc acatcatgca agcaggccag acactgcatc tccaatgcag gggggaagca
421 gcccataaat ggtctttgcc tgaaatggtg agtaaggaaa gcgaaaggct gagcataact
481 aaatctgcct gtggaagaaa tggcaaacaa ttctgcagta ctttaacctt gaacacagct
541 caagcaaacc acactggctt ctacagctgc aaatatctag ctgtacctac ttcaaagaag
601 aaggaaacag aatctgcaat ctatatattt attagtgata caggtagacc tttcgtagag
661 atgtacagtg aaatccccga aattatacac atgactgaag gaagggagct cgtcattccc
721 tgccgggtta cgtcacctaa catcactgtt actttaaaaa agtttccact tgacactttg
781 atccctgatg gaaaacgcat aatctgggac agtagaaagg gcttcatcat atcaaatgca
841 acgtacaaag aaatagggct tctgacctgt gaagcaacag tcaatgggca tttgtataag
901 acaaactatc tcacacatcg acaaaccaat acaatcatag atgtccaaat aagcacacca
961 cgcccagtca aattacttag aggccatact cttgtcctca attgtactgc taccactccc
1021 ttgaacacga gagttcaaat gacctggagt taccctgatg aaaaaaataa gagagcttcc
1081 gtaaggcgac gaattgacca aagcaattcc catgccaaca tattctacag tgttcttact
1141 attgacaaaa tgcagaacaa agacaaagga ctttatactt gtcgtgtaag gagtggacca
1201 tcattcaaat ctgttaacac ctcagtgcat atatatgata aagcattcat cactgtgaaa
1261 catcgaaaac agcaggtgct tgaaaccgta gctggcaagc ggtcttaccg gctctctatg
1321 aaagtgaagg catttccctc gccggaagtt gtatggttaa aagatgggtt acctgcgact
1381 gagaaatctg ctcgctattt gactcgtggc tactcgttaa ttatcaagga cgtaactgaa
1441 gaggatgcag ggaattatac aatcttgctg agcataaaac agtcaaatgt gtttaaaaac
1501 ctcactgcca ctctaattgt caatgtgaaa ccccagattt acgaaaaggc cgtgtcatcg
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1561 tttccagacc cggctctcta cccactgggc agcagacaaa tcctgacttg taccgoatat
1621 ggtatccctc aacctacaat caagtggttc tggcacccct gtaaccataa tcattccgaa
1681 gcaaggtgtg acttttgtto caataatgaa gagtccttta tcctggatgc tgacagcaac
1741 atgggaaaca gaattgagag catcactcag cgcatggcaa taatagaagg aaagaataag
1801 atggctagca ccttggttgt ggctgactct agaatttctg gaatctacat ttgcatagct
1861 tccaataaag ttgggactgt gggaagaaac ataagctttt atatcacaga tgtgccaaat
1921 gggtttcatg ttaacttgga aaaaatgccg acggaaggag aggacctgaa actgtcttgc
1981 acagttaaca agttcttata cagagacgtt acttggattt tactgcggac agttaataac
2041 agaacaatgc actacagtat tagcaagcaa aaaatggcca tcactaagga gcactccatc
2101 actcttaatc ttaccatcat gaatgtttcc ctgcaagatt caggcaccta tgcctgcaga
2161 gccaggaatg tatacacagg ggaagaaatc ctccagaaga aagaaattac aatcagagat
2221 caggaagcac catacctcct gcgaaacctc agtgatcaca cagtggccat cagcagttcc
2281 accactttag actgtcatgc taatggtgtc cccgagcctc agatcacttg gtttaaaaac
2341 aaccacaaaa tacaacaaga gcctggaatt attttaggac caggaagcag cacgctgttt
2401 attgaaagag tcacagaaga ggatgaaggt gtctatcact gcaaagccac caaccagaag
2461 ggctctgtgg aaagttcagc atacctcact gttcaaggaa cctcggacaa gtctaatctg
2521 gag
VEGFR2
1 atggagagca aggtgctgct ggccgtcgcc ctgtggctct gcgtggagac ccgggccgcc
61 tctgtgggtt tgcctagtgt ttctcttgat ctgcccaggc tcagcataca aaaagacata
121 cttacaatta aggctaatac aactcttcaa attacttgca ggggacagag ggaottggac
181 tggctttggc ccaataatca gagtggcagt gagcaaaggg tggaggtgac tgagtgcagc
241 gatggcctct tctgtaagac actcacaatt ccaaaagtga tcggaaatga cactggagcc
301 tacaagtgct tctaccggga aactgacttg gcctcggtca tttatgtcta tgttcaagat
361 tacagatctc catttattgc ttctgttagt gaccaacatg gagtcgtgta cattactgag
421 aacaaaaaca aaactgtggt gattccatgt ctcgggtcca tttcaaatct caacgtgtca
481 ctttgtgcaa gatacccaga aaagagattt gttcctgatg gtaacagaat ttcctgggac
541 agcaagaagg gctttactat tcccagctac atgatcagct atgctggcat ggtcttctgt
601 gaagcaaaaa ttaatgatga aagttaccag tctattatgt acatagttgt cgttgtaggg
661 tataggattt atgatgtggt tctgagtccg tctcatggaa ttgaactatc tgttggagaa
721 aagcttgtct taaattgtac agcaagaact gaactaaatg tggggattga cttcaactgg
781 gaataccctt cttcgaagca tcagcataag aaacttgtaa accgagacct aaaaacccag
841 tctgggagtg agatgaagaa atttttgagc accttaacta tagatggtgt aacccggagt
901 gaccaaggat tgtacacctg tgcagcatcc agtgggctga tgaccaagaa gaacagcaca
961 tttgtcaggg tccatgaaaa accttttgtt gcttttggaa gtggcatgga atctctggtg
1021 gaagccacgg tgggggagcg tgtcagaatc cctgcgaagt accttggtta cccaccccca
1081 gaaataaaat ggtataaaaa tggaataccc cttgagtcca atcacacaat taaagcgggg
1141 catgtactga cgattatgga agtgagtgaa agagacacag gaaattacac tgtcatcctt
1201 accaatccca tttcaaagga gaagcagagc catgtggtct ctctggttgt gtatgtccca
1261 ccccagattg gtgagaaatc tctaatctct cctgtggatt cctaccagta cggcaccact
1321 caaacgctga catgtacggt ctatgccatt cctcccccgc atcacatcca ctggtattgg
1381 oagttggagg aagagtgcgc caacgagccc agccaagctg tctcagtgac aaacccatac
1441 ccttgtgaag aatggagaag tgtggaggac ttccagggag gaaataaaat tgaagttaat
1501 aaaaatcaat ttgctctaat tgaaggaaaa aacaaaactg taagtaccct tgttatccaa
1561 gcggcaaatg tgtcagcttt gtacaaatgt gaagoggtca acaaagtcgg gagaggagag
1621 agggtgatct ccttccacgt gaccaggggt cctgaaatta ctttgcaacc tgacatgcag
1681 cccactgagc aggagagcgt gtctttgtgg tgcactgcag acagatctac gtttgagaac
1741 ctcacatggt acaagcttgg cccacagcct ctgccaatcc atgtgggaga gttgcccaca
1801 cctgtttgca agaacttgga tactctttgg aaattgaatg ccaccatgtt ctctaatagc
1861 acaaatgaca ttttgatcat ggagcttaag aatgcatcct tgcaggacca aggagactat
1921 gtctgccttg ctcaagacag gaagaccaag aaaagacatt gcgtggtcag gcagctcaca
1981 gtcctagagc gtgtggcacc cacgatcaca ggaaacctgg agaatcagac gacaagtatt
2041 ggggaaagca tcgaagtctc atgcacggca tctgggaatc cccctccaca gatcatgtgg
2101 tttaaagata atgagaccct tgtagaagac tcaggcattg tattgaagga tgggaaccgg
2161 aacctcacta tccgcagagt gaggaaggag gacgaaggcc tctacacctg ccaggcatgc
2221 agtgttcttg gctgtgcaaa agtggaggca tttttcataa tagaaggtgc ccaggaaaag
2281 acgaacttgg aaatcattat tctagtaggc acggcggtga ttgccatgtt cttctggcta
2341 cttcttgtca tcatcctacg gaccgttaag cgggccaatg gaggggaact gaagacaggc
2401 tacttgtcca tcgtcatgga tccagatgaa ctcccattgg atgaacattg tgaacgactg
2461 ccttatgatg ccagcaaatg ggaattcccc agagaccggc tgaagctagg taagcctctt
2521 ggccgtggtg cctttggcca agtgattgaa gcagatgcct ttggaattga caagacagca
2581 acttgcagga cagtagcagt caaaatgttg aaagaaggag caacacacag tgagcatcga
2641 gctctcatgt ctgaactcaa gatcctcatt catattggtc accatctcaa tgtggtcaac
2701 cttctaggtg cctgtaccaa gccaggaggg ccactcatgg tgattgtgga attctgcaaa
2761 tttggaaacc tgtccactta cctgaggagc aagagaaatg aatttgtccc ctacaagacc
2821 aaaggggcac gattccgtca agggaaagac tacgttggag caatccctgt ggatctgaaa
2881 cggcgcttgg acagcatcac cagtagccag agctcagcca gctctggatt tgtggaggag
2941 aagtccctca gtgatgtaga agaagaggaa gctcctgaag atctgtataa ggacttcctg
3001 accttggagc atctcatctg ttacagcttc caagtggcta agggcatgga gttcttggca
3061 tcgcgaaagt gtatccacag ggacctggcg gcacgaaata tcctcttatc ggagaagaac
3121 gtggttaaaa tctgtgactt tggcttggcc cgggatattt ataaagatcc agattatgtc
3181 agaaaaggag atgctcgcct ccctttgaaa tggatggccc cagaaacaat ttttgacaga
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3241 gtgtacacaa tccagagtga cgtctggtct tttggtgttt tgctgtggga aatattttcc
3301 ttaggtgctt ctccatatcc tggggtaaag attgatgaag aattttgtag gcgattgaaa
3361 gaaggaacta gaatgagggc ccctgattat actacaccag aaatgtacca gaccatgctg
3421 gactgctggc acggggagcc cagtcagaga cccacgtttt cagagttggt ggaacatttg
3481 ggaaatctct tgcaagctaa tgctcagcag gatggcaaag actacattgt tcttccgata
3541 tcagagactt tgagcatgga agaggattct ggactctctc tgcctacctc acctgtttcc
3601 tgtatggagg aggaggaagt atgtgacccc aaattccatt atgacaacac agcaggaatc
3661 agtcagtatc tgcagaacag taagcgaaag agccggcctg tgagtgtaaa aacatttgaa
3721 gatatcccgt tagaagaacc agaagtaaaa gtaatcccag atgacaacca gacggacagt
3781 ggtatggttc ttgcctcaga agagctgaaa actttggaag acagaaccaa attatctcca
3841 tcttttggtg gaatggtgcc cagcaaaagc agggagtctg tggcatctga aggctcaaac
3901 cagacaagcg gctaccagtc cggatatcac tccgatgaca cagacaccac cgtgtactcc
3961 agtgaggaag cagaactttt aaagctgata gagattggag tgcaaaccgg tagcacagcc
4021 cagattctcc agcctgactc ggggaccaca ctgagctctc ctcctgttta a
EG-VEGF
1 ggggaagcga gaggcatcta agcaggcagt gttttgcctt caccccaagt gaccatgaga
61 ggtgccacgc gagtctcaat catgctcctc ctagtaactg tgtctgactg tgctgtgatc
121 acaggggcct gtgagcggga tgtccagtgt ggggcaggca cctgctgtgc catcagcctg
181 tggcttcgag ggctgcggat gtgcaccccg ctggggcggg aaggcgagga gtgccacccc
241 ggcagccaca aggtcccctt cttcaggaaa cgcaagcacc acacctgtcc ttgcttgccc
301 aacctgctgt gctccaggtt cccggacggc aggtaccgct gotccatgga cttgaagaac
361 atcaattttt aggcgcttgc ctggtctcag gatacccacc atccttttct gagcacagcc
421 tggattttta tttctgccat gaaacccagc tcccatgaot ctcccagtcc ctacactgac
481 taccctgatc tctcttgtct agtacgcaca tatgcacaca ggcagacata cctcccatca
541 tgacatggtc cccaggctgg cctgaggatg tcacagcttg aggctgtggt gtgaaaggtg
601 gccagcctgg ttctcttccc tgctcaggct gccagagagg tggtaaatgg cagaaaggac
661 attccccctc ccctccccag gtgacctgct ctctttcctg ggccctgccc ctctccccac
721 atgtatccct cggtctgaat tagacattcc tgggcacagg ctcttgggtg cattgctcag
781 agtcccaggt cctggcctga ccctcaggcc cttcacgtga ggtctgtgag gaccaatttg
841 tgggtagttc atcttccctc gattggttaa ctccttagtt tcagaccaca gactcaagat
901 tggctcttcc cagagggcag cagacagtca ccccaaggca ggtgtaggga gcccagggag
961 gccaatcagc cccctgaaga ctctggtccc agtcagcctg tggcttgtgg cctgtgacct
1021 gtgaccttct gccagaattg tcatgcctct gaggccccct cttaccacac tttaccagtt
1081 aaccactgaa gcccccaatt cccacagctt ttccattaaa atgcaaatgg tggtggttca
1141 atctaatctg atattgacat attagaaggc aattagggtg tttccttaaa caactccttt
1201 ccaaggatca gccctgagag caggttggtg actttgagga gggcagtcct ctgtccagat
1261 tggggtggga gcaagggaca gggagcaggg caggggctga aaggggcact gattcagacc
1321 agggaggcaa ctacacacca acctgctggc tttagaataa aagcaccaac tgaactg
Aromatase
1 atggtcttgg aaatgctgaa cccgatgcat tataacatca ccagcatggt gcctgaagcc
61 atgcctgctg ccaccatgcc aatcctgctg ctcactggcc tttttctcct ggtgtggaat
121 tatgagggca catcctcaat accaggtccc ggctactgca tgggaattgg acccctcatc
181 tccoacggca gattcctgtg gatggggatc ggcaatgcct gcaactacta caaccggatg
241 tatggagaat tcatgagagt ctggatctct ggagaggaaa cactcattat cagcaagtcc
301 tcaagtatgt tccatgtaat gaagcacaat cattatagct ctcgattcgg cagcaaactt
361 gggctgcagt gcattggtat gcatgagaaa ggcatcatat ttaacaacaa tccagatctc
421 tggaaaacaa ctcggcccct ctttatgaaa gctctgtcag gccctggtct tgttcgcatg
481 gtcacagtct gtgctgaatc cctcaacacg catctggaca ggttggagga ggtgaccaat
541 gagtcaggct tcatcgacgt gttgaccctc ctgcggtgcg tcatgotgga cacctctaac
601 acgctcttct tgaggatccc tttggacgaa aatgccatcg tgtttaaaat ccaaggttat
661 tttgatgcat ggcaagctct cctcatcaaa ccagacatct tctttaagat ttcttggcta
721 tacaaaaagt atgagaagtc tgtcaaggat ttgaaagatg ccatagaagt tctgatggca
781 gaaaaaagac gcaggatttc cgcagaagag aaactggaag aacatataga ctttgccact
841 gagttgattt tagccgagaa acgtggtgac ctgacaagag agaacgtgaa ccagtgcatg
901 ttggaaatgc tgattgcagc tcctgacacc atgtctgtct ctctgttctt catgctattc
961 ctgattgcaa agcaccctaa tgtggaagag gcaataatga aggaaatcca gactgttgtt
1021 ggtgagagag acgtaaagat tgatgatata caaaaattaa aagtggtgga aaacttcatt
1081 tatgagagca tgcggtacca gcctgttgtg gacttggtca tgcgcaaagc cttagaagat
1141 gatgtgatcg atggctaccc agtgaaaaag gggacgaaca ttatcctgaa tattggaagg
1201 atgcacagac tcgagttttt ccccaaaccc aatgaattta ctcttgaaaa ttttgcaaag
1261 aatgttcctt acaggtactt tcagccattt ggttttgggc cccgtagctg tgcaggaaag
1321 tacatcgcca tggtgatgat gaaatccatt ctcgttacgc ttctgagaag attccacgtg
1381 aagacattgg ggggagagtg cgttgagagc ctacagaaga caaacgactt ggccttgcac
1441 ccagatcaca ctaaaagcat gctggaaatg atttttaccc caagaaactc aggctggtgc
1501 ctggaacact aa
Appendices 264
Appendix B: LightCycler primer and probe sequences
Primers are highlighted in red in the sequence.
VEGF
Forward 5' - cacccatggcagaaggag

















Forward 5' - ggcatcctcaccctgaagta















Appendix C: Number of follicles assessed.
The number of follicles from each follicular class and each treatment group
measured for each immunocytochemical and in situ analysis. ES = early secondary,
LS = late secondary, T = tertiary, Dom = dominant, A = atretic.
BrdU Dual CD31 VEGF mRNA Arom
mRNA
ES LS T Dom LS T Dom LS T Dom LS T Dom A Dom
LF Control 50 105 33 9 29 24 9 23 27 9 10 18 9 28 7
GnRH antag 0- 22 24 17 - 25 25 - 21 20 - 5 16 - 7 -
10




ES LS T Dom LS T Dom LS T Dom
LF Control 42 79 29 9 29 14 8 31 36 7
VEGF trap 0-10 14 14 14 - 17 17 - 13 15 -
VEGF trap 5-10 14 19 19 7 42 52 8 28 25 6
VEGF mRNA (Gran) VEGF mRNA (Theca) VEGFR1 mRNA VEGFR2 mRNA
LS T Dom LS T Dom A LS T Dom A LS T Dom A
LF Control 10 12 4 10 12 4 12 9 10 6 7 10 13 6 8
VEGF trap 0-10 10 9 - 10 9 - 12 11 8 - 10 10 14 10










































Animals used in studies
Treatment Group Gross morphology
Early follicular control Majority luteal tissue
Early follicular control Majority luteal tissue
Early follicular control Majority luteal tissue
Mid follicular control Many tertiary follicles
Mid follicular control Many tertiary follicles
Mid follicular control Many tertiary follicles
Mid follicular control Many tertiary follicles
Late follicular control 3 recent ovulations
Late follicular control 2 recent ovulations
Late follicular control 2 preovulatory follicles
Late follicular control 2 recent ovulations
Late follicular control 2 preovulatory follicles
Late follicular control 2 preovulatory follicles
Late follicular control 3 preovulatory follicles
GnRH antagonist 0-10 No dominant follicles
GnRH antagonist 0-10 No dominant follicles
GnRH antagonist 0-10 No dominant follicles
GnRH antagonist 0-10 No dominant follicles
GnRH antagonist 5-10 2 dominant atretic follicles
GnRH antagonist 5-10 2 dominant atretic follicles
GnRH antagonist 5-10 2 dominant atretic follicles
GnRH antagonist 5-10 1 dominant atretic follicle
GnRH antagonist 5-10 1 dominant atretic follicle
GnRH antagonist 5-10 2 dominant atretic follicle
R1R2 0-10 No dominant follicles
R1R2 0-10 No dominant follicles
R1R2 0-10 No dominant follicles
R1R2 5-10 2 recent ovulations
R1R2 5-10 3 dominant follicles, all partially luteiniscd
R1R2 5-10 2 dominant follicles, 1 healthy, 1 partially atretic
R1R2 5-10 2 dominant follicles, both heavily luteinised
R1R2 5-10 1 dominant follicle, partially luteinised
R1R2 5-15 3 micro CL
R1R2 5-15 4 dominant follicles, little sign of atresia in any
R1R2 5-15 2 dominant follicles, some atresia, 2 micro Cls
R1R2 5-15 1 recent ovulation
R1R2 5-15 2 micro CL, 1 luteinising follicle
R1R2 5-15 2 dominant follicles, some sign of atresia in both
R1R2 5-15 3 healthy dominant follicles
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Effects of GnRH antagonist treatment on follicular development and
angiogenesis in the primate ovary
P D Taylor1'2, S G Hillier2 and H M Fraser1'2
1 Medical Research Council Human Reproductive Sciences Unit, 49 Little France Crescent, Edinburgh EH 16 4SB, UK
2University of Edinburgh Centre for Reproductive Biology, 49 Little France Crescent, Edinburgh EH 16 4SB, UK
(Requests for offprints should be addressed to H M Fraser, Medical Research Council, Human Reproductive Sciences Unit, 49 Little France Crescent,
Edinburgh EH 16 4SB, UK; Email: h.fraser@hrsu.mrc.ac.uk)
Abstract
Angiogenesis is required for normal follicular development
but the role of gonadotrophins in the control of follicular
angiogenesis remains to be elucidated. This study investi¬
gated the effects of treatment with GnRH antagonist
in vivo on follicular development and angiogenesis in the
marmoset. GnRH antagonist was administered on either
follicular day 0 or day 5 of the 10-day follicular phase with
ovaries collected on day 10. Ovaries from control marmo¬
sets were studied at day 5 (mid follicular phase) and day 10
(periovulatory period). Ovaries were fixed, serial sectioned
and subjected to morphological analysis and immuno-
cytochemistry to determine cell proliferation and follicular
endothelial cell area and in situ hybridization to assess
changes in expression ofvascular endothelial growth factor
(VEGF). Treatment with GnRH antagonist from day
0-10 resulted in an absence of dominant preovulatory
follicles seen in controls. In the remaining tertiary follicles
granulosa, theca and endothelial cell proliferation was
reduced, resulting in a minor reduction in vascular density.
However, VEGF mRNA expression was unaffected by
treatment. Treatment from day 5-10 did not prevent
development of ovulatory size follicles, but they were
atretic and lacked VEGF mRNA. These results suggest
that while VEGF expression in the preovulatory follicle is
under gonadotrophic control it is not dependent on normal
gonadotrophin secretion in tertiary follicles, indicating
that there are other paracrine factors regulating VEGF
expression in the developing ovarian follicle.
Journal of Endocrinology (2004) 183, 1-17
Introduction
The ovary is one offew organs in the body to undergo serial
angiogenesis which is intimately involved in ovarian follicle
development (Fraser & Wulff 2001, Wulff et al. 2001 b,
2002, Zimmermann et al. 2001, 2003). Angiogenesis in
the ovarian follicle is restricted to the thecal compartment,
the resulting capillaries forming a vascular sheath around the
growing follicle that continues to develop during folliculo-
genesis (Wulff et al. 2001 b). The new blood vessels associ¬
ated with dominant follicles do not penetrate the mem-
brana propria, leaving the granulosa cells of the follicles
avascular until the point of ovulation at which time the
basement membrane breaks down. The degree of vascu¬
larization achieved has been hypothesized to be involved in
the establishment of follicle dominance (Zeleznik et al.
1981), facilitating the delivery of gonadotrophins, steroid
precursors, oxygen and nutrients from the blood stream,
but whether an abundant vasculature is a cause or conse¬
quence of follicle dominance remains to be determined.
The principal angiogenic factor with an established role
in follicular angiogenesis is vascular endothelial growth
factor (VEGF). VEGF mRNA and protein have been
localized in the ovary to the granulosa cells of the
developing follicles and the theca of preovulatory follicles
(Phillips et al. 1990, Ravindranath et al. 1992, Shweiki
et al. 1993). Inhibition of VEGF in vivo in the marmoset
monkey has been shown to severely suppress both thecal
vascularization and follicle development (Wulff et al.
2001 b, 2002) and to inhibit the follicular phase ofthe cycle
in macaques (Zimmermann et al. 2001, 2002).
VEGF is expressed in the granulosa and thecal cells
of follicles as they mature and is concurrent with the
acquisition of steroidogenic activity, suggesting that the
expression is hormonally regulated (Shweiki et al. 1993). It
has also been demonstrated that VEGF expression in
granulosa cells is up-regulated by follicle-stimulating hor¬
mone (FSH) stimulation in vitro (Christenson & Stouffer
1997, Hazzard et al. 1999). In the current study, the role
of the gonadotrophins was assessed by administration of
a gonadotrophin-releasing hormone (GnRH) antagonist
in vivo during follicular development in the marmoset, a
species in which we have described the development of
the follicular vasculature in detail (Wulff et al. 2001 b,
DOI: 10.1677/joe. 1.05685
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2002). Since it is established that GnRH antagonist
treatment suppresses follicular development by inhibiting
both FSH and luteinizing hormone (LH) secretion from
the pituitary (Fluker et al. 1991, Hall et al. 1991, Fraser
et al. 19996), the aim of the present study was to test the
hypothesis that this suppression resulted in a reduced
production of follicular VEGF inRNA with resultant
inhibition of angiogenesis. The effects of the antagonist
on follicular angiogenesis were examined using bromo-
deoxyuridine (BrdU) immunocytochemistry as a pro¬
liferation marker, CD31 as an endothelial specific cell
marker and dual staining to distinguish proliferating
endothelial cells. Effects of treatment on expression of




Adult female common marmoset monkeys (Callithrix jac-
chus), 2—3 years old with a body weight of approximately
350 g and regular (28-day) ovulatory cycles, as determined
by plasma progesterone concentrations on blood samples
collected three times per week (Wulff et al. 2001c), were
housed together with a younger sister or prepubertal
female, as described previously (Fraser et al. 1999a).
Treatment
Experiments were carried out in accordance with the
Animals (Scientific Procedures) Act 1986, and were ap¬
proved by the Local Ethical Review Process Committee.
To synchronize the timing of ovulation, marmosets
were treated with 1 fig prostaglandin (PG) F2ct analogue
(cloprostenol, Planate; Coopers Animal Health Ltd,
Crewe, Cheshire, UK), intramuscularly on days 12-15
of the 20-day luteal phase to induce luteolysis. The day of
PG injection was designated follicular day 0. This regime
was based upon that of Gilchrist et al. (2001), who
have described detailed changes in follicular populations
during the subsequent follicular phase. We employed the
GnRH antagonist Antarelix (Deghenghi et al. 1993),
[N-Ac-D-Nal1,D-pCl-Phe2,D-Pal3,D-(Hci)6,Lys(iPr)8,D-
Ala10]GnRH (Europeptides, Argenteuil, France) dissolved
in water to a concentration of 10 mg/ml. To provide
a slow-release depot Antarelix was administered at a
dose of 12 mg/kg, injected subcutaneously on follicular
day 0 (h = 4) or follicular day 5 (n= 6). Ovaries from the
treated animals were collected 10 days after PG admin¬
istration, corresponding to the periovulatory period in
control animals. Control marmosets were studied on day 0
(« = 3), day 5 (« = 4) and day 10 («= 6) relative to PG
administration. After PG administration, blood samples
continued to be collected from the animals three times
Journal of Endocrinology (2004) 183, 1-17
a week to monitor progesterone levels. All animals
were injected i.v. with 20 mg BrdU (Roche Molecular
Biochemicals, Essex, UK) in saline 1 h before being
sedated using 100 pi ketamine hydrochloride (Parke-Davis
Veterinary, Pontypool, Gwent, UK) and killed with an
i.v. injection of 400 pi Euthetal (sodium pentobarbitone;
Rhone Merieux, Harlow, Essex, UK). After cardiac
exsanguination, ovaries were removed, weighed and
immediately fixed in 4% neutral buffered formalin. After
24 h, the ovaries were transferred to 70% ethanol, dehy¬
drated and embedded in paraffin according to standard
procedures.
To confirm the potency of the GnRH antagonist
treatment, three marmosets with regular cycles were
given the treatment described above, but allowed to
recover normal cycles as determined by measuring plasma
progesterone in blood samples collected three times per
week.
Steroid assays
Oestradiol concentrations in serum collected by exsan¬
guination were determined by an ELISA assay adapted
from Mann et al. (1995). The detection limit for the assay
was 1 ng/1. Interassay coefficients of variation for low,
medium and high quality controls were 15-5%, 6-5% and
6-4% respectively. All samples were ran in a single assay.
Plasma progesterone concentrations were determined by
an ELISA assay, as previously described (Wulff et al.
2001c).
Morphological characterization of ovarian follicles
Stages of follicular development were defined as follows:
primary (oocyte surrounded by one granulosa cell layer),
early secondary (two to four granulosa cell layers, no
antrum), late secondary (more than four granulosa cell
layers, no antrum), tertiary (follicles containing an antrum)
and ovulatory (large antral follicles >2 mm). Follicles were
classified as healthy if they contained a normal-shaped
oocyte surrounded by granulosa cells that were regularly
apposed on an intact basement membrane with normal
appearance of granulosa cell nuclei without signs of
pycnosis. Follicles were classified as atretic when they
showed signs of granulosa cell pycnosis, the first morpho¬
logical sign of follicular atresia (Durlinger et al. 2000).
Only follicles with a visible oocyte containing a nucleus
were considered to ensure proper follicular classification.
Follicles not fulfilling these criteria were classified as
unsuitable for analyses.
Haematoxylin-eosin staining
The embedded ovaries were serially sectioned, and tissue
sections (5 pm) were placed onto BDH SuperFrost
www.endocrinology-journals.org
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slides (BDH, Merck Co., Inc., Poole, Dorset, UK). For
morphological and morphometric analyses every 40th
section of the ovaries was used. Sections in between were
subjected to immunocytochemistry and in situ hybridiza¬
tion. Sections were dewaxed in xylene, rehydrated in
descending concentrations of ethanol, washed in distilled
water and stained with haematoxylin (Richard-Allan,
Richland, MI, USA) for 5 min, followed by a wash in
water and acetic alcohol before staining with eosin
(Richard-Allan) for 20 s. After dehydrating in ascending
concentrations of ethanol and xylene, sections were
mounted.
Immunocytochemistry
The effects of the treatment on the establishment of the
thecal vascular network were studied by (1) quantifying
the number of proliferating cells stained for BrdU, (2)
identifying endothelial cells using CD31 staining and (3)
distinguishing proliferating endothelial from non-
endothelial cells by colocalization of BrdU and CD31.
For BrdU and CD31 immunostaining, antigen retrieval
was performed by pressure cooking (Tefal Clypso pressure
cooker; Tefal, Langley, Berks, UK) sections in 0-01 M
citrate buffer, pH 6, for 6 min at high pressure setting 2.
Slides were then left for 20 min in hot buffer and washed
in Tris-buffered saline (TBS; 0-05 mol/1 Tris and 9 g/1
NaCl). To reduce non-specific binding, sections were
blocked in normal rabbit serum (NRS; 1:5 diluted in TBS
containing 5% bovine serum albumin) for 30 min. Primary
antibodies CD31 (mouse anti-human CD31; DAKO
Corp., Copenhagen, Denmark) or BrdU (mouse anti-
BrdU; Roche Molecular Biochemicals) were diluted 1:20
or 1:30 in TBS respectively. Incubation was carried out
overnight at 4 °C. Slides were washed three times in
TBS. Incubation with the secondary antibody, rabbit
anti-mouse Ig (1:60 diluted in NRS:TBS; DAKO Corp.),
was performed for 40 min at room temperature, followed
after two washes in TBS by incubation of the alkaline
phosphatase—anti-alkaline phosphatase complex (1:100
dilution in TBS; DAKO Corp.) for 40 min at room
temperature. Visualization was performed using 500 pi/
slide nitro blue tetrazolium (NBT) solution containing
45 pi NBT substrate (Roche Molecular Biochemicals),
10 ml NBT buffer, 35 pi 5-bromo-3-chloro-3-indolyl-
phosphate and 10 pi levamisole. Sections for BrdU were
counterstained with haematoxylin, whereas sections for
CD31 were not counterstained, so that quantitative image
analysis could be performed. For dual labelling, slides were
incubated first with CD31 and visualized with Fast Red
(Sigma, Poole, Dorset, UK); 1 mg Fast Red in 1 ml Fast
Red buffer (20 mg 3-hydroxy-2-naphthoic acid 2,4-
dimethylamide phosphate, 2 ml dimethyl formamide and
98 ml 04 M Tris, pH 8-2)). After staining for CD31,
incubation with BrdU was performed. BrdU-stained cells
were visualized with NBT as described above.
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Quantification of immunocytochemistry
It was previously demonstrated that angiogenesis is initi¬
ated in follicles containing more than four granulosa cell
layers (Wulff et al. 2001 b). Thus, in this study, only
follicles with four or more granulosa cell layers were
analysed. Captured images were thresholded, and the
thecal and granulosa cell compartments were outlined and
analysed separately. Four sections per ovary were analysed
under x 200 magnification. Cellular proliferation was
measured using an image analysis system set up to measure
the number of dark-stained nuclei (BrdU positive), and
the number ofdark- and light-stained nuclei (total number
of cells) in the outlined compartment of interest. A
proliferation index (BrdU-positive cells expressed as a
percentage of the total number of cells) was calculated in
the thecal and granulosa compartments for each follicle.
The proliferation index is expressed as a mean value for the
number of follicles assessed within each follicular stage and
per animal.
The automated image analysis of BrdU in the granulosa
of secondary follicles failed to reliably distinguish between
single cells because granulosa cells have only a small
cytoplasmic volume, so that the nuclei of different cells are
in close vicinity. Thus, the granulosa cell proliferation
index in these follicles was obtained by manual counting of
the number of granulosa cells and the granulosa cell area
from 50 secondary follicles, calculating a mean cell number
per unit area and measuring granulosa cell area and
converting the area to cell number.
The endothelial cell area (CD31-positive cells) was
measured by thresholding a captured grey scale image and
converting it to a binary image. The whole area of the
thecal compartment and the CD31-positive area within
the compartment were measured. The CD31-positive
area was then calculated per unit area of the thecal
compartment and expressed as a mean value for the
number of follicles assessed within each follicular stage and
per animal.
Proliferating endothelial cells (dual-stained cells) were
counted manually at x 200. Only endothelial cells (red
stain) that were also BrdU positive (black stain) were
counted as proliferating endothelial cells. Non-endothelial
cell proliferation was calculated by multiplying the total
thecal proliferation index (BrdU count) by the percentage
of proliferation that was not endothelial (not dual-stained,
BrdU-positive cells on a dual-stained slide) per animal.
Quantitative analysis was performed using an image analy¬
sis system linked to an Olympus Corporation camera, and
the data were processed using Image-Pro Plus version 3-0
for Windows (Microsoft).
In situ hybridization
In situ hybridization was performed as described previously
(Fraser et al. 2000, Wulff et al. 2001c). As the marmoset
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Table 1 The number of follicles from each follicular class and each treatment group measured for each immunocytochemical and in situ
analysis
BrdU CD31 Dual VEGF mRNA Aromatase mRNA
LS T Dom LS T Dom LS T Dom LS T Dom A Dom
LF control 105 33 9 23 27 9 29 24 9 10 18 9 28 7
GnRH antag 0-10 24 17 21 20 25 25 5 16 7
GnRH antag 5-10 55 34 8 27 21 8 27 23 8 14 29 7 14 7
MF control 2 23 14
LF, late follicular phase; MF, mid follicular phase; CnRH antag 0-10, CnRH antagonist treatment on day 0-10; CnRH antag 5-10, CnRH antagonist treatment
on day 5-10.
shows very close homology of the known human gene
sequence, a cRNA probe for human VEGF probe was
used. For aromatase, a marmoset-specific cRNA probe
was generated. Sense and antisense probes were prepared
using an RNA transcription kit (Ambion, Inc. Austin,
TX, USA) and were labelled with [35S]uridine 5'-
triphosphate (NEN Life Science Products, Boston, MA,
USA). Deparaffinized sections were treated with 0-1 M
HC1 and then digested in proteinase K (5 ug/rnl; Sigma)
for 30 min at 37 °C. After prehybridization for 2 h at
55 °C subsequent hybridization was performed in a moist
chamber overnight. High stringency post-hybridization
washings and ribonuclease treatment were used to remove
excess probe. Slides were then dehydrated, dried and dipped
in Ilford G5 liquid emulsion (H A West, Edinburgh, UK)
and exposed for 3 weeks. Slides were subsequently devel¬
oped (D19 developer; Kodak, Rochester, NY, USA) and
fixed (GBX fixer; Kodak). All slides were counterstained
with haematoxylin (Richard-Allan), dehydrated and
mounted.
In situ slides were analysed blind by two investigators
separately. A scoring system of 0 = no hybridization above
background, + = detectable but low grain density clearly
above background levels, ++=moderate grain density and
+++ = high grain density was employed to denote the
level of hybridization observed in each follicle and the
results were compared for agreement.
Statistical analysis
Data obtained for different cycle and follicular stages were
tested for significant differences using ANOVA. Effects of
the treatment compared with late follicular controls were
determined using a two-tailed, unpaired f-test. In situ
analysis was tested for significant differences using the
Kruskal—Wallis test. Differences were considered to be
significant at P<0-05. The tests were performed using
SPSS version 11 for Macintosh (SPSS, Inc., Chicago, IL.
USA). All values are given as the mean ± s.e.m. Table 1




All marmosets responded to PG with a rapid fall in plasma
progesterone concentration that remained at follicular
phase levels for the duration of the study. Treatment
suppressed serum oestradiol-17P levels, consistent with
inhibition of gonadotrophin release, significant reductions
being observed between late follicular controls and both
treatment groups (day 0—10 P=0-022, day 5—10 P=0'027)
(Fig. 1). Additional evidence for potency of the GnRH
antagonist treatment was demonstrated in animals left to
recover after a single 12 mg/kg injection of Antarelix.
Ovulation was suppressed and a progesterone rise was not
observed until between 80 and 110 days after treatment
(data not shown).
Ovarian morphology
In a cross-section through a typical control ovary at












LF Control GnRH antag 0-10 GnRH antag 5-10
Figure 1 Plasma oestradiol levels in control marmosets at day 10
of the follicular phase (LF) and after treatment with GnRH
antagonist between day 0-10 (GnRH antag 0-10) or 5-10 (GnRH
antag 5-10). Oestradiol levels were significantly reduced by both
of the treatments. Values are means ± s.e.m. Different letters
indicate statistically significant differences.
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GnRH Antag 0-10 GnRH Antag 5-10
Figure 2 Haematoxylin and eosin-stained sections of (A) control early follicular phase (EF), representative of days 14-16 of the luteal
phase (CL = corpus luteum), (B) mid follicular phase (MF) with tertiary follicles, (C) late follicular phase (LF) with healthy dominant follicles
containing intact granulosa cells (inset), (D) early luteal phase (EL), (E) GnRH antagonist (Antag) treatment day 0-10 and (F) GnRH
antagonist treatment day 5-10 showing atretic granulosa cells (inset). Note the lack of healthy dominant follicles in both of the treated
groups.
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(Fig. 2A), the corpus luteum was the dominant tissue in
the organ, accompanied by numerous small and medium
sized antral follicles. By day 5 after PG injection, the mid
follicular phase (Fig. 2B), the corpus luteum had regressed
as a result of PG treatment, and many healthy and atretic
tertiary follicles dominated the ovary. In the day 10 control
ovaries, the periovulatory period, the predominant feature
was either the presence of one to three healthy dominant
follicles together with a combination of atretic and small
antral follicles (n = 3 marmosets) (Fig. 2C) or collapsed
follicles indicating that ovulation had just occurred in the
remaining three animals (Fig. 2D).
Both of the treatment schedules significantly reduced
paired ovary weight; day 0—10 (103 ± 21 mg), day 5—10
(109 ± 8 mg) compared with a mean day 10 control
weight of (165 ± 22 mg). After GnRFl antagonist treat¬
ment between day 0—10 of the follicular phase, there was
no evidence of dominant follicle development or freshly
ovulated follicles although tertiary follicles were present
(Fig. 2E). In contrast, after GnRH antagonist treatment
between days 5 and 10 of the follicular phase, there were
follicles of preovulatory size present in the ovaries, but
these follicles were atretic (Fig. 2F). Again tertiary and
atretic follicles were also observed.
Effect on tertiary follicle development
Frequency measurements of follicle populations are
shown in Fig 3. Healthy follicles with diameters>2000 pm
present in controls (Fig. 3A) were absent in both treatment
groups (Fig. 3B and C). The mean diameter of the
remaining tertiary follicles in late follicular control ovaries
was 680 pm. After GnRH antagonist, the mean follicle
diameter increased to 767 pm and 736 pm for treatment
between day 0-10 and day 5—10 respectively. Comparison
of the mean diameter (Fig. 3D) confirmed a significant
increase (P=0-048) in mean tertiary follicle (excluding
dominant) diameter after GnRH antagonist treatment
between day 0-10 compared with controls.
The number of atretic antral follicles (Fig. 3E) was
significantly decreased in both the treatment groups com¬
pared with late follicular controls (day 0—10 P= 0-007 and
day 5-10 P=0-044). Atretic dominant follicles (Fig. 3F)
were unique to the days 5—10 GnRH antagonist treatment
group.
Effect on cellular proliferation
The total number of proliferating cells was counted as a
percentage of the total number of cells present in the
follicle compartment in question. Comparison of a section
from the wall of a typical tertiary follicle from a late
follicular control (Fig. 4A), a GnRH antagonist-treated
ovary from day 0-10 (Fig. 4B) and a GnRH antagonist-
treated ovary from day 5—10 (Fig. 4C) revealed a decrease
in both granulosa and thecal proliferation after both
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treatment schedules. Quantitative analyses confirmed sig¬
nificantly decreased cell proliferation in both granulosa
(day 0—10 P= 0 013 and day 5—10 P= 0-009) and theca
(day 0-10 P=0-034 and day 5—10 P= 0-029) of tertiary
follicles after treatment compared with late follicular
controls (Fig. 4D). In the dominant follicles, a significant
reduction in cellular proliferation in the theca (P=0-01)
and granulosa (P= 0-044) compartments was also seen after
GnRH antagonist treatment between day 5—10 ofthe folli¬
cular phase compared with late follicular controls (Fig. 4E).
Endothelial cell proliferation
An index of the number of proliferating cells in the thecal
compartment that were endothelial cells by co-localization
of CD31 and BrdU was used to determine the extent to
which the treatment had impaired endothelial cell division
and hence ongoing angiogenesis. In late follicular control
ovaries (Fig. 5A), dual-labelled cells were readily apparent.
In tertiary follicles from ovaries from GnRH antagonist
treatment between day 0—10 dual-labelled cell were
reduced significantly (P=0-043). After treatment between
day 5—10 (Fig. 5C), there was a non-significant reduction
in dual-labelled cells. Endothelial cell proliferation was also
significantly reduced (P= 0-036) between dominant but
atretic follicles from the day 5-10 GnRH antagonist
treatment group and dominant follicles from late follicular
controls (Fig. 5D).
The amount of non-endothelial, presumably predomi¬
nantly thecal, cell proliferation in the theca was also
examined (data not shown). GnRH antagonist treatment
between day 0—10 resulted in a significant 49% (P= 0-029)
reduction in the number of non-endothelial cells prolifer¬
ating in tertiary follicles compared with late follicular
controls. GnRH antagonist treatment from day 5-10
resulted in a non-significant 57% (P=0-051) reduction in
non-endothelial cell proliferation in tertiary follicles and a
significant 45% (P=0-018) reduction in non-endothelial
cell proliferation in dominant but atretic follicles compared
with late follicular controls.
Effect on vasculature
Localization of blood vessels using an endothelial cell
marker in tertiary follicles is shown in Fig. 6. Large vessels
were located in the outer theca while smaller vessels were
observed within the vicinity of the lamina basalis. Exten¬
sive vascularization was observed in both controls (Fig. 6A)
and after GnRH antagonist treatment between day 0—10
(Fig. 6B) and day 5-10 (Fig. 6C) of the follicular phase.
Quantitative analysis of staining (Fig. 6D) indicated that
there was no difference in the extent of thecal vasculari¬
zation between the groups.
There was, however, a thinning of the theca between
follicles from late follicular controls and both treatment
groups, with a significant (P= 0-006) decrease in the mean
www.endocrinology-journals.org
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Figure 3 Histograms showing distribution of tertiary follicle size in (A) late follicular control animals, (B) days
0-10 GnRH antagonist-treated animals and (C) day 5-10 GnRH-treated animals. The effect of both the
treatments was to positively skew the frequency of antral follicles present in the ovaries compared with
controls, with (D) a significant increase in the mean tertiary follicle diameter between day 0-10-treated
animals and controls and (E) a significant decrease in the number of atretic follicles between controls and
either treatment group. (F) Number of atretic dominant follicles in controls and treated groups. Values are
means ± S.e.m. Different letters indicate statistically significant differences.
thecal thickness between dominant follicles from GnRH
antagonist treatment between day 5—10 of the follicular
phase and dominant follicles from late follicular controls
(Fig. 6E). To adjust for the effect of the thinner theca, a
conversion factor was used to quantify an absolute value of
CD31 -positive staining in each class of follicle, based on a
technique applied by Wulff et al. (2001a). The conversion
factors were calculated as a ratio ofmean thecal thickness
against the late follicular control mean for each class of
follicle, giving the late follicular control conversion a value
of one. After adjustment for thecal thickness a significant
(P=0-04) reduction in thecal vascularization was demon¬
strated between tertiary follicles from late follicular con-
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trols and day 0—10 GnRH antagonist treatment (Fig. 6F).
A significant reduction (P=0-014) was also observed
between dominant follicles after day 5—10 GnRH antag¬
onist treatment and late follicular controls after adjustment
for thecal thickness (Fig. 6F).
Localization of VEGF mRNA
In situ hybridization revealed that VEGF mRNA in both
control and treated groups was absent in primordial,
primary and early secondary follicles. VEGF mRNA was
expressed in the granulosa of late secondary and tertiary
follicles from late follicular controls (Fig. 7A and B), after
Journal of Endocrinology (2004) 183, 1-17






























Figure 4 Effects of the treatment on granulosa and thecal cell proliferation as indicated by BrdU immunocytochemistry. (A, B and C)
Tertiary follicles of a control, day 0-10- and day 5-10-treated ovary are shown respectively. Note the decrease in both granulosa and
thecal proliferation after both treatment schedules. Quantitative analyses confirms the observation of decreased cell proliferation in (D)
tertiary follicles and (E) dominant follicles after either treatment. Values are means ± S.e.m. Different letters indicate statistically significant
differences.
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Figure 5 Photomicrographs showing dual staining of proliferating endothelial cells (black nuclei and red cell surface). (A) Control (dual
stain shown in inset), (B) days 0-10 and (C) day 5-10 GnRH antagonist treatment. (D) Quantification showing that there was a
significant reduction in the number of proliferating endothelial cells between controls and GnRH antagonist treatment between day
0-10. Different letters indicate statistically significant differences.
GnRH antagonist treatment between day 0-10 (Fig. 7E
and F) and day 5-10 (Fig. 7G and H) and in mid follicular
controls (Fig. 71 and 7J). VEGF mRNA was also expressed
in the theca of atretic follicles in the late follicular controls
(Fig. 7C and D). However, thecal expression was absent in
the theca of atretic follicles from either of the treatment
groups and the mid follicular controls (Fig. 7E-J).
In the dominant follicles of late follicular controls,
VEGF mRNA continued to be expressed in the granulosa
cells (Fig. 8A and B). However, in folhcles that appeared
to be closer to the time of ovulation, VEGF mRNA
expression in the granulosa cells was reduced and an
intense punctate expression pattern in cells in the thecal
layer on the border of the granulosa cells was observed
(Fig. 8C and D). This punctate pattern was also observed
in postovulatory follicles (Fig. 8E and F) at the edge of the
newly forming corpus luteum.
www.endocrinology-journals.org
In contrast, VEGF mRNA expression was absent from
both granulosa and theca in all the dominant follicles from
the day 5-10 GnRH antagonist treatment group (Fig. 8G
and H). Quantitative analysis confirmed these observations
(Fig. 9A and B).
Aromatase mRNA
Aromatase mRNA expression was measured to establish
the level of differentiation of the granulosa cells. In control
preovulatory follicles, aromatase mRNA was expressed in
the mural granulosa cells closest to the membrana propria
(Fig. 10A and B), along with some expression in old luteal
tissue and newly forming extra-luteal tissue. After both
the GnRH antagonist treatment regimes there was an
absence of aromatase mRNA expression (day 5-10 shown
journal of Endocrinology (2004) 183, 1-17




















































Figure 6 Photomicrographs of tertiary follicles stained for CD31 to visualize endothelial cells. (A) A tertiary follicle from control,
(B) day 0-10 and (C) day 5-10 GnRH antagonist-treated ovaries. Note the uniformity between the control and treatment
groups. (D) Quantitative analyses confirmed the observation of uniform vascularization between the control and treated
groups. Measurement is the percentage CD31-positive staining divided by the total area of the thecal compartment. (E)
Measurement of mean thecal thickness between control and treated groups revealed a significant reduction between day
0-10-treated and control ovaries, t, theca; g, granulosa. (F) Quantification of endothelial area between control and treated
groups after conversion by the ratio of mean thecal thickness.
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Figure 7 Dark and light field photomicrographs showing in situ hybridization for
VEGF mRNA. (A and B) VEGF mRNA localized in the granulosa (g) of late
follicular phase tertiary follicles. The same expression pattern was found in both
treatment groups, (E and F) day 0-10, (G and H) day 5-10 and (I and J) in mid
follicular controls. VEGF mRNA was also expressed in the theca (t) of atretic
follicles in the late follicular controls (C and D) but was absent in atretic follicles
in both of the treatment groups and the mid follicular controls (E-J). Note the
frequent occurrence of high expression in cumulus cells surrounding oocyte (o).
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Figure 8 Dark and light field photomicrographs showing in situ hybridization for VEGF mRNA. (A and
B) VEGF mRNA localized in the dominant follicles of late follicular controls. VEGF mRNA is expressed
in the granulosa cells (g). (C and D) Before ovulation, VEGF mRNA expression in the granulosa cells is
reduced while a punctate expression pattern in the theca cells (t) on the border of the granulosa cells
is observed (arrows). (E and F) This punctate pattern is also observed in postovulatory follicles at the
edge of the newly forming corpus luteum (arrows). (G and H) This expression is absent in the
dominant follicles from the day 5-10 GnRH antagonist treatment group while expression is
maintained in the granulosa of tertiary follicles.
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in Fig. IOC and D). Some expression in old luteal tissue
was maintained. Quantitative analysis confirmed this
observation (Fig 9C).
Discussion
GnRH antagonists are widely used in the clinic during
ovarian hyperstimulation programmes to block endogen¬
ous gonadotrophin secretion and the preovulatory LH
surge while exogenous gonadotrophins are being admin¬
istered (Huime et al. 2004). Many studies have examined
the effects of GnRH antagonist treatment on pituitary-
ovarian function throughout the follicular phase in non-
human primates and in women and demonstrated a
suppression in LH and FSH secretion associated with a fall
in serum oestradiol production (Ditkoff et al. 1991, Fluker
et al. 1991, Hall et al. 1991, Karnitis et al. 1994, Nelson
et al. 1995, Fraser et al. 19996). However, the effect upon
vascularization of the follicles during GnRH antagonist
treatment has not been determined. In a previous study,
we have shown that GnRH antagonist treatment of
marmosets during the early luteal phase had a marked
inhibitory effect upon the intense angiogenesis normally
observed in the corpus luteum at this time (Dickson &
Fraser 2000) and that this was associated with luteal
cellular degeneration (Dickson & Fraser 2000) and a
marked reduction in expression of VEGF as demon¬
strated by in situ hybridization (H M Fraser, unpublished
observations).
Angiogenesis is intimately involved in ovarian follicle
development (Fraser & Wulff 2001, Zimmermann et al.
2001, 2003) and is necessary for normal follicular growth
(Wulff et al. 2001 b, 2002). The expression pattern of
VEGF mRNA in the ovarian follicle suggests that it is
regulated by gonadotrophic stimulation (Ravindranath
et al. 1992, Shweiki et al. 1993). Hence the effect of
GnRH antagonist treatment on follicular development and
vascularization in the marmoset ovary might be expected
to result in a suppression of VEGF expression, inhibition
of angiogenesis and follicular development. However, the
results revealed that the links between GnRH, follicular
VEGF expression and angiogenesis are more tenuous than
for the early corpus luteum.
The most expected findings were observed in the day
0-10 GnRH antagonist-treated animals in which devel¬
opment of large dominant follicles was completely inhib¬
ited and oestradiol secretion was markedly suppressed. In
the remaining healthy tertiary follicles, granulosa and theca
Figure 9 Quantification of in situ hybridization. (A) VECF mRNA
in granulosa cells of tertiary and dominant follicles. (B) VECF
mRNA in thecal compartment of tertiary, dominant and atretic
follicles. (C) Aromatase mRNA expression in the granulosa cells of
dominant follicles. Values are means ± S.e.m. Different letters
indicate statistically significant differences.
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Figure 10 Photomicrograph of in situ hybridization for aromatase mRNA. (A and B) Aromatase in situ in a preovulatory follicle and
(C and D) day 5-10 GnRH antagonist treated. Note the absence of aromatase mRNA expression in the treated ovary, t, theca; g,
granulosa.
cell proliferation was reduced. Angiogenesis was also lower
in these follicles and this resulted in a reduction in
endothelial cell area after the reduction in thecal thickness
was taken into account. However, these effects were
much less than after inhibition of VEGF by a specific
antagonist (Wulffet al. 2002). Surprisingly, VEGF mRNA
expression was similar to controls in these tertiary follicles.
Similarly, in the days 5—10-treated group, VEGF mRNA
continued to be highly expressed in the granulosa cells
of tertiary follicles. This suggested that, at this stage of
development, follicular VEGF expression is not tightly
controlled by the gonadotrophins. It is reasonable to
suggest that expression may be maintained by residual
gonadotrophin secretion. Unfortunately LH and FSH
could not be measured in the present study because these
assays are problematic in the marmoset and there are
restrictions in the volume of plasma that can be collected.
However, a degree of residual level of gonadotrophin
secretion would be expected to persist after GnRH
antagonist treatment, with FSH being less suppressed than
LH pitkoffet al. 1991, Fluker et al. 1991, Hall et al. 1991,
Nelson et al. 1995, Oberye et al. 1999). While this
suppression is sufficient to reduce the ability of mature
follicles to produce oestradiol, the low levels of LH and
FSH remaining may be sufficient to maintain the activity
of tertiary follicles. In addition, the possibility of stim¬
ulation of VEGF expression by hypoxia, as seen in solid
tumours (Shweiki et al. 1992) and the endometrium
(Sharkey et al. 2000), occurring in granulosa cells in
tertiary follicles deprived of gonadotrophic support re¬
quires to be investigated. However, this phenomenon does
not appear to occur in follicular granulosa cells from
preovulatory follicles (Martinez-Chequer et al. 2003).
Paracrine mechanisms could also be acting in these tertiary
follicles that may still function during the withdrawal of
the gonadotrophins to help maintain VEGF mRNA
expression. Recent evidence also suggests that locally
produced factors and cytokines such as insulin-like growth
Journal of Endocrinology (2004) 183, 1-17 www.endocrinology-journals.org
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factors-I and -II play a role in regulating ovarian VEGF
mRNA expression in preovulatory follicles (Martinez-
Chequer et al. 2003). Such mechanisms may also explain
the continued VEGF mRNA expression in tertiary fol¬
licles in the current study. The fact that there was a
decrease in endothelial cell proliferation in these follicles
after 10 days of GnRH antagonist treatment does suggest
that a deleterious effect on the VEGF pathway was
occurring, perhaps at the level of translation of VEGF
mRNA into biologically active protein or by disruption of
the process of transfer of the VEGF protein from the
granulosa cells to the thecal layer.
Although preovulatory follicles developed during treat¬
ment with GnRH antagonist between day 5-10, these
follicles were abnormal and cystic in appearance. This
indicates a stage of development after which normal levels
of gonadotrophic support for follicle expansion is not
required, presumably because the dominant follicles have
already been selected by the mid follicular phase, as
suggested by Gilchrist et al. (2001). Angiogenesis was
decreased in these cyst-like follicles and VEGF mRNA
was absent from both the theca and the granulosa cell
layers. The observation that follicles grew to preovulatory
size but undergo atresia and fail to produce oestradiol
indicates a differential level of gonadotrophic stimulation
required for proliferation (growth) and cellular differ¬
entiation (steroid synthesis) in the dominant follicle. In
addition, the marked reduction in aromatase mRNA
expression in these dominant but atretic follicles gives
further support to the hypothesis that a differential level of
gonadotrophic support is required for dominant follicle
expansion and differentiation. GnRH antagonist treatment
in cynomolgus monkeys has shown that FSH alone is
capable of stimulating follicle expansion as determined by
ultrasound monitoring, whilst not stimulating oestradiol
production due to lack of LH-stimulated androgen pro¬
duction (Karnitis et al. 1994), although the health of these
large follicles was not assessed.
It might have been expected that the rate of follicular
atresia would have increased after GnRH antagonist
treatment. However, there was a reduction in the number
of atretic follicles and an increase in the mean tertiary
follicle diameter after both GnRH antagonist treatment
schedules. This may be explained by the fact that tertiary
follicles not having sufficient FSH stimulation to continue
developing appear to be held in an arrested state of
development and fail to be cleared from the ovary by
apoptosis (Tsafriri & Braw 1984) as they would be in a
normal follicular phase ovary approaching ovulation. Also,
the reduction in thecal thickness observed in the dominant
follicle from the day 5—10 treatment group is probably
due to a deficiency in gonadotrophic support for both the
theca directly and the granulosa cells stimulating thecal
development in a paracrine manor.
In follicles close to the point of ovulation in control
ovaries, a shift in the VEGF mRNA expression pattern
www.endocrinology-journals.org
was observed, disappearing from the granulosa cells but
switching on in an intense punctate pattern in the theca in
cells close to the blood vessels. In healthy preovulatory
follicles, the reduction in VEGF mRNA expression was
consistent with the finding that VEGF production is
switched off in the granulosa cells of gilts after treatment
with human chorionic gonadotrophin (Barboni et al.
2000). The punctate VEGF mRNA expression observed
in the thecal compartment ofdominant follicles on follicu¬
lar day 10 in the marmoset appears to be similar to that
first noted in the rhesus monkey ovary (Ravindranath et al.
1992). It has also been suggested from observations in
the sheep ovary that pericytes in the thecal layer play a
key role in the transition from preovulatory follicle to the
new corpus luteum (Redmer et al. 2001). The VEGF
mRNA-positive cells observed in the marmoset theca are
possibly vascular pericytes. However, these conclusions
do not appear to concur with other studies on expression
of VEGF mRNA and protein in the rhesus monkey
(Christenson & Stouffer 1997, Hazzard et al. 1999), where
cultures of aspirated granulosa cells exposed to regimes of
FSH and LH in vivo showed that VEGF expression is
stimulated by the gonadotrophins.
The absence of VEGF mRNA expression in the theca
of atretic dominant follicles from the days 5-10 GnRH
antagonist-treated group indicates that the expression of
VEGF in the thecal cells directly prior to ovulation is
dependent upon the LH surge and not hypoxia as sug¬
gested by Neeman et al. (1997). The LH surge is absent in
both GnRH antagonist-treated groups, while the morpho¬
logically intact theca of these follicles would still be
responsive to LH. The absence of VEGF mRNA ex¬
pression in the dominant atretic follicles from the day 5-10
GnRH antagonist-treated group also suggests that normal
physiological levels ofVEGF are not required for dominant
follicle expansion between the mid to late follicular period,
even though VEGF is thought to play a role as a
permeability factor in follicle development (Koos 1995),
allowing the movement of fluid into the follicle to expand
the antral cavity.
Surprisingly, VEGF mRNA expression was also de¬
tected in the theca of atretic tertiary follicles in the late
follicular control animals. This expression was again absent
in GnRH antagonist-treated animals and was not present
in atretic follicles from mid follicular phase ovaries. This
suggests that the LH surge triggers the strong expression of
VEGF mRNA in the theca of atretic follicles at the time
of ovulation, which may play a role in the establishment
of extra luteal tissue from the atretic tertiary follicles
present at ovulation, a common feature in the marmoset
(McAnulty 1994).
It is of interest to compare the current results with the
effects of specific targeting of VEGF on follicular angio¬
genesis and development in the marmoset. A much higher
degree of inhibition of angiogenesis and follicular devel¬
opment was observed when directly inhibiting VEGF
Journal of Endocrinology (2004) 183, 1-17
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with a potent, receptor-based antagonist VEGF Trap
R1R2 (Wulff et al. 2002). This antagonist binds VEGF
with high affinity and prevents it reaching its receptors.
Thus, no matter what compensatory mechanisms come
into operation to restore VEGF, they are negated by the
VEGF inhibitor. In contrast, while treatment with GnRH
antagonist inhibits gonadotrophin secretion this may have
little effect on the ability of hypoxia and local paracrine
mechanisms to mediate or modulate VEGF action in the
ovarian follicle, as these compensatory mechanisms may be
allowed to function. It follows that the reason that GnRH
antagonist treatment is more effective in suppressing early
luteal angiogenesis (Dickson & Fraser 2000) is likely to be
because the corpus luteum is heavily dependent upon LH
(Fraser et al. 1986). This dependence would include the
local compensatory mechanisms that are relatively gonado¬
trophin independent in the developing follicle.
In conclusion, the use of a GnRH antagonist to block
gonadotrophin release did not result in complete inhibition
of follicular angiogenesis and vascularization and raises the
possibility of other factors and paracrine mechanisms
regulating VEGF and angiogenesis in the primate ovarian
follicle.
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Angiogenesis is essential for normal growth and function of
the corpus luteum. The roles of various angiogenic factors in
these events are being elucidated. Endocrine gland vascular
endothelial growth factor (EG-VEGF) has recently been de¬
scribed in the human ovary. To define the localization of EG-
VEGF mRNA in the corpus luteum and determine changes in
its expression, dated human corpora lutea were studied at the
early, mid-, and late luteal phases. Quantitative RT-PCR was
employed to determine changes in EG-VEGF mRNA and com¬
pare expression to its related factor prokineticin-2 and the
established angiogenic factor, VEGF. In situ hybridization
was used to localize sites of production of EG-VEGF. To in¬
vestigate whether expression of EG-VEGF was under the in¬
fluence ofLHor progesterone, luteinized granulosa cellswere
stimulated with human chorionic gonadotropin in the pres¬
ence or absence of a progesterone synthesis inhibitor. EG-
VEGF mRNA increased throughout the luteal phase, whereas
there was no change in VEGF mRNA. The relative abundance
of RNAs based upon PCR signal intensity showed that VEGF
and EG-VEGF were highly expressed, whereas expression ol
prokineticin-2 was low. EG-VEGF mRNA was localized pre¬
dominantly to granulosa-derived cells of the corpus luteum.
Human chorionic gonadotropin stimulated both VEGF and
EG-VEGF mRNA in vitro, but the level of expression was not
influenced by progesterone. These results establish that in the
human corpus luteum EG-VEGF is principally derived from
granulosa lutein cells and that its synthesis is highest during
the mid- to late luteal phase. (J Clin Endocrinol Metab 90:
427-434, 2005)
DURING THE TRANSFORMATION of the ovulatoryfollicle to a fully functional corpus luteum, the vas¬
cular endothelial cells undergo an intense period of prolif¬
eration followed by recruitment of perivascular cells.
Whereas endothelial cells in most tissues live for several
years, those in the corpus luteum of a nonfertile cycle die in
the space of a few weeks during the process of luteolysis (1).
Understanding the molecular mechanisms that regulate
these divergent mechanisms is a major challenge in repro¬
ductive biology with implications for the understanding of
pathological angiogenesis. Factors that regulate luteal vas¬
culature play a major role in the regulation of luteal function,
and several studies have described the localization ofmRNA
and protein for vascular endothelial growth factor (VEGF) in
the human corpus luteum (2, 3). Furthermore, inhibition of
VEGF in vivo during the luteal phase in the nonhuman pri¬
mate prevents luteal angiogenesis and suppresses proges¬
terone secretion (4, 5).
A novel angiogenic factor with a degree of specificity for
the ovary and endocrine glands, endocrine gland vascular
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Abbreviations: EG-VEGF, Endocrine gland VEGF; hCG, human cho¬
rionic gonadotropin; 3/3HSD, 3/3 hydroxysteroid dehydrogenase; LDL,
low-density lipoprotein; PK, prokineticin; RT, reverse transcription;
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endothelial growth factor.
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endothelial growth factor (EG-VEGF), has recently been de¬
scribed in the human ovary (6-8). The protein was desig¬
nated EG-VEGF because it was also found in the testis, ad¬
renal, and placenta (6), and this has been confirmed by others
(9). However, EG-VEGF is also present at much lower levels
in other tissues such as the small intestine (10), where it was
discovered independently and named prokineticin (PK)-l
(10). EG-VEGF/PK-1 acts via G protein-coupled receptors,
termed PK-R1 and PK-R2 (11). EG-VEGF is a member of a
class of proteins that includes Bv8, otherwise known as PK-2,
which has an 83% homology and appears to be preferentially
expressed in the testis (12). Structurally, EG-VEGF/ PK-1 is
distinct from VEGF but exhibits functional similarities.
The aim of the current study was to define the localization
of EG-VEGF mRNA and determine changes in its expression
in dated human corpora lutea from the early, mid-, and late
luteal phase using in situ hybridization and quantitative RT-
PCR analysis. In addition, to gain more information on the
factors regulating EG-VEGF expression, a primary culture
system for luteinized granulosa cells was employed in which
the cells were stimulated with human chorionic gonadotro¬
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all patients before tissue collection. Corpora lutea were enucleated at the
time of hysterectomy as described previously (13). All women were
healthy and aged 32-45 yr and with benign gynecological conditions,
typically uterine fibroids. Only women with regular menstrual cycles
who had not received any form of hormonal treatment during the
previous 3 months took part in the study. The date of the preovulatory
LH surge was determined by measuring LH concentration in serial
early-morning urine samples collected before operation (13). On this
basis, eight corpora lutea were classified as early luteal (LH + 1 to + 5 d),
12 as mid-luteal (LH + 6 to + 10 d), and six as late luteal (LH + 11 to
+ 14 d). There were no differences in the average age between the
groups. Serum was collected at the time of surgery for progesterone
determination (13).
Corpora lutea were enucleated from the ovary by blunt dissection.
The tissue was immediately divided into radial blocks to ensure stan¬
dard representation of all regions of the corpus luteum, and portions
were either frozen on dry ice and stored at -70 C until RNA extraction
or fixed in 4% neutral buffered formalin for paraffin embedding, fn each
case, an endometrial biopsy was obtained, and dating of the luteal-phase
endometrium (14) confirmed the luteal-phase classification.
Preparation of cDNA
A potential disadvantage of the RT-PCR approach using whole tissue
containing heterogeneous cell types is that specimens have variable
degrees of stromal or extracellular matrix component. To reduce this
potential problem in the present study, a large proportion of the corpus
luteum (between 30 and 50%) was extracted. Thus, total RNA was
extracted from 0.2- to 0.5-g frozen corpora lutea samples using Tri
Reagent (Sigma-Aid rich Co. Ltd., Gillingham, UK) according to the
manufacturer's instructions. The integrity of the RNA was confirmed
from the absorbance 260/280-nm ratio and by ethidium bromide gel
electrophoresis. RNA concentration was calculated by absorbance at 260
nm, measured on a Gene Quant-Pro spectrophotometer (Amersham
Biosciences, Little Chalfont, UK).
To eliminate genomic DNA contamination, 10 pig RNA was DNase
treated (RQ-1 RNase-free DNase, Promega, Southampton, UK) by in¬
cubation at 37 C for 30 min and the reaction stopped by the addition of
Stop Solution (20 mM EGTA, Promega) and heating to 70 C for 10 min.
Reverse transcription (RT) was performed under carefully controlled
conditions, using a Taqman Reverse Transcription kit with random
hexamers (Applera UK, Warrington, UK). All samples were treated
simultaneously from the same reagent mix containing 2 pil RT buffer; 2
pd deoxynucleotide triphosphates (10 mm); 1 pd each of RNase inhibitor
(20 U/pil), random hexamers (50 /am), and Multiscribe RT enzyme (50
U/pd);2.4 pdMgCl2 (25 mm); and 0.2 pig of DNase-treated RNA in a final
sample volume of 20 pd. RT was performed at room temperature for 10
min and at 42 C for 60 min and was stopped by incubation at 95 C for
10 min. The resulting cDNA was stored at -20 C until use. An equal
amount of human placental RNA (Cambridge Bioscience, Cambridge,
UK, 1 mg/ml) was concomitantly reverse transcribed to provide cDNA
for the generation of standard calibration curves for each gene examined.
Primer design
Oligonucleotide PCR primers for each gene investigated were de¬
signed using Primer3 software (available at http://www-genome.wi.
mit.edu/cgi-bin/primer/primer3_www.cgi) from DNA sequences ob¬
tained from GenBank (http://www.ncbi.nlm.nih.gov). Primers were
synthesized by MWG (MWG-AG Biotech, Milton Keynes, UK). For
VEGF-A (GenBank accession no. E15157), primers were 5'-TACCTC-
CACCATGCCAAGTG-3' and 5'-TAGCTGCGCTGATAGACATCCA-
3', giving a 103-bp product. Primers for EG-VEGF (GenBank accession
no. AF333024) were 5' -GCAAGCGCCTAAAAATTGAT-3' and 5'-CCT-
TCTTCAGGAAACGCAAG-3' and gave a 124-bp product, and for PK-2
(GenBank accession no. AF333025), the primers were 5'-CCCACTCCT-
GCTCCTCTTG-3' and 5' -CCAGATACTGACAGCACAGCA-3', and the
product was 133 bp.
Optimization of PCRs
Each assay was optimized with regard to anneal temperature and
magnesium concentration. Firstly, PCR amplification of human placen-
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tal cDNA was performed with Thermostart Taq Polymerase (Advanced
Biotechnologies, Epsom, UK) at anneal temperatures between 51 and 69
C, using the gradient feature of a DNA Engine gradient cycler (MJ
Research Inc., Watertown, MA). All products were examined by gel
electrophoresis to confirm the presence of a single band at the correct size
and to determine the optimum anneal temperature for each primer set.
The identity of each PCR product was further confirmed by sequence
analysis.
Successful reactions were then transferred to the LightCycler, and the
magnesium concentration was titrated in the range 3-5 mm, using the
LightCycler Fast Start DNA Master SYBR Green 1 kit (Roche, Lewes,
UK), according to the manufacturer's instructions. The PCR cycling
conditions were denaturation at 95 C for 10 min, followed by 45 cycles
of 95 C for 10 sec, annealing at the temperature defined above for 5 sec,
and extension at 72 C for 15 sec. A melting curve analysis following the
amplification schedule allowed optimization of the temperature used tc
quantify the level of gene expression by minimizing background fluo¬
rescence from nonspecifically amplified DNA. All PCR assays exhibited
a single DNA melting curve peak. The optimized PCR conditions were
as follows: VEGF-A annealed at 65 C using 3 mm MgCl2, and fluores¬
cence was measured at 83 C; EG-VEGF annealed at 61 C using 5 mM
MgCl2, and fluorescence was measured at 84 C; and PK-2 annealed al
66 C using 3 mM MgCl2, and fluorescence was measured at 83 C. The
VEGF-A product melted at 85 C, the EG-VEGF product at 87 C, and the
PK-2 product at 90 C.
Quantitative real-time PCR
Quantitative real-time PCRwas performed in duplicate 10-pd reaction
volumes on the LightCycler using the Mastermix supplied with the
LightCycler Fast Start DNA Master SYBR Green 1 kit (Roche), at the
optimized conditions described above. In each case a standard curve was
generated using serial dilutions of human placental cDNA.
Using the second derivativemaximummethod provided in the Light¬
Cycler software (version 3.3), a standard curve was generated by plot¬
ting the external standard concentration against threshold cycle. This
analysis method ensured interrun consistency. The software automat¬
ically calculated PCR product concentration for each tissue sample. All
samples were analyzed in duplicate, and assay variation was typically
within 10%. Data were normalized according to the expression level ol
glucose-6-phosphate-dehydrogenase determined in duplicate by refer¬
ence to a serial dilution calibration curve as above. The generation ol
calibration curves for both the gene of interest and the normalizing gene
allows for any difference in amplification efficiencies between the genes.
PCR products were extracted from the LightCycler capillaries and an¬
alyzed on 2% agarose gels to confirm product size and reaction
specificity.
In situ hybridization
To investigate possible changes in expression patterns of the mRNA
for EG-VEGF in the corpus luteum, in situ hybridization was performed
Forward 5'-AGAGGCATCTAAGCAGGC and reverse 5'-AGGTAT-
GTCTGCCTGTGTGC primers were used to generate a cDNA fragmenl
corresponding to nucleotides 10-533 of the human sequence (GenBank
accession no. NM032414). This fragment was cloned into a pGEM-T easy
vector (Promega Corp., Madison, WI) containing both T7 and SP6 tran¬
scription sites. Sense and antisense probes were prepared using a RNA
transcription kit (Ambion, Inc., Austin, TX) and were labeled with
[35S]UTP (NEN Life Science Products, Boston, MA). The synthesized
probes were purified from free bases using Chroma Spin-100 columns
(Clontech Laboratories, Inc., Palo Alto, CA).
Paraffin sections (5 /im) were mounted onto SuperFrost Plus glass
slides (BDH, Dorset, UK). Sections were deparaffinized in xylene and
hydrated through descending concentrations of ethanol. Sections were
treated with 0.1 n HC1 and then digested in proteinase K (5 /eg/ml
Sigma, St. Louis, MO) for 30 min at 37 C. The digestion was stopped by
treating the slides with 0.2% glycine for 10 min at 4 C. After acetylation
with 0.2% acetic anhydride in triethanolamine buffer (Sigma), the slides
were washed in 4X SSC (saline sodium citrate). A prehybridization step
was carried out by incubation in prehybridization buffer (50 pil/slide]
containing 50% formamide, 4X SSC, lx Denhardt's solution, 125 pig/ml
salmon testes DNA, 125 pig/ml yeast transfer RNA, and 10 mmol/litei
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dithiothreitol at 55 C in a moist chamber for 2 h. Hybridization was
performed in a moist chamber overnight at 55 C. The hybridization
buffer was similar to the prehybridization buffer, but contained 10%
dextran sulfate additionally. Two sections per slide were exposed to the
antisense or the sense sequences. After hybridization, slides were rinsed
in 4X SSC and treated with ribonuclease A (20 /xg/ml; Sigma) for 30 min
at 37 C to remove all excess probe; desalted in descending concentrations
of SSC (2x SSC for 30 min at room temperature, IX SSC at 65 C, and
0.1X SSC at room temperature); and dehydrated for 2 min each in 50,
84, and 94% ethanol containing 0.3 mol/liter ammonium acetate. Dry
slides were dipped in Ilford G5 liquid emulsion (Ilford Imaging,
Cheshire, UK), exposed for 5 wk at 4 C, and subsequently developed
(Kodak D19 developer, Eastman Kodak Co., Rochester, NY) and fixed
(Kodak GBS). All slides were counterstained with hematoxylin, dehy¬
drated, and mounted.
The slideswere analyzed under both light- and dark-field conditions.
The intensity of the hybridization signal was scored for the various
compartments (granulosa-derived lutein cells, theca-derived lutein cells,
stroma, and endothelium) as follows: 0, no expression above tissue
background; 1, detectable grains above background; 2, low expression;
3, moderate expression; 4, high expression; and 5, intense expression
with grain coalescence. Two observers scored the sections "blind." Com¬
parison of the results between the observers showed excellent
agreement.
lmmunohistochemistry
To determine the origin of the steroid-producing luteal cells, 5-/nm
paraffin-embedded sectionswere immunostained for 3(3 hydroxysteroid
dehydrogenase (3/3HSD), which stains granulosa-derived cells strongly
and theca-derived cells weakly, and 17a-hydroxylase, which stains theca-
derived cells only. Paraffin-embedded tissue sections were dewaxed in
xylene and rehydrated through decreasing grades of alcohol. Endoge¬
nous peroxidase activity was blocked by 30-min incubation in 3% hy¬
drogen peroxide in methanol. For the 3/3HSD immunostain, nonspecific
binding was reduced by blocking with normal goat serum and diluted
1:5 in Tris-buffered saline (TBS) containing 5% BSA. Sections were in¬
cubated overnight at 4 C in rabbit polyclonal 3/3HSD antibody (kindly
donated by Prof. J. I. Mason, University of Edinburgh, Edinburgh, UK)
diluted 1:1000 in normal goat serum block. Slides were washed three
times in TBS. Incubation with the secondary antibody biotinylated goat
antirabbit IgG (Dako Ltd, Cambridgeshire, UK), diluted 1:500, was per¬
formed for 40 min at room temperature. For the 17a-hydroxylase im¬
munostain, a normal porcine serum block was used to reduce nonspe¬
cific staining as above. The primary antibody, rabbit anti-pig 17a-
hydroxylase (CYP17, kindly donated by Prof. J. I. Mason), was applied
at a dilution of 1:750 and incubated overnight at 4 C. A biotinylated
swine antirabbit secondary antibody (Dako Ltd.) was used in a 40-min
incubation as above. Detection in each case involved, after washing in
TBS, a 30-min incubation in avidin-biotin horseradish peroxidase com¬
plex (Dako Ltd.) followed by incubation in diaminobenzidine (Dako
Ltd.) to give a brown color. Sections were lightly counterstained with
hematoxylin, dehydrated, and mounted in Pertex (CellPath, Powys,
UK). In each case negative controls, with omission of the primary an¬
tibody, were included.
Collection of human luteinized granulosa cells
The Reproductive Medicine Subcommittee of the Lothian Medical
Ethics Committee approved the collection of luteinized granulosa cells
from patients undergoing assisted conception. Follicular fluid was col¬
lected from women undergoing transvaginal oocyte retrieval for IVF
following ovarian stimulation using a standard procedure. Briefly, a
long protocol-stimulated cycle was followed, using nasal naferelin
(Pharmacia, Milton Keynes, Bucks, UK) for down-regulation and daily
purified gonadotrophins (Menopur, Ferring Pharmaceuticals, Langley,
Berks, UK) for ovarian stimulation. When at least three follicles reached
18 mm in diameter, 10,000 IU of hCG was administered. Transvaginal
oocyte collection was performed under sonographic guidance 35 h later.
Granulosa cells were obtained from the follicular aspirates after the
removal of the oocytes. Individual follicles were not distinguished, and
all follicular fluid from the same individual was pooled and centrifuged
at 1500 rpm for 10 min. The cells were resuspended in culture medium
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(DMEM/F12 Ham mixture, Life Technologies, Inc., Gaithersburg, MD),
layered over a 45% Percoll/culture medium mixture, and centrifuged at
1200 rpm for 30 min to pellet the blood cells. Luteinized granulosa cells,
visible in the interface, were collected by pipette and washed three times
in PBS. The cells were resuspended in culture medium, and viable cells
were counted using a Trypan blue exclusion test. Eighty thousand viable
cells were plated onto each well of 24-well plates precoated with Ma-
trigel (15,16) and cultured using 1 ml culture medium at 37 C in 5% C02
in air. Cells were cultured for 7-8 days using culture medium supple¬
mented with glutamine (2 mmol/liter), insulin (6.25 (rg/liter), trans¬
ferrin (6.25 mg/liter), selenious acid (6.25 /xg/liter), amphoteracin (2.5
mg/liter), penicillin (50 mg/liter), and streptomycin (60 mg/liter) as
described previously (16). Media were changed every 2-3 d over the
course of the culture period.
After 7-8 d in culture, fresh serum-free medium was added contain¬
ing the following treatments: 1) low-density lipoprotein (LDL; 50 mg/
liter) (Sigma), 2) hCG (10 ng/ml) (Serono) and LDL (50 mg/liter), 3) hCG
(100 ng/ml), and 4) hCG (100 ng/ml) and aminoglutethamide (100 ;xm)
(Sigma). This treatment regime was designed to manipulate progester¬
one concentrations in the presence of hCG. After 24 h, medium was
collected for progesterone measurement, and cells were collected foi
mRNA extraction. The treatment regimens and doses used had previ¬
ously been optimized, and the experiments were repeated in triplicate
on three different occasions.
Preparation of cDNA from cultured cells
After removal and storage of culture medium, cellswere rinsed in PBS
and Tri Reagent was added. The resulting solution was stored at -70 C
until batch extraction of RNA was carried out. RNA was extracted
following the manufacturer's instructions. To remove contaminating
genomic DNA, RNA was treated with DNase I at a concentration of 1
U per jug RNA for 30 min at 37 C. After stopping the reaction with Stop
Solution, the samples were heated to 70 C for 10 min. Using random
hexamers, 200 /ng RNA was reverse transcribed in a solution containing
5.5 mm MgCl2, 2.5 pm random hexamers, 500 /xm each deoxynucleotide
triphosphates, 0.4 U/ju.1 RNase inhibitor, and 1.25 U//nl Multiscribe
reverse transcriptase (PE Applied Biosystems, Warrington, Cheshire,
UK). Samples were incubated at room temperature for 10 min, followed
by 42 C for 60 min and 95 C for 10 min. Two controls were used; one
omitted the Multiscribe enzyme and the other the template RNA. The
resulting cDNA was used for PCR.
Measurement ofprogesterone
Progesterone concentrations in serum and in culture media collected
were measured using a plate modification of a standard in-house pro¬
gesterone RIA (13). This assay has a detection limit of 0.1 nmol/liter and
intra- and interassay coefficient of variation of less than 4% and less than
11%, respectively.
Statistical analysis
Differences between groups with respect to level of mRNA expres¬
sion after in situ hybridization were analyzed using the Kruskal-Wallis
test, significance being ascribed at a level of P < 0.05. To determine
changes in serum progesterone and differences in expression betweer
stages of the luteal phase after RT-PCR and after cell culture, data were
exported into Microsoft Excel, and statistical analyses (ANOVA) wit!
the Bonferroni test for pairwise comparisons were performed with SPSS
(Statistical Package for Social Sciences, SPSS Inc, Chicago, IL), versior
10.7 for Macintosh, with significance being indicated by P < 0.05.
Results
Serum progesterone
The serum concentrations of progesterone at the time oi
surgery were 24.7 ± 6.3 nmol/liter (mean ± sem) for the early
luteal phase, rising to 56.0 ± 8.1 nmol/liter at mid-luteal
phase before declining significantly (P < 0.05) to 10.3 ± 4.5
nmol/liter in the late luteal phase group.
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Quantitative RT-PCR
The amplification efficiencies of each primer set were sim¬
ilar as detected by generation of standard curves by the
LightCycler software. Quantitative RT-PCR showed there
was no significant change in the expression of VEGF mRNA
during the luteal phase (Fig. 1). EG-VEGF mRNA progres¬
sively increased throughout the luteal phase, showing a sig¬
nificant increase in expression (P < 0.05) between early and
late luteal phase (Fig. 1). Expression of PK-2 showed a non¬
significant trend to increase through the luteal phase, in a
similar pattern to EG-VEGF mRNA (Fig. 1).
Comparison of the levels of VEGF, EG-VEGF, and PK-2
based on crossing point data relative to glucose-6-phosphate-
dehydrogenase showed that VEGF and EG-VEGF were
highly expressed, whereas PK-2 expression was extremely
low.
In situ hybridization and immunohistochemistry
In situ hybridization showed that localized concentrations
of silver grains representing EG-VEGF mRNA were present
in all 26 specimens studied. Typical examples from the early,





Stage of luteal phase
Fig. 1. Changes in expression ofVEGF, EG-VEGF, and PK-2 mRNA
in the early, mid-, and late luteal phase as determined by RT-PCR.
EL, ML, and LL indicate early, mid-, and late luteal phases, respec¬
tively. Different letters show where differences are significant.
phase specimens had relatively low-intensity expression,
whereas those of the mid- and late luteal phase showed
EG-VEGF mRNA to be moderately to intensely expressed.
Grains were clearly predominantly localized to the granu-
losa-lutein cells over which they were uniformly distributed,
and this was confirmed by comparison with sections stained
with 3/3HSD and 17a-hydroxylase, which localized to
hormone-producing and theca-derived cells, respectively
(Fig. 2). The sense probe showed absence of tissue localiza¬
tion above background (Fig. 2J). Control sections for 3J3HSD
and 17a-hydroxylase immunostaining were negative (Fig. 2,
K and L).
Light-field examination of the in situ slides showed that in
early luteal phase specimens, granulosa-lutein cells ex¬
pressed in the weak to moderate range, whereas expression
was also observed in the theca-derived cells, generally at a
lower level. In the mid-luteal specimens, expression was
extensive in the granulosa lutein cells, whereas theca lutein
cells were negative. The late luteal specimens also confirmed
the granulosa-derived cells as the site of highest EG-VEGF
expression, whereas the theca-derived cells were negative or
demonstrated expression in the occasional cell (Fig. 3). En¬
dothelium showed no hybridization, whereas stromal ex¬
pression was weak or absent and was unaffected by stage
(Fig. 3).
Scoring showed that intensity of grains in granulosa lutein
cells was significantly increased (P = 0.0008) from the early
to mid- and late luteal phases, whereas in the theca-derived
cells intensity of grains was lower (P = 0.02) than in the other
two stages at the mid-luteal phase (Fig. 4). There were no
stage-specific significant differences in the low levels of stro¬
mal grain intensity.
Luteinized granulosa cells
Incubation of luteinized granulosa cells with hCG signif¬
icantly increased (P < 0.05) progesterone production and
significantly (P < 0.05) increased expression of both VEGF
and EG-VEGF mRNA (Fig. 5). However, stimulation of pro¬
gesterone production further by addition of LDL failed to
induce a further rise in either VEGF or EG-VEGF mRNA. In
addition, reduction of hCG and LDL-stimulated progester¬
one synthesis by aminoglutethamide also failed to alter syn¬
thesis of either factor.
Discussion
In this study, the complementary approaches of real-time
PCR and in situ hybridization have been used to define the
changes in expression of EG-VEGF mRNA in the human
corpus luteum throughout the luteal phase. Both techniques
showed that expression increased as the corpus luteum ma¬
tured. Comparison of expression with the established luteal
endothelial mitogen, VEGF, showed that by RT-PCR in con¬
trast to EG-VEGF, VEGF mRNA was already being ex¬
pressed at maximal levels during the early luteal phase and
was not significantly altered during the luteal phase, in
agreement with our previous in situ hybridization findings
(17). VEGF and EG-VEGF mRNA are largely similar in their
localization predominantly to the granulosa lutein cells. The
relative abundance ofRNAs based upon PCR signal intensity
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Fig. 2. Expression of EG-VEGF mRNA (silver grains) in
the human CL as revealed by in situ hybridization and
staining of the hormone-producing cells by 3/3HSD and
theca-derived cells by 17a-hydroxylase antibodies (brown
stain) from the same corpora lutea from the early (A-C),
mid- (D-F), and late (G-I) luteal phases. Dark-field in situ
photographs show grain density increasing from the early
to the mid- and late luteal phases. Immunoeytochemical
identification of the luteal cell types shows that expression
of EG-VEGF mRNA is localized predominantly to granu-
losa-derived luteal cells. Control slide for the late luteal
section hybridized with sense probe is shown in panel J,
whereas the slides shown in panels K and L were incubated
in the absence of antibodies for 3/3HSD and 17 a-hydrox-
ylase, respectively. Scale bar, 100 pm.
EG-VEGF 3PHSD 17a-hydroxylase
K LJ
showed that VEGF and EG-VEGF/PK-1 were highly ex¬
pressed, whereas expression of the related factor PK-2 was
low. These findings strongly suggest that EG-VEGF, in ad¬
dition to VEGF, has a physiological role in regulation of the
luteal vasculature. In contrast, PK-2 is unlikely to have a
significant role in the human corpus luteum as has been
suggested from studies in other species (18).
The observation of independent changes in levels of ex¬
pression between VEGF and EG-VEGF within the corpus
luteum also occurs in the human follicle (19) where EG-
VEGF, but not VEGF mRNA is found in granulosa cells of
primordial and primary follicles. As follicles mature, VEGF
expression increases, whereas that of EG-VEGF mRNA de¬
clines in the granulosa and increases in the theca (19). In
addition, different expression rates between the two factors
have also been reported in a human granulosa-lutein cell line
(20). The study on the human follicle (19) also described the
localization of both mRNAs in the human corpus luteum.
Although results on localization of VEGF mRNA to the gran¬
ulosa lutein cells agree with our results using in situ hybrid¬
ization (17), they differ in that the theca-lutein cells appeared
to be the predominant site of EG-VEGF production (19). In
our study, the site of major expression of EG-VEGF was
identified as the granulosa-derived cells by visual inspection
of hematoxylin-stained slides. To confirm the localization of
EG-VEGF mRNA, sections of all corpora lutea were stained
with 3/3HSD to localize steroidogenic cells and 17cc-hydrox-
ylase to localize theca-derived cells specifically. These results
established that the predominant site of EG-VEGF expres¬
sion was the granulosa-lutein cells with some expression in
theca-lutein cells in the early luteal specimens and the oc¬
casional positive theca-derived cell in the late luteal phase.
The previous study on human ovaries (19) was based upon
the ovaries of 13 patients collected at random stages of the
cycle (assuming six to seven in luteal phase) and staged by
histological criteria. This contrasts with the 26 corpora lutea
described herein that were staged according to hormonal
analysis. Staging from histological criteria alone may result
in inaccurate conclusions in some cases, especiallywith what
appears to be the late luteal phase. Both studies agree in that
the early corpus luteum exhibits relatively low expression of
EG-VEGF. Both studies agree that in the mid-luteal phase,
EG-VEGF is highly expressed, but our results provide stron¬
ger evidence of the granulosa-lutein cells, rather than the
theca-lutein, being the predominant source of EG-VEGF.
However, in an ovary estimated to be at d 8 postovulation,
a major decrease in VEGF signal with EG-VEGF confined to
apparent theca-derived cells was reported (19). At this stage
of the luteal phase, VEGF should be highly expressed (2,17).
In the absence of fundamental assessment by progesterone or
3/3HSD immunostaining, it is uncertain whether this sample
was correctly timed. In our study, this stage was character¬
ized by moderate to high EG-VEGF in all 12 specimens.
Finally, in the other study of a regressing corpus luteum, both
VEGF and EG-VEGF expression were virtually absent (19),
contrastingmarkedly with our results, which showed that in
all six late luteal specimens EG-VEGF mRNA was either
moderately or highly expressed, including in specimens with
apoptosis. It may be that for the late luteal phase ovary
described (19), the age may have been underestimated, es¬
pecially as the luteal cells were highly vacuolated and several
large antral follicles were present (19).
Downloaded from jcem.endojournals.org on June 6, 2005
432 J Clin Endocrinol Metab, January 2005, 90(11:427-434 Fraser et al. • EG-VEGF in Corpus Luteum
Fig. 3. Dark-field and corresponding light-field high-power photographs of in situ hybridization of EG-VEGF mRNA in human corpus luteum
to show sites ofexpression in detail. Mid-luteal phase corpus luteum (A-D) showing expression is localized predominantly to the granulosa lutein
cells (GL); virtually absent from theca lutein cells (TL); and absent from endothelial cells of blood vessels (b.v.), the luteal capsule, and stroma
(S). In a late-stage corpus luteum (E and F), a similar pattern of expression is observed, although low expression in some theca lutein cells can
also be observed. Scale bar, 50 /am.
With respect to the physiological roles of VEGF and EG-
VEGF in the corpus luteum, it has been shown that VEGF is
essential for normal luteal angiogenesis and function in the
nonhuman primate (4, 5). The high level of VEGF mRNA ex¬
pression during the early luteal phase (2) is likely to be respon¬
sible for the intense angiogenesis seen at this time (17). The
maintenance ofVEGF expression throughout the functional life
span of the corpus luteum may serve as a survival factor for
endothelial cells and as an ovarian permeability factor (21).
Immunoneutralization of VEGF during the mid-luteal phase
in the marmoset resulted in suppression of plasma proges¬
terone levels even though the luteal microvascular tree is
largely complete by this stage (21), suggesting a continued
requirement for VEGF for normal luteal function.
The role of EG-VEGF has been proposed as a regulator of
vascular function exhibiting a selectivity for the endocrine
glands (8, 22). The current findings support the view that
EG-VEGF could have an important role in the functioning of
the human corpus luteum. Establishing a physiological role
for EG-VEGF must await in vivo studies in which pharma¬
cological inhibitors can be employed to selectively prevent its
action or block its receptors as has been carried out for VEGF
(5, 23). From the current information, what is of greatest
interest is that EG-VEGF mRNA is most highly expressed
during the late luteal phase. By this period, the intense an¬
giogenesis associated with the establishment of the luteal
microvascular tree has subsided (3). This supports the es¬
tablished role for VEGF in the intense angiogenesis that takes
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Stage of luteal phase
Fig. 4. Scoring of sections after in situ hybridization for EG-VEGF
mRNA at different stages of the luteal phase in the various compart¬
ments of the tissue: granulosa-derived cells, theca-derived cells, and
stroma. Silver grain intensitywas significantly higher in themid- and
late luteal specimens than during the early luteal phase in the gran¬
ulosa-derived cells, whereas theca-derived cells had the highest ex¬
pression in the early and late luteal phases. EL, ML, and LL indicate
early, mid-, and late luteal phases, respectively. Different letters rep¬
resent significant differences.
place during the early luteal phase. It has been demonstrated
that EG-VEGF enhances the development of fenestrae that
allow the passage of molecules across the vascular endothe¬
lium. The most likely role for EG-VEGF at the mid- to late
luteal phase is the regulation of vascular permeability to
enhance transport of LDLs into the luteal cells and secretion
of progesterone and other luteal products into the blood¬
stream (6). This may be of particular importance in allowing
the corpus luteum to respond to hCG in early pregnancy.
With respect to the factors regulating the synthesis of
EG-VEGF within the corpus luteum, the two most likely
candidates are LH and progesterone. LH is an essential tro¬
phic factor for luteal function (24), whereas incubation of













Fig. 5. Progesterone secretion into culture medium and VEGF and
EG-VEGF expression in cultures of luteinized granulosa cells. Treat¬
ment groups were designed to expose the cells to hCG or increased
progesterone: hCG + LDL gave high progesterone concentrations,
hCG alone medium progesterone concentrations, and hCG + amin-
oglutethamide control levels ofprogesterone. The effect on VEGF and
EG-VEGF expression was the same regardless of progesterone con¬
centrations. Different lowercase letters represent significant differ-
expression (25,26). Our observation that hCG stimulates the
synthesis of both VEGF and EG-VEGF in human luteinized
granulosa cells provides evidence for a role of LH in the
regulation of this novel factor. Because the distinguishing
feature between patterns of VEGF and EG-VEGF synthesis in
the corpus luteumwas the increased production ofEG-VEGF
in the mature tissue, itwas tempting to believe that synthesis
of EG-VEGF could be stimulated as a result of progesterone
stimulation. We therefore manipulated progesterone con¬
centrations in the presence of hCG. The addition of LDL
significantly increased progesterone concentrations but
failed to produce a further rise in either factor. In addition,
the reduction of progesterone to basal levels by the addition
of aminogluthethamide for 24 h also failed to alter gene
expression. Although a role for basal progesterone secretion
cannot be excluded, these data suggest that a direct stimu¬
lation by progesterone is not a major factor in the regulation
ofEG-VEGFmRNA in the human corpus luteum. Additional
factors regulating ovarian EG-VEGF synthesis such as hyp-
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oxia (6, 20), thrombin (20), or local growth factors such as
insulin-like growth factors (27) require further investigation.
A clearer picture of the role of EG-VEGF in the ovary may
become apparent when the expression patterns of its recep¬
tors, PK-R1 and PK-R2, are determined. In our laboratory, we
have been unable to detect these receptors on the luteal
sections by in situ hybridization, probably as a result of
low levels of expression (H.W. and H.M.F., unpublished
observations).
In conclusion, a profile of the expression of EG-VEGF
within the corpus luteum has been provided by the com¬
plementary approach of in situ hybridization and RT-PCR.
The results provide support for a role for EG-VEGF within
the corpus luteumwith respect to the regulation of the luteal
vasculature, which is vital for normal function.
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